

RÉFÉRENCES - Referenzen

Last update: 28.5.2022
(4853 références)

Philippe Furger, md, cc, cme

Éditions D&F GmbH/sàrl depuis 1998

Auteur: philippe_furger@investimed.ch
Editeur: Editions D&F GmbH, Switzerland
E-mail: info@surfmed.ch
WEB: www.surfmed.ch

SCHWEIZ - Suisse

Deutsch

- SURF-med 2009, 2010, 2013, 2016, 2018 (reprint 2019), 2021/22
- TURBO-Notfallmedizin 2006, 2012, 2015
- INVESTI-MED© 2007, 2010
- Algo-SURF© 2011
- RED FLAGS© 2013 (bilingue), 2018, 2020
- Labor-SURF© 2013, 2014, 2020
- TURBO-Notfallmedizin & Kardiologie 2019

Français

- SURF 2006, 2009, 2012, 2016 (2x reprint), 2019
- TURBO - Médecine d'urgence 2006, 2012, 2019
- INVESTI-MED© 2007, 2010, 2020
- Labo-SURF© 2009, 2013
- RED FLAGS© 2013 (bilingue), 2018, 2020
- Intoxi-SURF© 2013
- Labo-SURF© Labo-DD - nouveau concept 2022

CANADA - FRANCE

- Dr.MED© 2006, 2009, 2012, 2016 (reprint), 2019
- Urgences@méd.ca 2006, 2010
- INVESTI-MED© 2010, 2014, 2020
- Labo-MED© 2009, 2012
- Intoxi-MED© 2009, 2013
- Labo-MED© 2022 Labo-DD - nouveau concept



Français



Deutsch



App Store

→ SURFmed



&

Plateforme web



www.SURFmed.co

Scheme used for classification of the evidence

- M Meta-analysis; use of statistical methods to combine results from clinical trials
- Ra Randomized controlled trials; also known as experimental studies
- Re Retrospective analyses; also known as case-control studies
- F Prospective study; also known as cohort studies, including historical or prospective follow-up studies
- X Cross-sectional survey; also known as prevalence studies
- Pr Previous review or position statements
- C Clinical interventions (nonrandomized)

son of vasopressin and epinephrine of out-of-hospital cardiopulmonary resuscitation. *N Engl J Med* 2004; 350: 105-13.

AHA in Collaboration with International Liaison Committee on Resuscitation. Guidelines 2005 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation* 2005; 112: IV-1IV211.

Coudray A, Romand J-C, Treggiari M, et al. Fluid responsiveness in spontaneously breathing patients: a review of indexes used in intensive care. *Crit Care Med* 2005; 33: 2757-62.

European Resuscitation Council. ERC Guidelines for Resuscitation 2005. *Resuscitation* 2005; 67: 157-341.

Holzer M, Bernard SA, Hachimi-Idrissi S, et al. Hypothermia for neuroprotection after cardiac arrest: systematic review and individual patient data meta-analysis. *Crit Care Med* 2005; 33: 1449-52.

Skowronski GA. Therapeutic Hypothermia After Cardiac Arrest - Not so Fast. *Crit Care Resusc* 2005; 7: 322-4.

Aberle J, Kluge S, Prohl J, et al. Hypothermie nach Reanimation durch Konduktion und Konvektion. *Intensivmedizin* 2006; 43: 37-43.

Monnet X, Rienzo N, Osman D et al. Passive leg raising predicts fluid responsiveness in the critically ill. *Crit Care Med* 2006; 34:1402-7.

Morrison LJ, Visentin LM, Kiss A, et al. Validation of a Rule for Termination of Resuscitation in Out-of-Hospital Cardiac Arrest. *N Engl J Med* 2006; 355: 478-87.

Nielsen N, Wetterslev J, Cronberg T et al. Targeted Temperature Management at 33°C versus 36°C after Cardiac Arrest. *N Engl J Med* 2013; 369: 2197-206.

Lima A, Bakker J. Clinical assessment of peripheral circulation. *Curr Opin Crit Care* 2015; 21(3): 226-31.

Soar J, Nolan JP, Böttiger BW et al. European Resuscitation Council Guidelines for Resuscitation 2015: Section 3. Adult advanced life support. *Resuscitation* 2015; 95: 100-47.

A Truhlář, CD Deakin, J Soar et al. European Resuscitation Council Guidelines for Resuscitation 2015: Section 4. Cardiac arrest in special circumstances. *Resuscitation* 2015; 95: 148-201.

Jabre P, Bougouin W, Dumas F, et al. Early Identification of Patients With Out-of-Hospital Cardiac Arrest With No Chance of Survival and Consideration for Organ Donation. *Ann Intern Med* 2016 6; 165: 770-778.

Kudenchuk PJ, Brown S.P., Daya M et al. Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Cardiac Arrest. *N Engl J Med* 2016; 374: 1711-22.

Westfall E, Rossetti AO, van Rootselaar AF et al. Standardized EEG interpretation accurately predicts prognosis after cardiac arrest. *Neurology* 2016; 86: 1482-90.

Andersen LW, Granfeldt A, Callaway CW et al. Association Between Tracheal Intubation During Adult In-Hospital Cardiac Arrest and Survival. *JAMA* 2017; 317: 494-506.

SOINS INTENSIFS

Réanimation

- Kloek W, Cummins R, Chamberlain DA, et al. The universal ALS Algorithm: an advisory statement by the advanced life support working group of the international liaison committee on resuscitation. *Resuscitation* 1997; 34: 109-11.
- Walpoth BH, et al. Outcome of survivors of accidental deep hypothermia and circulatory arrest treated with extracorporeal blood warming. *N Engl J Med* 1997; 337: 1500-5.
- Advanced life support working group of the european resuscitation council. The 1998 european resuscitation council guidelines for advanced life support. *Resuscitation* 1998; 37: 81-90.
- Beveridge R, Ducharme J, Janes L et al. Reliability of the canadian emergency department triage and acuity scale: interrater agreement. *Ann Emerg Med* 1999; 34: 1555-9.
- American Heart Association in collaboration with the International Liaison Committee on Resuscitation (ILCOR). International guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care - A consensus on science. *Resuscitation* 2000; 46: 103-252.
- Cummins RO, Hazinski MF, Baskett PJF, et al. Introduction to the international guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. A consensus on science. *Resuscitation* 2000; 46: 3-15.
- Eisenberg MS, Mengert TJ. Cardiac resuscitation. *N Engl J Med* 2001; 344: 1304-13.
- De Latorre F, Nolan J, Robertson C, et al. European resuscitation council guidelines 2000 for adult advanced life support. *Resuscitation* 2001; 48: 211-21.
- Fumeaux T, Dussoix P, Unger PF. Réanimation cardiopulmonaire en 2001: qu'est-ce qui a changé? *Med Hyg* 2001; 59: 1046-9.
- Bernard SA, Gray TW, Buist MD, et al. Treatment of Comatose Survivors of Out-of-Hospital Cardiac Arrest with Induced Hypothermia. *N Engl J Med* 2002; 346: 557-63.
- Holzer M and The Hypothermia after Cardiac Arrest Study Group. Mild Therapeutic Hypothermia to Improve the Neurologic Outcome after Cardiac Arrest. *N Engl J Med* 2002; 346: 549-56.
- Wenzel V, Krismer AC, Arntz HR, et al. A compari-

- Kragholm K, Wissenberg M, Mortensen RN et al. Bystander Efforts and 1-Year Outcomes in Out-of-Hospital Cardiac Arrest. *N Engl J Med.* 2017; 376: 1737-1747.
- Merchant RM, Topjian AA, Panchal AR et al. Part 1: Executive Summary: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation* 2020; 142(suppl 2): S337.
- Panchal AR, Bartos JA, Cabañas JG et al. Part 3: Adult Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. *Circulation* 2020; 142 (suppl 2): S366.
- Perkins GD, Graesner JT, Semeraro F et al. European Resuscitation Council Guidelines 2021: Executive summary. *Resuscitation* 2021;161:1-60.

Défibrillation - Kardioversion

- Dell'Orfano JT, Naccarelli GV. Update on external cardioversion and defibrillation. *Curr Opin Cardiol* 2001; 16: 54-7.
- Adgey AA, Walsh SJ. Theory and practice of defibrillation: (1) Atrial fibrillation and DC conversion. *Heart* 2004; 90: 1493-8.
- Hubner PJ, Gupta S, McClellan I. Simplified cardioversion service with intravenous midazolam. *Heart* 2004; 90: 1447-9.
- Nurmi J, Rosenberg P, Castren M. Adherence to guidelines when positioning the defibrillation electrodes. *Resuscitation* 2004; 61: 143-7.
- Adgey AA, Spence MS, Walsh SJ. Theory and practice of defibrillation: (2) defibrillation for ventricular fibrillation. *Heart* 2005; 91: 118.
- Stiel IG, Sivilotti MLA, Taljaard M et al. Electrical versus pharmacological cardioversion for emergency department patients with acute atrial fibrillation (RAFF2): a partial factorial randomised trial. *Lancet* 2020; 395: 339-349.

Triage

- <http://www.oru-mip.fr/docs/ccmu.pdf>
- Gerdzt MF, Bucknall TK. Triage nurses' clinical decision making. An observational study of urgency assessment. *J Adv Nurs* 2001; 34: 550-61.
- Wuerz R. Emergency severity index triage category is associated with six-month survival. ESI Triage Study Group. *Acad Emerg Med* 2001; 8: 61-4.
- Wuerz RC, Travers D, Gilboy N et al. Implementation and refinement of the emergency severity index. *Acad Emerg Med* 2001; 8: 170-6.
- Fishman D, Guyot E, Bertin N et al. Les urgences prises d'assaut: à qui le tour? *Me Hyg* 2004; 62: 1550-3.
- Tanabe P, Gimbel R, Yarnold PR et al. Reliability and validity of scores on The Emergency Severity Index version 3. *Acad Emerg Med* 2004; 11: 59-65.

Ventilation mécanique – SDRA/ARDS

- Lodato RF. Oxygen toxicity. *Crit Care Clin* 1990; 6: 749-65.

Schuster DP. A physiologic approach to initiating, maintaining, and withdraw mechanical ventilatory support during acute respiratory failure. *Am J Med* 1990; 88: 268-78.

Feihl F, Perret C. Permissive hypercapnia. How permissive should we be? *Am J Respir Crit Med* 1994; 150: 1722-37.

Slutsky AS. Consensus conference on mechanical ventilation – January 28-30, 1993 at Northbrook, Illinois, USA. Part 1. *Intensive Care Med* 1994; 20: 64-79.

Slutsky AS. Consensus conference on mechanical ventilation – January 28-30, 1993 at Northbrook, Illinois, USA. Part 2. *Intensive Care Med* 1994; 20: 150-62.

Bernard GR, Artigas A, Brigham KL, et al. The american-european consensus conference on ARDS: definitions, mechanisms, relevant outcomes, and clinical trial coordination. *Am J Respir Crit Care Med* 1994; 149: 818-24.

Corbridge TC, Hall JB. The assessment and management of adults with status asthmaticus. *Am J Respir Crit Care Med* 1995; 151: 1296-1316.

Kollef MH, Schuster DP. The acute distress syndrome. *N Engl J Med* 1995; 332: 27-37.

Thorens JB, Jolliet P, Ritz M, Chevrolet JC. Effects of rapid permissive hypercapnia on hemodynamics, gas exchange, and oxygen transport and consumption in ARDS. *Intensive Care Med* 1996; 22: 182-91.

Antonelli M, Conti G, Rocco M, et al. A comparison of noninvasive positive-pressure ventilation and conventional mechanical ventilation in patients with acute respiratory failure. *N Engl J Med* 1998; 339: 429-35.

Amato MBP, Barbas CSV, Medeiros DM, et al. Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. *N Engl J Med* 1998; 338: 347-54.

Artigas A, Bernard GR, Carlet J, et al. The american-european consensus conference on ARDS, part 2. *Am J Respir Crit Care Med* 1998; 157: 1332-47.

Eckert Ph, Burdet L, Liaudet L, et al. Stratégies ventilatoires actuelles du syndrome de détresse respiratoire aigu. *Med Hyg* 1998; 56: 1920-4.

International Consensus Conferences in Intensive Care Medicine: ventilator-associated lung injury in ARDS. *Am J Respir Crit Care Med* 1999; 160: 2118-24.

The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional volumes for acute lung injury and the acute respiratory distress syndrome. *N Engl J Med* 2000; 342: 1301-8.

Ware L, Matthay MA. The acute respiratory distress syndrome. *N Engl J Med* 2000; 342: 1334-49.

Gattinoni L, Tognoni G, Pesenti A, et al. Effect of prone positioning on the survival of patients with acute respiratory failure. *N Engl J Med* 2001; 345: 568-73.

Tobin MJ. Advances in mechanical ventilation. *N Engl J Med* 2001; 345: 1986-96.

Taskforce by the american college of chest physicians: Evidence-based guidelines for weaning

- and discontinuing ventilatory support. *Chest* 2001; 120: Suppl. 375S-395S.
- Esteban A, Frutos-Vivar F, Ferguson ND, et al. Noninvasive positive-pressure ventilation for respiratory failure after extubation. *N Engl J Med* 2004; 350: 2452-60.
- Mahotra A. Low-Tidal-Volume Ventilation in the Acute Respiratory Distress Syndrome. *N Engl J Med* 2007; 357: 1113-20.
- Acute Respiratory Distress Syndrome. The Berlin Definition. The ARDS Definition Task Force. *JAMA* 2012; 307: 2526-2533.
- Claude Guérin C, Reignier J, Richard J-C et al. Prone Positioning in Severe Acute Respiratory Distress Syndrome. *N Engl J Med* 2013; 368: 2159-68.
- Howell MD, Davis AM. Management of ARDS in Adults. *JAMA* 2018; 319: 711-12.
- ### Intubation en cas de trauma crânien
- Grande CM, Stene JK. Airway management: considerations in the trauma patient. *Crit Care Clin* 1990; 6: 37-59.
- Yang KL, Tobin MJ. A prospective study of indexes predicting the outcome of trials of weaning from mechanical ventilation. *N Engl J Med* 1991; 324: 1445-50.
- Walls RM. Rapid-sequence intubation in head trauma. *Ann Emerg Med* 1993; 22: 1008-11.
- Bullock R, Chesnut RM, Clifton G. Guidelines for the management of severe head injury. *Eur J Emerg Med* 1996; 2: 109-27.
- Ely EW, Baker AM, Dunagan DP, et al. Effect on the duration of mechanical ventilation of identifying patients capable of breathing spontaneously. *N Engl J Med* 1996; 335: 1864-9.
- Koleff MH. Critical care. In: Ahya SN, et al. (eds.). *The Washington Manual of medical therapeutics*. Lippincott Williams & Wilkins, 2001; p. 195-216.
- Moeschler O, Engler A. Un tournus de médecine d'urgence au cours de la formation en anesthésiologie. *Med Hyg* 1998; 56: 2368-73.
- ### Hyperthermie
- Allen GC. Malignant hyperthermia and associated disorders. *Curr Opin Rheumatol* 1993; 5: 719-24.
- Miranda AD, Donovan LA, Schuster LL, et al. Malignant hyperthermia. *Am J Crit Care* 1997; 6: 368-76.
- Ording H, et al. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group. Results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group. *Acta Anaesthesiol Scand* 1997; 41: 955-66.
- Denborough M. Malignant hyperthermia. *Lancet* 1998; 352: 1131-6.
- Morrison AG, Serpell MG. Malignant hyperthermia during prolonged surgery for tumor resection. *Eur J Anaesthesiol* 1998; 15: 114-7.
- Chastonay P, Bracco D, Freymond D, Ravussin P. L'hyperthermie maligne. *Rev Med Suisse Rom* 1999; 119, 191-202.
- Denborough M. Malignant hyperthermia. *Lancet* 1998; 3: 352:1131-6.
- Ali SZ, Taguchi A, Rosenberg H. Malignant hyperthermia. *Res Clin Anaesthesiol* 2003; 17: 519-33.
- ### Brûlures
- Scheulen JJ, Munster AM. The Parkland formula in patient with burns and inhalation injury. *J Trauma* 1982; 22: 869-71.
- 4ème Conférence de consensus en réanimation et en médecine d'urgence. Choix des produits de remplissage vasculaire pour le traitement des hypovolémies chez l'adulte. *Rean Soins Intens Med Urg* 1989; 5: 295-304.
- Warden GD. Burn shock resuscitation. *World J Surg* 1992; 16: 16-23.
- Ryan CM, Schoenfeld DA, Thorpe WP, et al. Objective estimates of the probability of death from burn injuries. *N Engl J Med* 1998; 338: 362-6.
- Bloch A, Merz T. Hämodynamische Instabilität. *Schweiz Med Forum* 2015; 15: 592-599.
- ### Choc
- Vincent JL, De Backer D. Circulatory Shock. *N Engl J Med* 2013; 369: 1726-34.
- Roberts I, Shakur H, Coats T, et al. The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. *Health Technol Assess* 2013; 17: 1-79.
- ### Choc cardiogénique
- Scheidt S, Wilner G, Mueller H, et al. Intra-aortic balloon counterpulsation in cardiogenic shock: report of a co-operative clinical trial. *N Engl J Med* 1973; 288: 979-84.
- Goldberg RJ, Gore JM, Alpert JS, et al. Cardiogenic shock after acute myocardial infarction: incidence and mortality from a community-wide perspective, 1975 to 1988. *N Engl J Med* 1991; 325: 1117-22.
- Califf RM, Bengtson JR. Cardiogenic shock. *N Engl J Med* 1994; 330: 1724-30.
- Follath F, Cleland J, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. *Lancet* 2002; 360: 196-202.
- Mebazaa A, Nieminen MS, Packer M, et al - SURVIVE Investigators. Levosimendan vs dobutamine for patients with acute decompensated heart failure: The SURVIVE Randomized Trial. *JAMA* 2007; 297: 1883-1891.
- Bloch A, Merz T. Hämodynamische Instabilität. *Schweiz Med Forum* 2015; 15: 592-599.
- ### Choc anaphylactique
- Valentine MD. Insect venom allergy: Diagnosis and treatment. *J Allergy Clin Immunol* 1984; 73: 299-304.
- Bochner BS, Lichtenstein LM. Anaphylaxis. *N Engl J Med* 1991; 324: 1785-90.
- Muller U, Mosbech H, Blaauw P, et al. Emergency treatment of allergic reactions to Hymenoptera stings. *Clin Exp Allergy* 1991; 21: 281-8.

- Atkinson TP, Kaliner MA. Anaphylaxis. *Med Clin North Am* 1992; 76: 841-55.
- Muller U. Adrenaline for emergency kits; EAACI position paper. *Allergy* 1995; 50: 783-7.
- Nicklas R, Bernstein IL, Li JT, et al. The diagnosis and management of anaphylaxis. *J Allerg Clin Immunol* 1998; 101(Suppl.): S465-528.
- Project Team of the Resuscitation Council (UK). The emergency treatment of anaphylactic reactions. *J Accid Emerg Med* 1999; 16: 243-7.
- Sepsis - choc septique**
- Davis JP, Chesney PJ, Want PJ, et al. Toxic-shock syndrome. *N Engl J Med* 1980; 303: 1429-35.
- The ACCP/SCCM Consensus Conference Committee: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. *Crit Care Med* 1992; 20: 864-74. Also published in: *Chest* 1992; 101: 1644-55.
- Rangel-Fausto MS, Pittet D, et al. The natural history of the systemic inflammatory response syndrome. *JAMA* 1995; 273:117-23.
- Vincent JL, Moreno R, Takala J, et al. Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. *Intensive Care Med* 1996; 22: 707-710.
- Vincent JL, de Mendonça A, Cantraine F, et al. Working Group on "Sepsis-Related Problems" of the European Society of Intensive Care Medicine. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. *Crit Care Med* 1998; 26: 1793-1800.
- Argenziano M, Choudhri AF, Oz MC, et al. A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. *Circulation* 1997; 96 (Suppl): II-286-90.
- Case definitions for infectious conditions under public health surveillance. *Morb Mortal Wkly Rep* 1997; 46: 39.
- Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. *Circulation* 1997; 95: 1122-5.
- Zanetti G, Baumgartner JD, Glauser MP. Sepsis and septic shock. *Schweiz Med Wochenschr* 1997; 127: 489-99.
- Practice parameters for hemodynamic support of sepsis in adult patients in sepsis. Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine. *Crit Care Med* 1999; 27: 639-60.
- Abraham E, Matthay MA, Dinarello CA, et al. Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: time for a reevaluation. *Crit Care Med* 2000; 28: 232-5.
- Wheeler AP, Bernard G. Treating patients with severe sepsis. *N Engl J Med* 1999; 340:207-14.
- Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. *N Engl J Med* 2001; 344: 699-709. Editorial: 2001; 344: 759-62.
- Werdan K. Intravenous immunoglobulin for prophylaxis and therapy of sepsis. *Curr Opin Crit Care* 2001; 7: 354-61.
- Tsuneyoshi I, Yamada H, Kakihana Y, et al. Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. *Crit Care Med* 2001; 29: 487-93.
- Vincent JL. Hemodynamic support in septic shock. *Intensive Care Med* 2001; 27 Suppl. 1: S80-S92.
- Matthy MA. Severe sepsis - a new treatment with both anticoagulant and antiinflammatory properties. *N Engl J Med* 2001; 344: 759-62.
- Alejandria MM, Lansang MA, Dans LF, et al. Intravenous immunoglobulin for treating sepsis and septic shock. *Cochrane Database Syst Rev* 2002; 1: CD001090.
- Annané D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. *JAMA* 2002; 288: 862-71.
- Patel BM, Chittock DR, Russel JA, et al. Beneficial effects of short-term vasopressin infusion during severe septic shock. *Anesthesiology* 2002; 96: 576-82.
- Vincent JL, de Carvalho FB, De Backer D. Management of septic shock. *Ann Med* 2002; 34: 606-13.
- Vincent JL, Sun Q, Dubois MJ. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. *Clin Infect Dis* 2002; 34: 1084-93.
- Dhainaut JF, Laterre PF, Janes JM, et al. Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from PROWESS trial. *Crit Care* 2003; 24 april [epub ahead of print]
- Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. *N Engl J Med* 2003; 348: 138-50.
- Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definition conference. *Intensive Care Med* 2003; 29: 530-8; also published in: *Crit Care Med* 2003; 31: 1250-6.
- Vincent JL, Angus DC, Artigas A, et al. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. *Crit Care Med* 2003; 31: 834-40.
- Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definition Conference. *Crit Care Med* 2003; 31: 1250-6.
- Dhainaut JF, Laterre PF, Janes JM, et al. Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from PROWESS trial. *Crit Care* 2003; 29: 894-903.
- Dellinger RP, Carlet JM, Masur H, et al. Surviving sepsis guidelines for management of sepsis and septic shock. *Crit Care Med* 2004; 32: 858-73.
- Gaieski DF, Mikkelsen ME, Band RA et al. Impact of time to antibiotics on survival in patients with

- severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med 2010; 38: 1045-53.
- Dellinger R, Moreno R, Aitken L et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41: 580-637.
- Seymour CW, Liu VX, Iwashyna TJ et al (2016) Assessment of clinical criteria for sepsis: for the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315:762-74.
- Singer M, Deutschman CF, Seymour CW et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315: 801-810.
doi:10.1001/jama.2016.0287.
- Rhodes A, Evans LE, Alhazzani W et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med 2017; 43: 304-7.
- Delir — Delir auf der IPS**
- Samaras N, Chevally Th, Samaras D, Gold. Older Patients in the Emergency Department: A Review. Annals of Emergency Medicine 2010; 56:261-9.
- Siegemund M, Massarotto P, Reuthebuch P et al. Postoperatives Delirium: Pathophysiologie und Diagnose. Schweiz Med Forum 2011;11: 354-357.
- Toxic shock syndrom**
- Centers for Disease Control and Prevention. Case definitions for infectious conditions under public health surveillance. MMWR Recomm Rep 1997; 46: 1-55.
- Oliveira DC, Tomasz A, de Lencastre H. Secrets of success of a human pathogen: molecular evolution of pandemic clones of methicillin-resistant Staphylococcus aureus. Lancet Infect Dis 2002; 2: 180-9.
- Coma**
- Höjer J. Diagnostic utility of flumazenil in coma with suspected poisoning: a double blind, randomized controlled study. Br Med J 1990; 301: 1308-11.
- Geller R. Risks and benefits of therapy with flumazenil in mixed drug intoxications. Eur Neurol 1991; 31: 241-50.
- Bates D. The management of medical coma. J Neurol Neurosurg Psychiatry 1993; 56: 589-98.
- Enrico JF. Le coma non traumatique en pratique extrahospitalière. Schweizerische Rundschau für Medizin 1995; 45: 1321-30.
- Hoffman RS. The poisoned patient with altered consciousness. JAMA 1995; 274: 562-9.
- Wijdicks EFM, Bamler WR et al. Validation of a New Coma Scale: The FOUR Score Ann Neurol 2005; 58: 585-93.
- GLASGOW-Score**
- Teasdale G, Jennett B. Assessment of coma impaired consciousness. Lancet 1974; 2: 83.
- Maladies de haute altitude**
- Johnson TS, Rock PB. Acute mountain sickness. N Engl J Med 1988; 319: 841-5.
- Levine BD, Yoshimura K, Kobayashi T, et al. Dexamethasone in the treatment of acute mountain sickness. N Engl J Med 1989; 321: 1707-13.
- Oelz O, Maggiorini M, Ritter M, et al. Nifedipine for high altitude pulmonary edema. Lancet 1989; 2: 1241-4.
- Bärtsch P, Maggiorini M, Ritter M, et al. Prevention of high-altitude pulmonary edema by nifedipine. N Engl J Med 1991; 325: 1284-9.
- Sutton JR, Coates G, Huston CS (eds). In: The Lake Louise Consensus on the definition and quantification of altitude illness. Queen City Printers, Burlington, Vermont, 1992.
- Cook S, Duplain H, Egli M, Sartori Claudio, et al. Edème pulmonaire de haute altitude: physiopathologie et traitement. Med Hyg 2000; 58: 1520-3.
- Hackett PH, Roach RC. High-altitude illness. N Engl J Med 2001; 345: 107-14.
- Sartori C, Allemann Y, Duplain H, et al. Salmeterol for the prevention of high-altitude pulmonary edema. N Engl J Med 2002; 346: 1631-6.
- Egli M, Sartori C, Scherrer U. Les maladies aiguës liées à la haute altitude. Recommandations pour leur prise en charge et avancées expérimentales récentes. Med Hyg 2003; 61: 1007-13.
- Maggiorini M, Brunner-La Rocca HP, Peth S, et al. Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: a randomized trial. Ann Intern Med 2006; 145:497-506.
- Rhabdomyolyse**
- Grossman RA, Hamilton RW, Morse BM, et al. Nontraumatic rhabdomyolysis and acute renal failure. N Engl J Med 1974; 291: 807-11.
- Schiff HB, MacSearraigh ET, Kallmeier JC. Myoglobinuria, rhabdomyolysis and marathon running. Q J Med 1978; 47: 463-72.
- Lonka L, Pedersen RS. Fatal rhabdomyolysis in marathon runner (letter). Lancet 1987; 11: 857-8.
- Eiser AR, Neff MS, Slifkin RF. Acute myoglobinuric renal failure. A consequence of the neuroleptic malignant syndrome. Arch Intern Med 1982; 142: 601-3.
- Knochel JP. Rhabdomyolysis and myoglobinuria. Annu Rev Med 1982; 33: 435-43.
- Curry SC, Chang D, Connor D. Drug- and toxin-induced rhabdomyolysis. Ann Emerg Med 1989; 18: 1068-84.
- Naschitz JE, Yeshurun D, Shagrawi I. Rhabdomyolysis in pneumococcal sepsis. Am J Med 1989; 87: 479-80.
- Better OS, Stein JH. Early management of shock and prophylaxis of acute renal failure in traumatic rhabdomyolysis. N Engl J Med 1990; 322: 825-9.
- Shemlin D, Cohn PS, Zipin SB. Pheochromocytoma presenting as rhabdomyolysis and acute myoglobinuric renal failure. Arch Intern Med 1990; 150: 2384-5.

Tonin P, Lewis P, Servidei S, et al. Metabolic causes of myoglobinuria. Ann Neurol 1990; 27: 181-5.

Singhal PC, Kumar A, Desroches L, et al. Prevalence and predictors of rhabdomyolysis in patients with hypophosphatemia. Am J Med 1992; 92: 458-64.

Barrett SA, Mourani S, Villareal CA, et al. Rhabdomyolysis associated with status asthmaticus. Crit Care Med 1993; 21: 151-3.

Knochel JP, Moore GE. Rhabdomyolysis in malaria (letter). N Engl J Med 1993; 329: 1206-7.

Pesik MT, Otten EJ. Severe rhabdomyolysis following a viral illness: a case report and review of the literature. J Emerg Med 1996; 14: 425-8.

Vanholder R, Sever MS, Erek E, et al. Acute renal failure related to the crush syndrome: towards an era of seismo-nephrology? Nephrol Dial Transplant 2000; 15: 1517-21.

Bedry R, Baudrimont I, Deffieux G, et al. Wild-mushroom intoxication as a cause of rhabdomyolysis. N Engl J Med 2001; 345: 798-802.

Bouchama A, Knochel JP. Heat stroke. N Engl J Med 2002; 346: 1978-88.

Syndrome malin des neuroleptiques

Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985; 142: 1137-45.

Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007; 164: 870-6.

Électrisation

Dixon GF. The evaluation and management of electrical injuries. Crit Care Med 1983; 11: 384-7.

Carleton SC. Cardiac problems associated with electrical injury. Cardiol Clin 1995; 13: 263-6.

Hypothermie

Danzel F. Accidental hypothermia. N Engl J Med 1994; 331: 1756-60.

Handrigan MT, Wright RO, Becker BM, et al. Factors and methodology in achieving ideal delivery very temperatures for intravenous and lavage fluid in hypothermia. Am J Emerg Med 1997; 15: 350-3.

Lazar HL. The treatment of hypothermia. N Engl J Med 1997; 337: 1545-7.

Walpot BH, Walpot-Aslan BN, Mattle HP, et al. Outcome of survivors of accidental deep hypothermia and circulatory arrest treated with extracorporeal blood warming. N Engl J Med 1997; 337: 1500-5.

Goodenberger D. Cold induced illness. In: Ahya SN, et al. (eds.). The Washington Manual of medical therapeutics. Lippincott Williams & Wilkins, 2001: 541-3.

Murray P, Hall J. Hypothermia. In: Hall J, et al. (eds.). Principles of Critical Care. McGraw-Hill, 1998: p. 1645-55.

Maladie du caisson -- Decompression

Schröder S, Lier H, Wiese S- Der Tauchunfall. Notfallmedizinische Versorgung des schweren Tauchunfalls. In: Der Anästhesist. Springer Medizin Verlag 2004.

Readmission hospitalière

Donzé J, Aujesky D, Williams D, et al. Potentially avoidable 30-day hospital readmissions in medical patients: derivation and validation of a prediction model. JAMA Intern Med 2013; 173: 632-8.

CARDIOLOGIE - Kardiologie

Aortenaneurysma - Aortendissektion

Elliott WJ. Clinical features in the management of selected hypertensive emergencies. Prog Cardiovasc Dis 2006; 48: 316-25.

Suzuki T, Distante A, Zizza A, et al. Diagnosis of acute aortic dissection by D-dimer: the International Registry of Acute Aortic Dissection Substudy on Biomarkers (IRAD-Bio) experience. Circulation 2009; 119: 2702-7.

Ranasinghe AM, Bonser RS. Biomarkers in acute aortic dissection and other aortic syndromes. J Am Coll Cardiol. 2010; 56: 1535-41.

Rogers AM, Hermann LK, Boher AM, et al. Sensitivity of the Aortic Dissection Detection Risk Score, a Novel Guideline-Based Tool for Identification of Acute Aortic Dissection at Initial Presentation Results From the International Registry of Acute Aortic Dissection. Circulation 2011; 123: 2213.

Myokardinfarkt → Akutes Koronarsyndrom

Syndrome coronarien aigu et chronique - Maladie coronarienne - KHK STEMI - NSTEMI - Angor instable

The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI). A randomised, placebo-controlled international trial. Eur Heart 1985; 6: 199-226.

Yusuf S, Peto R, Lewis J, Collins R, et al. Beta blockade during and after myocardial infarction: an overview of the randomised trials. Prog Cardiovasc Dis 1985; 27: 335-71.

ISIS-1 Collaborative Group. Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction. Lancet 1986; ii: 57-66.

Findings from aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1988; 318: 262-4.

ISIS-2 (second International Study of Infarct Survival). Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-60.

The Steering Committee of the Physicians' Health Study Research Group. Preliminary report. Findings from the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1988; 318: 262-4.

Braunwald E. Unstable angina: a classification. Circulation 1989; 80: 410-4.

ACC/AHA Guidelines for early management of patients with acute myocardial infarction. Circulation 1990; 82: 664-707.

GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no he-

- parin among 12490 patients with acute myocardial infarction. *Lancet* 1990; 336: 65-71.
- ISIS-3:** A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41299 cases of suspected acute myocardial infarction. *Lancet* 1992; 339: 753-70.
- Scandinavian Simvastatin Survival Study Group.** Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet* 1994; 344: 1383-89.
- Gurfinkel EP, Manos EJ, Mejail RI, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. *J Am Coll Cardiol* 1995; 26: 313-8.
- White HD et al. (for the GUSTO I Investigators). Age and outcome with contemporary thrombolytic therapy: results from the GUSTO I Trial. *Circulation* 1996; 94: 1826-33.
- Braunwald E, (ed.). *Heart disease: a textbook of cardiovascular medicine*. Philadelphia W.B. Saunders Company, 1997.
- Cohen M, Demers Ch, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. *N Engl J Med* 1997; 337: 447-52.
- Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). (Abstr.) *Am J Cardiol* 1997; 79: 115-19.
- The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. *N Engl J Med* 1998; 339: 436-43.
- The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limiting by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina pectoris and non-Q-wave myocardial infarction. *N Engl J Med* 1998; 338: 1488-97. [Erratum: *N Engl J Med* 1998; 339: 414].
- The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. *N Engl J Med* 1998; 338: 1498-505.
- ASSENT-2 Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. *Lancet* 1999; 354: 716-22.
- Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 1999; 34: 890-911.
- Théroux P, Fuster V. Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction. *Circulation* 1998; 97: 1195-1206.
- Anteman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischaemic events in unstable angina/non-Q-wave myocardial infarction: results of the thrombolytic infarction (TIMI) 11B trial. *Circulation* 1999; 100: 1602-8.
- Fragmin and fast revascularisation during instability in coronary artery disease investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. *Lancet* 1999; 354: 708-15.
- FRAXIS study group. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q-wave myocardial infarction. *Eur Heart J* 1999; 20: 1553-62.
- The ASSENT-2 Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. *Lancet* 1999; 354: 716-22.
- Zijlstra F, Hoornje JCA, de Boer MJ, et al. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. *N Engl J Med* 1999; 341: 1413-9.
- Gan SC, Beaver SK, Houck PM, et al. Treatment of acute myocardial infarction and 30-day mortality among women and men. *N Engl J Med* 2000; 343: 8-15.
- Hamm CW, Braunwald E. A classification of unstable angina revisited. *Circulation* 2000; 102: 118-22.
- Monrad ES. Role of low-molecular-weight heparins in the management of patients with unstable angina pectoris and non-Q-wave acute myocardial infarction. *Am J Cardiol* 2000; 85: 2C-9C.
- Scull GS, Martin JS, Weaver WD, et al. Early angiography versus conservative treatment in patients with non-ST elevation acute myocardial infarction: MITI Investigators. Myocardial Infarction Triage and Intervention. *J Am Coll Cardiol* 2000; 35: 895-902.
- Yeghiazarians Y, Brausestein JB, Askari A, Stone P. Unstable Angina pectoris. *N Engl J Med* 2000; 342: 101-14.
- Yusuf S, et al. Effects of an angiotensin-converting-enzyme inhibitor, Ramipril, on death from cardiovascular events in high-risk patients. *N Engl J Med* 2000; 342: 145-53.
- Hamm C, Bertrand M, Braunwald E. Acute coronary syndrome without ST elevation: implementation of new guidelines. *Lancet* 2001; 358: 1533-8.
- Ohman EM, Harrington RA, Cannon CP, et al. Intravenous thrombolysis in acute myocardial infarction. *Chest* 2001; 119 (Suppl): 253S-277S.
- Schwartz GG, Oliver MF, Ezekowitz MD, et al. Effects of Atorvastatin on early ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled study. *JAMA*; 2001;

- Simoons ML. Effet of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. *Lancet* 2001; 357: 1915-24.
- The ASSENT-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab or unfractionated heparin: the ASSENT-3 randomized trial in acute myocardial infarction. *Lancet* 2001; 358: 605-13.
- The Clopidogrel in unstable angina to prevent recurrent events trial investigators (CURE). Effects of Clopidogrel in addition to Aspirin in patients with acute coronary syndromes without ST-segment elevation. *N Engl J Med* 2001; 345: 494-502.
- Aviles RJ, Askari AT, Lindahl B, et al. Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. *N Engl J Med* 2002; 346: 2047-52.
- Fox KAA, Goodman SG, Klein W, et al. Management of acute coronary syndromes. Variations on practice and outcome. *Eur Heart J* 2002; 23: 1177-89.
- Bertrand ME, Simoons ML, Fox KAA, et al. Management of acute coronary syndromes in patients presenting without persistent ST segment elevation. The Task Force on the management of acute coronary syndromes of the European Society of Cardiology. *Eur Heart J* 2002; 23: 1809-40.
- Braunwald E, Antman EM, Beasley JW et al. ACC/AHA 2002 Guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002. *Circulation* 2002; 106: 1893-900 (<http://www.acc.org/clinical/guidelines/unstable/unstable.pdf>).
- Budaj A, Yusuf S, Mehta SR, et al. Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. *Circulation* 2002; 106: 1622-6.
- Steinhubel SR, Berger PB, Mann JF for the CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. A randomized controlled trial. *JAMA* 2002; 288: 2411-20.
- Andersen HR, Nielsen TT, Rasmussen K, et al. A comparison of coronary angioplastie with fibrinolytic therapy in acute myocardial infarction. *N Engl J Med* 2003; 349: 733-42.
- Brennan M-L, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. *N Engl J Med* 2003; 349: 1595-604.
- Fox K. The EUROPA trial. *Lancet* 2003; 362: 1936-7.
- Kinlay S, Schwartz GG, Olsson AG, et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. *Circulation* 2003; 108: 1560-6.
- Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, Captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. *N Engl J Med* 2003; 349: 1893-906.
- Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. *N Engl J Med* 2003; 348: 1309-1321.
- Van de Werf F, Ardissino D, Betriu A, et al. The Task Force of Management of acute myocardial infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the management of acute myocardial infarction of the European Society of Cardiology. *Eur Heart J* 2003; 24: 28-66.
- Cannon Ch, Braunwald E, McCabe C, et al. Comparison of moderate lipid lowering with statins after acute coronary syndromes. *N Engl J Med* 2004; 350: 1495-504.
- Keller KB, Lemberg L. Prinzmetal's angina. *Am J Crit Care* 2004; 13: 350-4.
- Jestra JA, Kromhout D, van der Schouw YT, et al. Effect size estimates of lifestyle and dietary changes on all-cause mortality in coronary artery disease patients: a systematic review. *Circulation* 2005; 112: 924-34.
- Nallamothu BK, Bradley EH, Krumholz HM. Time to Treatment in Primary Percutaneous Coronary Intervention. *N Engl J Med* 2007; 357: 1631-1638.
- The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. *Eur Heart J* 2008; 29, 2909-45.
- Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. *N Engl J Med* 2009; 361: 1045-57.
- Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J* 2011; 32: 2999-3054.
- Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. *N Engl J Med* 2011; 364: 11-21.
- Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). *Eur Heart J* 2012; 33: 2569-619.
- Bonaca MP, Bhatt DL, Braunwald E, et al. Design and rationale for the prevention of cardiovascular events in patients with prior heart attack using ticagrelor compared to placebo on a background of aspirin-thrombolysis in myocardial infarction 54 (PEGASUS-TIMI 54) trial. *Am*

- Heart J 2014; 167: 437-44.e5.
- Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014; 371: 2155-66.
- Windecker S, Kohl P, Alfonso F, et al. 2014 ESC/EACTS guidelines on myocardial revascularization : The task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35:2541-619.
- Bonaca MP, DL Bhatt, Cohen M, et al. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction N Engl J Med 2015; 372: 1791-800.
- Iglesias JF, Monney P, Pascale P et al. Cardiologie - nouveautés en médecine 2014. Rev Med Suisse 2015; 11: 30-43.
- Koskinas K, Räber L, Zanchin T et al. Clinical impact of gastrointestinal bleeding in patients undergoing percutaneous coronary interventions. Circ Cardiovasc Interv 2015;8:e002053.
- Roffi M, Patrono C, Collet J-P et al. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC) 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2016; 37: 267-315.
- Degrauwe S, Iglesias JF. Double antiagrégation plaquettaire pour le traitement et la prévention secondaire de la maladie coronarienne Indications, modalités et durées de traitement. Rev Med Suisse 2016 ; 12: 1022-34.
- 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39: 119-177.
- 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2020; 00:1-79.
- Syndrome coronarien chronique (CCS)**
- Foldyna B, Udelson JE, Karady J, et al. Pretest probability for patients with suspected obstructive coronary artery disease: re-evaluating Diamond-Forrester for the contemporary era and clinical implications: insights from the PROMISE trial. Eur Heart J Cardiovasc Imaging 2018;20:574-581.
- Reeh J, Therming CB, Heitmann M, et al. Prediction of obstructive coronary artery disease and prognosis in patients with suspected stable angina. Eur Heart J 2018;40:1426-1435.
- Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018; 39: 213-60.
- Juarez-Orozco LE, Saraste A, Capodanno D, Prescott E, Ballo H, Bax JJ, Wijns W, Knuuti J: Impact of a decreasing pretest probability on the performance of diagnostic tests for coronary artery disease. Eur Heart J Cardiovasc Imaging 2019; 20: 1198-1207. doi: 10.1093/ehjci/jez054
- ÉCG – EKG Elektrokardiogramm**
- Kossman CE. The normal electrocardiogram. Circulation 1953; 8: 929.
- Hiss RG, Lamb LE, Allen MF. Electrocardiographic findings in 67'375 asymptomatic patients. Am J Cardiol 1960; 6: 200.
- Wasserburger RH, Alt WJ, Lloyd CJ. The normal RS-T segment elevation variant. Am J Cardiol 1961;8:184.
- Warner RA. Recent advances in the diagnosis of myocardial infarction. Cardiol Clin 1987; 5: 381-92.
- Wellens HJJ, Conover MB, (eds.). The ECG in emergency decision making. Philadelphia Saunders 1992.
- Touboul P, Lefkiefre J, Fontaine F, et al. (eds.). In: Les troubles du rythme cardiaque. Editions Maloine 1993.
- Chou T. (ed.). In: Electrocardiography in Clinical Practice. W.B. Philadelphia Saunders Company, 1996.
- Scarbosa EB, Pinski SL, Barbagelata A, et al. Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle-branch block. GUSTO-1 Investigators. N Engl J Med 1996; 334: 481-7.
- Sgarbossa EB. Value of the ECG in suspected acute myocardial infarction with left bundle branch block. J Electrocardiol 2000; 33 Suppl: 87-92.
- Sztajzel J, Urban P. Early and late Q wave regression in the setting of acute myocardial infarction. Heart 2000; 83: 708-10.
- Lewis GD, Holmes CH, Holmvang G et al. Q 48-year-old man with chest pain followed by cardiac arrest. N Engl J Med 2007; 356; 1153-62.
- Smith SW, et al. Diagnosis of ST-Elevation Myocardial Infarction in the Presence of Left Bundle Branch Block With the ST-Elevation to S-Wave Ratio in a Modified Sgarbossa Rule. Ann Emerg Med 2012; 60: 766-76.
- Drezner JA, Fischbach P, Froelicher V et al. Normal electrocardiographic findings: recognising physiological adaptations in athletes. Br J Sports Med 2013; 47: 125-136.
- Meyers HP et al. Validation of the Modified Sgarbossa Criteria for Acute Coronary Occlusion in the Setting of Left Bundle Branch Block: A Re-

- prospective Case-Control Study. Am Heart J 2015; 170: 1255-64.
- Schindler MJ, Schmied Ch. EKG-Interpretation bei Sportlern – die «Seattle-Kriterien». Méd Cardiovasc 2016; 19: 72-76.
- Early repolarisation syndrome**
Syndrome de repolarisation précoce
- Haissaguerre M, Derval N, Sacher F, et al. Sudden cardiac arrest associated with early repolarization. N Engl J Med 2008; 358: 2016-23.
- Haissaguerre M, Sacher F, Nogami A, et al. Characteristics of recurrent ventricular fibrillation associated with inferolateral early repolarization role of drug therapy. J Am Coll Cardiol 2009; 53: 612-9.
- Antzelevitch C, Yan GX. J wave syndromes. Heart Rhythm 2010; 7: 549-58.
- Tikkanen JT, Junttila MJ, Anttonen O, et al. Early repolarization : Electrocardiographic phenotypes associated with favorable long-term outcome. Circulation 2011; 123: 2666-73.
- Burri H. Repolarisation précoce: quand s'inquiéter? Rev Med Suisse 2015; 11: 553-6.
- Echokardiographie**
- Buck T, Breithardt OA, Faber L et al. Manual zur Indikation und Durchführung der Echokardiographie. Clin Res Cardiol 2009; Suppl 4:3-51.
- Hagendorff A, Fehske W, Flachskampf F.A. et al. Manual zur Indikation und Durchführung der Echokardiographie – Update 2020 der Deutschen Gesellschaft für Kardiologie. Der Kardiologe 2020; 14: 396-431.
- Tachycardie supraventriculaire - QRS fins**
Supraventrikuläre Tachykardien
- Orejarena LA, Vidaillet H, DeStefano F, et al. Paroxysmal Supraventricular Tachycardia in the General Population. Journal of the American College of Cardiology 1998; 31: 150-7.
- Vohra J. Cardiac Arrhythmia: Mechanisms, Diagnosis and Management, Second Ed.: Philip J. Podrid, Peter R. Kowey (Eds.), Lippincott Williams and Wilkins Publication; 2004.
- Link MS. Clinical practice. Evaluation and initial treatment of supraventricular tachycardia. NEJM 2012; 367: 1438-48.
- Bibas L, Levi M and Essebag V. Diagnosis and management of supraventricular tachycardias. CMAJ 2016; 188:E466-E473.
- Page RL, Jugal JA, Caldwell MA, et al. 3rd, Field ME, Goldberger ZD, Hammill SC, Indik JH, Lindsay BD, Olshansky B, Russo AM, Shen WK, Tracy CM and Al-Khatib SM. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2016; 67: 1575-623.
- Lam A, Roten L. Supraventrikuläre Tachykardien. Schweiz Med Forum 2018; 18: 1028-36.
- Chen YL, Lin YS, Wang HT et al. Clinical outcomes of solitary atrial flutter patients using anti-coagulation therapy: a national cohort study. Europeac 2019; 21: 313-21.
- Brugada J, Katriotis DG, Arbelo E et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). Eur Heart J 2020; 41: 655-720.
- Fibrillation auriculaire - Vorhofflimmern**
- Dunn M, Alexander J, de Silva R, Hildner F. Anti-thrombotic therapy in atrial fibrillation. Chest 1989; 95 (Suppl.): 118S-127S.
- Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK Study. Lancet 1989; 1: 175-9.
- Weinberg DM, Mancini J. Anticoagulation for cardioversion of atrial fibrillation. Am J Cardiol 1989; 63: 745-6.
- The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505-11.
- Laupacis A, Albers G, Dunn M, et al. Antithrombotic therapy in atrial fibrillation. Chest 1992; 102 (Suppl. 4): 426S-433S.
- Pritchett ELC. Management of atrial fibrillation. N Engl J Med 1992; 326: 1264-71.
- The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation. In: clinical features of patients at risk. Ann Intern Med 1992; 116: 1-5.
- Gage BF, Cardinali AB, Albers GW, et al. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA 1995; 274: 1839-45.
- Prystowsky EN, Benson Jr DW, Fuster V, et al. Management of patients with atrial fibrillation. Circulation 1996; 93: 1262-77.
- Van Gelder IC, Crijns HJGM, Tielemans RG, et al. Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation. Arch Intern Med 1996; 156: 2585-92.
- Kaufmann W, (ed.). Internistische Differenzialdiagnostik. Entscheidungsprozesse in Flussdiagrammen. Schattauer, 4. Auflage 1997.
- Weigner MJ, Caulfield TA, Danias PG, et al. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med 1997; 126: 615-20.
- Zimmermann M. Les traitements de la fibrillation auriculaire. Med Hyg 1997; 55: 445-9.
- Benjamin EJ, Wolf PA, D'Agostino RB et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98: 946-52.
- Hart RG, Benavente O, McBride R et al. Anti-thrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131: 492-501.
- Steeds RP, Birchall AS, Smith N, et al. An open label, randomised, crossover study comparing sotalol and atenolol in the treatment of symptomatic paroxysmal atrial fibrillation. Heart 1999;

- 82: 170-5.
- Hart RG, Pearce LA, Rothbart RM et al. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. *Stroke Prevention in Atrial Fibrillation Investigators*. *J Am Coll Cardiol* 2000; 35: 183-7.
- Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. *N Engl J Med* 2000; 342: 913-20.
- Singh S, Zoble RG, Yellen L, et al. Efficacy and safety on oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. *Circulation* 2000; 102: 2385-90.
- Fuster V, Rydén LE, Asinger RW, et al. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. *Stroke Prevention in Atrial Fibrillation Investigators*. *J Am Coll Cardiol* 2000; 35: 183-7.
- ACC/AHA/ESC Guidelines for the management of patients with atrial fibrillation: executive summary. *Eur Heart J* 2001; 22: 1852-923.
- Falk RH. Atrial fibrillation. *N Engl J Med* 2001; 344: 1067-87.
- Gage BF, Waterman AD, Shannon W et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. *JAMA* 2001; 285: 2864-70.
- Klein AL, Grimm RA, Murray RD et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. *N Engl J Med* 2001; 344: 1411-20.
- The assessment of the safety and efficacy of a new thrombolytic regimen (ASSENT)-3 investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. *Lancet* 2001; 358: 605-13.
- Stewart S, Hart CL, Hole DJ et al. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. *Am J Med* 2002; 113: 359-64.
- Wyse DG, Waldo AL, DiMarco JP et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. *N Engl J Med* 2002; 347: 1825-33.
- Levy S, Camm AJ, Saksena S et al. International consensus on nomenclature and classification of atrial fibrillation: A collaborative project of the Working Group on Arrhythmias and the Working Group of Cardiac Pacing of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. *J Cardiovasc Electrophysiol* 2003; 14: 443-5.
- Steinberg JS, Sadaniantz A, Kron J, et al. Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. *Circulation* 2004; 109: 1973-80.
- De Denus S, et al. Rate vs. Rhythm Control in Patients with Atrial Fibrillation. *Arch Intern Med* 2005; 165; 258-262.
- Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus Sotalol for Atrial Fibrillation. *N Engl J Med* 2005; 352: 1861-72.
- Fuster V et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: Executive Summary. *Circulation* 2006; 114; 700-52.
- Stell IG, Macle L, CCS Atrial Fibrillation Guidelines Committee. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: management of recent-onset atrial fibrillation and flutter in the emergency department. *Can J Cardiol* 2011; 27: 38-46.
- Camm AJ, Lip GY, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. *Eur Heart J* 2012;33:2719.
- January CT, Wann LS, Alpert JS et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. *Circulation* 2014; 130: 2071-104..
- Meier B, Blaauw Y, Khattab AA et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion. *Europace* 2014; 16: 1397-416.
- Verma A, Cairns JA, Mitchell LB et al. 2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. *Can J Cardiol* 2014;30:1114-30.
- Authors/Task Force Members: Ponikowski P (Chairperson), Voors AA. (Co-Chairperson) Anker St.D. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur J Heart Failure* (2016) doi:10.1002/ejhf.592
- Kirchhof P, Benussi S et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J*. 2016. doi: 10.1093/eurheartj/ehw210. Forthcoming
- Packer DL, Mark DB, Robb RA, et al. Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial: Study Rationale and Design. *Am Heart J* 2018; 199: 192-199.
- Kirchhof P, Camm AJ, Goette A et al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. *NEJM* 2020; 383:1305-1316

Cardiomyopathie

- Towbin JA, Lorts A, Jefferies JL. Left ventricular non-compaction cardiomyopathy. *Lancet* 2015; 386: 813-25.
- Corrado D, Link MS, Calkins H. Arrhythmogenic Right Ventricular Cardiomyopathy. *N Engl J Med* 2017; 376: 61-72.
- Kato K, Lyon AR, Ghadri JR, Templin C. Takotsubo syndrome: aetiology, presentation and treatment. *Heart* 2017; 103: 1461-9.

- Veselka J, Anavekar NS, Charron Ph. Hypertrophic obstructive cardiomyopathy. Lancet 2017; 389: 1253-67.
- Weintraub RG, Christopher Semsarian C, Macdonald P. Dilated cardiomyopathy. Lancet 2017; 390: 400-14.
- Pereira NL, Grogan M, Dec GW. Spectrum of Restrictive and Infiltrative Cardiomyopathies: Part 1. J Am Coll Cardiol 2018; 71: 1130-48.
- Pereira NL, Grogan M, Dec GW. Spectrum of Restrictive and Infiltrative Cardiomyopathies: Part 2 of a 2-Part Series. J Am Coll Cardiol 2018; 71: 1149-66.
- Marcus FI, McKenna WJ, Sherrill D et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria. Circulation 2010; 31: 806-14.
- Ghadri JR, Wittstein IS, Prasad A et al. International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology. European Heart Journal 2018; 39: 2032-46.
- Syndrome du takotsubo**
- Stresskardiomyopathie**
- (cardiomyopathie de stress ou transient left ventricular apical ballooning)
- Haslett C et al. Davidson Médecine Interne, Principes et Pratique. Maloine Editions, 2004, 1267
- Miller TH, Kruse JE, Evaluation of syncope. Am Fam Physician. 2005; 72: 1492-500.
- Bybee KA et al. Systematic review: transient left ventricular apical ballooning: a syndrome that mimics ST-segment elevation myocardial infarction. Ann Intern Med 2004; 141: 858-65.
- Wittstein IS et al. Neurohumoral Features of Myocardial Stunning due to sudden emotional stress. N Engl J Med 2005; 352: 539-548.
- Akashi YJ et al. The clinical features of takotsubo cardiomyopathy. Q J Med 2003; 96: 563-573.
- Handschin R, Hess N, Rickenbacher P. Takotsubo-Kardiomyopathie: «transient left ventricular apical ballooning». Schweiz Med Forum 2004; 4: 147-148.
- Hurst RT, Askew JW, Reuss CS et al. Transient midventricular ballooning syndrome: a new variant. J Am Coll Cardiol. 2006; 48: 579-83.
- Templin C, Ghadri JR, Diekmann J et al. Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. NEJM 2015; 373: 929-38..
- Arrythmies**
- Dancy M, Camm AJ. Misdiagnosis of chronic recurrent ventricular tachycardia. Lancet 1985; 8450: 320-3.
- Stewart R, et al. Wide complex tachycardia: Misdiagnosis and outcome after emergency therapy. Ann Int Med 1986; 104: 766-71.
- Griffith MJ, Ward DE, Linker NJ, Camm AJ. Adenosine in the diagnosis of broad complex tachycardia. Lancet 1988; 8587: 672-75.
- Wellens HJJ, Brugada P. Treatment of cardiac arrhythmias: When, how and where? J Am Coll Cardiol 1989; 14: 1417-28.
- Adamec R, Conti F, Zimmermann M, et al. Les arythmies. In: Urgences Médicales. Restellini A, et al. (eds.). Editions Médecine et Hygiène, 1997, p: 104-33.
- Syndrome du QT long (LQTS)**
- Paavonen K, Swan H, Piippo K, Hokkanen L, Laitinen P, Viitasalo M, et al. Response of the QT interval to mental and physical stress in types LQT1 and LQT2 of the long QT syndrome. Heart 2001; 86: 39-44.
- Ackerman MJ, Khositseth A, Tester DJ, Hejlik JB, Shen W-K, Porter CJ. Epinephrine-Induced QT Interval Prolongation: A Gene-Specific Paradoxical Response in Congenital Long QT Syndrome. Mayo Clin Proc 2002; 77: 413-21.
- Pelliccia A, Fagard R, Bjørnstad H, Anastassakis A, Arbustini E, Assanelli D, et al. Recommendations for competitive sports participation in athletes with cardiovascular diseaseA consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart 2005; 26: 1422-45.
- BJ. Drew, MJ. Ackerman, M Funk, WB Gibler, P Kligfield, V Menon, et al. Prevention of Torsade de Pointes in Hospital Settings: A Scientific Statement From the American Heart Association and the American College of Cardiology Foundation. Journal of the American College of Cardiology 2010; 55:934-947.
- Viskin S, Postema PG, Bhuiyan ZA, Rosso R, Kalman JM, Vohra JK, et al. The Response of the QT Interval to the Brief Tachycardia Provoked by Standing A Bedside Test for Diagnosing Long QT Syndrome. J Am Coll Cardiol 2010; 55: 1955-61.
- Schwartz PJ, Crotti L, Insolia R. Long-QT Syndrome. Circ Arrhythmia Electrophysiol 2012; 5: 868-77.
- Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H, et al. HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies. Heart Rhythm. 2011; 8: 1308-39.
- Schwartz PJ, Crotti L. QTc Behavior During Exercise and Genetic Testing for the Long-QT Syndrome. Circulation 2011; 124: 2181-4.
- Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death Eur Heart J 2015; 36: 2793-867.
- Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Heart Rhythm 2018;15:e73-189.
- Ackerman MJ, Zipes DP, Kovacs RJ, Maron BJ, and of on and on and on in and of on Cardio-
logy A. Eligibility and Disqualification Recom-
mendations for Competitive Athletes With
Cardiovascular Abnormalities: Task Force 10:
The Cardiac Channelopathies. Circulation

2015;132:e326-9.

Mazzanti A, Maragna R, Vacanti G, Monteforte N, Bloise R, Marino M, et al. Interplay Between Genetic Substrate, QTc Duration, and Arrhythmia Risk in Patients With Long QT Syndrome. *J Am Coll Cardiol* 2018; 71: 1663-71.

Torsade de pointes (voir aussi LQTS)

Vukmir BB. Torsades de pointes: a review. *Am J Emerg Med* 1991; 9: 250-5.

Napolitano C, Priori SG, Schwartz PJ. Torsade de pointes. Mechanisms and management. *Drugs* 1994; 47: 51-65.

Roden DM. A practical approach to torsade de pointes. *Clin Cardiol* 1997; 20: 285-90.

Viskin S. Long QT syndromes and torsade de pointes. *Lancet* 1999; 354: 1625-33.

Delacretat E. Médicaments et long QT. *Forum Med Suisse* 2007; 7: 814-9.

Dissection aortique

De Bakey ME, Henly WS, Cooley DA, et al. Surgical management of dissecting aneurysms of the aorta. *J Thorac Cardiovasc Surg* 1965; 49: 130-49.

Daily PO, Trueblood HW, Stinson EB, et al. Management of acute aortic dissections. *Ann Thorac Surg* 1970; 10: 237-47.

Slater EE, DeSanctis RW. The clinical recognition of dissecting aortic aneurysm. *Am J Med* 1976; 60: 625-33.

Smith DC, Jang GC. Radiological diagnosis of aortic dissection. In: Doroghazi RM, Slater EE (eds.). *Aortic dissection*. New York: Mc Graw-Hill 1983; 71: 71-132.

Greenwood WR, Robinson MD. Painless dissection of the thoracic aorta. *Am J Emerg Med* 1986; 4: 330-3.

DeSanctis RW, Doroghazi RM, Austen WG, et al. Aortic dissection. *N Engl J Med* 1987; 317: 1060-7.

Erbel R, Engberding R, Daniel W, et al. Echocardiography in diagnosis of aortic dissection. *Lancet* 1989; 1: 457-61.

Crawford ES. The diagnosis and management of aortic dissection. *JAMA* 1990; 264: 2537-41.

Cheitlin MD, Alpert JS, Armstrong WF, et al.

ACC/AHA Guidelines for the clinical application of echocardiography. *Circulation* 1997; 95: 1686-1744.

Elefteriades JA, Lovoulos MA, Tellides G, et al. Management of descending aortic dissection. *Ann Thorac Surg* 1999; 67: 2002-5; discussion 2014-9.

Juvonen T, Ergin MA, Galla JD, et al. Risk factors for rupture of chronic type B dissections. *J Thorac Cardiovasc Surg* 1999; 117: 776-86.

Hagan PG, Nienaber CA, Isselbacher EM, et al. The international registry of acute aortic dissection (IRAD). New insights into an old disease. *JAMA* 2000; 283: 897-903.

Pepi M, Campodonico J, Galli C, et al. Rapid diagnosis and management of thoracic aortic dissection and intramural haematoma: a prospective study of advantages of multiplane vs. biplane transoesophageal echocardiogra-

phy. *Eur J Echocardiogr* 2000; 1: 72-9.

Erbel R, Alfonso F, Boileau C, et al. Diagnosis and management of aortic dissection. *Eur Heart J* 2001; 22: 1642-81.

Kawahito K, Adachi H, Yamaguchi A, et al. Predictive risk factors for hospital mortality in acute type A aortic dissection. *Ann Thorac Surg* 2001; 71: 1239-43.

Lederle AF, Wilson SE, Johnson GR, et al. Immediate repair compared with surveillance of small abdominal aortic aneurysms. *N Engl J Med* 2002; 346: 1437-44.

Syndrome de BRUGADA

Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. *Am J Coll Cardiol* 1992; 20: 1391-96.

Brugada P, Brugada R, Brugada J. The Brugada syndrome. *Curr Cardiol Rep* 2000; 2: 507-14.

Brugada J, Brugada R, Antzelevitch C, et al. Long-term follow-up of individuals with the electrocardiographic pattern of right bundle-branch block and ST-segment elevation in precordial leads V1 to V3. *Circulation* 2002; 105: 73-8.

Chevallier St, Forclaz A, Tenkorang J, Schlaepfer, J, Pruvot E et al. New Electrocardiographic Criteria for Discriminating Between Brugada Types 2 and 3 Patterns and Incomplete Right Bundle Branch Block. *JACC* 2011; 58: 2290-8.

Bayés de Luna A, Brugada J, Baranchuk A et al. Current electrocardiographic criteria for diagnosis of Brugada pattern: a consensus report. *J Electrocardiol* 2012; 45: 433-42.

Brugada, J, Campuzano O, Arbelo, E et. Present Status of Brugada Syndrome. *JACC State-of-the-Art Review*. *JACC* 2018; 9: 1046-59.

Intervalle QT - Long QT syndrome

Sudden death

Bazett HC. An analysis of the time relations of electrocardiograms. *Heart* 1920; 7: 353-70.

Hodges M, Salerno D, Erlien D. Bazett's QT correction reviewed. Evidence that a linear QT correction for heart is better [Abstract]. *J Am Coll Cardiol* 1983; 1: 694.

Schwartz PJ. Idiopathic long QT syndrome: progress and questions. *Am Heart J* 1985; 109: 399-411.

Campbell CJC, Yusoff K, Moore M, et al. Importance of lead selection in QT interval measurement. *Am J Cardiol* 1988; 61: 83-87.

Day CP, James OF, Budler TJ, et al. QT prolongation and sudden cardiac death in patients with alcoholic liver disease. *Lancet* 1993; 341: 1423-8.

Schwartz PJ, Moss AJ, Vincent GM, et al. Diagnostic criteria for the long QT syndrome. An Update. *Circulation* 1993; 88: 782-4.

Roden DM, Lazzara R, Rosen M, et al. Multiple mechanisms in the long-QT-syndrome. Current knowledge, gaps and future directions. *Circulation* 1996; 94: 1996-2012.

Reilly JG, Ayis SA, Ferrier IN, et al. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. *Lancet* 2000; 355: 1048-

- 52.
- Delacretat E. Médicaments et long QT. Forum Med Suisse 2007; 7: 814-9.
- Schwartz PJ , Crotti L. QTc Behavior During Exercise and Genetic Testing for the Long-QT Syndrome. Circulation 2011; 124: 2181-4.
- Priori SG, Blomström-Lundqvist C, Mazzanti A et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Eur Heart J 2015; 36: 2793-2867.
- Vie veineuse centrale, SWAN-GANZ**
- O'Quin R, Marini JJ. Pulmonary artery occlusion pressure: clinical physiology, measurement, and interpretation. Am Rev Respir Dis 1983; 128: 319-26.
- Sharkey SW. Beyond the wedge: clinical physiology and the Swan-Ganz catheter. Am J Med 1987; 83: 111-22.
- Perret C, Tagan D, Feihl F. (eds.). Le cathétérisme cardiaque droit en soins intensifs. Arnette 1993.
- Sandham JD, Hull RD, Brant RF, et al.; Canadian Critical Care Clinical Trials Group. A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. N Engl J Med 2003; 348: 5-14.
- Tachycardie supraventriculaires**
- Kastor JA. Multifocal atrial tachycardia. N Engl J Med 1990; 322: 1713-1717.
- Murgatroyd FD, Camm AJ. Atrial Fibrillation for the clinician. In: Camme AJ, (ed.). Clinical approaches to tachyarrhythmias. Volume 4. Futura Publishing Company Inc, Armonk, NY, 1995.
- Schläpfer J, Goy JJ. Urgences rythmiques. Praxis 1995; 84: 1314-20.
- Saoudi N, Cosio F, Waldo A, et al. A classification of atrial flutter and regular atrial tachycardia according to electrophysiological mechanisms and anatomical bases. European Heart Journal 2001; 22: 1162-82.
- 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Page RL, Joglar JA, Caldwell MA, Calkins H, Conti JB, Deal BJ, Estes NA 3rd, Field ME, Goldberger ZD, Hammill SC, Indik JH, Lindsay BD, Olshansky B, Russo AM, Shen WK, Tracy CM, Al-Khatib SM; Evidence Review Committee Chair. Circulation 2016; 133: e506-74.
- Syndromes de préexcitation - WPW**
- Wolf L, Parkinson J, White PD. Bundle-branch block with short P-R interval in healthy young people prone to paroxysmal tachycardia. Am Heart J 1930; 5: 685-704.
- Campbell RW, Smith RA, Gallagher JJ, et al. Atrial fibrillation in the preexcitation syndrome. Am J Cardiol 1977; 40: 514-20.
- Gallagher JJ, Pritchett EL, Sealy WC, Kasell J, Wallace AG: The preexcitation syndromes. Prog Cardiovasc Dis 1978; 20: 285-327.
- Gallagher JJ, Smith WM, Kasell JH, et al. Role of Mahaim fibers in cardiac arrhythmias in man. Circulation 1981; 64: 176-89.
- Bardy GH, Packer DL, German LD, et al. Preexcited reciprocating tachycardia in patients with Wolff-Parkinson-White syndrome: incidence and mechanisms. Circulation 1984; 70: 377-91.
- Guize L, Soria R, Chaouat JC, et al. Prevalence and course of Wolff-Parkinson-White syndrome in a population of 138,048 subjects. Ann Med Interne (Paris) 1985; 136: 474-8.
- Waspe LE, Brodman R, Kim SG, et al. Susceptibility to atrial fibrillation and ventricular tachyarhythmia in the Wolff-Parkinson-White syndrome: role of the accessory pathway. Am Heart J 1986; 112: 1141-52.
- Jackman WM, Wang XZ, Friday KJ, et al. Catheter ablation of accessory atrioventricular pathways (Wolff-Parkinson-White syndrome) by radiofrequency current. N Engl J Med 1991; 324: 1605-11.
- Gaita F, Giustetto C, Riccardi R, et al. Wolff-Parkinson-White syndrome. Identification and management. Drugs 1992; 43: 185-200.
- Gallay P, Grolleau R, Nicolai P. Les préexcitations ventriculaires. In: Touboul P, et al. (eds.). Les troubles du rythme cardiaque. Paris Editions Maloine 1993, p: 141-54.
- Munger TM, Packer DL, Hammill SC, et al.: A population study of the natural history of Wolff-Parkinson-White syndrome in Olmsted County, Minnesota, 1953-1989. Circulation 1993; 87: 866-73.
- Oren JW IV, Beckman KJ, McClelland JH, et al. A functional approach to the preexcitation syndromes. Cardiol Clin 1993; 11: 121-149.
- Ganz L, Friedman PL. Supraventricular tachycardia. N Engl J Med 1995; 332: 162-73.
- Al-Khatib SM, Pritchett EL. Clinical features of Wolff-Parkinson-White syndrome. Am Heart J 1999; 138: 403-13.
- Basson CT. A molecular basis for Wolff-Parkinson-White Syndrome. N Engl J Med 2001; 344: 1861-4.
- Fitzsimmons PJ, McWhirter PD, Peterson DW, Krueyer WB. The natural history of Wolff-Parkinson-White syndrome in 228 military aviators: a long-term follow-up of 22 years. Am Heart J 2001; 142: 530-6.
- Gollob MH, Green MS, Tang ASL, et al. Identification of a gene responsible for familial Wolff-Parkinson-White Syndrome. N Engl J Med 2001; 344: 1823-31.
- Pappone C, Santinelli V, Manguso F, et al. A randomized of prophylactic catheter ablation in asymptomatic patients with the Wolff-Parkinson-White syndrome. N Engl J Med 2003; 349: 1803-11.
- Pediatric and Congenital Electrophysiology Society (PACES) et al. PACES/HRS expert consensus statement on the management of the

- asymptomatic young patient with a Wolff-Parkinson-White (WPW, ventricular preexcitation) electrocardiographic pattern: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology Foundation (ACC), the American Heart Association (AHA), the American Academy of Pediatrics (AAP), and the Canadian Heart Rhythm Society (CHRS). Heart Rhythm 2012; 9: 1006-24.
- Brugada J, Katritsis DG, Arbelo E et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). Eur Heart J 2020;41: 655-720.
- Tachycardie ventriculaire, QRS larges**
- Breitkomplextachykardien**
- Lewis T. Clinical Electrocardiography. Clinical Electrocardiography. 5th Edition. Auricular fibrillation Shaw and Sons 1931: 87-100.
- Sandler IA, Marriott HJL. The differential morphology of anomalous ventricular complexes of RRBB type in V1. Ventricular ectopy versus aberration. Circulation 1965; 31: 551-6.
- Marriott HJL, Sandler IA. Criteria, old and new, for differentiating between ectopic ventricular beat and aberrant ventricular conduction in the presence of atrial fibrillation. Prog Cardiovasc Dis 1966; 9:18-2
- Swanick EJ, LaCamera F, Marriott HJL. Morphologic features of right ventricular ectopic beats. Am J Cardiol 1972; 30:888-91.
- Wellens HJJ, Bar FW, Lie KL. The value of the electrocardiograms in the differential diagnosis of tachycardia with a widened QRS complex. Am J Med 1978; 64:27-33.
- Wellens HJJ, Bar FW, Vanagt FJ, et al. The differentiation between ventricular tachycardia and supraventricular tachycardia with aberrant conduction: the value of the 12-lead electrocardiogram. In: Wellens HJJ, Kulbertus HE (eds). What's New in Electrocardiography. Boston: Nijhoff 1981, p: 184-99.
- Coumel P, Leclercq JF, Attuel P, Maisonblanche P. The QRS morphology in post myocardial infarction ventricular tachycardia. A study of 100 tracings compared with 70 cases of idiopathic ventricular tachycardia. Eur Heart J 1984; 5:792-805.
- Wellens HJJ, Brugada P. Diagnosis of ventricular tachycardia from the 12-lead electrocardiogram. Cardiol Clin 1987; 5: 511-25.
- Tchou P, Young P, Mahmud R, et al. Useful clinical criteria for the diagnosis of ventricular tachycardia. Am J Med 1988; 84: 53-6.
- Kindwall KE, Browns J, Josephson ME. Electrocardiographic criteria for ventricular tachycardia in wide complex left bundle branch block morphology tachycardias. AM J. Cardiol 1988; 61: 1279-83.
- Josephson ME, Wellens HJJ. Differential diagnosis of supraventricular tachycardia. Cardiol Clin 1990; 8: 411-42.
- Brugada P, Brugada J, Mont L, Smeets J, Andries EW. A new approach to the differential diagnosis of a regular tachycardia with a wide QRS complex. Circulation 1991; 83: 1649-59.
- Wyse DG. Pharmacologic therapy in patients with ventricular tachyarrhythmias. Cardiol Clin 1993; 11:65-83.
- Antunes E, Brugada J, Steurer G, Andries E, Brugada P The differential diagnosis of a regular tachycardia with a wide QRS complex on the 12-lead ECG: ventricular tachycardia, supraventricular tachycardia with aberrant intraventricular conduction, and supraventricular tachycardia with anterograde conduction over an accessory pathway. Pacin Clin Electrophysiol 1994; 17; 1515-24.
- Ganz LI., Friedmann P. Supraventricular tachycardia. N Engl J Med 1995; 332: 162-73.
- Vukmir RB. Cardiac arrhythmia therapy. Am J Emerg Med 1995; 13: 459-70.
- Vereckei A, Duray G, Szénási G, Altemose GT, Miller JM. Application of a new algorithm in the differential diagnosis of wide QRS complex tachycardia. Eur Heart J 2007; 28: 598-600.
- Vereckei A, Duray G, Szénási G, Altemose GT, Miller JM. New algorithm using only lead aVR for differential diagnosis of wide QRS complex tachycardia. Heart Rhythm 2008; 5: 89-98.
- Issa F, Miller JM, Zipes DP. Clinical arrhythmology and electrophysiology 2nd Edition. Approach towide QRS complex tachycardias. Elsevier, Saunders 2012: 499-511.
- Vereckei A. Current Algorithms for the Diagnosis of wide QRS Complex Tachycardias. Curr Cardiol Rev 2014; 10: 262-76.
- Priori SG, Blomström-Lundqvist C, Mazzanti A et al. 2015 ESC Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: The Task Force for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed By: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015;3 6: 2793-2867.
- AI-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2018; 72:e91
- Bloc atrio-ventriculaire**
- Wagner GS, Waugh RA, Ramo NW. (eds.). In: Cardiac arrhythmias. Churchill Livingstone 1983, p: 217-30.
- Wagner GS. (ed.). In: Marriot's Practical electrocardiography. 9th ed. Williams & Wilkins 1994, p: 388-94.
- Péricardite/Myocardite et tamponnade**
- Spodick DH. Differential diagnosis of acute peri-

- carditis. *Prog Cardiovasc Dis* 1971; 14: 192-209.
- Marini PV, Hull AR. Uremic pericarditis: a review of incidence and management. *Kidney Int Suppl* 1975; 2: 163-6.
- Spodick DH. Arrhythmias and pericardial disease. *Am J Cardiol* 1984; 53: 265.
- Spodick DH. Pericarditis, pericardial effusion, cardiac tamponade and constriction. *Crit Care Clin* 1989; 5: 455-76.
- Battle RW, Le Winter MM. The evaluation and management of pericardial disease. *Curr Opin Cardiol* 1990; 5: 331-9.
- Spodick DH. Pericardial disease. *Mayo Clin Proc* 1992; 67: 201-2.
- Zayas R, Anguita M, Torres F, et al. Incidence of specific etiology and role of methods for specific etiologic diagnosis of primary acute pericarditis. *Am J Cardiol* 1995; 75: 378-82.
- Marinella MA. Acute pericarditis. *Am Fam Phys* 1998; 57: 702-4.
- Adler Y, Finkelstein Y, Guindo J, et al. Colchicine treatment for recurrent pericarditis. A decade of experience. *Circulation* 1998; 97: 2183-5.
- Longo M, Jaffe CC. Electric alternans. *N Engl J Med* 1999; 341: 2060.
- Spodick DH. Acute cardiac tamponade. *N Engl J Med* 2003; 349: 684-90.
- Lange RA, Hillis LD. Clinical practice. Acute pericarditis. *N Engl J Med* 2004; 351:2195.
- Mäisch B, Seferovic PM, Ristic AD, et al. Guidelines on the diagnosis and management of pericardial disease: The task force on the diagnosis and management of pericardial disease of the European Society of Cardiology. *European Heart Journal* 2004; 25:587.
- Imazio M, Bobbio M, Cecchi Enrico et al. Colchicine in addition to conventional therapy for acute pericarditis. Results of the Colchicine for acute PEricarditis (COPE) trial. *Circulation* 2005; 112: 2012-2016.
- Imazio M, Bobbio M, Cecchi Enrico et al. Colchicine as first-choice therapy for recurrent pericarditis; results of the CORE (Colchicine for REcurrent pericarditis) trial. *Arch Intern Med*. 2005; 165: 1987-1991.
- Imazio M, Trinchero R. Myopericarditis: etiology, management, and prognosis. *Intern J Cardiol* 2008; 127: 17-26.
- Imazio M, Gaita F. Diagnosis and treatment of pericarditis. *Heart* 2015; 101: 1159-68.
- Mansoor AM, Karlapudi SP. Kussmaul's Sign. *NEJM* 2015;372: e3
- Hessulf F, Ljungberg J, Johansson PA, et al. Campylobacter jejuni-associated perimyocarditis: two case reports and review of the literature. *BMC Infections Disease* 2016; 16: 289-95.
- Maladie thromboembolique veineuse
MTEV (thrombose veineuse profonde,
embolie pulmonaire)- Lungenembolie,
Tiefe Venenthrombose**
- Hughes GRV. Thrombosis, abortion, cerebral disease and the lupus anti-coagulant. *BMJ* 1983; 287: 1088-9.
- Hughes GRV, Harris EN, Gharavi AE. The anti-cardiolipine syndrome. *J Rheumatol* 1986; 13: 486-9.
- Bernard C, de Moerloose P. Anticorps anticardiolipine et thromboses. *Med Hyg* 1990; 48: 166-9.
- Bounameaux H, Chevrolet JC. Le rôle de la thrombolyse dans le traitement de l'embolie pulmonaire. *Schweiz Med Wschr* 1991; 121: 1654-7.
- Stein PD, Perrin ML, Hales CA, et al. Clinical, laboratory, roentgenographic, and electrocardiographic findings in patients with acute pulmonary embolism and no pre-existing cardiac or pulmonary disease. *Chest* 1991; 10: 598-603.
- Lutter K, Kerr T, Roedersheimer L, et al. Superficial thrombophlebitis diagnosed by duplex scanning. *Surgery* 1991; 10: 42-6.
- Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial. *Ann Intern Med* 1993;119:874-81.
- Perrier A, Bounameaux H, Morabia A, et al. Contribution of Plasma D-dimer and lower limb venous ultrasound to the diagnosis pf pulmonary embolism: a decision analysis. *Am Heart J* 1994; 127: 624-35.
- Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. *N Engl J Med* 1994; 330: 518-22.
- Ginsberg JS, Wells PhS, Brill-Edwards P, et al. Antiphospholipid antibodies and venous thromboembolism. *Blood* 1995; 86: 3685-91.
- Lensing AWA, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. *Arch Intern Med* 1995; 155: 601-7.
- Bounameaux H, de Moerloose Ph, Sarasin FP. Optimal duration of oral anticoagulation therapy following deep vein thrombosis of lower limbs. *Blood Coag Fibrinol* 1996; 7: 507-14.
- Cavenagh JD, Colvin BT. Guidelines for the management of thrombophilia. *Postgrad Med J* 1996; 72: 87-94.
- Ginsberg JS. Management of venous thromboembolism. *N Engl J Med* 1996; 335: 1816-28.
- Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. *NEJM* 1996; 334: 677-81.
- Hirsh J, Hoak J. Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association. *Circulation* 1996; 93: 2212-45.
- Perrier A, Bounameaux H, Morabia A, et al. Diagnosis of pulmonary embolism by a decision analysis-based strategy including clinical probability D-dimer levels, and ultrasonography: a management study. *Arch Intern Med* 1996; 156: 531-6.
- Büller HR, Gent M, Gallus AS, et al. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. *N Engl J Med* 1997; 337: 657-62.

- Dalen JE, Alpert JA. Thrombolytic therapy for pulmonary embolism: is it effective ? is it safe ? Arch Intern Med 1997; 157: 2550-6.
- Daniels LB, Parker JA, Patel SR, et al. Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism. Am J Cardiol 1997; 80: 184-88
- Schulman S, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997; 336: 393-8.
- Wells PS, Anderson DR, Bormanis J, et al. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet 1997; 350: 1795-8.
- Büller H, ten Cate JW. Primary venous thromboembolism and cancer screening. N Engl J Med 1998; 338: 1221-2.
- Hyers TN, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 1998; 114(Suppl.): 561S-78S.
- Sorensen HT, Mellemkjaer L, Steffensen FH, et al. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 1998; 338: 1169-74.
- Bounameaux H, Beer J, Blättler W, et al. Le traitement ambulatoire de la thrombose veineuse profonde: prise de position d'un comité d'experts. Bull Med Suisse 1999; 80: 405-6.
- Huisman MV, Rosendaal RF. Thrombophilia. Curr Opin Hematol 1999; 6: 291-7.
- Perrier A, Desmarais S, Miron MJ, et al. Non-invasive diagnosis of venous thromboembolism in outpatients including clinical probability, D-dimer and ultrasonography. Lancet 1999; 353: 190-5.
- Wells PS, Anderson DR, Ginsberg J. Assessment of deep vein thrombosis or pulmonary embolism by the combined use of clinical model and noninvasive diagnostic tests. Semin Thromb Hemost 2000; 26: 643-56.
- Bounameaux H, de Moerloose Ph, Perrier A. Diagnostic de la thrombose veineuse profonde et de l'embolie pulmonaire. Med Hyg 2000; 58: 161-9.
- Wells PS, Anderson DR, Rodger M, et al. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost 2000; 83: 416-420.
- Perrier A, Bounameaux H. Cost-effective diagnosis of deep vein thrombosis and pulmonary embolism. Thromb Haemost 2001; 86: 475-87.
- Sixth ACCP Consensus Conference on anti-thrombotic therapy. Chest 2001; 119 (Suppl. 1): 1S-336S.
- Wicki J, Perneger TV, Junod AV, et al. Assessing clinical probability of pulmonary embolism in the emergency ward: a simple score. Arch Intern Med 2001; 161: 92-7.
- Goldhaber SZ. Thrombolysis for pulmonary embolism. N Engl J Med 2002; 347: 1131-2.
- Konstantinides S, Geibel A, Heusel G. Heparin plus Alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002; 347: 1143-50.
- Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003; 107 Suppl. 1: I17-21.
- Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003; 348: 1425-34.
- Kearon C, Ginsberg JS, Kovacs M, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349: 631-9.
- Crowther MA, Ginsberg JS, Math JJ, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133-8.
- Fedullo PF, Tapson VF. The evaluation of suspected pulmonary embolism. N Engl J Med 2003; 349: 1247-56.
- Superficial thrombophlebitis treated by enoxaparin Study Group. A pilot randomised double-blind comparison of a low-molecular-weight heparin, a nonsteroidal anti-inflammatory agent, and placebo in the treatment of superficial vein thrombosis. Arch Intern Med 2003; 163: 1657-63.
- Wells PA, Anderson DR, Rodger M, et al. Evaluation of d-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med 2003; 349: 1227-35.
- The Matisse Investigators. Subcutaneous Fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349: 1695-702.
- Bates SM, Ginsberg JS. Treatment of deep-vein thrombosis. N Engl J Med 2004; 351: 268-77.
- Kytle P, Minar E, Bialonczyk C et al. The risk of recurrent venous thromboembolism in men and women. N Engl J Med 2004; 350: 2558-63.
- Antithrombotische und thrombolytische Behandlung: Internationale EBM-Guidelines, kommentiert von Schweizer Experten. The 7th ACCP Conference on Antithrombotic and thrombolytic therapy. Swiss Med Forum 2005 (Suppl 27):1-48S.
- Aujesky D, Obrosky DS, Stone RA, Auble TE, Perrier A, Cornuz J, Roy PM, Fine MJ. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med 2005; 172: 1041-1046.
- Perrier A, Roy P.-M, Sanchez O, et al. Multidetector-Row Computed Tomography in Suspected Pulmonary Embolism. N Engl J Med 2005; 352: 1760-8.
- Traitement antithrombotique et thrombolytique: Commentaires des experts suisses concentrant les «EBM-guidelines» internationales. 7th Conference on antithrombotic and thrombolytic therapy. Swiss Med Forum 2005 (Suppl 28): 1-48S.
- Jeanneret Ch, Baldi Th, Jenelten R. Die oberflächliche Thrombophlebitis: ein Überblick. Schweiz Med For 2006; 6: 190-195.
- The van Gogh Investigators. Idraparinix versus Standard Therapy for Venous Thromboembolic

- Disease. *N Engl J Med* 2007; 357: 1094-1104.
- The van Gogh Investigators. Extended Prophylaxis of Venous Thromboembolism with Idaraparin. *N Engl J Med* 2007; 357: 1105-12.
- Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-based clinical practice guidelines (8th Editions). *Chest* 2008; 133 (suppl): 1-968S.
- Carrier M, et al. Systematic review: the Trouseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism? *Ann Intern Med* 2008; 149: 323-33.
- Gibson NS, Sohne M, Krup MJHA, et al.; Christopher study investigators. Further validation and simplification of the Wells clinical decision rule in pulmonary embolism. *Thromb Haemost* 2008; 99: 229-234.
- Guyatt GH, Oxman AD, Vist GE et al. for the GRADE working group. GRADE: an emerging consensuss on rating quality of evidence and strength of recommendations. *BMJ* 2008; 336: 924-6.
- Kahn SR, Shrier I, Julian JA, et al. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. *Ann Intern Med* 2008; 149:698-707.
- Righini M, Perrier A, De Moerloose P, et al. D-Dimer for venous thromboembolism diagnosis: 20 years later. *J Thromb Haemost* 2008; 6: 1059- 71.
- Weitz JL, Hirsh J, Samama MM. New antithrombotic drugs: American College of Chest Physicians Evidence-based clinical practice guidelines (8th Edition). *Chest* 2008; 133 (Suppl):234-56.S.
- Eklöf B, Perrin M, Delis KT, et al. Updated terminology of chronic venous disorders: The VEIN-TERM transatlantic interdisciplinary consensus document. *J Vasc Surg* 2009;49:498-501.
- Jiménez D, Aujesky D, Moores L, Gomez V, Lobo JL, Uresandi F, Otero R, Monreal M, Muriel A, Yusen RD; RIETE Investigators. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. *Arch Intern Med* 2010;170:1383-1389.
- Karthikesalingam A, Young EL, Hinchliffe RJ, et al. A systematic review of percutaneous mechanical thrombectomy in the treatment of deep venous thrombosis. *Eur J Vasc Endovasc Surg* 2011; 41: 554-65.
- Pollack CV, Schreiber D, Goldhaber SZ, et al. Clinical characteristics, management, and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department: initial report of EMPEROR (Multicenter Emergency Medicine Pulmonary Embolism in the Real World Registry). *J Am Coll Cardiol* 2011; 57: 700-706.
- Zondag W, Mos IC, Creemers-Schild D et al. Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study. *J Thromb Haemost* 2011;9:1500-7.
- Kearon C, Akl EA, Comerota AJ et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012 ;141 (2 Suppl):e419S-94S.
- Prins MH, Lensing A.WA, Bauersachs R et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. *Thromb J* 2013; 11: 21.
- Fontana P, Goldhaber SZ, Bounameaux H. Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism. *Eur Heart J* 2014; 35: 1836-43.
- Meyer G, Vicaut E, Danays T et al. PEITHO Investigators. Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism. *N Engl J Med* 2014; 370:1402-11.
- Kakkos SK, Kirkilesis GI, Tsolakis IA. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials. *Eur J Vasc Endovasc Surg* 2014; 48: 565-75.
- Righini M, Van Es J, Den Exter PL et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. *JAMA*. 2014; 311: 1117-24. doi: 10.1001/jama.2014.2135.
- The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. *European Heart Journal* 2014; 35: 3033-80.
- Bates SH, Greer IA, Middeldorp S et al. VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *CHEST* 2012; 141(2)(Suppl):e691S-e736S.
- National Clinical Guideline, National Institute for Health and Clinical Excellence: Guidance, in Venous Thromboembolic Diseases: The Management of Venous Thromboembolic Diseases and the Role of Thrombophilia Testing. Londres: Royal College of Physicians (UK) National Clinical Guideline Centre, 2012.
- Fahri J, Engelberger RP, Kucher N, et al. Catheter-based treatment of ilio-femoral deep vein thrombosis – an update on current evidence. *Vasa* 2013; 42: 161-7.
- Kakkos SK, Kirkilesis GI, Tsolakis IA. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials. *Eur J Vasc Endovasc Surg* 2014; 48: 565-575.
- Engelberger RP, Alatri A, Qanadli SD et al. Traitement percutané de la thrombose veineuse profonde aiguë. *Rev Med Suisse* 2015; 11 : 348-51.
- Kearon C, Elien K, Ornelas J et al. Antithrombotic

- Therapy for VTE Disease. CHEST Guideline and Expert Panel Report. *Chest* 2016; 149: 315-352.
- Klok FA, Hosel V, Clemens A, et al. Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment. *Eur Respir J* 2016; 48: 1369-76.
- Jara-Palomares L, et al. Development of a risk prediction score for occult cancer in patients with VTE. *Chest* 2017; 151: 564-71.
- Klok FA, Barco S, Konstantinides SV. External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. *Thromb Haemost* 2017; 117: 1164-70.
- Penaloza A, Soulie C, Mourmeh T, et al. Pulmonary embolism rule-out criteria (PERC) rule in European patients with low implicit clinical probability (PERCEPIC): a multicentre, prospective, observational study. *Lancet Haematol* 2017; 4(12): e615-e21.
- Carcaterra A, Serratrice J, Righinin, et al. Maladie thromboembolique veineuse idiopathique : faut-il rechercher un cancer occulte? *Rev Med Suisse* 2018; 14: 1840-3.
- Konstantinides SV, Meyer G, Becattini C et al. The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): supplementary data. *Eur Heart J* 2019; 00:1-19.
- Konstantinides SV, Meyer G, Becattini C et al. The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). *Eur Heart J* 2020; 41: 543-603

Hypertension artérielle (HTA)

- WEB - Canada (mise à jour: Luc Lanthier, Sherbrooke):
www.hypertension.qc.ca
- WEB - Suisse: www.swisshypertension.ch
- Strandgaard S, Olesen J, Skinhøj E, et al. Autoregulation of brain circulation in severe arterial hypertension. *BMJ* 1973; 1: 507-10.
- Messerli FH, Ventura HO, Amodeo C. Osler's maneuver and pseudohypertension. *N Engl J Med* 1985; 312: 1548-51.
- Dahlhof B, Lindholm LH, Hansson L, et al. Morbidity and mortality in Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). *Lancet* 1991; 338: 1281-5.
- Melburne Diabetic Nephropathy Study Group: comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. *BMJ* 1991; 302: 210-6.
- Phillips SJ. Pathophysiology and management of hypertension in acute ischemic stroke. *Hypertension* 1994; 23: 131-6.

- Laragh JH, Brenner BM (eds.). In: *Hypertension: Pathophysiology, diagnosis, and management*. New York: Raven Press, 1995.
- Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. *Systolic Hypertension in the Elderly Program Cooperative Research Group*. *JAMA* 1996; 276: 1886-92.
- Elliott J. ALLHAT: The largest and most important clinical trial in hypertension ever done in the USA. Antihypertensive and lipid lowering treatment to prevent heart attack trial. *Am J Hypertension* 1996; 9: 409-11.
- Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). *Lancet* 1997; 349: 747-52.
- The Sixth Report of the Joint National Committee on Detection, Evaluation, and Diagnosis of High Blood Pressure. *Arch Intern Med* 1997; 157: 2413-46.
- Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. *N Engl J Med* 1998; 338: 645-52.
- Frishman WH, Nalamati J. Carvedilol: a new alpha- and beta-adrenergic blocker for heart failure and hypertension. *N Engl J Med* 1998; 339: 1759-65.
- Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the hypertension optimal treatment (HOT) randomised trial. *Lancet* 1998; 351: 1755-62.
- Recommendations of the Second Joint Task Force of European and other Societies on coronary Prevention. *Eur Heart J* 1998; 19: 1434-1503.
- Tati P, Pahor M, Byington RP, et al. Fosinopril Amlodipine Cardiovascular Events Trial. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomised trial (FACET) in patients with hypertension and NIDDM. *Diabetes Care* 1998; 21: 597-603.
- UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. *BMJ* 1998; 317: 703-13.
- UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. *BMJ* 1998; 317: 713-20.
- Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. *Lancet* 1999; 354: 1751-6.
- Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition

- compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomised trial. *Lancet* 1999; 353: 611-6.
- Ramsay LE, Williams B, Johnston D, et al. British Hypertension Society guidelines for hypertension management 1999: summary. *BMJ* 1999; 319: 630-5.
- Tuomilehto J, Rastenyte D, Birkenhäger WH, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. *N Engl J Med* 1999; 340: 677-84.
- 1999 World Health Organization-International Society of Hypertension. Guidelines for the management of hypertension. *J Hypertens* 1999; 17: 905-83.
- Campbell NR, McKay DW. Accurate blood pressure measurement: why does it matter? *Can Med Assoc* 1999; 161: 277-8.
- Dickerson JEFC, Hingorani HG, Ashby MJ, et al. Optimisation of antihypertensive treatment by crossover rotation of four major classes. *Lancet* 1999; 353: 2008-13.
- ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosine vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). *JAMA* 2000; 283: 1967-75.
- Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). *Lancet* 2000; 356: 366-72.
- Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. *Lancet* 2000; 356: 359-65.
- Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-microalbuminuria (CALM) study. *BMJ* 2000; 321: 1440-4.
- Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. *Lancet* 2000; 355: 1582-7.
- The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. *N Engl J Med* 2000; 342: 145-53.
- Van den Hoogen PCW, Feskens EJM, Nagelkerke NJD, et al. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. *N Engl J Med* 2000; 342: 1-8.
- American Diabetes Association. Aspirin therapy in diabetes. Position statement. *Diabetes Care* 2001; 24: S62-S63.
- Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of Losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med* 2001; 345: 861-9.
- Brown M. Hypertension: Matching the right drug to the right patient in essential hypertension. *Heart* 2001; 86: 113-120.
- Cohn JN, Tognoni G, et al. A randomized trial of the angiotensin-receptor blocker Valsartan in chronic heart failure. *N Engl J Med* 2001; 345: 1667-75.
- Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist Irbesartan in patients with nephropathy due to type 2 diabetes. *N Engl J Med* 2001; 345: 851-60.
- Parving HH, Lehnhert H, Brochner-Mortensen J, et al. The effect of Irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. *N Engl J Med* 2001; 345: 870-8.
- PROGRESS Collaborative Group. Randomised trial of perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. *Lancet* 2001; 358: 1033-41.
- Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and Dietary Approaches to Stop Hypertension (DASH) diet. *N Engl J Med* 2001; 344: 3-10.
- Sammuganathan PS, Ghahramani P, Jackson PR, et al. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. *Heart* 2001; 85: 265-71.
- The Canadian recommendations for the management of hypertension: Part 1 - Therapy. *Can J Cardiol* 2001; 17: 543-59.
- The Canadian recommendations for the management of hypertension: Part 2 - Diagnosis and assessment of people with high blood pressure. *Can J Cardiol* 2001; 17: 1249-63.
- Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. *N Engl J Med* 2001; 345: 1291-7.
- American Diabetes Association: clinical practice recommendations 2002. *Diabetes Care* 2002; 25 (Suppl.1): S1-S147.
- Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ* 2002; 324: 71-86.
- Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet* 2002; 359: 995-1003.
- Kjeldsen SE, Dahlöf B, Devereux RB, et al. Effects of Losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy. A Losartan Intervention For Endpoint Reduction (LIFE) Substudy. *JAMA* 2002; 288: 1491-8.
- Lauer MS. Aspirin for primary prevention of coronary events. *N Engl J Med* 2002; 346: 1468-74.
- Lindholm LH, Ibsen H, Dahlöf B, et al. Cardio-

- vascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint Reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet* 2002; 359: 1004-10.
- McAlister FA, Zarnke KB, Campbell NR, et al. The 2001 Canadian recommendations for the management of hypertension: Part 2- therapy. *Can J Cardiol* 2002; 18: 625-41.
- Wallis EJ, Ramsay LE, Jackson PR. Cardiovascular and coronary risk estimation in hypertension management. *Heart* 2002; 88: 306-12.
- Société québécoise de l'hypertension artérielle. Guide thérapeutique 2002 (ISBN 2-9806257-1-X); mise à jour: www.hypertension.qc.ca
- The ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). *JAMA* 2002; 289: 30-309-42.
- Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and treatment of high blood pressure. *JAMA* 2003; 289: 2560-72.
- U.S. Preventive Services Task Force (Chair: Berg AO). Aspirin for the prevention of cardiovascular events: recommendation and rationale. *Ann Intern Med* 2002; 136: 157-60.
- August P. Initial treatment of hypertension. *N Engl J Med* 2003; 348: 610-17.
- Imoberdorf R. Tous les diabétiques devraient-ils prendre de l'aspirine? *Forum Med Suisse* 2003; 7: 149-54.
- Wing LMH, Reid CM, Ryan PH, et al. (ANBP2). A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. *N Engl J Med* 2003; 348: 583-92.
- Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. *Lancet* 2003; 361: 1149-58.
- Adrogué HJ, Madias NE. Sodium and potassium in the pathogenesis of hypertension. *N Engl J Med* 2007; 356: 1966-78.
- Mancia G, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens* 2013; 31: 1281-357 and *Eur Heart J* 2013; 34: 2159-219.
- Cloutier L, Poirier L. éd. Prise en charge systématisée des personnes atteintes d'hypertension artérielle. Montréal, Canada Société québécoise d'hypertension artérielle, 2015; 1-101.
- Daskalopoulou SS, Rabi DM, Zarnke KB et al. The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. *Can J Cardiol* 2015; 3: 549-68.
- Franz H, Messerli FH, Rimoldi SF, Bangalore S et al. When an Increase in Central Systolic Pressure Overrides the Benefits of Heart Rate Lowering. *J Am Coll Cardiol* 2016; 68: 754-62.
- Rimoldi SF, Messerli FH, Cerny D et al. Selective Heart Rate Reduction With Ivabradine Increases Central Blood Pressure in Stable Coronary Artery Disease. *Hypertension* 2016; 67: 1205-10.
- Sorbets E, Greenlaw N, Ferrari R, et al. CLARIFY Investigators. Rationale, design, and baseline characteristics of the CLARIFY registry of outpatients with stable coronary artery disease. *Clin Cardiol* 2017; 40: 797-806.
- Messerli FH, Rimoldi SF, Bangalore S. Changing definition of hypertension in guidelines: how innocent a number game? *Eur Heart J* 2018; 39: 2241-42.
- Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/APA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Hypertension* 2018; 71: 1269-1324.
- Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J* 2018; 39: 3021-3104.
- ### Urgence hypertensive
- McGregor E, Isles CG, Jay JL, et al. Retinal changes in malignant hypertension. *Br Med J* 1986; 292: 233-4.
- O'Mailia JJ, Sander GE, Giles TD. Nifedipine-associated myocardial ischemia or infarction in the treatment of hypertensive urgencies. *Ann Intern Med* 1987; 107: 185-6.
- Emergency Cardiac care Committee and subcommittees, American Heart Association. Guidelines for cardiopulmonary resuscitation and emergency cardiac care: Part IV. special resuscitation situations: stroke. *JAMA* 1992; 268: 2242-50.
- Kaplan NM. (ed.) Hypertensive crisis. In: *Clinical Hypertension*. Baltimore: Williams & Wilkins, 1994, p: 281-97.
- Kaplan NM. Management of hypertensive emergencies. *Lancet* 1994; 344: 1335-8.
- Hirschl MM. Guidelines for the drug treatment of hypertensive crises. *Drugs* 1995; 50: 991-1000.
- Ram CVS. Immediate management of severe hypertension. *Cardiol Clin* 1995; 13: 579-91.
- Varon J, Marik PE. The diagnosis and management of hypertensive crises. *Chest* 2000; 118: 214-27.
- Vaughan CJ, Delanty N. Hypertensive emergencies. *Lancet* 2000; 356: 411-7.
- Vidt DG. Emergency room management of hypertensive urgencies and emergencies. *J Clin Hypertens* 201; 3: 158-64.

- Elliott WJ. Hypertensive emergencies. Crit Care Clin 2001; 17: 435-51.
- Elliot WJ. Clinical features and management of selected hypertensive emergencies. J Clin Hypertens (Greenwich) 2004; 6: 587-92.
- Messerli FH, Rimoldi SF, Bangalore S. Changing definition of hypertension in guidelines: how innocent a number game? Eur Heart J 2018; 39: 2241-2242.
- Hypotension orthostatische**
- Orthostatische Hypotonie**
- Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension: a clinical-pathologic study. Arch Neurol 1960; 2: 511-27.
- Thomas JE, Schirger A, Fealey RD, Sheps SG. Orthostatic hypotension. Mayo Clin Proc 1981; 56: 117-25.
- Weidmann P. Orthostatic hypotension. Schweiz Med Wochenschr 1984; 114: 246-60.
- Lipsitz LA. Orthostatic hypotension in the elderly. N Engl J Med 1989; 321: 952-7.
- Freistuhler M, et al. The Shy-Drager syndrome. Dtsch Med Wochenschr 1992; 117: 1146-8.
- Rutan GH, Hermanson B, Bild DE, Kittner SJ, LaBaw F, Tell GS. Orthostatic hypotension in older adults. The Cardiovascular Health Study. CHS Collaborative Research Group Hypertension 1992; 19: 508-19.
- Bula C. Orthostatic hypotension in the elderly. Schweiz Rundsch Med Prax 1996; 85: 145-9.
- Consensus statement. The definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. J Auton Nervous Syst 1996; 58: 123-4.
- Freeman R, Landsberg L, Young J. The treatment of neurogenic orthostatic hypotension with 3,4-DL-threo-dihydroxyphenylserine. A randomised, placebo-controlled, crossover trial. Neurology 1999; 53: 2151-7.
- Fagard RH, De Cort P. Orthostatic hypotension is a more robust predictor of cardiovascular events than nighttime reverse dipping in elderly. Hypertension 2010; 56: 56-61.
- Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res 2011; 21: 69-72.
- Ricci F, De Caterina R, Fedorowski A. Orthostatic hypotension: epidemiology, prognosis, and treatment. J Am Coll Cardiol 2015; 66: 848-860.
- Syncope - Synkope**
- Franke H. Über das Karotissinus-Syndrom und den sogenannten hyperaktiven Karotissinus-Reflex. Stuttgart: Schlatter-Verlag, 1963: 149.
- Kapoor WN, et al. A prospective evaluation and follow-up of patients with syncope. N Engl J Med 1983; 309: 197-204.
- Hoefnagels WAJ, Padberg GW, Overweg J, et al. Transient loss of consciousness: the value of the history for distinguishing seizure from syncope. J Neurol 1991; 238: 39-43.
- Sra JS, Jazayeri MR, Avitall B, et al. Comparison of cardiac pacing with drug therapy in the treatment of neurocardiogenic (vasovagal) syncope with bradycardia or asystole. N Engl J Med 1993; 328: 1085-90.
- Linzer M, Yang EH, Estes NA, et al. Diagnosing syncope Part 1. Value of history, physical examination, and electrocardiography. Ann Intern Med 1997; 126: 989-96.
- Linzer M, Yang EH, et al. Diagnosing syncope Part 2. Unexplained syncope. Ann Intern Med 1997; 127: 76-86.
- Jeong HOH, Hanusa BH, Kapoor WN. Do symptoms predict cardiac arrhythmias and mortality in patients with syncope? Arch Intern Med 1999; 159: 375-80.
- Pruvet E, Vasallei G, Kappenberger L. De l'approche diagnostique au traitement de la syncope. Med Hyg 1999; 57: 1182-9.
- Kapoor WN. Syncope. N Engl J Med 2000; 343: 1856-62.
- Brignole M, Alboni P, Benditt D, et al. Task force on syncope, European Society of Cardiology. Part 1. The initial evaluation of patients with syncope. Europace 2001; 3: 253-60.
- Brignole M, Alboni P, Benditt D, et al. Task force on syncope, European Society of Cardiology. Part 2. Diagnostic tests and treatment: summary of recommendations. Europace 2001; 3: 261-8.
- Brignole M, Alboni P, Benditt D, et al. Guidelines on management (diagnosis and treatment) of syncope. Eur Heart J. 2001; 22: 1256-1306.
- Sarasin FP, Louis-Simonet M, Carballo D, et al. Prospective evaluation of patients with syncope: a population-based study. Am J Med 2001; 111: 177-84.
- Sarasin FP, Louis-Simonet M, Carballo D, et al. Prevalence of orthostatic hypotension among patients presenting with syncope in the ED. A J Emerg Med 2002; 20: 497-501.
- Sarasin FP, Junod AV, Carballo D, et al. Role of echocardiography in the evaluation of syncope: a prospective study. Heart 2002; 88: 363-7.
- Kapoor WN. Current evaluation and management of syncope. Circulation 2002; 106: 1606-9.
- Brigole M, Alboni P, Benditt DG, et al. Guidelines on management (diagnosis and treatment) of syncope - Update 2004. Eur Heart J 2004; 25: 2054-72.
- Sarasin FP, Pruvot E, Louis-Simonet M, et al. Stepwise evaluation of syncope: A prospective population-based controlled study. Int J Cardiol 2008; 127: 103-11.
- Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res 2011; 21: 69-72.
- Thiruganasambandamoorthy V, Stiell IG, Wells GA, et al. Outcomes in presyncope patients: a prospective cohort study. Ann Emerg Med 2015; 65: 268-276.e6.
- Brignole M, Moya A, de Lange FJ, et al. 2018 ESC Guidelines for the diagnosis and management of syncope. Eur Heart J 2018; 39:1883-48.

Insuffisance cardiaque, OAP

Herzinsuffizienz und akutes Lungenödem

- Criteria Committee, New York Heart Association. Diseases of the heart and blood vessels. Nomenclature and criteria for diagnosis. 6th ed. Boston, Little Brown and Co. 1964; p: 114.
- Killip T, et al. Am J Cardiol 1967; 20: 257-64.
- Campeau L. Grading of angina pectoris. Circulation 1975; 54: 522.
- Constant J. (ed.). The jugular pulse. In: Bedside Cardiology. Little Brown and Company; 1976; p: 69-75.
- The CONSENSUS Trial Study Group. Effect of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-35.
- Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990; 82: 1724-9.
- Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-10.
- Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991; 325: 293-302.
- Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 1992; 327: 685-91.
- Pfeffer MA, Braunwald E, Moy LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial: N Engl J Med 1992; 327: 669-77.
- Goldsmith SR, Dick C. Differentiating systolic from diastolic heart failure: Pathophysiologic and therapeutic considerations. Am J Med 1993; 95: 645-55.
- Ho KK, Anderson KM, Kannel WB, et al. Survival after the onset of congestive heart failure in Framingham Heart Study subject. Circulation 1993; 88: 107-15.
- ACC/AHA Task Force Report. Guidelines for the evaluation and management of heart failure. Circulation.1995; 92: 2764-84.
- Dickstein K, Chang P, Willenheimer R, et al. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol 1995; 26: 438-45.
- Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 273: 1450-6.
- Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmias. N Engl J Med 1995; 333: 77-82.
- Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996; 94: 2807-16.
- Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349-55.
- Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335: 1107-14.
- The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996; 78: 902-7.
- Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-Heft III. Circulation 1997; 96: 856-63.
- Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747-52.
- The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525-33.
- Tsuyuki RT, Yusuf S, Rouleau JL, et al. Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Can J Cardiol 1997; 13: 1166-74.
- European study group on diastolic heart failure. How to diagnose diastolic heart failure. Eur Heart J 1998; 19: 990-1003.
- Recommendations of the Second Joint Task Force of European and other Societies on coronary Prevention. Prevention of coronary heart disease in clinical practice. Eur Heart J 1998; 19: 1434-1503.
- Van Veldhuisen DJ, Genth-Zotz S, Brouwer J, et al. High- versus low-dose ACE inhibition in chronic heart failure. J Am Coll Cardiol 1998; 32: 1811-8.
- Whelton PK, Appel LJ, Espeland MA, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons. JAMA 1998; 279: 839-46.
- Bart BA, Ertl G, Held P, et al. Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. Eur Heart J 1999; 20: 1182-90.
- Baruch L, Anand I, Cohen IS, et al. Augmented

- short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group. *Circulation* 1999; 99: 2658-64.
- Brunner-La Rocca HP, Weilenmann D, Kiowski W, et al. Within-patient comparison of effects of different dosages of enalapril on functional capacity and neurohormone levels in patients with chronic heart failure. *Am Heart J* 1999; 138: 654-62.
- Packer M, Cohn JN. Consensus recommendations for the management of chronic heart failure. *Am J Cardiol* 1999; 83: 1-38.
- Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. *Circulation* 1999; 100: 2312-8.
- Stevenson LW. Tailored therapy to hemodynamic goals for advanced heart failure. *Eur J Heart Failure* 1999; 1: 251-7.
- Swedberg K, Pfeffer M, Granger C, et al. Candesartan in heart failure-assessment of reduction in mortality and morbidity (CHARM): rationale and design. CHARM-Programme Investigators. *J Card Fail* 1999; 5: 276-82.
- De Vries RJ, van Veldhuisen DJ, Dunselman PH. Efficacy and safety of calcium channel blockers in heart failure: focus on recent trials with second-generation dihydropyridines. *Am Heart J* 2000; 139: 185-94.
- Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. *Lancet* 2000; 355: 1582-7.
- Suter TM, Eberli FR, Hess OM. Herzinsuffizienz im neuen Millennium – welche Rolle spielen die Angiotensin-II-Antagonisten? *Kardiovask Med* 2000; 3: 467-75.
- Vasan RS, Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. *Circulation* 2000; 105: 1503-08.
- Yusuf S, Sleight P, Pogue J, et al. Effect on angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *N Engl J Med* 2000; 342: 145-53.
- ACC/AHA Guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the american college of cardiology/american heart association task force on practice guidelines. *Circulation* 2001; 104: 2996-3007. Also published in: *J Am Coll Cardiol* 2001; 38: 2101-13.
- Cohn JN, Tognoni G, et al. A randomized trial of the angiotensin-receptor blocker Valsartan in chronic heart failure. *N Engl J Med* 2001; 345: 1667-75.
- Packer M, Coats AJS, Fowler MB, et al. Effects of Carvedilol on survival in severe chronic heart failure. *N Engl J Med* 2001; 344: 1651-8.
- Remme WJ, Swedberg K. Guidelines for diagnosis and treatment of chronic heart failure. Task Force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. *Eur Heart J* 2001; 22: 1527-60.
- Zile MR, Gaasch WH, Carroll JD, et al. Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? *Circulation* 2001; 104: 779-82.
- Cosin J, Diez J. Torasemide in chronic heart failure: results of the TORIC study. *Eur J Heart Fail* 2002; 4: 507-13.
- Paris R, Flather M, Purcell H, Henein M, Poole-Wilson P, Coats A. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials. *Int J Cardiol* 2002; 82: 149-158.
- Hess OM (Arbeitsgruppe für Herzinsuffizienz der schweizerischen Gesellschaft für Kardiologie). Empfehlungen zur Diagnose und Behandlung der chronischen Herzinsuffizienz. *Schweizerische Ärztezeitung* 2002; 83: 1233-42.
- Kjeldsen SE, Dahlöf B, Devereux RB, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. *JAMA* 2002; 288: 1491-8.
- Lubien E, DeMaria A, Krishnaswamy P, Clopton P, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with doppler velocity recordings. *Circulation* 2002; 105: 595-601.
- Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. *Circulation* 2002; 105: 1387-93.
- Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. *Circulation* 2002; 105: 1503-8.
- Funder JW. The role of mineralocorticoid receptor antagonists in the treatment of cardiac failure. *Expert Opin Investig Drugs* 2003; 12: 1963-9.
- Granger CB, McMurray JJV, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. *Lancet* 2003; 362: 772-776.
- Jessup M, Brozena S. Heart failure. *N Engl J Med* 2003; 348: 2007-18.
- Nohria A, Tsang SW, Fang JC, Stevenson LW. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. *J Am Coll Cardiol* 2003; 41: 1797-1804.
- Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, Captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. *N Engl J Med* 2003; 349: 1893-906.
- Pfeffer M, Swedberg K, Granger C, et al. Effect of Candesartan on mortality and morbidity in patients with chronic heart failure. The CHARM-Overall Programme. *Lancet* 2003; 362: 759-66.

- Yusuf S, Pfeffer M, Swedberg K et al. Effects of Candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. *Lancet* 2003; 362: 777-81.
- Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without implantable defibrillator in advanced chronic heart failure. *N Engl J Med* 2004; 350: 2140-50.
- Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure - abnormalities in active relaxation and passive stiffness of the left ventricle. *N Engl J Med* 2004; 350: 1953-9.
- Palmer BF. Managing hypokalemia caused by inhibitors of the renin-angiotensin-aldosterone system. *N Engl J Med* 2004; 351: 585-92.
- Stevenson LW. Design of therapy for advanced heart failure. *Eur J Heart Fail* 2005; 7: 323-31.
- Kjekshus J., Apetrei E, Barrios V et al. Rosuvastatin in Older Patients with Systolic Heart Failure. *N Engl J Med* 2007; 357: 2248-61.
- Beshai JF, Grimm RA, Nagueh SF, et al. Cardiac Resynchronization Therapy in Heart Failure with Narrow QRS Complexes. *N Engl J Med* 2007; 357: 2461-71.
- Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. *N Engl J Med* 2008; 359: 2456-2467.
- Moya A, Sutton R, Ammirati F, et al. Guidelines for the diagnosis and management of syncope (2009). *Eur Heart J* 2009 ; 30: 2631-71.
- De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. *N Engl J Med* 2010;362:779-789.
- Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. *N Engl J Med* 2012;367: 2296-2304.
- ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. McMurray JJ, Adamopoulos S, Anker SD et al. *Eur J Heart Fail* 2012; 14: 803-69.
- Faris RF, Flather M, Purcell H, et al. Diuretics for heart failure. *Cochrane Database Syst Rev* 2012; 2: CD003838.
- Jankowska EA, von Haehling S, Anker SD et al. Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. *Eur Heart J* 2013;34:816-26.
- McMurray J, Packer M, Desai A, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. *N Engl J Med* 2014; 371: 993-1004.
- Pitt B, Pfeffer MA, Assmann SF et al. Spironolactone for heart failure with preserved ejection fraction. *N Engl J Med*. 2014; 370: 1383-92.
- Felker GM, Mentz RJ, Teerlink JR, et al. Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX-AHF study. *Eur J Heart Fail* 2015;17:1262-70.
- Mebazaa A, Yilmaz MB, Levy P, et al. Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the HFA of the ESC, the European Society of emergency Medicine and the Society of Academic Emergency Medicine. *Eur J Heart Fail* 2015;17:544-58.
- Savarese G, Perrone-Filardi P, D'Amore C, et al. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: a meta-analysis. *Int J Cardiol* 2015;181:239-244.
- Zinman B, Wanner C, Lachin JM, et al. EMPAREG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med* 2015;373:2117-28.
- Authors/Task Force Members: Ponikowski P (Chairperson), Voors AA. (Co-Chairperson) Anker St.D. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur J Heart Failure* (2016) doi:10.1002/ejhf.592
- Kirchhof P, Benussi S et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J*. 2016. doi: 10.1093/eurheartj/ehw210. Forthcoming
- Køber L, Thune JJ, Nielsen JJ et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure *N Engl J Med* 2016; 375: 1221-30.
- Kirchhof P, Benussi S, Koteka D et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J* 2016; 37: 2893-2962.
- McMurray JJ, Krum H, Abraham WT et al. Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure. *N Engl J Med* 2016; 374: 1521-32.
- Eikelboom JW, Connolly SJ, Bosch J et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. *N Engl J Med* 2017; 377: 1319–1330.
- Guasch-Ferre M, Salas-Salvado J, Ros E, et al. The PREDIMED trial, Mediterranean diet and health outcomes: How strong is the evidence? *Nutr Metab Cardiovasc Dis* 2017; 27: 624-32.
- Neal B, Perkovic V, Mahaffey KW et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. *NEJM* 2017;377:644-657.
- Núñez J, Bayés-Genís A, Zannad F et al. Long-Term Potassium Monitoring and Dynamics in Heart Failure and Risk of Mortality. *Circulation* 2018; 137: 1320-30.
- De Lorgeril M, Salen P, Martin JL et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. *Circulation* 1999; 99: 779-85.
- McDonagh TA, Metra M, Adamo M et ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J* 2021; 42: 3599-3726. doi: 10.1093/eurheartj/ehab368

Cardiomyopathie - Kardiomyopathie

Abelmann WH. Classification and natural history of primary myocardial disease. *Prog Cardiovasc*

- Dis 1984; 27: 73-94.
- Packer DL, Bardy GH, Worley SJ, et al. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol 1986; 57: 563-70.
- Lampert MB, Lang RM. Peripartum cardiomyopathy. Am Heart J 1995; 130: 860-70.
- Manolio TA, Baughman KL, Rodeheffer R, et al. Prevalence and etiology of idiopathic dilated cardiomyopathy. Am J Cardiol 1992; 69: 1458-66.
- Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med 1994; 331: 1564-75.
- Richardson R, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of the cardiomyopathy. Circulation 1996; 93: 841-2.
- Felker CM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000; 342: 1077-84.
- Nagueh SF, Ommen SR, Lakkis NM, et al. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2001; 15: 1701-6.
- Frustaci A, Cuoco L, Chimenti C, et al. Celiac disease associated with autoimmune myocarditis. Circulation 2002; 105: 2611-8.
- Felker GM, Thompson RE, Joshua M, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000; 342: 1077-84.
- Bhagwandin R, Woo A, Ross J, et al. Septal ethanol ablation for hypertrophic obstructive cardiomyopathy: early and intermediate results of a Canadian referral center. Can J Cardiol 2003; 19: 912-7.
- Nielsen CD, Killip D, Spencer WH 3rd. Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy; short-term results in 50 consecutive procedures. Clin Cardiol 2003; 26: 275-9.
- Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140-50.
- Kadish A, Dyer A, Dauber JP, et al. Prophylactic defibrillator implantation in patients with non-ischemic dilated cardiomyopathy. N Engl J Med 2004; 350: 2151-8.
- Templin C, Ghadri JR, Diekmann J, et al. Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. NEJM 2015; 373: 929-38.
- McDonagh TA, Metra M, Adamo M, Gardner RS et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2021; 42: 3599-3726, <https://doi.org/10.1093/eurheartj/ehab368>
- Stimulateur cardiaque - Pacemaker**
- Javier RP, Maramba LC, Hildner FJ, et al. Temporary cardiac pacing: technique and indications. Chest 1971; 59: 498-500.
- Goy JJ. La stimulation cardiaque: indication et évolution actuelle. Rev Med Suisse Rom 1986; 106: 359-63.
- ACC/AHA Guidelines for early management of patients with acute myocardial infarction. Circulation 1990; 82: 664-707.
- Dreifus LS, Fisch C, Griffin JC, et al. Guidelines for implantation of cardiac pacemakers and antiarrhythmia devices. Circulation 1991; 84: 455-67.
- Jafri SM, Kruse JA. Temporary transvenous cardiac pacing. Crit Care Clin 1992; 8: 713-25.
- Report of the joint American College of Cardiology/ American Heart Association task force on assessment of cardiovascular procedures (subcommittee on pacemaker implantation): Guidelines for permanent cardiac pacemaker implantation. JACC 1994; 4: 433-42.
- Kusumoto FM, Goldschlager N. Cardiac pacing. N Engl J Med 1996; 332: 89-98.
- Committee on pacemaker implantation. ACC/ AHA Guidelines for implantation of cardiac pacemakers and antiarrhythmia devices: executive summary. Circulation 1998; 97: 1325-35.
- Valvulopathie - Klappenvitien**
- Folland ED, Kriegel BJ, Hernderson WG, et al. Implication of third heart sounds in patients with valvular heart disease. N Engl J Med 1992; 327: 458-62.
- Carabello BA, Crawford FA. Valvular heart disease. N Engl J Med 1997; 337: 32-41.
- ACC/AHA Guidelines for Management of Patients With Valvular Heart Disease. JACC 1998; 32: 1486-588.
- Bonow RO et al. ACC/AHA guidelines for the management of patients with valvular heart disease. Circulation 1998; 98: 1949-84. Also published in: J Heart Valve Dis 1998 ; 7: 672-707 and JACC 1998; 32: 1486-588.
- Quinones MA. Management of mitral regurgitation. Cardiology Clinics 1998; 16: 421-35.
- Braunwald E, Zipes DP, Libby P. (eds.). Valvular heart disease. In: Heart disease: a textbook of cardiovascular medicine. W.B. Saunders Company. 2001; p. 1643-1704.
- Khot UN, Novaro GM, Popovic Z, et al. Nitroprussiate in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med 2003; 348: 1756-63.
- Christen T., Lercha R., Trindadea PT. Die Aortenklappenstenose beim Erwachsenen. Schweiz Med Forum 2006;6:647-651.
- Leon MB, Smith CR, Mack M et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. NEJM 2010; 363: 1597-607.
- Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC). Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 2012; 33: 2451-96.

- Nishimura RA, Otto CM, Bonow RO et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation* 2014;129:2440-92.
- Baumgartner H, Falk V, Bax JJ et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur Heart J* 2017; 38: 2739-2791.
- Kang DH, Park SJ, Lee SA et al. Early surgery versus conservative care for asymptomatic aortic stenosis. *NEJM* 2020; 382: 111-119.
- Auscultation cardiaque - Herzauskultation**
- Folland ED, Kriegel BJ, Hernderson WG, et al. Implication of third heart sounds in patients with valvular heart disease. *N Engl J Med* 1992; 327: 458-62.
- Carabello BA, Crawford FA. Valvular heart disease. *N Engl J Med* 1997; 337: 32-41.
- Etchells E, Bell C, Robb K. Does this patient have an abnormal systolic murmur? *JAMA* 1997; 277: 564-71.
- Shry EA. Auscultation versus echography in a healthy population with precordial murmur. *Am J Cardiol* 2001; 87:1428-30.
- Shub C. Echography or auscultation. *Can Fam Phys* 2003; 49: 163-7.
- Bouchardy J, Schlueter L. Souffle cardiaque et indications à l'échocardiographie. *Rev Med Suisse* 2005; 21: 1400-2, 1405.
- Insuffisance artérielle -AOMI - PAVK**
- Cranley JJ. Ischemic rest pain. *Arch Surg* 1969;98: 187-8.
- Spittell JA. Recognition and management of chronic atherosclerotic occlusive peripheral arterial disease. *Mod Concepts Cardiovasc Dis* 1981;50:19-23.
- Jamieson C. The definition of critical ischaemia of a limb. *Br J Surg* 1982;69(Suppl.):S1.
- Second European consensus document on chronic critical leg ischemia. *Circulation* 1991;84:IV1-26.
- Pentecost MJ, Criqui MH, Dorros G, et al. Guidelines for peripheral percutaneous transluminal angioplasty of the abdominal aorta and lower extremity vessels. A statement for health professionals from a special writing group of the Councils on Cardiovascular Radiology, Arteriosclerosis, Cardio-Thoracic and Vascular Surgery, Clinical Cardiology, and Epidemiology and Prevention, the American Heart Association. *Circulation* 1994;89: 511-31.
- Pahlsson HI, Wahlberg E, Olofsson P, Swedeborg J. The toe pole test for evaluation of arterial insufficiency in diabetic patients. *Eur J Vasc Endovasc Surg* 1999;18: 133-7.
- Hankey GJ, Norman PE, Eikelboom JW. Medical treatment of peripheral arterial disease. *JAMA* 2006; 295: 547-53.
- Hirsch AT, Haskal ZJ, Hertzler NR, et al. ACC/AHA 2005 Practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic). *Circulation* 2006;113:e463-654.
- Khan NA, Rahim SA, Anand SS, Simel DL, Panju A. Does the clinical examination predict lower extremity peripheral arterial disease ? *JAMA* 2006;295:536-46.
- Burrows, C., et al. Best practice recommendations for the prevention and treatment of venous leg ulcers: Update 2006. *Wound Care Canada* 2006: 4: 45-55.
- Paraskevas N, Ayari R, Malikov S, et al. «Pole test» measurements in critical leg ischaemia. *Eur J Vasc Endovasc Surg* 2006;31:253-7.
- Norgen L, Hiatt WR, Dormandy JA, et al. International consensus for the management of peripheral arterial disease (TASC II). *Eur J Vasc Endovasc Surg* 2007;33(Suppl.1):S1-75.
- Fowkes FG, Price JF, Stewart MC et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. *JAMA* 2010; 303: 841-8.
- Varu VN, Hogg ME, Kibbe MR. Critical limb ischemia. *J Vasc Surg* 2010;51:230-41.
- Becker F, Robert-Ebadi H, Ricco JB, et al. ESVS guidelines for critical limb ischemia and diabetic foot. Chapter I : Definitions, epidemiology, clinical presentation and prognosis. *Eur J Vasc Endovasc Surg* 2011;42 (Suppl.2):S4-12.
- Murphy TP, Cutlip DE, Regensteiner JG et al. Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) study. *Circulation*. 2012; 125: 130-9.
- Becker F, Robert-Ebadi H. Diagnostic clinique de l'ischémie critique chronique de membre inférieur. *Rev Med Suisse* 2013;302-305.
- Rooke TW, Hirsch AT, Misra S et al. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA Guideline Recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2013; 61: 1555-70.
- Pouls**
- Spodick DH. Acute cardiac tamponade: pathologic physiology, diagnosis and management. *Prog Cardiovasc Dis* 1967; 10: 64-96.
- Gubermann BA, Fowler NO, Engel PJ, et al. Cardiac tamponade in medical patients. *Circulation* 1982; 64: 633-40.
- Anticoagulation**
- Sixth ACCP Consensus Conference on anti-thrombotic therapy. *Chest* 2001; 119 (Suppl. 1): 1S-336S.
- The Warfarin Antiplatelet Vascular Evaluation Trial Investigators. Oral Anticoagulant and Anti-platelet Therapy and Peripheral Arterial Disease. *N Engl J Med* 2007; 357: 217-27.
- Stratific. risque périop. coronarien**
- Palda VA, Detsky AS. Perioperative assessment and management of risk from coronary artery

disease. Ann Intern Med 1997; 127: 131-28.
Fleisher LA, Eagle K. Lowering cardiac risk in noncardiac surgery. N Engl J Med 2001; 345: 1677-82.

Vie veineuse centrale

<http://content.nejm.org/cgi/content/short/357/24/e26?query=TOC>

PNEUMOLOGIE

Dyspnée — Dyspnée

Lavanchy AS, Bahri Ksouri A, Garcia W, Ribordy V. Dyspnée haute chez l'adulte. Rev Med Suisse 2015; 11: 1486-90.

Lungenauskultation

Auscultation pulmonaire

Forcas P. (ed.). Lung sounds. Baillière Tindall, 1978.

Zellweger JP. Anamnesis and physical examination in pneumology. Praxis 1992; 81: 278-81.

Maitre B, Similowski T, Derenne JP, et al. Physical examination of the adult patient with respiratory diseases: inspection and palpation. Eur Respir J 1995; 8: 1584-93.

Marquet P. Les bruits d'origine ventilatoire. Rev Mal Resp 1995; 12: 87-101.

Meslier N, Charbonneau G, Racineux JL, et al. Wheezes. Eur Respir J 1995; 8: 1942-8.

Sharma OP. Symptoms and signs in pulmonary medicine: old observations and new interpretations. Disease-A-Month 1995; 41: 577-638.

Breitenstein E, Aubert JD. Signes cliniques en pneumologie: faut-il encore les rechercher ? Med Hyg 1996; 54: 2231-3.

Asthme

NET: www.ginasthma.com

McFadden ER, Lyons HA. Arterial blood gas tension in asthma. N Engl J Med 1968; 278: 1027-32.

McFadden ER, Gilbert IA. Asthma. N Engl J Med 1992; 327: 1928-37.

Corbridge TC, Hall JB. The assessment and management of adults with status asthmaticus. Am J Respir Crit Care Med 1995; 151: 1296-1316.

McFadden ER, Hejal R. Asthma. Lancet 1995; 345: 1215-20.

Schaller MD, Tagan D, Perret C. Asthme aigu grave. Encycl Med Chir (Elsevier, Paris), Anesthésie-reanimation, 36-970-A-10, 1996.

Evans DJ, Taylor DA, Zetterstrom O, et al. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 1997; 337: 1412-8.

O'Byrne PM, Israel E, Drazen JM. Antileucotrienes in the treatment of asthma. Ann Intern Med 1997; 127: 472-80.

The British Thoracic Society. Guidelines and asthma management. Thorax 1997; 52 (Suppl.1): S1-S21.

Van der Molen T, et al. Effects of the long acting β-agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. Thorax 1997; 52: 535-9.

Leff JA, Busse WW, Pearlman D, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med, 1998; 339: 147-52.

Li JT, et al. Algorithm for the diagnosis and management of asthma: a practice parameter update: Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998; 81: 415-20.

Nelson JA, Strauss LS, et al. Effect of long-term salmeterol treatment on exercise-induced asthma. N Engl J Med 1998; 339: 141-6.

Pralong G, Leuenberger Ph. Les bêta-2 stimulants à longue durée d'action dans le traitement de l'asthme: utiles ou dangereux ? Med Hyg 1998; 56: 2322-6.

BPCO - COPD - MPOC

Fletcher CM, Elmes PC, Fairbairn MB, et al. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br Med J 1959; 2: 257-266.

Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest 1988; 93: 580-6.

Medical Research Council. Definition and classification of chronic bronchitis for clinical and epidemiological purposes. Lancet 1965; i: 775-9.

Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease. Ann Intern Med 1980; 93: 391-8.

Medical Research Council. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981; 1: 681-6.

Antoniou NR, Manfreda J, Warren CPW, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204.

American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 1991; 144: 1202-18.

Callahan CM, Dittus RS, Katz BP. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease. A meta-analysis. Ann Intern Med 1991; 114: 216-23.

Murphy TF, Sethi S. Bacterial infection in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992; 146: 1067-83.

Curtis JR, et al. Emergent assessment and management of acute respiratory failure in COPD. Clin in Chest Med 1994; 3: 481-500.

American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Resp Crit Care Med 1995; 152: 77-120.

Brochard L, Manecebo J, Wysocky M, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl

- J Med 1995; 333: 817-22.
- Kramer N, Meyer TJ, Meharg J, et al. Randomized, prospective trial of noninvasive positive pressure ventilation in acute respiratory failure. Am J Respir Crit Care Med 1995; 151: 1799-1806.
- Saint S, Bent S, Vittinghoff E, et al. Antibiotics in chronic obstructive pulmonary diseases exacerbations. A meta-analysis. JAMA 1995; 273: 957-60.
- Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 1995; 8: 1398-1420.
- Tarpy SP, Celli BR. Long-term oxygen therapy. N Engl J Med 1995; 333: 710-4.
- Aboussouan LS. Acute exacerbations of chronic bronchitis. Postgrad Med 1996; 99: 89-103.
- Leuenberger Ph, Anderhub HP, Brändli O, et al. Management 1997 of chronic obstructive pulmonary disease. Schweiz Med Wochenschr 1997; 127: 766-82.
- McEvoy CE, Niewoehner DE. Adverse effects of corticosteroid therapy for COPD. A critical review. Chest 1997; 111: 732-43.
- O'Donohue WJ. Home oxygen therapy. Clin Chest Med 1997; 18: 535-45.
- Maurer JR, Frost AE, Estenne M, et al. International guidelines for the selection of lung transplant candidates. The international society for heart and lung transplantation, the american thoracic society. Transplantation 1998; 66: 951-6.
- Davies L, Angus RM, Calverley PMA. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999; 354: 456-60.
- Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999; 340: 1941-7.
- Vincken W, Greefhorst APM, Westbroek J, et al. Once daily tiotropium is more efficacious than q.i.d. ipratropium as maintenance treatment of COPD. Eur Resp J 1999; 14 (Suppl. 30): 520S.
- Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 269-80.
- Lancaster T, Stead L, Silagy C, et al. Effectiveness of interventions to help people stop smoking: findings from the Cochrane Library. BMJ 2000; 321: 355-8.
- Niewoehner DE, Collins D, Erbland ML. Relation of FEV₁ to clinical outcomes during exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 1201-5.
- Rice KL, Rubins JB, Lebahn F, et al. Withdrawal of chronic systemic corticosteroids in patients with COPD; a randomized trial. Am J Respir Crit Care Med 2000; 162: 174-8.
- Fitting JW, Rochat Th. Corticostéroïdes dans la broncho-pneumopathie obstructive chronique. Réhabilitation respiratoire. Med Hyg 2000; 58: 60-4.
- McCrory DC, Brown C, Gelfand SE, et al. Management of acute exacerbations of COPD. Chest 2001; 119: 1190-1209.
- Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary diseases. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care 2001; 163: 1256-76.
- Snow V, Lascher S, Mottur-Pilson C. The evidence base for management of acute exacerbations of COPD: clinical practice guideline. Chest 2001; 119: 1185-9.
- Donohue JA, van Noord JA, Bateman ED, et al. A 6-month placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47-55.
- Casburn R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217-24.
- Aron SD, Vandemheen KL, Hebert P, et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med 2003; 348: 2618-25.
- Irwin RS, Madison M. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2003; 348: 2679-81.
- National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003; 348: 2059-73.
- Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005-12.
- Løkke A, Lange P, Vestbo J, et al. Developing COPD—25 years follow-up study of the general population. Thorax 2006; 61: 935-9.
- Ozalevli S, Ozden A, Itil O, Akkoclu A: Comparison of the Sit-to-Stand Test with 6 min walk test in patients with chronic obstructive pulmonary disease. Respir Med 2007; 101: 286-93.
- Tashkin DP, Celli B, Senn S, et al. UPLIFT Study Investigators. A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease. N Engl J Med 2008; 359: 1543-54.
- Leuppi JD, Schuetz P, Bingisser R et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA 2013; 5; 309(21):2223-31. doi: 10.1001/jama.2013.5023.
- García-Sidro P, Naval E, Martinez Rivera C et al. The CAT (COPD Assessment Test) questionnaire as a predictor of the evolution of severe COPD exacerbations. Resp Med 2015; 109: 1546-52.
- Weill D, Benden C, Corris PA et al. A consensus document for the selection of lung transplant candidates: 2014 - an update from the Pulmonary Transplantation Council of the International

- Society for Heart and Lung Transplantation. *J Heart Lung Transplant* 2015; 34: 1-15.
- Vogelmeier CF, Criner GJ, Martinez FJ et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. *Am J Respir Crit Care Med* 2017; 195: 557-82.
- Fonction pulmonaire, spirométrie, ERF**
- Weinberger SE. Principles of pulmonary medicine. Philadelphia, Saunders, 1986.
- West JB. (ed.). Physiologie respiratoire. 2ème édition. MEDSI, Paris, 1986.
- Gold WM, Boushey HA. Pulmonary function testing. Murray JF, Nadel JA (eds.). In: Textbook of respiratory medicine. Philadelphia, Saunders, 1988, p: 611-82.
- Altose MD. Practical aspects of pulmonary function testing. In: Baum GL, Wolinsky E. (eds.). Textbook of Pulmonary Disease. Little Brown and Company, 1989; p: 101-3.
- Clausen JL. Pulmonary testing. In: Kelly WN, et al. (eds.). Textbook of Internal Medicine, Philadelphia, JB. Lippincott, 1992, p: 182.
- Débit de pointe (Peak flow)
- Gregg I, Nunn AJ. Peak expiratory flow on normal subjects. *BMJ* 1973; 3: 282-4.
- Nunn AJ, Gregg I. New regression equations for predicting peak expiratory flow in adults. *BMJ* 1989; 298: 1068-70.
- Regan EA, Lynch DA, Curran-Everett D et al. Clinical and Radiologic Disease in Smokers With Normal Spirometry. *JAMA Intern Med* 2015; 175: 1539-49.
- Pleuraerguss**
- Bintcliffe OJ, Hooper CE, Rider IJ, et al. Unilateral pleural effusions with more than one apparent etiology. A prospective observational study. *Ann Am Thorac Soc* 2016; 13: 1050-6.
- Jany B, Welte T. Pleuraerguss des Erwachsenen – Ursachen, Diagnostik und Therapie Deutsches Ärzteblatt 2019; 116: 377-386.
- Pneumothorax**
- Miller AC, Harvey JE on behalf of Standards of Care Committee, British Thoracic Society. Guidelines for the management of spontaneous pneumothorax. *Br Med J* 1993; 307: 114-6.
- Jant MA, Pierson DJ. Pneumothorax and barotrauma. *Clin Chest Med* 1994; 15: 75-91.
- Light RW. Tension pneumothorax. *Intensive Care Med* 1994; 20: 468-9.
- Light RW. Pleural diseases. 3rd edition. Baltimore, Williams and Wilkins 1995.
- Wysler C, Ullmer E, Bolliger CT. Pneumothorax. Bulletin des Médecins Suisses. 1998; 79: 28-31.
- Sahn SA, Heffner JE. Spontaneous pneumothorax. *N Engl J Med* 2000; 342: 868-74.
- Baumann HM, Strange C, Heffner HE, et al. Management of spontaneous pneumothorax: an American College of Chest Physician Delphi consensus statement. *Chest* 2001; 119: 590-602.
- Noppen M, Alexander P, Driesen P, et al. Manual aspiration versus chest tube drainage in first episodes of primary spontaneous pneumothorax: a multicentre, prospective, randomized pilot study. *Am Respir Crit Care Med* 2002; 165: 1202-3.
- Henry M, Arnold T, Harvey J, et al. BTS guidelines for the management of spontaneous pneumothorax. *Thorax* 2003; 58 (Suppl. II): ii39-ii52.
- Dev SP, Nascimento B Jr, Simone C, Chien V. Videos in clinical medicine. Chest-tube insertion. *N Engl J Med* 2007; 357(15): e15.
- Dev SP, Nascimento B Jr, Simone C, Chien V. Videos in clinical medicine. Chest-tube insertion. *N Engl J Med* 2007; 357(15): e15.
- MacDuff A, Arnold A, Harvey J. BTS Pleural Disease Guideline Group. Management of spontaneous pneumothorax: British Thoracic Society Pleural Disease Guideline 2010. *Thorax* 2010; 65 Suppl 2: ii18-31.
- Ho KK, Ong ME, Koh MS, et al. A randomized controlled trial comparing minichest tube and needle aspiration in outpatient management of primary spontaneous pneumothorax. *Am J Emerg Med* 2011; 29: 1152-7.
- Lai SM, Tee AK. Outpatient treatment of primary spontaneous pneumothorax using a small-bore chest drain with a Heimlich valve: the experience of a Singapore emergency department. *Eur J Emerg Med* 2012; 19: 400-4.
- Hu X, Cowl CT, Baqir M, Ryu JH. Air travel and pneumothorax. *Chest* 2014; 145: 688-94.
- Roberts DJ, Leigh-Smith S, Faris PD, Blackmore C et al. Clinical Presentation of Patients With Tension Pneumothorax: A Systematic Review. *Ann Surg* 2015; 261: 1068-78.
- Chang SH, Kang YN, Chiu HY et al. A Systematic Review and Meta-Analysis Comparing Pigtail Catheter and Chest Tube as the Initial Treatment for Pneumothorax. *Chest* 2018; 153: 1201-1212.
- Test aux stéroïdes - Steroidtest**
- Leuenberger Ph, Anderhub HP, Brändli O, et al. Management 1997 of chronic obstructive pulmonary disease. *Schweiz Med Wochenschr* 1997; 127: 766-82.
- Fitting JW, Rochat Th. Corticostéroïdes dans la broncho-pneumopathie obstructive chronique. Rehabilitation respiratoire. *Med Hyg* 2000; 58: 60-4.
- Pneumonie**
- Guidelines for the management of community-acquired pneumonia in adults admitted to hospital. *British J Hosp Med* 1993; 49: 346-50.
- Marrie TJ. Community-acquired pneumonia. *Clin Infect Dis* 1994; 18: 501-15.
- American Thoracic Society. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. *Am J Respir Crit Care Med* 1996; 153: 1711-25.
- Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcome of patients with community-acquired pneumonia. A meta-analysis. *JAMA* 1996; 275: 134-41.
- Fine JM, Auble TE, Yealy DM, Hanusa BH, et al. A prediction rule to identify low-risk patients with

- community-acquired pneumonia. *N Engl J Med* 1997; 336: 243-50.
- Metyl JP, Kapoor WN, Fine JM. Does this patient have community-acquired pneumonia ? *JAMA* 1997; 278: 1440-5.
- Bartlett JG, Breiman RF, Mandell LA, File TM. Guidelines from the infectious diseases society of America. Community-acquired pneumonia in adults: guidelines for management. *Clin Infect Dis* 1998; 26: 811-38.
- ESOCAP committee: management of adult community-acquired lower respiratory tract infections. *Eur Respir J* 1998; 61: 391-426.
- Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalised with community-acquired pneumonia. Implications for practice guidelines. *JAMA* 1998; 279: 1452-7.
- Nathwani D. Sequential switch therapy for lower respiratory tract infections. *Chest* 1998; 113: 211S-218S.
- Fine MJ, Stone RA, Singer DE, et al. Process and outcomes of care for patients with community-acquired pneumonia. *Arch Intern Med* 1999; 159: 970-80.
- Lamy O, Zanetti G, Bille J, et al. Diagnostic et traitement de la pneumonie acquise à domicile de l'adulte. *Rev Suisse Rom* 1999; 119: 403-27.
- Mandell LA, Marrie TJ, Grossman RF, et al. Summary of canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the canadian infectious disease and the canadian thoracic society. *Can Respir J* 2000; 7: 371-82.
- Guthrie R. Community-acquired lower respiratory tract infections. Etiology and treatment. *Chest* 2001; 120: 2021-34.
- McCory DC, Brown C, Gelfand SE, et al. Management of acute exacerbation of COPD. *Chest* 2001; 119: 1190-1209.
- Halm EA, Teirstein AS. Managemenet of community-acquired pneumonia. *N Engl J Med* 2002; 347: 2039-45.
- Lim WS, van der Eerden MM, Laing R et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. *Thorax* 2003; 58: 377-82.
- Woodhead M1, Blasi F, Ewig S et al. Guidelines for the management of adult lower respiratory tract infections. *Clin Microbiol Infect* 2011; 17 (Suppl 6):E1-59.
- Pneumonie acquise en communauté (PAC)**
- Erworbene Pneumonie (CAP)**
- Ferreira-Gonzalez I, Permanyer-Miralda G, Busse JW, et al. Methodologic discussions for using and interpreting composite endpoints are limited, but still identify major concerns. *J Clin Epidemiol* 2007; 60: 651-57.
- Ewig S, Birkner N, Strauss R et al. New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. *Thorax* 2009; 64: 1062-9.
- Hemkens LG, Grouven U, Bender R, Sawicki PT. Insufficient evaluation of adverse events is not a proof of safety. *Diabetologia* 2010; 53: 790-92.
- Hirata Y, Tomioka H, Sekiya R, et al. Association of hyperglycemia on admission and during hospitalization with mortality in diabetic patients admitted for pneumonia. *Intern Med* 2013; 52: 2431-38.
- Garin N, Genné D, Carballo S et al. β -Lactam monotherapy vs β -lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. *JAMA Intern Med* 2014; 174: 1894-901.
- Annané D. Corticosteroids and pneumonia: time to change practice. *Lancet* 2015; 385: 1484-85.
- Claudine Blum CA, Nigro N, Briel M, et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. *Lancet* 2015; 385: 1511-18.
- Épanchement pleural**
- Yam LT. Diagnostic significance of lymphocytes in pleural effusions. *Ann Intern Med* 1967; 66: 972-82.
- Light RW, et al. Pleural effusions: the diagnostic separation of transudates and exudates. *Ann Intern Med* 1972; 77: 507-13.
- Hurwitz S, Leiman G, Shapiro C. Mesothelial cells in pleural fluid: TB or not TB? *SAfr Med J* 1980; 57: 937-39.
- Ocana IM, et al. Adenosine deaminase in pleural fluids. *Chest* 1983; 84: 51-53.
- Seneff MG, et al. Complications associated with thoracocentesis. *Chest* 1986; 90: 97-100.
- Rodríguez-Panadero, Lopez Mejías J. Low glucose and pH levels in malignant pleural effusions. *Am Rev Respir* 1989; 139: 663-7.
- Light RW. Pleural diseases. 3rd ed. Baltimore, Williams and Wilkins 1995.
- Marel M, et al. Diagnosis of pleural effusions. *Chest* 1995; 107: 1598-1603.
- Hamm H, Light RW. Parapneumonic effusion and empyema. *Eur Respir J* 1997; 10: 1150-6.
- Light RW. Diagnostic principles in pleural disease. *Eur Respir J* 1997; 10: 476-81.
- Trachiotis GD, Vricella LA, Aaron BL, et al. Reexpansion pulmonary edema. *Ann Thorac Surg* 1997; 63: 1206-7.
- Nicod LP. Épanchement parapneumoniques: évaluation et traitement. *Med Hyg* 1997; 55: 2312-5.
- Aleman C, Alegre J, Armadans L, et al. The value of chest roentgenography in the diagnosis of pneumothorax after thoracentesis. *Am J Med* 1999; 107: 340-3.
- Light RW. Pleural effusion. *N Engl J Med* 2002; 346: 1971-7.
- Thomsen TW, DeLaPena J, Setnik GS. Thoracentesis. *N Engl J Med* 2007; 355: e16.
- Havelock T, Teoh R, Laws D et al. Pleural procedures and thoracic ultrasound: British Thoracic Society pleural disease guideline 2010. *Thorax* 2010; 65(Suppl 2): ii61eii76.
- Rahman NM, Maskell NA, West A et al. Intrapleural Use of Tissue Plasminogen Activator and

- DNase in Pleural Infection. *N Engl J Med* 2011; 365: 518-26.
- Denkinger CM, Schumacher SG, Boehme CC et al. Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis. *Eur Respir J* 2014; 44: 435-46.
- Pneumopathies interstitielles**
- Dunkalek E. Interstitielle (diffuse) Lungenerkrankungen. In: Kaufmann W. (ed.). *Internistische Differenzialdiagnostik*. Schattauer Verlag, 1997, p. 580-99.
- Siegenthaler W, Kaufmann W, Hornbostel H, et al (eds.). In: *Lehrbuch der inneren Medizin*. Thieme, 1997.
- Fibrose pulmonaire idiopathique**
- Katzenstein ALA, Myers JL. Idiopathic pulmonary fibrosis - clinical relevance of pathologic classification. *Am J Respir Crit Care Med* 1998; 157: 1301-15.
- Mason RJ, Schwarz MI, Hunninghake GW, et al. Pharmacological therapy for idiopathic pulmonary fibrosis: past, present, future. *Am J Respir Crit Care Med* 1999; 160: 1771-7.
- King TE, Costabel U, Cordier JE, et al. ATS/ERS. Idiopathic pulmonary fibrosis: Diagnosis and treatment. *Am J Respir Crit Care Med* 2000; 161: 646-64.
- Idiopathic pulmonary fibrosis: diagnosis and treatment: international consensus statement. *Am J Respir Crit Care Med* 2000; 161: 646-64.
- Gross TG, Hunninghake GW. Idiopathic pulmonary fibrosis. *N Engl J Med* 2001; 345: 517-25.
- Travis WE, King TE, Bateman ED, et al. ATS/ERS international multidisciplinary consensus classification of idiopathic interstitial pneumonias. General principles and recommendations. *Am J Respir Crit Care Med* 2002; 165: 277-304.
- Noble P, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomized trials. *Lancet* 2011; 377: 1760-9.
- Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. *N Engl J Med* 2011; 365: 1079-87.
- King TE, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis (ASCEND). *N Engl J Med* 2014; 370: 2083-92.
- Richeldi L, du Bois R, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis (INPULSIS). *N Engl J Med* 2014; 370: 2071-82.
- Travis WD, Costabel U, Hansell DM et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. *Am J Respir Crit Care Med* 2013; 188: 733-48.
- Hypertension pulmonaire (HP)**
- Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. *Ann Intern Med* 1987; 107: 216-23.
- Rich S, Chomka E, Hasara L, et al. The prevalence of pulmonary hypertension in the United States. Adult population estimates obtained from measurements of chest roentgenograms from the NHANES II Survey. *Chest* 1989; 96: 236-41.
- Speich R, Jenni R, Opravil M, et al. Primary pulmonary hypertension in HIV infection. *Chest* 1991; 100: 1268-71.
- Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. *N Engl J Med* 1992; 327: 76-81.
- Rubin LJ. ACCP consensus statement: primary pulmonary hypertension. *Chest* 1993; 104: 236-50.
- Rich S, Kaufmann P, Lew PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. *N Engl J Med* 1992; 327: 76-81.
- Abenhami L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. *N Engl J Med* 1996; 335: 609-16.
- Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. *N Engl J Med* 1996; 334: 296-301.
- Gaine SP, Rubin LJ. Primary pulmonary hypertension. *Lancet* 1998; 352: 719-25.
- Rich S, (ed). Primary pulmonary hypertension: executive summary from the world symposium. Geneva: World Health Organization, 1998.
- Benigni A, Ramuzzi G. Endothelin antagonists. *Lancet* 1999; 353: 133-8.
- Sanchez O, Humbert M, Sitbon O, et al. Treatment of pulmonary hypertension secondary to connective tissue disease. *Thorax* 1999; 54: 274-7.
- Hooper MM, Schwarze M, Ehlerding St, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. *N Engl J Med* 2000; 342: 1866-70.
- Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. *Lancet* 2001; 358: 1119-23.
- Hooper MM, Galie N, Simonneau G, et al. New treatments for pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2002; 165: 1209-16.
- Kim NHS, Rubin LJ. Endothelin in health and disease: endothelin receptor antagonist in the management of pulmonary artery hypertension. *J Cardiovasc Pharmacol Therapeut* 2002; 7: 9-19.
- Prakash A, Perry CM. Bosentan. *Am J Cardiovasc Drugs* 2002; 2: 335-42.
- Olschewski H, G Simonneau, Galie N, et al. Inhaled Iloprost for severe pulmonary hypertension. *N Engl J Med* 2002; 347: 322-9.
- Rubin LJ. Therapy of pulmonary hypertension: the evolution from vasodilators to antiproliferative agents. *Am J Respir Crit Care* 2002; 166:

- 1308-9.
- Rubin LJ, Badesch DB, Barst R, et al. Bosentan therapy for pulmonary arterial hypertension. *N Engl J Med* 2002; 346: 896-903.
- Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. *J Am Coll Cardiol* 2003; 41: 2119-25.
- Widlitz A, Barst RJ. Pulmonary arterial hypertension in children. *Eur Respir J* 2003; 21: 155-76.
- Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. *J Am Coll Cardiol* 2004; 43 (12 Suppl): S40-7.
- Pietra GG, Capron F, Stewart S, et al. Pathologic assessment of vasculopathies in pulmonary hypertension. *J Am Coll Cardiol* 2004; 43 (12 Suppl): S25-32.
- Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. *J Am Coll Cardiol* 2004; 43 (12 Suppl): S5-12.
- Pengo V, Lensing AWA, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. *N Engl J Med* 2004; 350: 2257-64.
- Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France : Results from a national registry. *Am J Respir Crit Care Med* 2006; 173: 1023-30.
- Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT), Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G. Guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Respir J* 2009; 34: 1219-63.
- Taichman DB, McGoon MD, Harhay MO, et al. Wide variation in clinicians' assessment of New York Heart Association/World Health Organization functional class in patients with pulmonary arterial hypertension. *Mayo Clin Proc* 2009; 84: 586-592.
- Benza RL, Gomberg-Maitland M, Miller DP, et al. The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. *Chest* 2012; 141: 354-362.
- Hooper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. *J Am Coll Cardiol* 2013; 62(25 Suppl): D42-50.
- Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. *J Am Coll Cardiol* 2013; 62 (25 Suppl): D34-41.
- Galié N, Humbert M, Vachiery J-L, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Respir J* 2015; 46: 903-75.
- Sarcoidose — Sarkoidose**
- Panel of the world association of sarcoidosis and other granulomatous disease. Consensus conference: activity of sarcoidosis. *Eur Respir J* 1994; 7: 624-7.
- Peckham DG, Spiteri MA. Sarcoidosis. *Postgrad Med J* 1996; 72: 196-200.
- Newman LS, Rose CS, Maier LA. Sarcoidosis. *N Engl J Med* 1997; 336: 1224-34.
- American Thoracic Society, European Respiratory Society, World Association of Sarcoidosis and other Granulomatous Disorders. Statement on sarcoidosis. *Am J Respir Crit Care Med* 1999; 160: 736-55.
- Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. *N Engl J Med* 2007; 357: 2153-65.
- Mostard RL, Voo S, van Kroonenburgh MJ, et al.: Inflammatory activity assessment by F18 FDG-PET/CT in persistent symptomatic sarcoidosis. *Respir Med* 2011; 105: 1917-24.
- Mostard RL, Verschakelen JA, van Kroonenburgh MJ, et al.: Severity of pulmonary involvement and (18)F-FDG PET activity in sarcoidosis. *Respir Med* 2013; 107: 439-47.
- Baughman RP, Judson MA: Relapses of sarcoidosis: what are they and can we predict who will get them? *Eur Respir J* 2014; 43: 337-9.
- Kandolin R, Lehtonen J, Airaksinen J, et al.: Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. *Circulation* 2015; 131: 624-32.
- Taimeh Z, Hertz MI, Shumway S, Pritzker M: Lung transplantation for pulmonary sarcoidosis. Twenty-five years of experience in the USA. *Thorax* 2016; 71: 378-9.
- Rhinite — Rhinitis**
- Laursen LC, Faurschou P, Pals H, et al. Intramuscular betamethasone dipropionate vs. oral prednisolone in hay feverpatients. *Allergy* 1987; 42: 168-72.
- Brogden RN, McTavish D. Acrivastine. A review of its pharmacological properties and therapeutic efficacy in allergic rhinitis, urticaria and related disorders. *Ann Allergy* 1991; 67: 541-7.
- Naclerio RM. Allergic rhinitis. *N Engl J Med* 1991; 325: 860-9.
- Brooks CD, Karl KJ, Francom SF. Oral methylprednisolone acetate (Medrol tablets) for seasonal rhinitis: examination of dose and symptom response. *J Clin Pharmacol* 1993; 33: 816-22.
- International Rhinitis Management Working Group. International consensus report on the diagnosis and management of rhinitis. *Allergy* 1994; 49 (Suppl. 9): S5-S34.
- Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. *Am J Respir Crit Care Med* 1995; 151: 969-74.
- Bernstein IL, Storm WW. Practice parameters for allergy diagnostic testing. Joint tasc force on practice parameters for the diagnosis and treatment of asthma. The american academy of allergy, asthma and immunology. *Ann Allergy Asthma Immunol* 1995; 75: 43-625.
- Desager JP, Horsmans Y. Pharmacokinetic-pharmacodynamic relationships of H1-antihistamines. *Clin Pharmacokinet* 1995; 28: 419-32.
- Small P, Hule PA, et al. A comparison of triamci-

- nolone acetonide nasal aerosol spray and fluticasone propionate aqueous solution spray in the treatment of spring allergic rhinitis. *J Allergy Clin Immunol* 1997; 100: 592-5.
- Stern MA, Dahl R, et al. A comparison of aqueous suspensions of budesonide nasal spray and fluticasone propionate nasal spray in the treatment of adult patients with seasonal allergic rhinitis. *Am J Rhinol* 1997; 11: 323-30.
- Bousquet J, Lockey R, Malling HJ, et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. *J Allergy Clin Immunol* 1998; 102: 558-562.
- Dykewicz MS, et al. Joint Task Force Algorithm and Annotations for Diagnosis and Management of Rhinitis. *Ann Allergy Asthma Immunol* 1998; 81: 469-73.
- Dykewicz MS, et al. Joint Task Force summary statements on Diagnosis and Management of Rhinitis. *Ann Allergy Asthma Immunol* 1998; 81: 463-8, et al. 474-7.
- Dykewicz MS, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. *Ann Allergy Asthma Immunol* 1998; 81: 478-518.
- Lundbäck B. Epidemiology of rhinitis and asthma. *Clin Exp Allerg* 1998; 28: 3-10.
- Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. *N Engl J Med* 1999; 341: 468-75.
- Howarth PH. A comparison of the anti-inflammatory properties of intranasal corticosteroids and antihistamines in allergic rhinitis. *Allergy* 2000; 62: 6-11.
- Van Cauwenberge P, Bachert P, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis. European academy of allergology and clinical immunology. *Allergy* 2000; 55: 116-34.
- Bousquet J, can Cauwenberger P, Khaltaev N. Allergic rhinitis and its impact on asthma. *J Allergy Clin Immunol* 2001; 101 (Supp. 5): S147-S334.
- Kaszuba SM, Baroody FM, deTineo M, et al. Superiority of an intranasal corticoid compared with an oral antihistamine in the as-needed treatment of seasonal allergic rhinitis. *Arch Intern Med* 2001; 161: 2581-7.
- Pullerits T, Praks L, Ristioja V, et al. Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. *J Allergy Clin Immunol* 2002; 109: 949-55.
- Toux**
- Pratter MR, Bartter Th, Akers St, et al. An algorithmic approach to chronic cough. *Ann Intern Med* 1993; 119: 977-83.
- O'Connell F, Thomas VE, Pride NB, et al. Capsaicin cough sensitivity decreases with successful treatment of chronic cough. *Am J Respir Crit Care Med* 1994; 150: 374-80.
- Patrick H, Patrick F. Chronic cough. *Med Clin North Am* 1995; 79: 361-72.
- Chung KF, Laloo UG. Diagnosis and management of chronic persistent dry cough. *Postgrad Med J* 1996; 72: 594-8.
- Lawler WR. An office approach to the diagnosis of chronic cough. *Am Family Physician* 1998; 58: 2015-22.
- Smyrnios NA, Irwin RS, Curley FJ, et al. From a prospective study of chronic cough. *Arch Intern Med* 1998; 158: 1222-8.
- Palombini BC, Villanova CAC, Araújo E, et al. A pathogenic triad in chronic cough. *Chest* 1999; 116: 279-84.
- Pratter MR, Bartter Th, Lotano R. The role of sinus imaging in the treatment of chronic cough in adults. *Chest* 1999; 116: 1287-91.
- Irwin RS, Madison JM. The diagnosis and treatment of cough. *N Engl J Med* 2000; 343: 1715-21.
- Irwin RS, Madison JM. Diagnosis and treatment of chronic cough due to gastro-esophageal reflux disease and postnasal drip syndrome. *Pulm Pharmacol Ther* 2002; 15: 261-6.
- Madison JM, Irwin RS. Pharmacotherapy of chronic cough. *Expert Opin Pharmacother* 2003; 4: 1039-48.
- Birring SS, Prudon B, Carr AJ, et al. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). *Thorax* 2003; 58:339-43.
- Morice AH, Fontana GA, Sovijarvi AR, et al. The diagnosis and management of chronic cough. *Eur Respir J* 2004; 24:481-92.
- Jeyakumar A, Brickman TM, Haben M. Effectiveness of amitriptyline versus cough suppressants in the treatment of chronic cough resulting from postviral vagal neuropathy. *Laryngoscope* 2006; 116: 2108-12.
- Morice AH, McGarvey L, Pavord I, British Thoracic Society Cough Guideline G. Recommendations for the management of cough in adults. *Thorax* 2006; 61 Suppl 1: i1-24.
- Irwin RS, Baumann MH, Bolser DC, et al. Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines. *Chest* 2006; 129(1 Suppl): 1S-23S
- Kastelik JA, Aziz I, Ojoo JC et al. Investigation and management of chronic cough using a probability-based algorithm. *Eur Respir J* 2005; 25: 235-43.
- Chung KF, Pavord ID. Prevalence, pathogenesis, and causes of chronic cough. *Lancet* 2008; 371: 1364-74.
- Birring SS. Controversies in the evaluation and management of chronic cough. *Am J Respir Crit Care Med* 2011; 183:708-15.
- Ryan NM, Birring SS, Gibson PG. Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. *Lancet* 2012; 380: 1583-9.
- Keller D, Nicod L. La toux chez l'adulte. *Forum Med Suisse* 2015; 15: 702-708.
- Wei W, Liu R, Zhang Tong Y, Qiu Z. The efficacy of specific neuromodulators on human refractory chronic cough: a systematic review and meta-analysis. *J Thorac Dis* 2016; 8: 2942-2951.

- Gibson P, Wang G, McGarvey L et al. Treatment of Unexplained Chronic Cough: CHEST Guideline and Expert Panel Report. *Chest* 2016; 149: 27-44.
- Vertigan AE, Kapela SL, Ryan NM et al. Pregabalin and Speech Pathology Combination Therapy for Refractory Chronic Cough: A Randomized Controlled Trial. *Chest* 2016; 149: 639-48.
- Hoquet chronique**
- Kolodzki PW, Eilers MA. Hiccups (*singultus*): review and approach to management. *Ann Emerg Med.* 1991; 20: 565-73.
- Launois S, Bizec JL, Whitelaw WA, et al. Hiccup in adults: an overview. *Eur Respir J.* 1993; 6: 563-75.
- Friedgood CE, Ripstein CB. Chlorpromazine (Thorazine) in the treatment of intractable hiccups. *JAMA* 1995; 273: 309-10.
- Friedman NL. Hiccups: a treatment review. *Pharmacotherapy.* 1996; 16: 986-95.
- Fedderspil PA, Zenk J. Singultus. *HNO.* 1999; 47: 867-75.
- Schlafapnoesyndrom (SAS)**
- Syndrome de l'apnée du sommeil**
- Rosenow F, McCarthy V, Caruso AC. Sleep apnoea in endocrine disease. *J Sleep Res* 1998; 7: 3-11.
- American Thoracic Society: Indications and standards for cardiopulmonary sleep studies. *Am Rev Respir Dis* 1989; 139: 559-68.
- Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. *Sleep* 1991; 14: 540-5.
- Bradley TD, Phillipson EA. Central sleep apnea. *Clin Chest Med* 1992; 13: 493-505.
- Douglas N, Thomas S, Jan M. Clinical value of polysomnography. *Lancet* 1992; 339: 347-50.
- Guilleminault C, Stoohs R, Clerk A, et al. A cause excessive daytime sleepiness: The upper airway resistance syndrome. *Chest* 1993; 104: 781-7.
- McNamara SG, Grunstein RR, Sullivan CE. Obstructive sleep apnoea. *Thorax* 1993; 48: 754-64.
- Young T, Palta M, Dempsey J, et al. The occurrence of sleep-disordered breathing among middle-aged adults. *N Engl J Med* 1993; 328: 1230-5.
- Flemons WW, Whitelaw WA, Brant R, et al. Likelihood ratios for a sleep apnea clinical prediction rule. *Am J Respir Crit Care Med* 1994; 150: 1279-85.
- Meurice JC, Marc I, Series F. Efficacy of auto-CPAP in the treatment of obstructive sleep apnea/hypopnea syndrome. *Am J Respir Crit Care Med* 1996; 153: 794-8.
- Series F. Auto CPAP in the treatment of sleep apnea hypopnea syndrome. *Sleep* 1996; 19 (10 Suppl): S281-3.
- Young T, Peppard P, Palta M, et al. Population-based study of sleep-disordered breathing as a risk factor for hypertension. *Arch Intern Med* 1997; 157: 1746-52.
- Naughton MT. Heart failure and central apnea. *Reviews. Sleep Medicine* 1998; 2: 105-16.
- Worsnop CJ, Naughton MT, Barter CE, et al. The prevalence of obstructive sleep apnea in hypertensives. *Am J Respir Crit Care Med* 1998; 157: 111-5.
- Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The report of an American Academy of Sleep Medicine task force. *Sleep* 1999; 22: 667-89.
- Peppard PE, Young T, Palta M, et al. Prospective study of the association between sleep-disordered breathing and hypertension. *N Engl J Med* 2000; 342: 1378-84.
- Logan AG, Perlikowski SM, Mente A, et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. *J Hypertens* 2001; 19: 2271-7.
- Kohnlein T, Welte T, Tan LB, et al. Central sleep apnoea syndrome in patients with chronic heart disease: a critical review of the current literature. *Thorax* 2002; 57: 547-54.
- Series F. Interpretation of home oxymetry tracings. *Chest* 2002; 121: 1006-7.
- Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea. *Am J Respir Crit Care Med* 2002; 165: 1217-39.
- Bottini P, Tantucci C. Sleep apnea syndrome in endocrine diseases. *Respiration* 2003; 70: 320-7.
- Young T, Skatrud J, Peppard PE. Risk factors for obstructive sleep apnea in adults. *JAMA* 2004; 291: 2013-6.
- Brack Th. Therapie der Cheyne-Stokes-Atmung bei Herzinsuffizienz. *Schweiz Med Forum* 2006; 6: 1092-6.
- Collip NA, Anderson WM, Boehlecke B, et al. Clinical guidelines for the use of unattended portable monitors in the diagnosis of obstructive sleep apnea in adult patients. Portable Monitoring Task Force of the American Academy of Sleep Medicine. *J Clin Sleep Med.* 2007; 3: 737-47.
- Javaheri S, Smith J, Chung E. The prevalence and natural history of complex sleep apnea. *J Clin Sleep Med* 2009; 5: 205-11.
- Gottlieb DJ, Yenokyan G, Newman AB, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the Sleep Heart Health Study. *Circulation* 2010; 122: 352-60.
- Berry RB et al. Update from 2007 des guidelines AASM. *J Clin Sleep Med* 2012; 8: 597-619.
- Sateia MJ. International classification of sleep disorders-third edition: highlights and modifications. *Chest* 2014; 146: 1387-1394.
- Heinzer R, Vat S, Marques-Vidal P, et al. Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study. *Lancet Respir Med* 2015; 3: 310-8.
- Marti-Soler H, Hirotsu C, Marques-Vidal P, et al. The NoSAS score for screening of sleep-disordered breathing: a derivation and validation study. *Lancet Respir Med* 2016; 4: 742-748.
- Turnheer R. Das obstruktive (und zentrale) Schlafapnoesyndrom. *Schweiz Med Forum* 2018; 18: 482-88.

Piqûre d'insecte

Valentine MD. Insect venom allergy: Diagnosis and treatment. *J Allergy Clin Immunol* 1984; 73: 299-304.

Reisman RE. Natural history of insect sting allergy. *J Allergy Clin Immunol* 1992; 90: 335-9.

Mosbech H. Hymenoptera immunotherapy. *Allergy* 1997; 52: 1-3.

Golden DB, Demain J, Freeman T, et al. Stinging insect hypersensitivity: A practice parameter update 2016. *Ann Allergy Asthma Immunol* 2017; 118: 28-54.

Urticaire

Sibbald RG, Cheema AS, Lozinski A, et al. Chronic urticaria: evaluation of the role of physical, immunologic, and other contributory factors. *Int J Dermatol* 1991; 30: 381-6.

Charlesworth EN. Urticaria and angioedema: a clinical spectrum. *Ann Allergy Asthma Immunol* 1996; 76: 484-99.

Tharp MD. Chronic urticaria. Pathophysiology and treatment approaches. *J Allergy Clin Immunol* 1996; 98: 325-30.

Golkar L, Bernhard JD. Mastocytosis. *Lancet* 1997; 349: 1379-85.

Tong LJ, Balakrishnan G, Kochan JP, et al. Assessment of autoimmunity in patients with chronic urticaria. *J Allergy Clin Immunol* 1997; 99: 461-5.

Montureux P, Leaute-Labreze C, Legrain-Lifermann V, et al. Acute urticaria in infancy and early childhood. *Arch Dermatol* 1998; 134: 319-23.

Lee EE, Maibach HI. Treatment of urticaria. An evidence-based evaluation of antihistamines. *Am J Clin Dermatol* 2001; 2: 27-32

Negro-Alvarez JM, Miralles-Lopez JC. Chronic idiopathic urticaria treatment. *Allergol Immunopathol (Madr)* 2001; 29: 129-32.

Kaplan AP. Chronic urticaria. *N Engl J Med* 2002; 346: 175-9.

Doutre MS, Joly P. Prise en charge de l'urticaire chronique: recommandations de la conférence de consensus. *La Revue de Médecine interne* 2004; 24: 637-9.

Kozel MA, Sabroe RA. Chronic urticaria. *Drugs* 2004; 64: 2515-36.

Zuberbier T, Asero R, Bindslev-Jensen C, et al. *Allergy* 2009; 64: 1417-26.

EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria.

Viswanathan RK, Moss MH, Mathur SK. Retrospective analysis of the efficacy of omalizumab in chronic refractory urticaria. *Allergy Asthma Proc* 2013; 34: 446-52.

Maurer M, Magerl M, Metz M, et al. Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria. *J Dtsch Dermatol Ges* 2013; 11: 971-7.

Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. *NEJM* 2013; 368: 924-35.

Spoerl D, Harr T, Seebach JD. Allergologie Omalizumab dans le traitement de l'urticaire chronique: quoi de neuf en 2013? *Rev Med Suisse*

2014; 10: 18-23.

Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2)LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Update. *Allergy*. 2018 Jan 15. doi: 10.1111/all.13397.

ABPA (Allergic bronchopulmonary aspergillosis)

Rosenberg M, Patterson R, Mintzer RA, et al. Clinical and immunological criteria for the diagnosis of ABPA. *Am J Int Med* 1977; 86: 405-14.

Patterson R, Greenberger PA, Radin RC, et al. Allergic bronchopulmonary aspergillosis: staging as an aid to management. *Ann Intern Med* 1982; 96: 286-91.

Ricketti AJ, Greenberger PA, Patterson R. Serum IgE as an important aid in management of allergic bronchopulmonary aspergillosis. *J Allergy Clin Immunol* 1984; 74: 68-77.

Greenberger PA. Allergic bronchopulmonary aspergillosis. *J Allergy Clin Immunol* 1984; 74: 645-53.

Greenberger PA, Patterson R. Diagnosis and management of allergic bronchopulmonary aspergillosis. *Ann Allergy* 1986; 56: 444-8.

Patterson R, Greenberger PA, Halwig JM, et al. Allergic bronchopulmonary aspergillosis. Natural history and classification of early disease by serologic and roentgenographic studies. *Arch Intern Med* 1986; 146: 916-8.

Denning DW, Van Wye JE, Lewiston, et al. Adjunctive therapy of allergic bronchopulmonary aspergillosis with itraconazole. *Chest* 1991; 100: 813-9.

Wardlaw A, Geddes DM. Allergic bronchopulmonary aspergillosis. *J Roy Soc Med* 1992; 85: 747-51.

Greenberger PA. Diagnosis and management of allergic bronchopulmonary aspergillosis. *Allerg Proc* 1994; 15: 335-9.

Seaton A, Seaton RA, Wightman AJ. Management of allergic bronchopulmonary aspergillosis without maintenance oral corticosteroids: a fifteen-year follow-up. *QJM* 1994; 87: 529-37.

Salez F, Brichet A, Desurmort S, et al. Effects of itraconazole therapy in allergic bronchopulmonary aspergillosis. *Chest* 1999; 116: 1665-8.

Stevens DA, Schwartz HJ, Lee JY, et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis.

Agarwal R, Chakrabarti A, Shah A, et al. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. *Clin Exp Allergy* 2013; 43: 850-73.

Maladie de WIDAL

Samter M, Beers RF. Concerning the nature of intolerance to aspirin. *J Allergy* 1967; 40: 281.

Zeitz HJ. Bronchial asthma, nasal polyps, and aspirin sensitivity: Sampter's syndrome. *Clin Chest Med* 1988; 9: 567-76.

Israel E, Fischer AR, Rosenberg MA, et al. The pivotal role of 5 lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin.

Am Rev Respir Dis 1993; 144: 1447-51.
Leimgruber A. La triade de Widal: une anomalie du métabolisme inflammatoire. Med Rev Suisse 2005; 1: 15-8.

Mucoviscidose - Fibrose kystique / CF

www.genet.sickkids.on.ca/cftr/app

<https://www.cftr2.org/>

Rosenstein BJ. What is a cystic fibrosis diagnosis? Clin Chest Med 1998;19:423-41.

Rosenstein BJ, Cutting GR. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. J Pediatr 1998;132:589-95.

Groman JD, Meyer ME, Wilmott RW, Zeitlin PL, Cutting GR. Variant cystic fibrosis phenotypes in the absence of CFTR mutations. N Engl J Med 2002;347:401-7.

Borowitz D. Use of fecal Elastase 1 to classify pancreatic status in patients with cystic fibrosis. J Pediatr 2004; 145: 322-6.

Mishra A, Greaves R, Massie J. The relevance of sweat testing for the diagnosis of cystic fibrosis in the genomic era. Clin Biochem Rev 2005;26:135-53.

De Boeck K, Wilschanski M, Castellani C, et al. Cystic fibrosis: terminology and diagnostic algorithms. Thorax 2006; 61: 627-35.

LeGrys VA, Yankaskas JR, Quittell LM, Marshall BC, Mogayzel PJ, Jr. Diagnostic sweat testing: the Cystic Fibrosis Foundation guidelines. J Pediatr 2007;151:85-9.

Wallis C. Diagnosis of cystic fibrosis. Cystic fibrosis Edited by MHodson, DGeddes, ABush (CRC Press, 3rd Edition) 2007:101.

Farrell PM, Rosenstein BJ, White TB, et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 2008;153:S4-S14.

Dequeker E, Stuhrmann M, Morris MA, et al. Best practice guidelines for molecular genetic diagnosis of cystic fibrosis and CFTR-related disorders--updated European recommendations. Eur J Hum Genet 2009;17:51-65.

Flume PA. Cystic fibrosis pulmonary guidelines Treatment of pulmonary exacerbations. AJRCCM 2009; 180: 802-8.

Derichs N, Sanz J, Von Kanel T, et al. Intestinal current measurement for diagnostic classification of patients with questionable cystic fibrosis: validation and reference data. Thorax 2010;65:594-9.

Flume PA. Cystic fibrosis pulmonary guidelines :pulmonary complications. Hemoptysis and pneumothorax . AJRCCM 2010; 182: 298-306.

Bombieri C, Claustres M, De Boeck K, et al. Recommendations for the classification of diseases as CFTR-related disorders. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2011;10 Suppl 2:S86-102.

Ramsey BW. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. NEJM 2011; 365:1663-72.

Ooi CY, Dupuis A, Ellis L, et al. Comparing the

American and European diagnostic guidelines for cystic fibrosis: same disease, different language? Thorax 2012;67:618-24.

Mogayzel PJ. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health AJRCCM 2013; 187: 680-9.

Rueegg CS, Kuehni CE, Gallati S, et al. One-year evaluation of a neonatal screening program for cystic fibrosis in Switzerland. Deutsches Arzteblatt international 2013;110:356-63.

Bagheri-Hanson A, Nedwed S, Rueckes-Nilges C, Naehrlich L. Intestinal current measurement versus nasal potential difference measurements for diagnosis of cystic fibrosis: a case-control study. BMC Pulm Med 2014;14:156.

Gugliani L, Stabel D, Weiner JD. False-positive and false-negative sweat tests: systematic review of the evidence. Pediatr Allergy Immunol Pulmonol 2015;28:198-211.

Wainwright CE. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. NEJM 2015; 373: 1783-4.

Boudreau V. Sensitivity and specificity of cystic fibrosis -related diabetes screening methods: which test should be the reference method ? J Pediatr Endocrinol Metab 2017; 30: 885-887.

Farrell Ph.M et al. Diagnosis of cystic fibrosis: consensus guidelines from the cystic fibrosis foundation. J Pediatr 2017; 181: Suppl S4-15.

Leung DH, Narkewicz MR. Cystic fibrosis – related cirrhosis. J Cyst Fibros 2017; 16 Suppl 2: S50-S61.

Jung A. La mucoviscidose aujourd'hui. Swiss Med Forum 2017; 17: 514–522.

Jung A. Zystische Fibrose heute: Diagnose, Management und Therapie. Schweiz Med Forum 2017; 17: 514-522

GASTROENTEROLOGIE

Douleur abdominale - Bauchschmerzen

Ouhaci de Saussure E. Anderegg Quand référer aux urgences un patient présentant des douleurs abdominales? Rev Med Suisse 2010; 6: 1546-49.

Bates B. Abdomen, chapitre 11. Guide de l'examen clinique, édition 17 2014.

Fitzgibbons RA. Forse Clinical Practice. Groin hernias in adults. NEJM 2015; 372: 756-63.

Piquerol S, Staeger Ph, Pasche O. Examen de l'abdomen : et si nous refaisions nos gammes? Rev Med Suisse 2016; 12:1866-72.

Oesophagite toxique induite par des médicaments

Vălean S, Petrescu M, Cătinean A, et al. Pill esophagitis. Rom J Gastroenterol 2005; 14: 159-63.

Becker B, Zimmermann D, Borovicka J. Dabigatran-induzierte exfoliative Ösophagitis. Schweiz Med Forum 2014; 14: 802-4.

Dağ MS, Öztürk ZA, Akin I et al. Drug-induced esophageal ulcers: Case series and the review of the Literature. Turk J Gastroenterol 2014; 25: 180-4.

Muhammed SD et al. Drug-induced esophageal

- ulcers: Case series and the review of the literature. *Turk J Gastroenterol* 2014; 25: 180-4.
- Rottenstreich M, Rottenstreich M, Shapira S. Doxycycline induced oesophageal ulcers in a navy ship crewmember. *Int Marit Health* 2015; 66: 181-3.
- Brown IS, Bettington M. Doxycycline induced oesophagitis: five cases highlighting a distinctive pattern of injury. *Pathology* 2017; 49: 90-2.
- Senna JD, Bauerfeind P, Hubera LC. Schluckschmerzen nach Zeckenstich. *Schweiz Med Forum* 2019; 19: 423-25.
- Insuffisance hépatocellulaire**
- Trey C, Burns DG, Saunders SJ. Treatment of hepatic coma by exchange blood transfusion. *N Engl J Med* 1966; 274: 473-81.
- Trey C, Davidson CS. The management of fulminant hepatic failure. *Prog Liver Dis* 1970; 3: 282-298.
- Pugh RNH, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. *Brit J Surg* 1973; 60: 646-9.
- Bernau J, Rueff B, Benhamou JP. Fulminant and subfulminant liver failure: definitions and causes. *Semin Liver Dis*. 1986;6:97-106.
- Starzl TE, Demetris AJ, Van Thiel D. Liver transplantation. *N Engl J Med* 1989; 321: 1014-22 et 1092-9.
- Chapman RW, Forman D, Peto R, Smallwood R. Liver transplantation for acute hepatic failure? *Lancet* 1990; 1: 32-5.
- Caraceni P, van Thiel DH. Acute liver failure. *Lancet* 1995; 345: 163-9.
- Giostra E, Mentha G, Malè PJ, et al. Insuffisance hépatocellulaire (IHC) aiguë et hépatite fulminante. In: Urgences Médicales, Restellini A et al. (eds.). Editions Médecine et Hygiène, 1997, p: 278-83.
- Lebrec D. Pharmacological treatment of portal hypertension: present and future. *J Hepatol* 1998; 28: 869-907.
- O'Grady JG. Acute liver failure. *Postgrad Med J* 2005; 81: 148-154.
- GÖR — Reflux — GERD**
- Sami, SS, et al. The Los Angeles classification of gastroesophageal reflux disease. *Video journal and encyclopedia of GI Endoscopy* 2013; 1: 103-104.
- Vakil N, Van Zanten SV, Kahrilas P et al. The Montreal Definition and Classification of Gastroesophageal Reflux Disease: A Global Evidence-Based Consensus. *Am J Gastroenterol* 2006; 101: 1900-20.
- Hémorragie gastro-intestinale, varices œsophagiennes**
- Graham DY, Smith JL. The course of patients after variceal haemorrhage. *Gastroenterology* 1981; 80: 800-9.
- Burroughs AK, McCormick PA, Hughes MD, et al. Randomized, double-blind, placebo-controlled trial of somatostatin for variceal bleeding. *Gastroenterology* 1990; 99: 1388-95.
- Morrissey JF, Reichelderfer M. Gastrointestinal endoscopy. *N Engl J Med* 1991; 325: 1142-9.
- Poynard T, Cales P, Pasta L, et al. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. *N Engl J Med* 1991; 324: 1532-8.
- Daneshmend TK, Hawkey CJ, Langman MJ, et al. Omeprazole versus placebo for acute upper gastrointestinal bleeding: randomized double blind controlled study. *BMJ* 1992; 304: 143-7.
- Blaise M, Pateron D, Trinchet JC, et al. Systemic antibiotic therapy prevents bacterial infection in cirrhotic patients with gastrointestinal hemorrhage. *Hepatology* 1994; 20: 34-8.
- Lin HJ, Wang K, Perng CL, et al. Early or delayed endoscopy for patients with peptic ulcer bleeding. A prospective randomized study. *J Clin Gastroenterol* 1996; 22: 267-71.
- Rockall TA, Logan RF, Devlin HB, et al. Risk assessment after acute upper gastrointestinal hemorrhage. *Gut* 1996; 38: 316-21.
- Bernard R, Lebrec D, Mathurin P, et al. Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. *Hepatology* 1997; 25: 63-70.
- Burroughs AK, Planas R, Svoboda P. Optimizing emergency care of upper gastrointestinal bleeding in cirrhotic patients. *Scand J Gastroenterol* 1998; 226: (Suppl) 14-24.
- Burroughs AK. Pharmacological treatment of acute variceal bleeding. *Digestion* 1998; 59 (Suppl. 2): 28-36.
- D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. *Semin Liver Dis* 1999; 19: 475-505.
- Hébert PC, Wells F, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. *N Engl J Med* 1999; 340: 409-17.
- Schiff ER, Sorrell MF, Maddrey WC. In: Diseases of the liver. 8th ed. Philadelphia, Lippincott-Raven Publishers, 1999.
- Fishman D, Burnand D, Dorta G, et al. Hémorragie digestive haute. *Med Hyg* 2000; 58: 1685.
- Lau YJ, Sung JJ, Lee KK, et al. Effect of intravenous omeprazol on recurrences bleeding after endoscopic treatment of bleeding peptic ulcers. *N Engl J Med* 2000; 343: 310-6.
- Schmassmann A, Di Nicola A. Prophylaxe und Therapie der Ösophagusvarizen. *Forum Med Suisse* 2001; 12: 313-9.
- Sharara AI, Rockey DC. Gastroesophageal variceal hemorrhage. *N Engl J Med* 2001; 345: 669-81.
- Villanueva C, Minana J, Ortiz J, et al. Endoscopic ligation compared with combined treatment with Nadolol and Isosorbide Mononitrate to prevent recurrent variceal bleeding. *N Engl J Med* 2001; 345: 647-55.
- Thrombose portale (veine porte)**
- Meuwly J-Y, Saverot-Chevalier A-L, Sgourdos G. Thrombose veineuse porte. *Forum Med Suisse* 2012; 12: 119-25.
- Garcia-Pagán J-C et al. Directives de pratiques cliniques EASL : les pathologies vasculaires du foie. *Journal of Hepatology* 2016; 64: 179-202.

Deleve Laurie D., Valla D-C, Garcia-Tsao G. Vascular Disorders of the Liver. *Hepatology* 2009; 1729-1764.

Diverticulite - Divertikulitis

Brodribb AJM. Treatment of symptomatic diverticular disease with a high fibre diet. *Lancet* 1977; 1: 664-5.

Almy TP, Howel DA. Diverticular disease of the colon. *N Engl J Med* 1980; 302: 324-31.

Konvolinka CW. Acute diverticulitis under age of forty. *Am J Surg* 1994; 167: 562-5.

Roberts PL, Veidemheimer MC. Current management of diverticulitis. *Adv Surg* 1994; 27: 189-208

Vignati PV, Welch JP, Cohen JL. Long-term management of diverticulitis in young patients. *Dis Colon Rectum* 1995; 38: 627-9.

Ambrosetti P, Grossholz M, Becker C, et al. Computed tomography in acute left colonic diverticulitis. *Br J Surg* 1997; 84: 532-4.

Cunningham MA, Davis JW, Kaups KL. Medical versus surgical management of diverticulitis in patients under age 40. *Am J Surg* 1997; 174: 733-6.

Stollman NH, Raskin JB. Diagnosis and management of diverticular disease of the colon in adults. *Am J Gastroenterol* 1999; 94: 3110-21.

Jacobs DO. Diverticulitis. *N Engl J Med* 2007; 357: 2057-66.

Ulñi C, de Korte N, Daniels L et al. A multicenter randomized clinical trial investigating the cost-effectiveness of treatment strategies with or without antibiotics for uncomplicated acute diverticulitis (DIABOLO trial). *BMC Surg* 2010; 20:10:23.

Strate LL, Modi R, Cohen E, Spiegel BM. Diverticular disease as a chronic illness: evolving epidemiologic and clinical insights. *Am J Gastroenterol* 2012; 107:1486.

Shahedi K, Fuller G, Bolus R, et al. Long-term risk of acute diverticulitis among patients with incidental diverticulosis found during colonoscopy. *Clin Gastroenterol Hepatol* 2013; 11:1609.

Hall J, Hardiman K, Lee S et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Treatment of Left-Sided Colonic Diverticulitis. *Dis Colon Rectum* 2020; 63: 728-747.

Cholezystitis

Dyrhovden R., Øvrebo K.K., Nordahl M.V., Nygaard R.M., Ulvestad E., Kommedal Ø. Bacteria and fungi in acute cholecystitis. A prospective study comparing next generation sequencing to culture. *J Infect* 2020;80:16-23

Akute Diarröhö — Diarrhées aiguës

Fine KD et al. In: Sleisenger MH, Fordtran JS, Gastrointestinal Disease 1989; p: 290-316.

Bandres JC, DuPont H. Approach to the patient with diarrhea. In: Gorbach SL, et al. (eds.). Infectious Diseases. Philadelphia: Saunders, 1992; p: 572-575.

Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. *N Engl J Med* 1994; 330: 257-62.

Praz JO, Stalder H. Les diarrhées aiguës. *Med*

Hyg 1996; 54: 1719-22.

DuPont HL. Guidelines on acute infections diarrhea in adults. The practice parameters committee of the American College of Gastro-enterology. *Am J Gastroenterol* 1997; 92: 1962-75.

DuPont HL. Guidelines on acute infectious diarrhea in adults. The Practice Parameters Committee of the American College of Gastroenterology. *Am J Gastroenterol* 1997; 92: 1962-75.

Aranda-Michel J, Giannella RA. Acute diarrhea: a practical review. *Am J Med* 1999; 106: 670-7.

Guerrant RL, Van Gilder T, Steiner TS et al. Practice guidelines for the management of infectious diarrhea. *Clin Infect Dis* 2001; 32: 331-51.

Haque R, Huston C, Hughes M, et al. Amebiasis. *N Engl J Med* 2003; 348: 1565-73.

Vallière S, Pasche O, Cornuz J, Felley Chr. Diarrhées aiguës : propositions de prise en charge ambulatoire. *Rev Med Suisse* 2008; 181: 2586-90.

Truninger: Diarrhoe beim älteren Patienten. In: Therapeutische Umschau. Band 71, Nummer 9, 2014.

Chronische Diarröhö - Diarrhées chroniques

Rambaud JC. Diarrhée chronique: orientation diagnostique et conduite à tenir. *Rev Prat (Paris)* 1989; 39: 1809-16.

Descos L. Diarrhée chronique sans malabsorption intestinale du grêle. Etiologie, diagnostic, évolution et pronostic, principes de traitement. *Rev du Prat* 1990; 9: 846-8.

Greenberger NJ. Diagnostic approach to the patient with a chronic diarrhea disorder. *Dis Mon* 1990; 36: 131-79.

Cerf M. Stratégie diagnostique devant une diarrhée chronique de l'adulte. *Gastroenterol Clin Biol* 1992; 16: T12-T21.

Donowitz M, Kokke FT, Saidi R. Evaluation of patients with chronic diarrhea. *N Engl J Med* 1995; 332: 725-9.

Fine KD. Diarrhea. In: Feldman M, et al. (eds.). Sleisenger and Fordtran's Gastrointestinal and hepatic disease: pathophysiology, diagnosis, management. Philadelphia: Saunders WB 1998, p: 128-52.

Marteau Ph. Les diarrhées chroniques. *Gastroenterol Clin Biol* 1999; 23: 73-95.

Fine KD, Schiller LR. American Gastroenterological Association Medical position statement: Guidelines for the evaluation and management of chronic diarrhea. *Gastroenterology* 1999; 116: 1461-3.

Binder HJ. Causes of Chronic Diarrhea. *N Engl J Med* 2006; 355: 236-9.5

Schiller LR, Pardi DS, Spiller R, et al. Gastro 2013 APDW/WCOG Shanghai Working Party Report: Chronic diarrhea: Definition, classification, diagnosis. *J Gastroenterol Hepatol* 2014; 29: 6-25.

Arasaradnam RP, Brown S, Forbes A et al. Guidelines for the investigation of chronic diarrhoea in adults: British Society of Gastroenterology, 3rd edition. *Gut* 2018;0:1-20.

Laktosemalabsorption - Laktoseintoleranz

Misselwitz B, Butter M, Verbeke K et al. Update on lactose malabsorption and intolerance: pathogenesis, diagnosis and clinical management. Gut 2019; 68: 2080-91.

Giardiasis lambliaise

Greig JD, Michel P, Wilson JB et al. A descriptive analysis of giardiasis cases reported in Ontario, 1990-1998. Can J Public Health. 2001; 92: 361-5.

Cavallo JD, Garrabé E. Infectious aetiologies of travelers' diarrhea. Med Mal Infect 2007; 37: 722-7.

Gétaz L, Chappuis F, Loutan L. Parasitoses intestinales et hépatiques: diagnostic et traitement. Rev Med Suisse 2007; 3: 1254-8.

Escobedo AA, Cimerman S. Giardiasis: A pharmacotherapy review. Expert Opin Pharmacother 2007; 8: 1885-902.

Morken MH, Lind RA, Valeur J et al. Subjective health complaints and quality of life in patients with irritable bowel syndrome following Giardia lamblia infection: a case control study. Scand J Gastroenterol 2009; 44: 308-13.

Stensvold CR, Smith HV, Nagel R et al. Eradication of Blastocystis carriage with antimicrobials: Reality or delusion? J Clin Gastroenterol 2010; 44: 85-90.

Chappuis F, Gétaz L. Parasitoses digestives d'ici et d'ailleurs. Rev Med Suisse 2011; 279: 200-202.

Clostridium difficile - C. difficile

Kelly CP, LaMont JT. Clostridium difficile--more difficult than ever. N Engl J Med 2008; 359: 1932.

You DM, Franzos MA, Holman RP. Successful treatment of fulminant Clostridium difficile infection with fecal bacteriotherapy. Ann Intern Med 2008; 148:632.

Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31:431.

Trubiano JA, Gardiner B, Kwong JC, et al. Faecal microbiota transplantation for severe Clostridium difficile infection in the intensive care unit. Eur J Gastroenterol Hepatol 2013; 25:255.

Bagdasarian N, Rao K, Malani PN. Diagnosis and treatment of Clostridium difficile in adults: a systematic review. JAMA 2015; 313:398.

Pankreatitis – Pancréatite

Knaus WA, Draper EA, Wagner DP et al. APACHE II: a severity of disease classification system. Critical Care Medicine 1985; 13: 818-29.

Ranson JHC et al. Computed tomography and the prediction of pancreatic abscess in acute pancreatitis. Ann Surg 1985; 201: 656-65.

Reynaert MS, Dugernier T, Kestens PJ. Current therapeutic strategies in severe acute pancreatitis. Intensive Care Med 1990; 16: 352-62.

Ros E, Navarro S, Bru C, et al. Occult microlithiasis in "idiopathic" acute pancreatitis: prevention of relapses by cholecystectomy or ursodeoxycholic acid therapy. Gastroenterology 1991; 101: 1701-9.

Tenner SM, Steinberg W. The admission serum lipase: amylase ratio differentiates alcoholic from nonalcoholic acute pancreatitis. Am J Gastroenterol 1992; 12: 1755-8.

Steinberg W, Tenner S. Acute Pancreatitis. N Engl J Med 1994; 330: 1198-1210.

Grangé JD, Biour M. Pancréatites aiguës médicamenteuses. Gastroenterol Clin Biol 1995; 19: B67-B70.

Delcenserie R, Yzet T, Ducroix JP. Prophylactic antibiotics in treatment of severe acute alcoholic pancreatitis. Pancreas 1996; 13: 198-201.

Sainio V, Kemppainen E, Poukkainen P et al. Early antibiotic treatment in acute necrotising pancreatitis. Lancet 1995; 346 :663-7.

Brown A, Hugues M, Tenner S, Banks P. Does pancreatic enzyme supplementation reduce pain in patients with chronic pancreatitis: a meta-analysis. Am J Gastroenterol 1997; 92: 2032-5.

Gaillard Ph, Restellini A, Malè PJ, et al. Pancréatite aiguë. In: Urgences Médicales, Restellini A et al. (eds.). Médecine et Hygiène, 1997, p: 267-72.

Bassi C, Falconi M, Talamini G, et al. Controlled clinical trial of pefloxacin versus imipenem in severe acute pancreatitis. Gastroenterology 1998; 115: 1513-7.

Pitchumoni CS. Chronic pancreatitis, pathogenesis and management of pain. J Clin Gastroenterol 1998; 27: 101-7.

Etemad B, Whitcomb DC: Chronic pancreatitis: diagnosis, classification, and new genetic developments. Gastroenterology 2001; 120: 682-707.

Nathens AB, Curtis R, Beale RJ, et al. Management of the critically ill patient with severe acute pancreatitis. Crit Care Med 2004; 32: 2524-36.

Michel Biour M, Daoud H, Ben Salem C. Pancréatotoxicité des médicaments. Seconde mise à jour du fichier bibliographique des atteintes pancréatiques et des médicaments responsables. Gastroenterol Clin Biol 2005; 29: 353-359.

Frossard JL, Nicolet Th. Pancréatite chronique et insuffisance pancréatique. Forum Med Suisse 2007; 7: 75-80.

Catalano MF, Sahai A, Levy M, Romagnuolo J et al. EUS-based criteria for the diagnosis of chronic pancreatitis: the Rosemont classification. Gastrointest Endosc 2009; 69: 1251-61.

Banks PA, Bollen TL, Dervenis C et al. Classification of acute pancreatitis–2012: revision of the Atlanta classification and definitions by international consensus. Gut 2013; 62: 102-11.

Nadkarni NA, Khanna S, Vege SS. Splanchnic venous thrombosis and pancreatitis. Pancreas 2013; 42: 924-31.

Working Group IAP/APA Acute Pancreatitis Guidelines. IAP/APA evidence-based guidelines for the management of acute pancreatitis. Pancreatology 2013; 13(4 Suppl 2): e1-15.

Cholangite biliaire primitive (CBP)**Primär biliäre Cholangitis (PBC)**

- Angulo P, Lindor KD. Primary biliary cirrhosis and primary sclerosing cholangitis. *Clin Liver Dis* 1999; 3: 529-70.
- Leuschner M, Maier KP, Schlichtling J, et al. Oral budesonide and ursodeoxycholic acid treatment of primary biliary cirrhosis: results of a prospective double-blind trial. *Gastroenterology* 1999; 117: 918-25.
- Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the study of liver diseases practice guidelines. *Hepatology* 2000; 31: 1005-13.
- Holtmeier J, Leuschner U. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis. *Digestion* 2001; 64: 137-50.
- Floreani A. Preventive therapy in primary biliary cirrhosis. *Clin Liver Dis* 2003; 7: 911-21.
- Levy C, Lindor KD. Management of primary biliary cirrhosis. *Curr Treat Options Gastroenterol* 2003; 6: 493-8.
- Talwalker JA, Lindor KD. Primary biliary cirrhosis. *Lancet* 2003; 362: 53-61.
- Pares A, Cisneros L, Salmeron JM, et al. Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis. *Am J Gastroenterol* 2004; 99: 1105-10.
- Bressler B, Pinto R, El-Ashry D, Heathcote EJ. Which patients with primary biliary cirrhosis or primary sclerosing cholangitis should undergo endoscopic screening for oesophageal varices detection? *Gut* 2005; 54: 407-10.
- Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. *Hepatology* 2019; 69: 394-419

Cholangite sclérosante primitive (CSP)**Primär sklerosierende Cholangitis (PSC)**

- Stiehl A, Benz C, Sauer P. Primary sclerosing cholangitis. *Can J Gastroenterol* 2000; 14: 311-5.
- Holtmeier J, Leuschner U. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis. *Digestion* 2001; 64: 137-50.
- Zein CO, Lindor KD. Primary sclerosing cholangitis. *Semin Gastrointest Dis* 2001; 12: 103-12.

Foetor ex ore

- Rosenberg M, Kozlovsky A, Gelernter I, et al. Self-estimation of oral malodor. *J Dent Res* 1995; 74: 1577-82.
- Rosenberg M. Clinical assessment of bad breath: current concepts. *J Am Dent Assoc* 1996; 127: 475-82.
- Rosenberg M. The science of bad breath. *Sci Am* 2002; 286: 72-9.
- Quirynen M, Zhao H, van Steenberghe D. Review of the treatment strategies for oral malodour. *Clin Oral Invest* 2002; 6: 1-10.
- Filippi A, Meyer J. Haltinosis - Ursachen, Diagnose, Therapie. *Schweiz Med Forum* 2004; 4: 585-9.

Hépatite auto-immune (HAI)**Autoimmunhepatitis (AIH)**

- Bieri-Tehovnik S, Marbert U, Bertschinger P. Autoimmune hepatitis in Switzerland. *Schweiz Med Wochenschr* 1998; 128: 850-2.
- Alvarez F, Berg PA, Bianchi L, et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. *J Hepatol* 1999; 31: 929-38.
- Manns MP. Autoantibodies to soluble liver antigen: specific marker of autoimmune hepatitis. *J Hepatol* 2000; 33: 326-8.
- Al-Khalidi JA, Czaja AJ. Current concepts in the diagnosis, pathology, and treatment of autoimmune hepatitis. *Mayo Clin Proc* 2001; 76: 1237-52.
- Czaja AJ. Autoimmune hepatitis. *Clin Liver Dis* 2002; 6: xi-xii.
- Czaja AJ, Freese DK; American Association for the study of Liver Disease. Diagnosis and treatment of autoimmune hepatitis. *Hepatology* 2002; 36: 479-97.
- McFarlane IG. Autoimmune hepatitis: diagnostic criteria, subclassifications, and clinical features. *Clin Liver Dis* 2002; 6: 317-33.
- Strassburg CP, Manns MP. Autoantibodies and autoimmune hepatitis. *Semin Liver Dis* 2002; 22: 339-52.
- Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. *Hepatology* 2008; 48: 169-76.
- Björnsson E, Talwalkar J, Treeprasertskul S, et al. Patients with typical laboratory features of autoimmune hepatitis rarely need a liver biopsy for diagnosis. *Clin Gastroenterol Hepatol* 2011; 9: 57-63.

NASH (nonalcoholic steatohépatite)

- Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an evolving diagnosis. *Can J Gastroenterol* 2000; 14: 321-6.
- Farrell GC. Drugs and steatohepatitis. *Semin Liver Dis* 2002; 22: 185-94.
- Brunt EM. Nonalcoholic steatohepatitis. *Semin Liver Dis* 2004; 24: 3-20.

Cirrhose hépatique - Ascite

- Goldberg BB, Goodman GA, Clearfield HR. Evaluation of ascites by ultrasound. *Radiology* 1970; 96: 15-22.
- Rocco VK, Ware AJ. Cirrhotic ascites: Pathophysiology, diagnosis and management. *Ann Intern Med* 1986; 105: 573-85.
- Runyon BA. Low protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis. *Gastroenterology* 1986; 91: 1343-6.
- Ariza J, Xiol X, Esteve M, et al. Aztreonam vs. cefotaxime in the treatment of gram-negative spontaneous peritonitis in cirrhotic patients. *Hepatology* 1991; 14: 91-8.
- Gines P, Arroyo V, et al. Paracentesis with intravenous infusion of albumin compared with peritoneovenous shunting in cirrhosis with refractory ascites. *N Engl J Med* 1991; 325: 829-35.
- Garcia-Pagan JC, et al. Effects of low-sodium diet

- and spironolactone on portal pressure in patients with compensated cirrhosis. *Hepatology* 1994; 19: 1095-99.
- Runyon BA. Care of patients with ascites. *N Engl J Med* 1994; 330: 337-42.
- Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. *Hepatology* 1996; 23: 164-76.
- Gines A, Fernández-Esparrach G, Monescillo A, et al. Randomized trial comparing albumin, Dextran-70 plus polygeline in cirrhotic patients with ascites treated with paracentesis. *Gastroenterol* 1996; 111: 1002-10.
- Bataller R, Gines P, Arroyo V. Practical recommendations for the treatment of ascites and its complications. *Drugs* 1997; 54: 571-80.
- Gines P, Fernandez-Esparrach G, Arroyo V, et al. Pathogenesis of ascites in cirrhosis. *Semin Liver Dis* 1997; 17: 175-89.
- Arroyo V, Cardenas A. TIPS in the treatment of refractory ascites. In: Arroyo V, et al. (ed.). Treatment of liver diseases. 1999, Masson.
- Akriviadis E, Botla R, Briggs W, et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. *Gastroenterology* 2000; 119: 1637-48.
- Cardenas A, Bataller R, Arroyo V. Mechanisms of ascites formation. *Clin Liver Dis* 2000; 4: 447-65.
- Rössle M, Ochs A, Veit G, et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. *N Engl J Med* 2000; 342: 1701-7.
- Gines P, Cárdenas A, Arroyo V, Rodés J. Management of Cirrhosis and Ascites. *N Engl J Med* 2004; 350:1646-54.
- Sign SH, Stanca CM, Fernandez J, et al. Restricted use of albumin for spontaneous bacterial peritonitis. *Gut* 2007; 56: 597-9.
- European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. *J of Hepatol* 2010; 53: 397-417.
- Runyon BA. The American Association for the Study of Liver Diseases (AASLD). Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. *Hepatology* 2013; 57: 1651-3.
- Bureau C, Adebayo D, de Rieu MC, et al. Alfa-pump System vs. Large Volume Paracentesis for Refractory Ascites: A Multicenter Randomized Controlled Study. *J Hepatol* 2017; 67: 940-949.
- ### Péritonite bactérienne spontanée
- Runyon BA, Hoefs JC. Culture-negative neutrocytic ascites: a variant of spontaneous bacterial peritonitis. *Hepatology* 1984; 4: 1209-11.
- Yang CY, Liaw YF, Chu CM, et al. White count, pH and lactate in ascites in the diagnosis of spontaneous bacterial peritonitis. *Hepatology* 1985; 5: 85-90.
- Titó L, Rimola A, Ginès P, et al. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. *Hepatology* 1988; 8: 27-31.
- Ginès P, Rimola A, Planas R, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind placebo-controlled trial. *Hepatology* 1990; 12: 716-24.
- Arroyo V, Navasa M, Rimola A. Spontaneous bacterial peritonitis in liver cirrhosis: treatment and prophylaxis. *Infection* 1994; 22 (Suppl.3): S1-8.
- Gilbert JA, Kamath PS. Spontaneous bacterial peritonitis: An update. *Mayo Clin Proc* 1995; 70: 365-70.
- Ginès P, Navasa M. Antibiotic prophylaxis for spontaneous bacterial peritonitis: how and whom ?. *J Hepatology* 1998; 29: 490-94.
- Rimola A, García-Tsao G, Navasa M, et al. (and the International Ascites Club). Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. *J Hepatol* 2000; 32: 142-53.
- Wu JC, Chan FK. Esophageal bleeding disorders. *Curr Opin Gastroenterol* 2004; 20: 386-90.
- ### Syndrome hépatorénal
- Arroyo A, Ginès P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. *Hepatology* 1996; 23: 164-73.
- Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. *Hepatology* 1999; 29: 1690-7.
- Cardenas A, Uriz J, Gines P et al. Hepatorenal syndrome. *Liver Transpl* 2000; 6 (4 Suppl. 1): S63-71.
- Uriz J, Gines P, Cardenas A, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. *J Hepatol* 2000; 33: 43-8.
- Bataller R, Ginès P, Arroyo V et al. Hepatorenal syndrome. *Clin Liver Dis* 2000; 4: 487-507.
- ### Insuffisance hépatocellulaire
- Trey C, Burns DG, Saunders SJ. Treatment of hepatic coma by exchange blood transfusion. *N Engl J Med* 1966; 274: 473-81.
- Pugh RHN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. *Brit J Surg* 1973; 60: 646-9.
- Starzl TE, Demetris AJ, Van Thiel D. Liver transplantation. *N Engl J Med* 1989; 321: 1014-22 et 1092-9.
- Chapman RW, Forman D, Peto R, Smallwood R. Liver transplantation for acute hepatic failure ? *Lancet* 1990; 1: 32-5.
- Caraceni P, van Thiel DH. Acute liver failure. *Lancet* 1995; 345: 163-9.
- Giostra E, Mentha G, Malè PJ, et al. Insuffisance hépatocellulaire (IHC) aiguë et hépatite fulminante. In: Urgences Médicales, Restellini A et al. (eds.). Editions Médecine et Hygiène, 1997, p: 278-83.

Lebrec D. Pharmacological treatment of portal hypertension: present and future. *J Hepatol* 1998; 28: 869-907.

Ictère

Zimmermann HJ, Deschner KW. Differential diagnosis of jaundice. *Hosp Practice (Off Ed)* 1987; 22: 99-103.

Reisman Y, Gips CH, Lavelle SM, Wilson JHP. Clinical presentation of (subclinical) jaundice. The Euricterus project in the Netherlands. *Hepato-Gastroenterology* 1996; 43: 1190-5.

Insuffisance pancréatique exocrine

Steer ML, Waxman I, Feedman S. Chronic pancreatitis. *N Engl J Med* 1995; 332: 1482-90.

Pitchumoni CS. Chronic pancreatitis, pathogenesis and management of pain. *J Clin Gastroenterol* 1998; 27: 101-7.

Hépatites - Hépatites: A, B, C. Vaccins

Bernau J, Goudeau A, Poynard T, et al. Multivariate analysis of prognostic factors in fulminant hepatitis B. *Hepatology* 1986; 6: 648-51.

Bismuth H, Samuel D, Gugenheim J, et al. Emergency liver transplantation for fulminant hepatitis. *Ann Int Med* 1987; 107: 337-41.

Malè PJ. Hépatites virales. *Rev Med Suisse Rom* 1989; 109: 889-99.

Tormans G, Van Damme P, Van Doorslaer E. Recommendations for prevention of hepatitis A based on a effectiveness analysis. *J Travel Med* 1994; 1: 127-135.

Béguelin Ch, Fall F, Seydi M, Wandeler G. The current situation and challenges of screening for and treating hepatitis B in sub-Saharan Africa. *Expert Rev Gastroenterol Hepatol* 2018; 12:537-546.

The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. *Hepatology* 1994; 29 :15.

Swiss Association for the Study of the Liver; Groupe d'Experts Suisses pour les Hépatites Virales; Société Suisse de Gastro-entérologie et d'Hépatologie. Recommandations pour le traitement par l'interféron de l'hépatite C chronique. *Bulletin des Médecins Suisses* 1996; 43: 1746-7.

Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. *Hepatology* 1996; 24:289.

Lee WM. Hepatitis B virus infection. *N Engl J Med* 1997; 337: 1733-44.

Hoofnagle JH, Di Bisceglie AM. The treatment of chronic hepatitis. *N Engl J Med* 1997; 336: 347-56.

Poynard T, Bedossa P, Opolon P, et al . Natural history of liver fibrosis progression with chronic hepatitis C. *Lancet* 1997; 349: 825-32.

Koff RS. Hepatitis A. *Lancet* 1998; 351: 1643-9.

Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine of chronic hepatitis B. *N Engl J Med* 1998; 339: 61-8.

Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribava-

rin for the treatment of relapse of chronic hepatitis C. *N Engl J Med* 1998; 339: 1493-9.

McHutchinson JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavarin as initial treatment for chronic hepatitis C. *N Engl J Med* 1998; 339: 1485-92.

Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large prospective cohort study. *Hepatology* 1998; 28: 1687-95.

Resti M, Azzari C, Mannelli F, et al. Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. *BMJ* 1998; 317: 437-40.

Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. *N Engl J Med* 1998; 338: 286-90.

Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. *N Engl J Med* 1999; 341: 1256-63.

EASL International Consensus Conference on Hepatitis C. *J Hepatol* 1999; 31 (Suppl.1): 3-8.

Jack AD, Hall AJ, Maine N, et al. What level of hepatitis B antibody is protective? *J Infect Dis* 1999; 179: 489-92.

Marcellin P. Hepatitis C: the clinical spectrum of the disease. *J Hepatol* 1999; 31 (Suppl.1): 9-16.

Sobesky R, Mathurin P, Charlotte F, et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. *Gastroenterology* 1999; 116: 378-86.

Jaeckel E, Cornberg M, Wedmeyer H, et al. Treatment of acute hepatitis C with Interferon alpha 2b. *N Engl J Med* 2001; 345: 1452-7.

Lauer GM, Walker BD. Hepatitis C virus infection. *N Engl J Med* 2001; 345: 41-52.

Perillo R, Schiff ER, Yoshida E, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. *Hepatology* 2000 , 32: 129-34.

Lok AS, McMahon BJ. Chronic hepatitis B. *Hepatology* 2001; 34: 1225-41.

Alberti A, Boccato S, Vario A, et al. Therapy of acute hepatitis C. *Hepatology* 2002; 36 (suppl 1): S195-S200.

Conjeevaram HS, Lok AS. Management of chronic hepatitis B. *J Hepatol* 2003;38 Suppl 1:S90-103. Erratum in: *J Hepatol*. 2003; 38: 876.

Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. *Gastroenterology* 2003; 125: 80-88.

Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. *N Engl J Med* 2003; 348: 800-7.

Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. *Gastroenterology* 2003; 125: 1714-22.

Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-

positiv chronic hepatitis B. N Engl J Med 2003; 348: 808-16.

Lin KW, Kirchner JT. Hepatitis B. Am Fam Physician 2004; 69: 75-82.

Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus Ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438-50.

Wiegand J, Jeckel E, Cornberg M, et al. Long-term follow-up after successful interferon therapy of acute hepatitis C. Hepatology 2004; 40: 98-107.

Lok AS. New treatment of chronic hepatitis B. Semin Liver Dis. 2004;24 Suppl 1:77-82.

Lok AS, McMahon BJ. Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations. Hepatology 2004; 39: 857-61.

Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126: 1015-23.

Hépatite alcoolique

Maddrey WC, Boitnott JK, Bedine MS, et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterol 1978; 75: 193-9.

Carithers RL, Herlong HF, Diehl AM, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. Ann Intern Med 1989; 110: 685-90.

Ramond MJ, Poinard T, Rueff B, et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 1992; 326: 507-12.

Salaspuro M. Biological state makers of alcohol abuse. Alcohol Health Res World 1994; 18: 131-5.

Lieber CS. Medical disorders of alcoholism. M Engl J Med 1995; 333: 1058 -65.

Stauber RE, Stepan V, Trauner M, et al. Evaluation of carbohydrate-deficient transferrin for detection of alcohol abuse in patients with liver dysfunction. Alcohol Alcohol 1995; 30: 171-6.

Lesch OM, Walter H. A new " state " marker for the detection of alcoholism. Alcohol Alcohol 1996; 31 (Suppl.1): 59-62.

Mathurin P, Duchatelle V, Ramond MJ, et al. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterol 1996; 110: 1847-53.

Naveau S. Les indications de la ponction-biopsie hépatique chez les sujets alcooliques. Hepato Gastro 1999; 1: 11-5.

Sphar L, Burckhardt B, Hadengue A. La maladie alcoolique du foie. Med Hyg 2000; 8: 262-6.

Louvet A, Naveau S, Abdelnoor M et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 2007; 45: 1348-54.

Thursz MR, Forrest EH, Ryder S; STOPAH investigators. Prednisolone or Pentoxifylline for Alcoholic Hepatitis.NEJM 2015; 373: 282-3.

Encéphalopathie hépatique

Vilstrup H, Amiodio P, Bajaj J, et al. Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 2014; 60:715.

Alcool

Prochaska JO, Di Clemente CC. Stages and processes of self change in smoking towards an integrative model of change. J Consulting and Clinical Psychology 1983; 51: 390-95.

Sullivan JT, Sykora K, Schneiderman J, et al. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict 1989; 84: 1353-7. Classification Internationale des Maladies. CIM-10/ICD-10. OMS 1992. Paris: Masson.

Krahenbuhl B. La force de l'autre. Ou l'entretien de motivation avec la personne alcoolique. Med et Hyg 1993; 51: 2263-6.

Saunders JB, Aasland OG, Babor TF, et al. Development of the Alcohol Use Disorders Identification Test (AUDIT). Addiction 1993; 88: 791-804.

Steinweg DL, Worth H. Alcoholism: The keys of the CAGE. Am J Med 1993; 94: 520-523.

Mayo-Smith MF. Pharmacological Management of Alcohol Withdrawal. A Meta-analysis and Evidence-Based Practice Guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. JAMA 1997; 278: 144-51.

Gache P, Siegrist G. Les traitements médicamenteux de l'alcoolodépendance. Rev Med Suisse romande 1998; 118: 767-769.

Yersin B, Pilet F. Syndrome de sevrage alcoolique : Prise en charge ambulatoire par le médecin praticien. Rev Med Suisse romande 1998; 118: 777-781.

Daeppen JB, Gache P, Landry U, et al. Symptom-triggered vs fixed-schedule doses of benzodiazepine for alcohol withdrawal: a randomized treatment trial. Arch Intern Med 2002; 162: 1117-21.

Mukamal KJ, Conigrave KM, Mittelmann MA, et al. Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. N Engl J Med 2003; 348: 109-18.

Mayo-Smith MF, Beecher LH, Fischer TL, et al. Management of Alcohol Withdrawal Delirium. An Evidence-Based Practice Guideline. Arch Intern Med 2004; 164: 2068 and Arch Intern Med 2004; 164: 1405-12.

Schlüter V, Narring F, Münsch U, et al. Trends in violent deaths among young people 10-24 years old in Switzerland, 1969-1997. Eur J Epidemiol 2004; 19: 291-7.

Saitz R et al., Unhealthy alcohol use, clinical practice, N Engl J Med 2005; 352: 596-607.

Broers B, Humair JP, Haaz S, et al. Dépister l'usage de substances psychoactives: pourquoi, comment, et ensuite ? Rev Med Suisse 2007; 3: 2157-61.

ISPA (2009). Chiffres calculés sur la base de l'Enquête suisse sur la santé 2007.

- Seitz HK, Becker P. Alcohol metabolism and cancer risk. *Alcohol Res Health* 2007; 30: 38-47.
- Schukit MA. Alcohol-use disorders. *Lancet* 2009; 373: 492-501.
- Smith PC, Schmidt SM, Allensworth-Davies D, et al. Primary care validation of a single question alcohol screening test. *J Gen Intern Med* 2009; 24: 881-3.
- Jürgen R, Taylor B, Mohapatra S, et al. Alcohol as a risk factor for liver cirrhosis : A systematic review and meta-analysis. *Drug Alcohol Rev* 2010; 29: 437-45.
- Righetti V, Favrod-Coune T. Questionnaires de dépistage et d'évaluation des consommations de substances psychoactives. *Rev Med Suisse* 2010; 6: 1821-5.
- Chen WY, Rosner B, Hankinson SE, et al. Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk. *JAMA* 2011; 306: 1884-90.
- Rehm J, Kehoe T, Gmel G, et al. Alcohol attributable burden of incidence of cancer in eight European countries based on results from prospective cohort study. *BMJ* 2011; 342: d1584.
- Ronksley PE, Brien SE, Turner BJ, et al. Association of alcohol consumption with selected cardiovascular disease outcomes : A systematic review and meta-analysis. *BMJ* 2011; 342: d671.
- Pasche S, Broers B, Favrod-Coune Th. Comment y voir clair face à toutes les recommandations relatives à la consommation d'alcool? *Rev Med Suisse* 2012; 1831-1835.
- Wood E, MD, Albarqouni L, Tkachuk S et al. Will This Hospitalized Patient Develop Severe AlcoholWithdrawal Syndrome? The Rational Clinical Examination Systematic Review. *JAMA* 2018; 320: 825-33.
- TFI - Colón irritable - Reizdarmsyndrom**
- Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. *BMJ* 1978; 2: 653-4.
- Lennard-Jones JE. Functional gastrointestinal disorders. *N Engl J Med* 1983; 308: 431-5.
- Otte JJ, Larsen L, Anderson JR. Irritable bowel syndrome and symptomatic diverticular disease-different diseases ? *Am J Gastroenterol* 1986; 81: 529-31.
- Camilleri M, Prather CM. The irritable bowel syndrome: mechanisms and a practical approach to management. *Ann Intern Med* 1992; 116: 1001-8.
- Cullingford GL, Coffey JF, Carr-Locke DL. Irritable bowel syndrome: can the patient's response to colonoscopy help with diagnosis. *Digestion* 1992; 52: 209-13.
- Accarino AM, Azpiroz F, Malagelada JR. Selective dysfunction of mechanosensitive intestinal afferents in irritable bowel syndrome. *Gastroenterology* 1995; 108: 636-43.
- Agréus L, Svärdsudd K, Nyren O, et al. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. *Gastroenterology* 1995; 109: 671-80.
- Delvaux M, Denis P, Allemand H. Sexual abuse is more frequently reported by IBS patients than by patients with organic digestive diseases or controls. Results of a multicentre inquiry. *French Club of Digestive Motility. Eur J Gastroenterol Hepatol* 1997; 9: 345-52.
- Drossmann DA, Whitehead WE, Camilleri M. Irritable bowel syndrome: a technical review for practice guideline development. *Gastroenterology* 1997; 112: 2120-37.
- Aziz A, Thompson DG. Brain-gut axis in health and disease. *Gastroenterol* 1998; 114: 559-78.
- Farthing JMG. New drugs in the management of the irritable bowel syndrome. *Drugs* 1998; 56: 11-21.
- Camilleri M. Review article: clinical evidence to support therapies of irritable bowel syndrome. *Aliment Pharmacol Therap Ther* 1999; 13: 48-53.
- Drossmann DA. The functional gastrointestinal disorders and the Rome II process. *Gut* 1999; 45: 1-5.
- Hammer J, Talley NJ. Diagnostic criteria for the irritable bowel syndrome. *Am J Med* 1999; 107: 5S-11S.
- Isaacs D, Fitzgerald D. Seven alternatives to evidence based medicine. *BMJ* 1999; 319: 1618.
- Thompson WG. Irritable bowel syndrome: a management strategy. *Baillière's clinical Gastroenterology* 1999; 13: 453-60.
- Drossmann DA. The functional gastrointestinal disorders, their diagnosis, and the Rome II process. In: Drossmann DA, Corazziari E, Talley NJ, et al. (eds.). *Rome II. The functional gastrointestinal disorders: diagnosis, pathophysiology and treatment: a multinational consensus*. McLean VA: DeGruyter, 2000: 1-36.
- De Ponti F, Tonini M. Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. *Drugs* 2001; 61: 317-32.
- Camilleri M. Management of the irritable bowel syndrome. *Gastroenterology* 2001; 120: 652-68.
- Spiller RC. Postinfectious irritable bowel syndrome. *Gastroenterology* 2003; 124: 1662-71.
- Mearin F, Perez-Oliveras M, Perello A, et al. Dyspepsia and irritable bowel syndrome after a *Salmonella* gastroenteritis outbreak : One-year follow-up cohort study. *Gastroenterology* 2005; 129: 98-104.
- Drossmann DA. The functional gastrointestinal disorders and the Rome III process. *Gastroenterology* 2006; 130: 1377-90.
- Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. *Gastroenterology* 2006; 130: 1480.
- Track J., Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. *Gastroenterology* 2006; 130: 1466-79.
- Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. *JAMA* 2015; 313: 949-958.
- Drossmann DA. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features, and Rome IV. *Gastroenterology* 2016; 150: 1262-1279.e2

Ferreiro-Iglesias R, Barreiro-de Acosta M, Otero Santiago M et al. Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance Infliximab Therapy. *J Clin Gastroenterol* 2016; 50:147-51.

Mearin F, Lacy BE, Chang L, et al. Bowel Disorders. *Gastroenterology* 2016 Feb 18. pii: S0016-5085(16)00222-5. doi: 10.1053/j.gastro.2016.02.031.

Heinrich H, Schwizer, W. Das Reizdarm Syndrom. Der informierte arzt 2017; 7(8): 22-24.

Kostas A, Siakavellas SI, Kosmidis C et al. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel diseases. *World J Gastroenterol* 2017; 23: 7387-7396.

Cholélithiasse - Cholécystite

Everhart JE, Khare M, Hill M, Maurer KR. Prevalence and ethnic differences in gallbladder disease in the United States. *Gastroenterology*. 1999; 117: 632-9.

Warttig S, Ward S, Rogers G, Guideline Development Group. Diagnosis and management of gallstone disease: summary of NICE guidance. *BMJ* 2014; 349: g6241.

Intolérance au lactose

Bayless TM, et al. A racial difference in incidence of lactase deficiency: a survey of milk intolerance and lactase deficiency in healthy adult males. *JAMA* 1966; 197: 968-72.

Bayless TM, et al. Lactose and milk intolerance: clinical implications. *N Engl J Med* 1975; 292: 1156-9.

Newcomer AD, McGill DB, Thomas PJ, et al. Prospective comparison of indirect methods for detecting lactase deficiency. *N Engl J Med* 1975; 293: 1232-6.

Rosade JL, Solomons NW. Sensitivity and specificity of the hydrogen breath-analysis test for detecting malabsorption of physiological doses of lactose. *Clin Chem* 1983; 29: 545-8.

Hammer HF, Petrisch W, Pristautz H et al. Assessment of the influence of hydrogen nonexcretion on the usefulness of the hydrogen breath test and lactose tolerance test. *Wien Klin Wochenschr* 1996; 108: 137-41.

Shaw AD, Davies GJ. Lactose intolerance: problems in diagnosis and treatment. *J Clin Gastroenterol* 1999; 28: 208-16.

Högenauer C, Hammer HF, Mellitzer K et al. Evaluation of a new DNA test compared with the lactose hydrogen breath test for the diagnosis of lactase non-persistence. *Eur J Gastroenterol Hepatol* 2004; 17: 371-6.

Kubli M, Tuitan R, Fried M et al. Chronische Diarrhoe - Fallgrube Laktasemangel. *Forum Med Schweiz* 2007; 7: 422-4.

Maladie de WHIPPLE

Galperin C, Gershwin ME. Immunopathogenesis of gastrointestinal and hepatobiliary diseases. *JAMA* 1997; 278: 1946-55.

Feldman M, Scharschmidt BF, Sleisenger MH (eds.). In: *Sleisenger and Fordtran's gastrointest-*

inal and liver diseases. W Saunders Company, 1998.

André R, Ehresmann B, Stirnemann J et al. Maladie de Whipple : un diagnostic différentiel de polyarthrite à ne pas oublier. *Rev Med Suisse 2015*; 448: 1582-1586.

Cunningham S, Maulucci F, Zufferey P et al. Maladie de Whipple: quand y penser? *Rev Med Suisse* 2015; 11: 1582-6.

Malabsorption

De la Morena ES, Chantar R. Malabsorción intestinal. In: Rodés J, et al. (eds.). *El Manual de Medicina*. Masson, S.A, 1993, p: 539-61.

Falk R, Comenzo RL, Skinner M. The systemic amyloidoses. *N Engl J Med* 1997; 337: 898-909.

Feldman M, Scharschmidt BF, Sleisenger MH (eds). *Sleisenger and Fordtran's gastrointestinal and liver diseases*. W. Saunders Company, 1998.

Furness BW, Beach MJ, Roberts JM. Giardiasis surveillance - United States. 1992-1997. *MMWR CDC Surveill Summ* 2000; 49: 1-13.

Colite microscopique

Burgel N, Bojarski C, Mankertz J, et al. Mechanisms of diarrhea in collagenous colitis. *Gastroenterology* 2002; 123: 433-43.

Shaz BH, Reddy SI, Ayata G, et al. Sequential clinical and histopathological changes in collagenous and lymphocytic colitis over time. *Mod Pathol* 2004; 17: 1475- 1485.

Wildt S, Nordgaard-Lassen I, Bendtsen F, Rummessen JJ.. Metabolic and inflammatory faecal markers in collagenous colitis. *Eur J Gastroenterol Hepatol* 2007; 19: 567-74.

Chande N, MacDonald JK, MacDonald JW.. Interventions for treating microscopic colitis : A Cochrane inflammatory bowel disease and function bowel disorder review group systematic review of randomized trials. *Am J Gastroenterol* 2009; 104: 235-41.

Nyhlin N, Montgomery SM, Wickbom A, et al. Symptom burden in collagenous and lymphocytic colitis compared to a matched control group. *Gut* 2009; 58(Suppl. II): A309.

Stewart MJ, Seow CH, Storr MA.. Prednisolone and budesonide for short- and long-term treatment of microscopic colitis : Systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 2011; 9: 881-90.

Vigren L, Sjoberg K, Benoni C, et al. Is smoking a risk factor for collagenous colitis. *Scand J Gastroenterol* 2011; 46: 1334-9.

Münch A, Aust D, Bohr J, et al. Microscopic colitis : Current status, present und future challenges – Statements of the European Microscopic Colitis Club. *J Crohns Colitis* 2012; 6: 932-45.

Burgmann K, Fraga M, Yan P, et al. Colites microscopiques – quoi de neuf? *Rev Med Suisse* 2014; 440: 1586-1590.

Coeliakie / Sprue / Zöliakie Glutenintoleranz

Trier JS. Celiac sprue and refractory sprue. *Gastroenterology* 1978; 75: 307-16.

Revised criteria for diagnosis of coeliac disease:

- report of working group of european society of paediatric gastroenterology and nutrition. Arch Dis Child 1990; 65: 909-11.
- Dietrich W, Ehnis T, Bauer M, et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med 1997; 3: 797-801.
- Greco L, Romino R, Coto I et al. Ther fist large population based twin study of coelica disease. Gut 2002; 50: 624-8.
- Farrell RJ, Kelly CP. Celiac sprue. N Engl J Med 2001 , 346: 180-8.
- Green PHR, Cellier Ch. Celiac Disease. N Engl J Med 2007; 357: 1731-43.
- Leffler DA, Schuppan D. Update on serologic testing in celiac disease. Am J Gastroenterol 2010; 105: 2520-4.
- Rashid M. Tests sérologiques dans la maladie cœliaque Guide pratique à l'usage des cliniciens. Can Fam Physician 2016; 62: e11-e17.
- Maladie de CROHN**
- Best WR, Bechtel JM, Singleton JW, et al. Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-44.
- Best WR, Bechtel JM, Singleton JW, et al. Rederived values of the eight coefficients of the Crohn's disease activity index (CDAI). Gastroenterology 1979; 77: 843-6.
- Hodgson HJF, Mazlam MZ. Assessment of drug therapy in inflammatory bowel disease. Aliment Pharmacol Ther 1991; 5: 555-84.
- Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994; 331: 842-5.
- Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn's disease: a meta-analysis. Ann Intern Med 1995; 123: 132-42.
- Hanauer SB. Inflammatory bowel disease. N Engl J Med 1996; 334: 841-8.
- Guyot J, Hess J, Fasel J. Maladies inflammatoires intestinales. Med Hyg 1999; 57: 199-206.
- Pimentel M, Chang M, Chow EJ et al. Identification of a prodromal period in Crohn's disease but not ulcerative colitis. Am J Gastroenterol. 2000; 95: 3458-62.
- Tibble JA, Sighorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119: 15-22.
- Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-29.
- Best WR. Predicting the Crohn's disease activity index from the Harvey-Bradshaw Index. Inflamm Bowel Dis 2006; 12: 304-10.
- Sandborn WJ, Feagan BG, Stoinov S et al. Certolizumab Pegol for the Treatment of Crohn's Disease. N Engl J Med 2007; 357: 228-38.
- Schreiber S, Khalil-Kareemi M, Lawrence IC et al. Maintenance Therapy with Certolizumab Pegol for Crohn's Disease. N Engl J Med 2007; 357: 239-50.
- Van Rheenen PF, Van de Vijver E, Fidler V, Fae cal calprotectin for screening of patients with suspected inflammatory bowel disease: Diagnostic meta-analysis. BMJ 2010; 341: c3369.
- Fraga M, Godat S, Nydegger A et al. Calprotectine fécale: outil diagnostique dans les maladies inflammatoires chroniques de l'intestin. Rev Med Suisse 2012; 8: 1669-73.
- Toxischer Megakolon - Mégaçôlon toxique**
- Jalan KN, Sircus W, Card WI, Falconer CW, Bruce CB, Crean GP, McManus JP, Small WP, Smith AN (1969) An experience of ulcerative colitis. I. Toxic dilation in 55 cases. Gastroenterology 1969; 57: 68-82.
- Autenrieth DM, Baumgart DC. Toxic megacolon. Inflamm Bowel Dis 2012; 18: 584-91.
- Rectocolite ulcéro-hémorragique (RCUH)**
- **Colitis ulcerosa**
- Truelove SC, Witts LJ. Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. Br Med J 1954; 2: 375-378.
- Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. BMJ 1955; 2: 1041-8.
- Hanauer SB. Inflammatory bowel disease. N Engl J Med 1996; 334: 841-8.
- Guyot J, Hess J, Fasel J. Maladies inflammatoires intestinales. Med Hyg 1999; 57: 199-206.
- Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-29.
- Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19(suppl A):5-36.
- Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis 2017; 11: 649-70.
- Moschouri E., Hessler R., Pittet V., et al. Mise au point sur la rectocolite ulcéro-hémorragique en 2017. Rev Med Suisse 2017; 13: 1480-6.
- Constipation**
- Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut 1999; 45: 43-7.
- Lembo A, Camilleri M. Chronic constipation. N Engl J Med 2003; 349: 1360-8.
- Reflux gastro-oesophagien (RGO)**
- Oesophagite**
- Monnier P, Savary M. Contribution of endoscopy to gastroesophageal reflux disease. Scand J Gastroenterol 1984; 19(Suppl 106): 26.
- Rockall TA, Logan RF, Devlin HB, et al. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom. Steering Committee and members of the National Audit of Acute Upper Gastrointestinal Haemorrhage. BMJ 1995; 311: 222-6.
- El-Serag HB, Sonnenberg A. Associations between different forms of gastro-oesophageal re-

- flux disease. Gut 1997; 41: 594-9.
- Ferraris R, Bonelli L, Conio M, et al. Incidence of Barrett's adenocarcinoma in an Italian population: an endoscopic surveillance programme. Eur J Gastroenterol Hepatol 1997; 9: 881-5.
- Dent J. Gastro-oesophageal reflux disease. Digestion 1998; 59: 433-45.
- Lagergren J, Bergström R, Lingren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-31.
- Jornod Ph, Blum AL, Armstrong D. Oesophagite par reflux: classification. In: Dupas JL, Fléjou (eds.). *Maladies de l'œsophage, de l'estomac et du duodénum*. Editions Arnette, 1999.
- Jornod Ph, Vouillamoz D, Blum AL. Oesophagite peptique. Med Hyg 2000; 58: 209-15.
- Hilton D, Iman N, Burke GJ et al. Absence of abdominal pain in older persons with endoscopic ulcers: a prospective study. Am J Gastroenterol 2001; 96: 380-4.
- Spechler SJ. Barrett's esophagus. N Engl J Med 2002; 2002: 346: 836-42.
- Behrman SW. Management of complicated peptic ulcer disease. Arch Surg 2005; 140: 201-8.
- Vakil N, van Zanten SV, Kahrilas P, et al. Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101: 1900-20; quiz 1943.
- Burri E, Meier R. Ulcères peptiques – mise à jour 2011. Forum Med Suisse 2011; 11: 897-906.
- Helicobacter pylori (Hp)**
- NH Consensus development conference. Helicobacter pylori in peptic ulcer disease. JAMA 1994; 272: 65-9.
- Lind T, et al. Eradication of helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the Mach I study. Helicobacter 1996; 1: 138-44.
- Soll AH. Medical treatment of peptic ulcer disease. Practice guidelines. JAMA 1996; 275: 622-9. [Erratum: JAMA 1996; 275: 1314].
- Dominguez-Munoz, et al. A citric acid solution is an optimal test drink in the ¹³C-urea breath test for the diagnosis of Helicobacter pylori infection. Gut 1997; 40: 459-62.
- The European Helicobacter Pylori Study Group (EHPSG). Current European concepts in the management of H. pylori infection. The Maastricht consensus report. Gut 1997; 41: 8-13.
- Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998; 93: 2330-8.
- Hunt RH, Thompson ABR. Canadian helicobacter pylori consensus conference. Can J Gastroenterol 1998; 12: 31-41.
- Hunt RH, Fallone CA, Thomson AB. Canadian helicobacter pylori consensus conference update: infections in adults. Can J Gastroenterol 1999; 13: 213-7.
- Viani F, Blum AL, Koelz HR, Pantoflickova D. Helicobacter pylori, ulcère gastro-duodénal et AINS. Med Hyg 2000; 58: 216-24.
- Harris A, Misiewicz JJ. ABC of the upper gastrointestinal tract. Management of helicobacter pylori infection. BMJ 2001; 323: 1047-50.
- Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-9.
- Vuillamoz D, Viani F, Jornod P, et al. Maladies peptiques. Rev Med Suisse 2005; 1: 200-8.
- Chey WD, Wong BC, Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102: 1808-25.
- Malfertheiner P, Megraud F, O'Morain CA et al. Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report. Gut 2017; 66: 6-30.
- Fallone CA, Chiba N, van Zanten SV et al. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology 2016; 151: 51-69.
- Moayyedi PM, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N. ACG and CAG clinical guideline: management of dyspepsia. Am J Gastroenterol. 2017;112:988-1013.
- Siddique O, Ovalle A, Siddique AS et al. Helicobacter pylori Infection: An Update for the Internist in the Age of Increasing Global Antibiotic Resistance. Am J Med 2018; 131: 473-479.
- Gressot P, Frossard JL, Grosgeurin O et al. Traitement d'éradication d'Helicobacter pylori en 2019. Rev Med Suisse 2019; 15: 1854-8.
- Raiss R, Koehli L, Schoepfer A, Gouveia A. Nichtinvasive Methoden zum Nachweis von Helicobacter pylori. Swiss Med Forum 2022;22: 329-331.
- ZOLLINGER-ELLISON Syndrome**
- Jensen RT, Fraker DL. Zollinger-Ellison syndrome. Advances in treatment of gastric hypersecretion and the gastrinoma. JAMA 1994; 271: 1429-35.
- Meko JB, Norton JA. Management of patients with Zollinger-Ellison syndrome. Ann Rev Med 1995; 46: 395-411.
- Wolfe MM, Jensen RT. Zollinger-Ellison syndrome. Current concepts in diagnosis and management. N Engl J Med 1997 ;317: 1200-9.
- Norton JA, Fraker DL Surgery, Alexander R, et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 1999; 341: 635-44.
- Wells SA, Jr. Surgery for the Zollinger-Ellison syndrome. N Engl J Med 1999; 341: 689-90.
- Dumping syndrome**
- Lev-Ran A, Anderson RW. The diagnosis of post-prandial hypoglycemia. Diabetes 1981; 30: 996-9.
- Parardi J, Havrankova J, Lepage R, et al. Blood glucose measurement during symptomatic episodes in patients with suspected postprandial hypoglycemia. N Engl J Med 1989; 321: 1421-5.

NEUROLOGIE

Hémorragie cérébrale

Anderson CS, Heeley E, Huang Y, et al. INTER-ACT2 Investigators. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. *N Engl J Med* 2013; 368: 2355-65.

Hirnschlag — Schlaganfall — Iktus — Ictus

CVI — Accident cérébro-vasculaire (AVC)

Goldstein M, Bolis CL, (eds.). Cerebrovascular disorders: a clinical and research classification. Geneva: World Health Organization, 1978. (WHO offset publication no 43.)

Bogousslavsky J. Embolies cérébrales d'origine cardiaque: quand anticoaguler ? *Schweiz Med Wschr* 1985; 115: 1381-6.

Garcia JH, et al. Physiopathology of cerebral ischemia. *Crit Rev Neurol Biol* 1989; 4: 303-24.

Farell B, et al. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. *J Neurol Neurosurg Psychiatry* 1991; 54: 1044-54.

North American symptomatic carotid endarterectomy trial collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. *N Engl J Med* 1991; 325: 445-53.

Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation study. Final results. *Circulation* 1991; 84: 527-39.

The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. *N Engl J Med* 1991; 325: 1261-6.

Sieber FE, Traystman RJ. Special issues: glucose and brain. *Crit Care Med* 1992; 20: 104-14.

European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. *Lancet* 1993; 342: 1255-62.

Powers WJ. Acute hypertension after stroke. *Neurology* 1993; 43: 461-7.

Adams HPJ, Brott TG, Crowell RM, et al. Guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. *Stroke* 1994; 25: 1901-14.

Feinberg WM, Albers GW, Barnett HJM, et al. Guidelines for the management of transient ischemic attacks. *Stroke* 1994; 25: 1320-35.

Matchar DB, McCrory DC, Barnett HJM, et al. Guidelines for medical treatment for stroke prevention. *Ann Intern Med* 1994; 121: 54-5.

Bleic S, Bogousslavsky J. General management of patients with ischemic stroke: Clinical features and epidemiology. *Curr Opin Neurol* 1995; 8: 30-7.

Bronner LL, Kanter DS, Manson JE. Primary prevention of stroke. *N Engl J Med* 1995; 333: 1392-1400.

Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for

asymptomatic carotid artery stenosis. *JAMA* 1995; 273: 1421-8.

Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European cooperative acute stroke study (ECASS). *JAMA* 1995; 274: 1017-25.

The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. *N Engl J Med* 1995; 333: 1581-7.

Berger JP. Petits débits cérébraux, attaques d'ischémie transitoire et syncopes. *Rev Med Suisse Rom*. 1996; 116: 597-604.

CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events. *Lancet* 1996; 348: 1329-39.

Dewarrat A, Bogousslavsky J. Antithrombotiques et prévention des accidents vasculaires cérébraux. *Rev Med Suisse Rom* 1996; 116: 629-34.

Fisher M, Garcia JH. Evolving stroke and the ischemic penumbra. *Neurology* 1996; 47: 884-8.

CAST Collaborative Group. CAST: Randomized placebo-controlled trial of early aspirin use in 20000 patients with acute ischemic stroke. *Lancet* 1997; 349: 1641-9.

International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischemic stroke. *Lancet* 1997; 349: 1569-81.

Barnett HJM, Taylor DW, Eliasziw M, et al. for the North American Symptomatic Carotid-Endarterectomy Trial Collaborators (NASCET). Benefit of carotid endarterectomy in patients with symptomatic moderate to severe stenosis. *N Engl J Med* 1998; 339: 1415-25.

Christ M, Diener HC, Kurth T, et al. Sekundärprävention atherosklerotischer Erkrankungen in der täglichen Praxis. *Internist* 1998; 39: 1080-97.

European Carotid Surgery Trialists' Cooperative Group. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). *Lancet* 1998; 351: 1379-87.

Kidwell CS, Saver JL, Schubert GB, et al. Design and retrospective analysis of the Los Angeles prehospital stroke screen (LAPSS). *Prehosp Emerg Care* 1998; 2: 267-73.

Schrader J, Rothenmeyer M, Luders s, et al. Hypertension and stroke - rationale behind the ACCESS trial. Acute candesartan cilexetil evaluation in stroke survivors. *Bas Res Cardiol* 1998; 93 (Suppl. 2): 69-78.

Broderick JP et al. Am. Stroke Assoc. Guidelines for intracerebral hemorrhage: *Stroke* 1999; 30:905-15.

Kappelle LJ, Eliasziw M, Fox AJ, et al. for the North American Symptomatic Carotid-Endarterectomy Trial Group. Importance of intracranial atherosclerotic disease in patients with symptomatic stenosis of the internal carotid artery. *Stroke* 1999; 30: 282-6.

- Kothari RU, Panciolo A, Liu T, et al. Cincinnati Prehospital Stroke Scale: reproducibility and validity. *Ann Emerg Med* 1999; 33: 373-8.
- Brott Th, Bogousslavsky J. Treatment of acute ischemic stroke. *N Engl J Med* 2000; 343: 710-22.
- Inzitari D, Eliasziw M, Gates P, et al. The causes and risk of stroke in patients with asymptomatic internal-carotid-artery stenosis. *N Engl J Med* 2000; 342: 1693-700.
- Kidwell CS, Starkman S, Eckstein M, et al. Identifying stroke in the field: prospective validation of the Los Angeles Prehospital Stroke Screen (LAPSS). *Stroke* 2000; 31: 71-6.
- Kistler JP, Furie KL. Carotid endarterectomy revisited. *N Engl J Med* 2000; 342: 1743-45.
- Steiner Th, Hennes HJ, Kretz R, et al. Akute klinische Schlaganfallbehandlung. *Anaesthesia* 2000; 49: 2-8.
- Zerebrovaskuläre Arbeitsgruppe der Schweiz (ZAS) und Schweizerische Herzstiftung (SHS). Sekundärprävention nach ischämischen Schlaganfall. *Schweiz Aerztezeitung* 2000; 81: 1105-15.
- Albers GW, Amarenco P, Easton JD, et al. Anti-thrombotic and thrombolytic therapy for ischemic stroke. Sixth ACCP Consensus Conference on antithrombotic therapy. *Chest* 2001; 119 (Suppl. 1): 300S-320S.
- Goldstein LB, Adams R, Becker K, et al. Primary prevention of ischemic Stroke. A statement for healthcare professionals from the stroke council of the american heart association. *Stroke* 2001; 32: 280-99. Or in: *Circulation* 2001; 103: 163-82.
- Sacco RL. Extracranial carotid stenosis. *N Engl J Med* 2001; 345: 1113-8.
- Barnett HJM, Meldrum HE, Eliasziw M, et al. The appropriate use of carotid endarterectomy. *CMAJ* 2002; 166: 1169-79.
- Schrader J, Luders S, Kulszewski A, et al. AC-CESS study: Acute Candesartan Cilexetil Evaluation in Stroke Survivors [Abstract]. *Am J Hypertension* 2002; 15: 17A.
- Adams HP et al. Am. Stroke Assoc. Guidelines for ischemic stroke. *Stroke* 2003; 34: 1056-83.
- Diener HC, Bogousslavsky J, Brass LM et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. *Lancet* 2004; 364: 331-37.
- Toni D et al. European Stroke Initiative recommendations. *Cerebrovasc Dis* 2004; 17 Suppl 2:30-46.
- Adams H, Adams R, del Zoppo G, et al. Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update: AHA/ASA. *Stroke* 2005; 36: 916-32.
- AHA Part 9: Adult Stroke. *Circulation* 2005; 112: 111-20.
- Rothwell PM, Giles MF, Flossmann E et al. A simple score (ABCD) to identify individuals at high early risk of stroke after transient ischaemic attack. *Lancet* 2005; 366: 29-36.
- Johnston SC, Nguyen-Huynh MN, Schwarz ME, et al. National Stroke Association guidelines for the management of transient ischemic attacks. *Ann Neurol* 2006; 60: 301-13.
- Adams HP, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke (AHA). *Stroke* 2007; 38: 1655-711 (Erratum *Stroke* 2007; 38: e38).
- Bart von der Worp H, Gijn J. Acute ischemic stroke. *N Engl J Med* 2007; 357: 572-9.
- Johnston SC, Rothwell PM, Huynh-Huynh MN, et al. Validation and refinement of scores to predict very early stroke risk after transient ischemic attack. *Lancet* 2007; 369: 283-92.
- Paciaroni M, Agnelli G, Micheli S, et al. Efficacy and safety of anticoagulation treatment in acute cardioembolic stroke; a meta-analysis of randomized controlled trials. *Stroke* 2007; 38: 423-30.
- Easton JD, Saver JL, Albers GW et al. Definition and evaluation of transient ischemic attack : a scientific statement for healthcare professionals. *Stroke* 2009; 40: 2276-93.
- Giles MF, Rothwell PM. Transient ischaemic attack: clinical relevance, risk prediction and urgency of secondary prevention. *Curr Opin Neurol* 2009; 22: 46-53.
- Amarenco P, Lareuche J, Lavallée PC et al. Does ABCD2 score below 4 allow more time to evaluate patients with a transient ischemic attack? *Stroke* 2009; 40: 3091-5.
- Ní Chróinín D, Callaly EL, Duggan J, et al. Association between acute statin therapy, survival, and improved functional outcome after ischemic stroke: the North Dublin Population Stroke Study. *Stroke* 2011; 42(4): 1021-9.
- Booth JN 3rd, Levitan EB, Brown TM, et al. Effect of sustaining lifestyle modifications (nonsmoking, weight reduction, physical activity, and Mediterranean diet) after healing of myocardial infarction, percutaneous intervention, or coronary bypass (from the REasons for Geographic and Racial Differences in Stroke study). *Am J Cardiol* 2014; 113: 1933-40.
- Pérez de la Ossa N, Carrera D, Gorchs M et al. Design and validation of a prehospital stroke scale to predict large arterial occlusion: the rapid arterial occlusion evaluation scale. *Stroke* 2014; 45: 87-91. (RACE)
- Afshin A, Micha R, Khatibzadeh S, Mozaffarian D. Consumption of nuts and legumes and risk of incident ischemic heart disease, stroke, and diabetes: a systematic review and meta-analysis. *Am J Clin Nutr* 2014; 100: 278-88.
- David Carrera R, Campbell BCV, Cortés J et al. Predictive Value of Modifications of the Prehospital Rapid Arterial Occlusion Evaluation Scale for Large Vessel Occlusion in Patients with Acute Stroke. *J Stroke Cerebrovasc Dis* 2017; 26: 74-77.
- GBD 2017 Diet Collaborators. Health effects of dietary risks in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2019; 393: 1958-72.
- Johnston SC, Easton JD, Farrant M et al. Clopidogrel and Aspirin in Acute Ischemic Stroke and

High-Risk TIA. NEJM 2018; 379: 215-25.
Schnabel RB, Haeusler KG, Healey JS et al. Searching for Atrial Fibrillation Poststroke A White Paper of the AF-SCREEN International Collaboration. Circulation 2019;140:1834-185.

Thrombolyse de l'AVC

The national institute of neurological disorders and stroke, rt-PA stroke study group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-7.
Bogousslavsky J. Thrombolysis in acute stroke. BMJ 1996; 313: 640-1.

Bogousslavsky J, Buettner UW, Hess K, et al. Thrombolyse intraveineuse par rt-PA (recombinant tissue plasminogen activator) dans le traitement aiguë des accidents vasculaires cérébraux. Bull Médecins Suisses 1998; 79: 114-5.

Fifth consensus conference on antithrombotic therapy (1998): summary recommendations. Chest 1998; 114 (Suppl.): 439S-769S.

Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australian Acute Stroke Study Investigators. Lancet 1998; 352: 1245-51.

Norris JW, Buchman A, Cote, et al. Canadian guidelines for intravenous thrombolytic treatment in acute stroke. Can J Neurol Sci 1998; 25: 257-9.

Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999; 282: 2019-26.

Furlan A et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomised controlled trial. Prolyse in acute cerebral thromboembolism. JAMA 1999; 282: 2003-11.

Hallan S et al. A decision analysis of thrombolytic therapy compared with standard therapy in acute ischemic stroke. J Intern Med 1999; 246: 549-59.

Ueda T et al. Multivariable analysis of predictive factors related to outcome at 6 month after intra-arterial thrombolysis for acute ischemic stroke. Stroke 1999; 30: 2360-5.

Brott Th, Bogousslavsky J. Treatment of ischemic stroke. N Engl J Med 2000; 343: 710-22.

Albers GW, Amarenco P, Easton JD, et al. Anti-thrombotic and thrombolytic therapy for ischemic stroke. Chest 2001; 119 (Suppl.): 300S-320S.

ANAES Recommandations pour la pratique clinique. Prise en charge initiale des patients adultes atteints d'accident vasculaire cérébral. Aspects médicaux. Septembre 2002, p. 1.127. AHA Part 9: Adult Stroke. Circulation 2005; 112: 111-20.

Reversibles zébrales

Vasokonstriktionssyndrom (RCVS)

Beerle N, Hader CI, Kleger GR et al. Das reversibile zerebrale Vasokonstriktionssyndrom. Swiss Med Forum 2019; 19: 232-236.

Aphasie

Geschwind N. Aphasia. N Engl J Med 1971; 284: 654-6.

Damasio AR. Aphasia. N Engl J Med 1992; 326: 531-8.

Mesulam MM. Primary progressive aphasia - a language-based dementia. N Engl J Med 2003; 349: 1535-42.

Trombose veineuse cérébrale

Hirnvenenthrombosen - Sinusvenenthrombose

Stam J. Thrombosis of the Cerebral Veins and Sinuses. N Engl J Med 2004; 352: 1791-8.

Silvis SM, Middeldorp S, Zuurbier SM et al. Risk Factors for Cerebral Venous Thrombosis. Semin Thromb Hemost 2016; 42: 622-31.

FOP - Foramen ovale perméable

Kent DM, Thaler DE. The Risk of Paradoxical Embolism (RoPE) study: developing risk models for application to ongoing randomized trials of percutaneous patent foramen ovale closure for cryptogenic stroke. Trials. 2011; 12: 185-194.

Dystonie aiguë - Dyskinésies tardives

De Gowin EL, De Gowin RL (eds.). Diagnostic au lit du malade. Doin Editions-Paris, 1980, p: 808-18.

Marschen D, Fahn S. (eds.). Mouvement disorders 1, 2, 3. Butterworth Heinemann, 1996.

Van Harten P, Hoek HW, Kahn RS. Acute dystonia induced by drug treatment. BMJ 1999; 319: 623-6.

Céphalée, migraine

NET: <http://www.ihhs-classification.org/>

Bruyn GW. Intracranial arteriovenous malformation and migraine. Cephalgia 1984; 4:191-207.

Mitchell CS, Osborn RE, Grosskreutz SR. Computed tomography in the headache patient: is routine evaluation really necessary? Headache 1993; 33:82-86.

Frishberg BM. The utility of neuroimaging in the evaluation of headache in patients with normal neurologic examinations. Neurology 1994; 44:1191-1197.

Akpek S, Arac M, Atilla S, Onal B, Yucel C, Isik S. Cost-effectiveness of computed tomography in the evaluation of patients with headache. Headache 1995; 35:228-230.

Weiller C, May A, Limroth V, Juptner M, Kaube H, Schayck RV, Coenen HH, Diener HC. Brain stem activation in spontaneous human migraine attacks. Nat Med 1995; 1:658-660.

Dde Bruijn SF, Stam J, Kappelle LJ. Thunderclap headache as first symptom of cerebral venous sinus thrombosis. CVST Study Group. Lancet 1996; 348:1623-1625.

Ophoff RA, Terwindt GM, Vergouwe MN, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca²⁺

- channel gene CACNL1A4. *Cell* 1996; 87:543-552.
- Frishberg BM. Neuroimaging in presumed primary headache disorders. *Semin Neurol* 1997; 17:373-382.
- Morgenstern LB, Luna-Gonzales H, Huber JC, Jr., Wong SS, Uthman MO, Gurian JH, Castillo PR, Shaw SG, Frankowski RF, Grotta JC. Worst headache and subarachnoid hemorrhage: prospective, modern computed tomography and spinal fluid analysis. *Ann Emerg Med* 1998; 32:297-304.
- Newman LC, Lipton RB. Emergency department evaluation of headache. *Neurol Clin* 1998; 16:285-303.
- Sommer-Bühler J, Sztajzel R, Le Floch-Rohr J, et al. Les céphalées. *Med Hyg* 2000; 58: 788-96.
- Bahra A, Matharu MS, Buchel C, Frackowiak RS, Goadsby PJ. Brainstem activation specific to migraine headache. *Lancet* 2001; 357:1016-1017.
- Goadsby PJ. Neuroimaging in headache. *Microsc Res Tech* 2001; 53:179-187.
- Morgenstern LB, Huber JC, Luna-Gonzales H, Saldin KR, Grotta JC, Shaw SG, Knudson L, Frankowski RF. Headache in the emergency department. *Headache* 2001; 41:537-541.
- Van GJ, Rinkel GJ. Subarachnoid haemorrhage: diagnosis, causes and management. *Brain* 2001; 124:249-278.
- Dodick DW. Thunderclap headache. *Headache* 2002; 42:309-315.
- Ekbom K, Hardebo JE. Cluster Headache aetiology, diagnosis and management. *Durgs* 2002; 62: 61-9.
- Goadsby PJ. Pathophysiology of cluster headache: a trigeminal autonomic cephalgia. *Lancet Neurol* 2002; 1:251-257.
- Goadsby PJ, Lipton RB, Ferrari MD, et al. Migraine - current understanding and treatment. *N Engl J Med* 2002; 346: 257-70.
- Mattle HP, Sturzenegger M, Meyer C. Céphalée symptomatiques. *Forum Med Suisse* 2002; 5: 93-9.
- Medina LS, D'Souza B, Vasconcellos E. Adults and children with headache: evidence-based diagnostic evaluation. *Neuroimaging Clin N Am* 2003; 13:225-235.
- Ramadan, N. M. Headache update. Headache update. Continuum lifelong learning in neurology from the american academy of neurology 9, 9-24. 2003. Lippincott, Williams, Wilkins.
- Cortelli P, Cevoli S, Nonino F, Baronciani D, Magrini N, Re G, De BG, Manzoni GC, Querzani P, Vandelli A. Evidence-based diagnosis of non-traumatic headache in the emergency department: a consensus statement on four clinical scenarios. *Headache* 2004; 44:587-595.
- Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria criteria for headache disorders, cranial neuralgias, and facial pain. *Cephalgia Suppl 1*, S1-S160. 2004.
- Lipton RB, Bigal ME, Steiner TJ, Silberstein SD, Olesen J. Classification of primary headaches. *Neurology* 2004; 63:427-435.
- Olesen J, Lipton RB. Headache classification update 2004. *Curr Opin Neurol* 2004; 17:275-282.
- Swartz RH, Kern RZ. Migraine is associated with magnetic resonance imaging white matter abnormalities: a meta-analysis. *Arch Neurol* 2004; 61:1366-1368.
- Sempere A, Porta-Etessam J, Medrano V, García-Morales I, Concepcion L, Ramos A, Florencio I, Bermejo F, Botella C. Neuroimaging in the evaluation of patients with non-acute headache. *Cephalgia* 2005; 25:30-35.
- Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). *Cephalgia* 2013; 33: 629-808.
- Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. *Cephalgia* 2018; 38:1-211.

Épilepsie

- Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical classification and electroencephalographic classification of epileptic seizures. *Epilepsia* 1981; 22: 489-501.
- Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical classification and epileptic syndromes. *Epilepsia* 1989; 30: 389-99.
- De Lorenzo. Status epilepticus in children, adult and the elderly. *Epilepsia* 1992; 33 (Suppl.4): S15- S25.
- Greenberg MK, Barsan WG, Starkman S. Neuroimaging in the emergency patient presenting with seizure. *Neurology* 1996; 47: 26-32.
- Desland PA, Foletti G. Stratégies thérapeutiques dans l'état de mal épileptique. Les urgences neurologiques. Les 60 premières minutes. *Med Hyg* 1997; 55: 1073-7.
- Marson AG, Kadir ZA, Hutton JL, Chadwick DW. The new antiepileptic drugs: A systematic review of their efficacy and tolerability. *Epilepsia* 1997; 38: 859-80.
- Lowenstein DH, Alldredge BK. Status epilepticus. *N Engl J Med* 1998; 338: 970-6.
- Markand ON. Epilepsie in adults. In: Biller J. (ed.). *Practical Neurology*. Lippincott-Raven Publishers 1997, pages 418-36.
- Bleck TP. Management approaches to prolonged seizures and status epilepticus. *Epilepsia* 1999; 40: Suppl. 1:S59-S63.
- Alldredge BK, Gelb AM, Isaacs SM, et al. A comparison of Lorazepam, Diazepam and placebo for the treatment of out-of-hospital status epilepticus. *N Engl J Med* 2001; 345: 631-7.
- Browne TR, Holmes GL. Epilepsy. *N Engl J Med* 2001; 344: 1145-51.
- Chang BS, Lowenstein DH. Epilepsy. *N Engl J Med* 2003; 349: 1257-66.
- Leppert D, Stöckli HR, Fuhr P. Directives pour le traitement de l'état de mal épileptique. *Schweiz Ärztezeitung* 2005; 86: 1-14. Erratum: *Schweiz Ärztezeitung* 2007; 88: 39

Mort cérébrale, test d'apnée

- The Ad Hoc Committee of the Harvard Medical School to examine the definition of brain death. A definition of irreversible coma. JAMA 1968; 205: 337-40.
- Black PM. Brain death (first of two parts). N Engl J Med 1978; 299: 338-44.
- Black PM. Brain death (second of two parts). N Engl J Med 1978; 299: 393-401.
- Brain death task force: guideline for the diagnosis of brain death. Can Med Assoc J 1987; 136: 200A-200B.
- Benzel EC, Gross CD, Hadden TA, et al. The apnea test for the determination of brain death. J Neurosurg 1989; 71: 191-194.
- Asbury AK, McKhann GM, McDonald WI. (eds.). Neurologic manifestation of systemic diseases. In: Diseases of the nervous system clinical neurobiology. W.B. Saunders Company , 1992.
- Academie Suisse des Sciences Médicales: Directives pour la définition et le diagnostic de la mort en vue d'une transplantation d'organes. Bulletin des médecins suisses 1996; 77: 1821-9.
- Favre J. Brain stem death. In: Palmer JD (ed.) Manual of Neurosurgery. New York, Churchill Livingstone 1996; chapter 118: 573-81.
- Favre J. La mort cérébrale. Rev Med Suisse Rom 1998; 118: 531-6.
- Canadian Neurocritical Care Group. Guidelines for the diagnosis of brain death. Can J Neurol Sci 1999; 26: 64-66. (www.canjneurosci.org)
- Wijdicks EFM. The diagnosis of brain death. N Engl J Med 2001; 344: 1215-21.
- Meier N, Duner P., Sturzenegger M. Der Kopfschmerzpatient in der Hausarztpraxis. Schweiz Med Forum 2015; 15: 420-4.
- Encéphalite - Méningoencéphalite**
- von Arx S, Leib SL, Sturzenegger M, Sendi P. Infektionen des zentralen Nervensystems – Teil 1: Meningitis bei Erwachsenen. Schweiz Med Forum 2017; 17: 464-70.
- von Arx S, Leib SL, Sturzenegger M, Sendi P. Infektionen des zentralen Nervensystems – Teil 2: Enzephalitis beim Erwachsenen. Schweiz Med Forum 2017; 17: 492-98.
- Dermatomes**
- International standards for neurological and functional classification of spinal cord injury. Chapter II: Neurological Assessment: the sensory examination, 1996: 5-14
www.sci-queri.research.med.va.gov/Registry.htm
- Locked-in-syndrome (LIS)**
- Virgle RS (1984) Locked-in syndrome. Case and literature review. Clin Neurol Neurosurg 1984; 86: 275-9.
- Patterson JR, Grabois M. Locked-in syndrome: a review of 139 cases. Stroke 1986; 17: 758-64.
- Malm J, Kristensen B, Carlberg B, et al. Clinical features and prognosis in young adults with infratentorial infarcts. Cerebrovasc Dis 1999; 9: 282-9.
- Raab A, Sandner E. Ein Betreuungskonzept für Betroffene mit Locked-in-Syndrom. Schweiz Med For 2015; 15: 106-110.
- Neuropathie**
- Adour KK, Wingerd JW, Doty HE. Prevalence of concurrent diabetes mellitus and idiopathic facial paralysis (Bell's palsy). Diabetes 1975; 24: 449-51.
- Raskin NH, Fishman RA. Neurologic disorders in renal failure (first of two parts). N Engl J Med 1976; 294: 143-8.
- Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4.400 patients observed between 1947 and 1973. Diabète Care 1978; 1: 168-188.
- Pecket P, Schatter A. Concurrent Bell's palsy and diabetes mellitus: a diabetic mononeuropathy? J Neurol Neurosurg Psychiatry 1982; 45: 652-5.
- Wall PD, Melzack R. (eds.). Peripheral neuropathies. In: Textbook of Pain. Churchill Livingstone 1989.
- Ropper AH. The Guillain-Barré syndrome. N Engl J Med 1992; 326: 1130-6.
- Dyck PJ, Kratz KM, Carnes JL et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993; 43: 817-24. [Erratum Neurology 1993; 43: 2345.]
- Barohn RJ. Approach to peripheral neuropathy and neuronopathy. Semin 1998; 18: 7-18.
- Parésie faciale — Gesichtslähmung**
- Karnes WE. Diseases of the seventh cranial nerve. In: Dyck PJ (ed.). Peripheral Neuropathy. Philadelphia, Saunders, 1984 Berg K, Wood-Dauphinee S, Williams JI, Gayton D: Measuring balance in the elderly: Preliminary development of an instrument. Physiotherapy Canada, 41:304-311, 1989.
 :1266-99.
- Adour KK, Ruboyianes JM, Von Doersten PG, et al. Bell's palsy treatment with acyclovir and prednisone compared with prednisone alone: a double-blind, randomized, controlled trial. Ann Otol Rhinol Laryngol 1996; 105: 371-78.
- Murakami S, Nakashiro Y, Doi T, et al. Bell palsy and herpes simplex virus: identification of viral DNA in endoneurial fluid and muscle. Ann Intern Med 1996; 124: 27-30.
- Robb G, Fazekas F, Hartung HP. Peripheral facial palsies: etiology, diagnosis and treatment. Eur Neurol 1999; 41: 3-6.
- Ramsey MJ, DerSimonian R, Hotel MR, et al. Corticosteroid treatment for idiopathic facial nerve paralysis: a meta-analysis. Laryngoscope 2000; 110: 335-41.
- Sullivan FM, Swan RC, Donnan PT et al. Early Treatment with Prednisolone or Acyclovir in Bell's Palsy. N Engl J Med 2007; 357: 1598-1607.
- GUILAIN-BARRE, MILLER-FISHER**
- Hurwitz E, Schonberger L, Nelson D, et al. Guillain-Barré Syndrome and the 1978-79 influenza vaccine. N Engl J Med 1981; 304: 1557-61.
- Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990; 27 (Suppl.): 1123-1129.

- Ropper A. Guillain-Barré syndrome. *N Engl J Med* 1992; 326: 1130-6.
- Van der Meche F, Schmitz P. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain Barré Study Group. *N Engl J Med* 1992; 326: 1123-9.
- Bolton CF. The changing of concepts of Guillain-Barré Syndrome. *N Engl J Med* 1995; 333: 1415-7.
- Hughes RA, Hadden RD, Gregson NA, et al. Pathogenesis of Guillain-Barre syndrome. *J Neuropathol Immunol* 1999; 100: 74-97.
- Willison HJ, O'Hanlon GM. The immunopathogenesis of Miller Fisher syndrome. *J Neuropathol Immunol* 1999; 100: 3-12.
- Mori M, Kuwabara S, Fukutate T, et al. Clinical features and prognosis of Miller Fisher syndrome. *Neurology* 2001; 56: 1104-6.
- Van der Meche FG, Van Doorn PA, Meulstee J, et al. Diagnostic and classification criteria for the Guillain-Barré syndrome. *Eur Neurol* 2001; 45: 133-9.
- Yuki N, Hartung HP. Guillain-Barré syndrome. *N Engl J Med* 2012; 366: 2294.
- Hypertension intracrânienne, Oedème cérébral**
- Brunn FJ, Fraley DS, Haigh J, et al. Control of organ blood flow. In: Snyder JV, Pinsky MR (eds.). *Oxygen transport in the critically ill*. Chicago: Year Book Medical Publishers 1987; 87-124.
- Drummond JC, Shapiro HM. Cerebral physiology. In: Miller RD (ed.). *Anesthesia*. Churchill Livingstone, 1990, p: 625.
- Lang EW, Chesnut RM. Intracranial pressure and cerebral perfusion pressure in severe head injury. *New Horiz* 1995; 3: 400-9.
- Levy MH. Pharmacologic treatment of cancer pain. *N Engl J Med* 1996; 335: 1124-32.
- Chesnut RM. The management of severe traumatic brain injury. *Emerg Med Clin North Am* 1997; 15: 581-604.
- Lam CH, Villemure JG. Comparison between ventriculoatrial and ventriculoperitoneal shunting in the adult population. *Br J Neurosurg* 1997; 11: 43-8.
- Corkill RG, Cadoux-Hudson TA. Normal pressure hydrocephalus: developments in determining surgical prognosis. *Curr Opin Neurol* 1999; 12: 671-7.
- Zemack G, Romner B. Seven years of clinical experience with the programmable Codman Hakim valve: a retrospective study of 583 patients. *J Neurosurg* 2000; 92: 941-8.
- Hydrocéphalie à pression normale (NPH)**
- Adams RD, Fisher CM, Hakim S, Ojemann RG, Sweet WH. Symptomatic Occult Hydrocephalus with «Normal» Cerebrospinal-Fluid Pressure. A Treatable Syndrome. *NEJM* 1965; 273: 117-26.
- Hakim S, Adams RD. The special clinical problem of symptomatic hydrocephalus with normal cerebrospinal fluid pressure. Observations on cerebrospinal fluid hydrodynamics. *J Neurol Sciences* 1965; 2: 307-27.
- Berg K, Wood-Dauphinee S, Williams JI, Maki, B: Measuring balance in the elderly: Validation of an instrument. *Can. J. Pub. Health* 1992; Suppl. 2: S7-11.
- Berg K, Wood-Dauphinee S, Williams JI: The Balance Scale: Reliability assessment for elderly residents and patients with an acute stroke. *Scand J Rehab Med* 1995; 27: 27-36.
- Wood-Dauphinee S, Berg K, Bravo G, Williams JI: The Balance Scale: Responding to clinically meaningful changes. *Canadian Journal of Rehabilitation* 1997; 10: 35-50.
- Hebb AO, Cusimano MD. Idiopathic normal pressure hydrocephalus: a systematic review of diagnosis and outcome. *Neurosurgery* 2001; 49: 1166-86.
- Momjian S, Owler BK, Czosnyka Z, et al. Pattern of white matter regional cerebral blood flow and autoregulation in normal pressure hydrocephalus. *Brain* 2004; 127: 9 65-72.
- Nasreddine, Z. S., Phillips, N. A., Bédirian, V., et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc* 2005; 53: 695-699.
- Kahlon B, Sjunnesson J, Rehncrona S. Long-term outcome in patients with suspected normal pressure hydrocephalus. *Neurosurgery* 2007; 60:327-32; discussion 32.
- Brean A, Eide PK. Prevalence of probable idiopathic normal pressure hydrocephalus in a Norwegian population. *Acta Neurol Scand* 2008; 118: 48-53.
- Marmarou A, Black P, Bergsneider M, et al. Guidelines for management of idiopathic normal pressure hydrocephalus: progress to date. *Acta Neurochir Suppl*. 2005; 95: 237-40.
- Reikin N, Marmarou A, Klinge P, Bergsneider M, Black PM. Diagnosing idiopathic normal-pressure hydrocephalus. *Neurosurgery* 2005; 57: 4-16; discussion ii-v.
- Jaraj D, Rabiei K, Marlow T, Jensen C, Skoog I and Wikkelso C. Prevalence of idiopathic normal-pressure hydrocephalus. *Neurology* 2014; 82: 1449-54.
- McGirt MJ, Woodworth G, Coon AL, et al. Diagnosis, treatment, and analysis of long-term outcomes in idiopathic normal-pressure hydrocephalus. *Neurosurgery* 2005; 57: 699-705; discussion 699-705.
- Lemcke J, Meier U, Muller C, et al. Safety and efficacy of gravitational shunt valves in patients with idiopathic normal pressure hydrocephalus: a pragmatic, randomised, open label, multicentre trial (SVASONA). *J of Neurology, Neurosurgery, and psychiatry* 2013;84:850-7.
- Jahn K, Zwergal A. *Normaldruckhydrocephalus*. In: Diener HC, Gerloff C, Dieterich M, editors. *Therapie und Verlauf neurologischer Erkrankungen*. Stuttgart: Kohlhammer. 2017.
- Fichtner J, Hänia L, Raabea A et al. *Normaldruck-Hydrocephalus*. *Schweiz Med Forum* 2019; 19: 476-80.
- Syndrome lombo-vertébral aigu**
- Calin A, Porta J, Fries JF, et al. Clinical history as a screening test for ankylosing spondylitis.

- JAMA 1977; 237: 2613-4.
- Weber H. Lumbar disc herniation. A controlled, prospective study with ten years of observation. Spine 1983; 8: 131-40.
- Deyo RA, Tsui-Wu JY. Descriptive epidemiology of low-back pain and its related care in the United States. Spine 1987; 12: 264-8.
- Kosteljanetz M, Bang F, Schmidt-Olsen S. The clinical significance of straight-leg-raising (Lasegue's sign) in the diagnosis of prolapsed lumbar disc. Spine 1988; 13: 393-5.
- McCombe PF, Fairbank JCT, Cockersole BC, et al. Reproducibility of physical signs in low-back pain. Spine 1989; 14: 908-18.
- Boden SD, Davis DO, Dina TS, et al. Abnormal magnetic resonance scans of the lumbar spine in asymptomatic subjects. J Bone Joint Surg Am 1990; 72: 403-8.
- Deyo RA, Rainville J, Kent DL. What can the history and the physical examination tell us about low back pain ? JAMA 1992; 268: 760-5.
- Leuba Manueddu B, Stalder H. Lombalgie aiguë. Med Hyg 1995; 54: 1745-9.
- Malmivaara A, Häkkinen U, Aro T, et al. The treatment of acute low back pain – bedrest, exercises, or ordinary activity. N Engl J Med 1995; 332: 351-5.
- Syndromes extrapyramidal, pyramidal, cérébellaire. Réflexes**
- Babinski J, tourney A. Symptômes des maladies du cervelet. Rev Neurol 1993; 18: 306-22.
- De Gowin EL, De Gowin RL (eds.). Diagnostic au lit du malade. Doin Editions-Paris, 1980, p: 808-18.
- Marschen D, Fahn S. (eds.). Mouvement disorders 1, 2, 3. Butterworth Heinemann, 1996.
- Syndrome d'impatience des membres inférieurs à l'éveil**
- Restless legs syndrome (RLS)**
- Walters AS. Toward a better definition of the restless legs syndrome: the international restless legs syndrome study group. Mov Disord 1995; 10: 634-42.
- Rothdach AJ, Trenkwalder C, Haberstock J, et al. Prevalence and risk factors of RLS in an elderly population. Neurology 2000; 54: 1064-8.
- Mathis J. Das restless legs Syndrom und periodische Beinbewegungen im Schlaf. Med Hyg 2003; 61: 106-7.
- Comella CL. Restless legs syndrome: treatment with dopaminergic agents. Neurology 2002; 58 (Suppl. 4): S87-S92.
- Odin P, Mrowka M, Shing M. Restless legs syndrome. Eur J Neurol 2002; 9 (Suppl 3): S59-S67.
- Stiasny K, OPertel WH, Trenkwalder C. Clinical symptomatology and treatment of restless legs syndrome and periodic limb movement disorder. Sleep Med Rev 2002; 6: 253-65.
- Mathis J. Das Restless Legs Syndrom in der Praxis. Swiss Medical Forum 2002; 4: 67-71.
- Allen RP, Walters AS, Montplaisir J, Hening W, Myers A, Bell TJ, et al. Restless legs syndrome prevalence and impact: REST general population study. Archs Intern Med 2005;165:1286-92.
- Garcia-Borreguero D et.al., The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. Sleep Med 2013; 14: 675-684.
- Allen RP, Picchietti DL, Garcia-Borreguero D et al. Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria--history, rationale, description, and significance. Sleep Med 2014; 15: 860-73. doi: 10.1016/j.sleep.2014.03.025
- Sateia MJ. International classification of sleep disorders-third edition: highlights and modifications. Chest 2014; 146: 1387-94.
- Mathis J. Langzeittherapie beim Restless-Legs Syndrom. Rev Med Suisse 2015; 11: 268-70.
- Tremblement - Trémor**
- Elbe RJ, Koller WC. Tremor. Johns Hopkins University Press, Baltimore 1990.
- Ghika J, Kuntzer R, Regli F. Les tremblements. Revue Suisse de medecins (Praxis). 1993; 82: 759-68.
- Deuschl G, Bain P, Brin M. Consensus statement of the Movement Disorder Society on Tremor. Ad Hoc Scientific Committee. Mov Disord 1998; 13 (Suppl. 3): 2-23.
- Findly LJ, Koller WC. (eds.). Handbook of tremor disorders. Marcel Dekker, 1999.
- Bain P, Brin M, Deuschl G et al. Criteria for the diagnosis of essential tremor. Neurology 2000; 54 (Suppl. 4): S7
- Habib ur-Rehman. Diagnosis and management of tremor. Arch Intern Med 2000; 160: 2438-44.
- Sullivan KL, Hauser RA, Zesiewicz TA. Essential tremor. Epidemiology, diagnosis, and treatment. Neurologist 2004; 10: 250-8.
- Practice parameter. Therapies for Essential Tremor. Neurology 2005; 64: 2008-20.
- Wenning GK, Kiechl S, Seppi K, et al. Prevalence of movement disorders in men and women aged 50-89 years (Bruneck Study cohort): a population-based study. Lancet Neurol 2005; 4: 815-20.
- Rodrigues JP, Edwards DJ, Walters SE et al. Blinded placebo crossover study of gabapentin in primary orthostatic tremor. Mov Disord 2006; 21: 900-905.
- Louis ED, Ferreira JJ. How common is the most common adult movement disorder? Update on the worldwide prevalence of essential tremor. Mov Disord 2010; 25: 534-41. doi: 10.1002/mds.22838.
- Deuschl G, Raethjen J, Hellriegel H et al. Treatment of patients with essential tremor. Lancet Neurol 2011; 10: 148-161.
- Parkinsonisme — M. PARKINSON**
- Calne DB. Treatment of parkinson's disease. N Engl J Med 1993; 329: 1021-7.
- Ghika J, Regli F. Nouvelles acquisitions thérapeutiques dans la maladie de Parkinson. Med Hyg 1995; 53: 32-6.
- Dooley M, Markham A. Pramipexole. A review of

- its use in the management of early and advanced Parkinson's disease. *Drugs & Aging* 1998; 12: 495-514.
- Groupe de travail de la commission de thérapie de la Société suisse de neurologie (SNN). Recommandations pour le traitement du syndrome de Parkinson idiopathique. *Bulletin des Médecins Suisses* 1998; 79: 425-7.
- Lang AE, Lozano AM. Parkinson's disease, first of two parts. *N Eng J Med* 1998; 339: 1044-53.
- Lang AE, Lozano AM. Parkinson's disease, second of two parts. *N Eng J Med* 1998; 339: 1130-43.
- Dewey RB Jr, Hutton JT, LeWitt PA, et al. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. *Arch Neurol* 2001; 58: 1385-92.
- Krack P, Batir A, Van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. *N Engl J Med* 2003; 349: 1925-34.
- Groupe de travail de la commission de thérapie de la Société suisse de neurologie. Archives de Suisses de Neurologie et de Psychiatrie 2004; 155: 74-8.
- Burkhardt PR, Villemure JG, Vingerhoets FJG. Traitement actuel de la maladie de Parkinson: difficultés et controverses. *Rev Med Suisse* 2005; 1: 1214-9.
- Nutt JG, Woon GF. Diagnosis and initial management of Parkinson's Disease. *N Engl J Med* 2005; 353: 1021-7.
- ### FRIEDREICH Ataxie
- Bürk K. Friedreich Ataxia: current status and future prospects. *Cerebellum Ataxias* 2017; 4:4.
- ### Drop attack
- Brust JCM, Plank CR, Healton EB, et al. The pathology of drop attacks: a case report. *Neurology* 1979; 29: 786-790.
- Lipsitz LA. The drop attack: a common geriatric symptom. *J Am Geriatric So c* 1983; 31: 617-20.
- Meissner I, Wiebers DO, Swanson JW, et al. The natural history of drop attacks. *Neurology* 1986; 36: 1029-34.
- Baloh RW, Jacobson K, Winder T. Drop attacks with Meniere's syndrome. *Ann Neurol* 1990; 28: 384-7.
- Morillo CA, Villar JC. Neurocardiology. Neurogenic syncope. *Baillieres Clin Neurol* 1997; 6: 357-80.
- Shaw FE, Kenny RA. The overlap between syncope and falls in the elderly. *Postgrad Med J* 1997; 73: 635-9.
- ### Encépalopathie de (GAYET)-WERNICKE, KORSAKOFF
- Reuler JB, Girard DE, Cooney TG. Wernicke's encephalopathy. *N Engl J Med* 1985; 312: 1035-9.
- Lindberg MC, Oyler RA. Wernicke's encephalopathy. *Am Fam Physician* 1990; 41: 1205-9.
- Heye N, Terstegge K, Sirtl C, et al. Wernicke's encephalopathy - causes to consider. *Intensive Care Med* 1994; 20: 282-6.
- Kril JJ. Neuropathology of thiamine deficiency disorders. *Metab Brain Dis* 1996; 11: 9-17.
- Preuss UW, Soyka M. Wernicke-Korsakoff syndrome: clinical aspects, pathophysiology and therapeutic approaches. *Fortschr Neurol Psychiatr* 1997; 65: 413-20.
- Zubaran C, Fernandes JG, Rodnight R. Wernicke-Korsakoff syndrome. *Postgrad Med J* 1997; 73: 27-31.
- ### Ponction lombaire, LCR
- Kuntz KM, Kokmen E, Stevens JC, et al. Post-lumbar puncture headaches: experience in 501 consecutive procedures. *Neurology* 1992; 42: 1884-7.
- Broadley SA, Fuller GN. Lumbar puncture needn't be a headache. Use blunt needles and no bed rest. *BMJ* 1997; 315: 1324-5.
- Hasbun R, Abrahams J, Jekel J, et al. Computed tomography of the head before lumbar puncture in adults with suspected meningitis. *N Engl J Med* 2001; 345: 1727-33.
- ### Amyotrophe Lateralsklerose (ALS) Sclérose latérale amyotrophante (SLA)
- Swash M, Leigh N. Criteria for diagnosis of familial amyotrophic lateral sclerosis: European FALS Collaborative Group. *Neuromuscul Disord* 1992; 2: 7-9.
- Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial «Clinical limits of amyotrophic lateral sclerosis» workshop contributors. *J Neurol Sci* 1994; 124, Suppl.: 96-107
- Ince PG, Lowe J, Shaw PJ. Amyotrophic lateral sclerosis: current issues in classification, pathogenesis and molecular pathology. *Neuropathol Appl Neurobiol* 1998; 24: 104-17.
- Brooks BR, Miller RG, Swash M et al. Revised Criteria for the Diagnosis of Amyotrophic Lateral Sclerosis. A Consensus Conference held at Airlie House, Warrenton, Virginia April 2-4, 1998.
- Brooks BR, Miller RG, Swash M, Munsat TL. World Federation of Neurology Research Group on Motor Neuron Diseases (2000) El Escorial revised: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. *Amyotroph Lateral Scler Other Motor Neuron Disord* 2000; 1: 293-9.
- De Carvalho M, Dengler R, Eisen A, et al. Electodiagnostic criteria for diagnosis of ALS. *Clin Neurophysiol* 2008; 119: 497-503.
- Ludolph A, Drory V, Hardiman O et al. A revision of the El Escorial criteria - 2015. *Amyotroph Lateral Scler Frontotemporal Degener* 2015; 16: 291-2.
- ### Restless legs syndrome - RLS Syndrome des impatiences des jambes
- Walters AS1, LeBrocq C, Dhar A et al Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. *Sleep Med* 2003; 4: 121-32.

Sclérose en plaque - SEP - MS

- Polman CH, Reingold SC, Edan G et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". *Ann Neurol* 2005; 58: 840-6.
- Ransohoff RM. Natalizumab for Multiple Sclerosis. *N Engl J Med* 2007; 356: 2622-9.
- Polman CH, Reingold SC, Banwell B et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. *Ann Neurol* 2011; 69: 292-302.
- Christian P, Kammer CP, Uitdehaag BM, Polman CH et al. Multiple Sclerosis: Current Knowledge and Future Outlook. *Eur Neurol* 2014; 72: 132-41.
- Khanna D, Distler JHW, Sandner P, Distler O. Emerging strategies for treatment of systemic sclerosis. *Journal of Scleroderma and Related Disorders* 2016; 1: 186-93.
- Da D. Sclérose systémique. *Forum Médical Suisse* 2017; 17: 808-15.
- Kowal-Bielecka O, Fransen J, Avouac J et al. Update of EULAR recommendations for the treatment of systemic sclerosis. *Ann Rheum Dis* 2017; 76: 1327-39.
- Thompson AJ, Banwell BL, Barkhof F et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *Lancet Neurol* 2017; pii: S1474-4422(17)30470-2.
- Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *Lancet Neurol* 2018; 17: 162-173.

Sturz im Alter

- Sloan JP. Protocols in primary care geriatrics. 2d ed. New York: Springer, 1997

NÉPHROLOGIE

Insuffisance rénale aiguë

Akute Niereninsuffizienz

- Espinel CH. The FENa test: use in the differential diagnosis of acute renal failure. *JAMA* 1976; 236: 579-81.
- Miller TR, Anderson RJ, Linas SL et al. Urinary diagnostic indices in acute renal failure: a prospective study. *Ann Intern Med* 1978; 89: 47-50.
- Humes HD. Aminoglycosides nephrotoxicity. *Kidney Int* 1988; 33: 900-8.
- Solomon R, Werner C, Mann D, et al. Effects of saline, mannitol, and furosemide to prevent decreases in renal function induced by radiocontrast agents. *N Engl J Med* 1994; 331:1416-20.
- Brady HR, Singer GG. Acute renal failure. *Lancet* 1995; 346: 1533-40.
- Thadani R, Pascual M, Bonventre JV. Acute renal failure. *N Engl J Med* 1996; 334: 1448-60.
- Mindell JA, Chertow GM. A practical approach to acute renal failure. *Med Clin North Am* 1997; 81: 731-48.
- NKF-DOQI clinical practice guidelines for hemodialysis adequacy. National Kidney Foundation. *Am J Kidney Dis*. 1997; 30 (Suppl 2): S15-66.
- Schrier RW, Gottschalk CW (eds). Diseases of the kidney. 6th edition, Little Brown & Co 1997.
- Halperin ML, Goldstein MB, (ed). Fluid, electrolyte, and acid-base physiology: a problem-based-approach, 3rd edition. W.B. Saunders Company, 1999.
- Tepel M, Van der Giet M, Schwarzfeld C, et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. *N Engl J Med* 2000; 343: 180-4.
- Kellum JA, Decker JM. Use of dopamine in acute renal failure: a metaanalysis. *Crit Care Med* 2001; 29: 1526-31.
- Hoste EAJ, Clermont G, Kersten A et al. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. *Crit Care* 2006; 10: R73.
- Kidney Disease Improving Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guidelines for Acute Kidney Injury. *Kidney Inter. supp* 2012; 2:1-138.
- McClave SA, Taylor BE, Martindale RG et al. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). *JPN J Parenter Enteral Nutr* 2016; 40 : 159-211.
- Ostermann M, Joannidis M. Acute kidney injury 2016: diagnosis and diagnostic workup. *Crit Care* 2016; 20: 299.
- Ehrmann S, Quarton A, Hobbs BP et al. Contrast-associated acute kidney injury in the critically ill: systematic review and Bayesian meta-analysis. *Intensive Care Med* 2017; 43: 785-94.
- Ehrmann S, Quarton A, Hobbs BP et al. Contrast-associated acute kidney injury in the critically ill: systematic review and Bayesian meta-analysis. *Intensive Care Med* 2017; 43: 785-94.
- Levey AS, James MT. Acute Kidney Injury. *Ann Intern Med* 2017; 167: ITC66-ITC80.
- Claudio Ronco C, Bellomo R, Kellum JA. Acute kidney injury. *Lancet* 2019; 394: 1949-64.
- Ellison DH. Clinical Pharmacology in Diuretic Use. *Clin J Am Soc Nephrol* 2019; 14: 1248-1257.
- IRA sur produit de contraste**
- Kontrastmittelinduzierte Nephropathie**
- Barrett BJ. Contrast nephrotoxicity. *J Am Soc Nephrol* 1994; 5: 25-37.
- Gutierrez NV, Diaz A, Timmis GC, O'Neill WW, et al. Determinants of serum creatinine trajectory in acute contrast nephropathy. *J Interv Cardiol* 2002; 15: 349-54.
- Barrett BJ, Parfrey S. Preventing Nephropathy Induced by Contrast Medium. *N Engl J Med* 2006; 354:379-86.
- Marenzi G, Assanelli E, Marana I, et al. N-Acetyl-cysteine and Contrast-Induced Nephropathy in Primary Angioplasty. *N Engl J Med* 2006; 354: 2773-82.
- Dialyse**
- Gillium DM, Dixon BS, Yanover MJ, et al. The role of intensive dialysis in acute renal failure. *Clin Nephrol* 1986; 25: 249-55.
- Conger JD. Interventions in clinical acute renal

- failure: what are the data? Am J Kidney Dis 1995; 26:565-76.
- Clark WR, Mueller BA, Kraus MA, Macias WL. Extracorporeal therapy requirements for patients with acute renal failure. J Am Soc Nephrol 1997; 8:804-12.
- Insuffisance surrenalienne**
- Nebenniereninsuffizienz - ADDISON**
- Werbel SS, Ober KP. Acute adrenal insufficiency. Endocrinol Metab Clin North Am 1993; 22: 303-28.
- Howlett TA. An assessment of optimal hydrocortisone replacement therapy. Clin Endocrinol 1997; 46: 263-8.
- Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med 2003; 348: 727-34.
- Hamrahi AH, Oseni TS, Arafah BM. Measurements of Serum Free Cortisol in Critically Ill Patients. N Engl J Med 2004; 350: 1629-38.
- Prete A, Taylor AE, Bancos I et al. Prevention of Adrenal Crisis: Cortisol Responses to Major Stress Compared to Stress Dose Hydrocortisone Delivery. J Clin Endocrinol Metab 2020; 105: 2262-74.
- Colique néphrétique, néphrolithiasie**
- Ettinger B, Tang A, Citron JT, et al. Randomized trial of allopurinol in the prevention of calcium oxalat calculi. N Engl J Med 1986; 315: 1386-9.
- Consensus Conference. Prevention and treatment of kidney stones. JAMA 1988; 260: 977-81.
- Coe FL, Parks JH, Asplin JR. The pathogenesis and treatment of kidney stones. N Engl J Med 1992; 327: 1141-52.
- Curhan GC, Willet WC, Speizer FE, et al. Beverage use and risk for kidney stones in women. Ann Intern Med 1998; 128: 534-40.
- Dobbins JM, Rao PM, Novelline RA, Bush JA. Unenhanced helical computed tomography for suspected urinary tract stones: current state of the art. Em Radiol 1998; 5: 97-102.
- Hess B, Jost C, Zipperle L, et al. High calcium intake abolishes hyperoxaluria and reduces urinary crystallization during a 20-fold normal oxalate load in humans. Nephrol Dial Transplant 1998; 13: 2241-7.
- Borghi L, Schianchi T, Meschi T, et al. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med 2001; 346: 77-84.
- Sodium**
- Berl T, Schrier RW. Water metabolism and the hypo-osmolar syndrome. In: Brenner BM, Stein JH (eds). Sodium and Water Homeostasis. Churchill Livingstone, New York, 1978.
- Ayus JC, Krothapalli RK, Arieff AI. Changing concepts in treatment of severe symptomatic hypnatremia. Am J Med 1985; 78: 897-902.
- Rose BD. New approach to disturbances in the plasma sodium concentration. Am J Med 1986; 81: 1033-40.
- Weisberg LS. Pseudohyponatremia. Am J Med 1989; 86: 315-18.
- Clutimans FHM, Meinders AE. Management of severe hyponatremia: rapid or slow correction ? Am J Med 1990; 88: 161-6.
- Schrier RW, Briner A. The differential diagnosis of hyponatremia. Hosp Pract 1990; 30: 29-37.
- Lauriat SM, Berl T. The hyponatremic patients: Practical focus on therapy. J Am Soc Nephrol 1997; 8: 1599-1607.
- Kumar S, Berl T. Sodium. Lancet 1998; 352: 220-8.
- Adrogue HJ, Madias NE. Hyernatremia. N Engl J Med 2000; 342; 1493-9.
- Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med 2000; 342; 1581-9.
- Singer GG. Fluid and electrolyte management. In: Ahy SN. et al. (eds.). The Washington Manual of medical therapeutics. Lippincott Williams & Wilkins, 2001; p. 43-75.
- Potassium**
- Milne FJ, Gear JS, Laidley L, Ritchie M, et. al. Spot urinary electrolyte concentrations and 24 hour excretion. Lancet 1980; 2: 1135.
- Blumberg A, Weidmann P, Ferrari P. Effect of prolonged intravenous bicarbonate administration on plasma potassium in terminal renal failure. Kidney Int 1992; 41: 369-74.
- Wallach J, (ed.) Interpretation of Diagnostic Tests. Little Brown, 1996.
- Gennari FJ. Hypokalemia. N Engl J Med 1998; 339: 451-8.
- Cohn JN, Kowey PR, Whelton PK, et al. New Guidelines for potassium replacement in clinical practice. Arch Intern Med 2000; 160: 2429-36.
- Calcium et magnésium**
- Reinhard RA, Desbien NA. Hypomagnesemia in patients entering the ICU. Crit Care Med 1985; 13: 506-7.
- Whang R. Management deficiency: pathogenesis, prevalence, and clinical implications. Am J Med 1987; 82: 24-9.
- Arramida K, Toto RD. Tumor lysis syndrome. Semin Nephrol 1993; 13: 273-80.
- Wallach J, (ed.). Interpretation of Diagnostic Tests. Little Brown, 1996.
- Rose BD, Post TW, (ed). Clinical physiology of acid-base and electrolyte disorders. 5th edition, McGraw-Hill, New York, 2001.
- Singer GG. Fluid and electrolyte management. In: Ahy SN. et al. (eds.). The Washington Manual of medical therapeutics. Lippincott Williams & Wilkins, 2001; p. 43-75.
- Phosphate**
- Newman JH, Neff TA, Ziporen P. Acute respiratory failure associated with hypophosphatemia. N Engl J Med 1977; 296: 1101-3.
- Kingston M, Badawi Al-Siba'i M. Treatment of severe hypophosphatemia. Crit Care Med 1985; 13: 16-8.
- Knochel JP. Hypophosphatemia and rhabdomyolysis. Am J Med 1992; 92: 455-7.
- Brooks MJ, Melnik G. The refeeding syndrome: an approach to understanding its complications and preventing its occurrence. Pharmacotherapy 1995; 15: 713-26.

- Weisinger JR, Bellorin-Font E. Magnesium and phosphorus. Lancet 1998; 352: 391-6.
- Subramanian R, Khadri R. Severe hypophosphatemia. Medicine (Baltimore) 2000; 79: 1-8.
- Crook MA, Hally V, Pantelli JV. The importance of the refeeding syndrome. Nutrition 2001; 17: 632-7.

Syndrome de renutrition Refeeding syndrome

- Brooks MJ, Melnik G. The refeeding syndrome: an approach to understanding its complications and preventing its occurrence. Pharmacotherapy 1995; 15: 713-26.
- Crook MA, Hally V, Pantelli JV. The importance of the refeeding syndrome. Nutrition 2001; 17: 632-7.
- National Institute for Health and Clinical Excellence (NICE). Oral nutrition support, enteral tube feeding and parenteral nutrition. Clinical Guideline. London: National Health Service; 2006. Report No. 32.
- Stanga Z, Brunner A, Leuenberger M, et al. Nutrition in clinical practice-the refeeding syndrome: illustrative cases and guidelines for prevention and treatment. Eur J Clin Nutr 2008; 62: 687-94.
- Do L, Ballmer PE, Rühlin M. Die Komplexität des Refeeding-Syndroms. Swiss Med Forum 2017; 17: 523-528.

Insuffisance rénale chronique Urémie

- NET (Adaptations des posologies en cas d'IR)
www.med.uni-heidelberg.de/med/klinpharm/Nierebck.htm
- Smith HW. The kidney: structure and function in health and disease. Oxford University Press, New York 1951, 231-238.
- Berlyne G. Endogenous creatinine clearance and glomerular filtration rate. Lancet 1964; II: 874-6.
- Lubowitz H, Slatopolsky E, Shankel S, et al. Glomerular filtration rate. Determination in patients with chronic renal disease. JAMA 1967; 199: 252-6.
- Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
- Brenner B, Meyer T, Hostetter T. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 1982; 307: 652-9.
- Fine LG. El sindrome uremico: mecanismos de adaptacion y tratamiento. Hosp Pract (Ed Españo); 1988; 3: 9-19.
- Caravaca F, Santos I, Cubero JJ. Calcium acetate versus calcium carbonate as phosphate binders in hemodialysis patients. Nephron 1992; 60:423-7.
- Perrone RD, Madias NE, Levey AS.- Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 1992; 38: 1933-53.
- Van Acker BA, Koomen GC, Koopman MG, et al.

- Creatinine clearance during cimetidine administration for measurement of glomerular filtration rate. Lancet 1992; 340: 1326-9.
- Klahr S, Levey AS, Beck GJ, et al. The effect of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 1994; 330: 877-84.
- Lach F. Secondary hyperparathyroidism in renal failure the trade-off hypothesis revisited. Am J Kidney Dis 1995; 25: 663-79.
- Peterson JC, Adler S, Burkart JM, et al.: MDRD Group: Blood pressure control, proteinuria, and the progression of renal disease: The modification of Diet in Renal Disease Study. Ann Intern Med 1995; 123: 754-62.
- Klahr S. Role of dietary protein and blood pressure in the progression of renal disease. Kidney Int 1996; 49: 1783-6.
- Kopple JD, Levey AS, Greene T, et al. Effect of dietary protein restriction on nutritional status in the modification of diet in renal disease study. Kidney Int 1997; 52: 778-91.
- NKF-DQI clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis 1997; 30 (Suppl.3): S192-S240.
- The Sixth Report of the Joint National Committee on Detection, Evaluation, and Diagnosis of High Blood Pressure (JNC VI). Arch Intern Med 1997; 157: 2413-46.
- Cameron J, Greger R. Renal function and testing of function, in AM Davidson, JS Cameron, JP Grunfeld, et al., Oxford textbook of clinical nephrology. Oxford University Press Oxford 1998, 39-69.
- Gallieni M. Iron in the treatment of anemia in dialysis patients: an important support to erythropoietin. Int J Artific Organe 1998; 21: 681-6.
- Walser M.- Assessing renal function from creatinine measurements in adults with chronic renal failure. Am J Kidney Dis 1998; 32: 23-31.
- Rahn KH, Heidenreich S, Bruckner D. How to assess glomerular function and damage in humans. J Hypertens 1999; p. 309-317.
- Halabi G, Vogel G, Wauters JP. Hypertparathyroïdie secondaire: Prévention et traitement. Med Hyg 1999; 57: 432-6.
- Levey AS, Bosch JP, Lewis JB, et al.- A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130 , 461-70.
- Rahn KH, Heidenreich S, Bruckner D. How to assess glomerular function and damage in humans. J Hypertens 1999; 309-17.
- Working Party for European Management of Anaemia in patients with chronic renal failure. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 1999; 14 (Suppl. 5): 1-50.
- Ruedin P. Nouvelles recommandations du traitement de l'anémie au cours de l'insuffisance rénale chronique. Med Hyg 2001; 59: 495-9.

- Eknayan G, Levin NW, Eschbach JW, et al. Continuous quality improvement: DOQI becomes K/DOQI and is updated. National kidney foundation's dialysis outcomes quality initiative. *Am J Kidney Dis* 2001; 37: 179-94.
- Eknayan G, Levin NW. Impact of the new K/DOQI guidelines. *Blood Purif* 2002; 20: 103-8.
- K/DOQI. Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Kidney Disease Outcome Quality Initiative*. *Am J Kidney Dis*, 2002; 39 , 1-246.
- National Kidney Foundation (NKF) Kidney Disease Outcome Quality Initiative (K/DOQI) Advisory Board. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis* 2002; 39 (Suppl. 2): S1-S246.
- Vervoort G, Willems HL, Wetzel JS. Assessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: validity of a new (MDRD) prediction equation. *Nephrol Dial Transplant* 2002; 17: 1909-13.
- Darbepoetin alfa: new preparation. Just a me-too: no advantage in anaemia of chronic renal failure. *Prescribe Int* 2003; 12: 14-6.
- Meyer TW, Hostetter TH. Uremia. *N Engl J Med* 2007; 357: 1316-1325.
- Brück K, Stel VS, Gambaro G et al. CKD Prevalence Varies across the European General Population. *J Am Soc Nephrol* 2016; 27: 2135-47.
- Urine: pH, protéine, «spot»**
- Harrington JT, Cohen JJ. Measurement of urinary electrolytes - indications and limitations. *N Engl J Med* 1975; 293: 1241-43.
- Glasscock RJ. Postural (orthostatic) proteinuria: no cause for concern. *N Engl J Med* 1981; 305: 639-41.
- Lenke RR, Van Dorsten JP. The efficacy of the nitrate test and microscopic urinalysis in predicting urine culture test. *Am J Obstet Gynecol* 1981; 140: 427-9.
- Abuelo JG. Proteinuria: diagnostic principles and procedures. *Ann Intern Med* 1983; 98: 186-91.
- Ginsberg J, et al. Use of single voided urine samples to estimate quantitative proteinuria. *N Engl J Med* 1983; 309: 1543-6.
- Shaw AB, Risdon P, Lewis-Jackson JD. Protein creatinine index and albustix in assessment of proteinuria. *Brit Med J* 1983; 287: 929-32.
- Dufel SE. Urinary electrolytes. *Emerg Med Clin North Am* 1986; 4: 185-92.
- Elseviers MM, Verpoeten GA, DeBroe ME. Interpretation of creatinine clearance. *Lancet* 1987; 1: 457.
- Nathan DM, Rosenbaum C, Protasowicki D. Single-void urine samples can be used to estimate quantitative microalbuminuria. *Diabetes Care* 1987; 10: 414-18.
- De Torrenté A. Analyse d'urine au cabinet médical: méthodes et interprétation. *Ther Umsch* 1988; 45: 528-34.
- De Torrenté A. Protéinurie isolée. *Schweiz Med Wschr* 1989; 119: 851-3.
- Kamel SK, Ethier JH, Richardson RMA, et al. Urine electrolytes and osmolality: when and how to use them. *Am J Nephrol* 1990; 10: 89-102.
- Watts GF, Kubal C, Chinn S. Long-term variation of urinary albumin excretion in insulin-dependent diabetes mellitus: some practical recommendations for monitoring micro-albuminuria. *Diabetes Res Clin Pract* 1990; 9: 169-77.
- Pappas PG. Laboratory in the diagnosis and management of urinary tract infections. *Med Clin North Am* 1991; 75: 313-25.
- Haldimann B. Electrolytes urinaires: indications et interprétation. *Rev Med Suisse Rom* 1993; 113: 1035-38.
- Peterson JC, Adler S, Burkart JM, et al.: MDRD Group: Blood pressure control, proteinuria, and the progression of renal disease: The modification of Diet in Renal Disease Study. *Ann Intern Med* 1995; 123: 754-762.
- Parving HH, Osterby R, Anderson PW, et al. Diabetic nephropathy. In: Brenner BM (ed.). *The Kidney*. W.B. Saunders Company, 1996, p: 1864 ff.
- Kaene WF, Eknayan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE); a position paper of the National Kidney Foundation. *Am J Kidney Dis* 1999; 33: 1001-10.
- Levey AS, Bosch JP, Breyer Lewis J, et al. A more accurate method to estimate glomerular filtration rate from serum creatinin: a new prediction equation. *Ann Intern Med* 1999; 130: 461-70.
- Kaene WF. Proteinuria: its clinical importance and the role in progressive renal disease. *Am J Kidney Dis* 2000; 35 (Suppl. 1): S97-105.
- David S, Wauters JP. Fonction rénale et protéinurie: nouveaux concepts pour vieux dosages. *Med Hyg* 2001; 59: 471-81.
- NFK-K/DOQI Clinical practice guidelines for anemia of chronic kidney disease Update 2000. *Am Kidney Dis* 2001;37 (Suppl 1):S182-238.
- Syndrome néphrotique
Syndrome néphritique**
- Cameron JS, Glasscock RJ (eds.). In: *The nephrotic syndrome*. New York, Dekker, 1988.
- Brenner BM (ed.). *The Kidney*. W.B. Saunders Company, 1996.
- Couser WG. Glomerulonephritis. *Lancet* 1999; 353: 1509-15.
- Nolin L, Courteau M. Management of IgA nephropathy: evidence-based recommendations. *Kidney Int Suppl* 1999; 70: S56-62.
- Savage CO. ANCA-associated renal vasculitis. *Kidney Int* 2001; 60: 1614-27.
- Hématurie microscopique**
- Froom P, Ribak J, Benbassat J. Significance of microhaematuria in young adults. *Br Med J* 1984; 288: 20-2.
- Mohr DN, Offord KP, Owen RA, et al. Asymptomatic microhematuria and urologic disease. A population-based study. *JAMA* 1986; 256: 224-9.
- Copley JB, Hasbargen JA. Idiopathic hematuria. *Arch Intern Med* 1987 147: 434-7.
- Corwin HL, Silverstein MD. The diagnosis of neo-

- plasia in patients with asymptomatic microscopic hematuria: a decision analysis. *J Urol* 1988; 139: 1002-6.
- Andres A, Praga M, Bello I, et al. Hematuria due to hypercalcemia and hyperuricosuria in adult patients. *Int Kidney* 1989; 36: 96-9.
- Woolhandler S, Pels RJ, Bor DH, et al. Dipstick urinalysis screening of asymptomatic adults for urinary tract disorders. I. Hematuria and proteinuria. *JAMA* 1989; 262: 1214-9.
- Murakami S, Igarashi T, Hara S, et al. Strategies for asymptomatic microscopic hematuria: a prospective study of 1,034 patients. *J Urol* 1990; 144: 99-101.
- Culclasure TF, Bray VJ, Hasbargen JA. The significance of hematuria in the anticoagulant patient. *Arch Intern Med* 1994; 154: 649-52.
- Schröder FH. Microscopic haematuria. *BMJ* 1994; 309: 70-2.
- Fogazzi GB, Ponticelli C. Microscopic hematuria diagnosis and management. *Nephron* 1996; 72: 125-34.
- Cohen RA, Brown RS. Microscopic hematuria. *N Engl J Med* 2003; 248: 2330-8.
- Yanagihara T, Hamada R, Ishikura K, et al. Urinary screening and urinary abnormalities in 3-year-old children in Japan. *Pediatr Int* 2015; 57: 354-8.
- ### Gaz artériel
- Goldberg M, Green SB, Moss ML, et al. Computer-based instruction and diagnosis of acid-base disorders. *JAMA* 1973; 223: 269.
- Guinand O. Interprétation de la gazométrie. *Med Hyg* 1984; 42: 334-8.
- Fauci A, Braunwald E, (eds.) et al. In: *Harrison: Principles of Internal Medicine*, 1998 Mc Graw Hill.
- Hall JB, Schmidt GA, Wood LDH. (eds). *Principles of critical care*. McGraw-Hill, 1998.
- ### Équilibre acido-basique
- Textbook: Rose BD, Post TW, (ed). *Clinical physiology of acid-base and electrolyte disorders*. 5th edition, McGraw-Hill, New York, 2001.
- Baldwin Ef, Cournand A, Richards DW. Pulmonary insufficiency III. A study of 122 cases of chronic pulmonary emphysema. *Medicine* 1948; 28: 201-37.
- Oh MS, Carroll HJ. The anion gap. *N Engl J Med* 1977; 297: 814-7.
- Van Dixhorn J, Duivenvoorden HJ. Efficacy of Nijmegen questionnaire in recognition of hyperventilation syndrome. *J Psychosomatic Research* 1985; 29: 199-206.
- Battle DC, Hizon M, Cohen E, et al. The use of the urinary anion gap in the diagnosis of hyperchloremic metabolic acidosis. *N Engl J Med* 1988; 318: 594-9.
- Winter SD, Pearson JR, Gabow PA, et al. The fall of the serum anion gap. *Arch Intern Med* 1990; 150: 311-3.
- Paillard M, Boronsztein P, Houillier P, et al. Les désordres de la balance acido-basique. *Med Hyg* 1991; 49: 794-807.
- Shapiro JI, Kaehny WD. Pathogenesis and management of metabolic acidosis and alkaloasis. In: Schrier RW (ed). *Renal and Electrolyte Disorders*. Little Brown 1992, p: 161-210.
- Hanson CW 3rd, Marshall BE, Frasch HF, et al. Causes of hypercarbia with oxygen therapy in patients with chronic obstructive pulmonary disease. *Crit Care Med* 1996; 24: 23-8.
- Adrogue HJ, Madias NE. Management of life-threatening acid-base disorders. *N Engl J Med* 1998; 338: 26-34.
- ### Néphropathie IgA
- Cattran DC, Greenwood C, Ritchie S. Long-term benefit of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: a comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. *Am J Kidney Dis* 1994; 23: 247-54.
- Nolin L, Courteau M. Management of IgA-nephropathy: evidence-based recommandations. *Kidney International* 1999; 55 (Suppl 70): S56-S62.
- Pozzi C, Bolasco PG, Folazzi GB, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. *Lancet* 1999; 353: 883-7.
- D'Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. *Am J Kidney Dis* 2000; 36: 227-37.
- Russo D, Minutolo R, Pisani A, et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. *Am J Kidney Dis* 2001; 38: 18-25.
- Appel AB, Glasscock RJ et al. Syllbus. Glomerular, vascular, tubulointerstitial, and genetic diseases. *Nephrology Self-Assessment program* 2002; 1: 12-19.
- Donadio JV, Grande JP. IgA nephropathy. *N Engl J Med* 2002; 347: 738-49.
- ### ENDOCRINOLOGIE
- #### Diabète mellitus / Hyperglycémie / Insuline
- The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 1993; 329: 977-86.
- Philippe J, Marini M, Pometta D. *Le diabète. Guide du praticien*. Editions Médecine et Hygiène, 1994.
- Peters AL, Davidson MB, Schriger DL, et al. A clinical approach for the diagnosis of diabetes mellitus. An analysis using glycosylated hemoglobin levels. *JAMA*, 1996; 276: 1246-52.
- Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 1997; 20: 1183-97.
- A desktop guide to type 2 diabetes mellitus. European Diabetes Policy Group 1999. *Diabet Med* 1999; 116: 716-30.
- American Diabetes Association. Aspirin therapy in diabetes. *Diabetes Care* 1999; 22, Suppl 1:

- S60-61.
- Bolli GB, Di Marchi RD, Park GD et al. Insulin analogues and their potential in the management of diabetes mellitus. *Diabetologia* 1999; 42: 1151-67.
- De Fronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. *Ann Intern Med* 1999; 131: 281-303.
- Makoto T, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the funagata diabetes study. *Diabetes Care* 1999; 22: 920-4.
- UKPDS Group. Effect of intensive blood-glucose control with Metformin on complications on overweight patients with type 2 diabetes. *Lancet* 1999; 352: 1557.
- Horton ES, Clinkinbeard C, Gatlin M, et al. Nateglinid alone and in combination with Metformin improves glycemic control by reducing meal-time glucose levels in type 2 diabetes. *Diabetes Care* 2000; 23: 1660-5.
- Recommandation de l'association suisse du diabète. Groupe de travail SSE/ASD, 2000.
- Ruiz J, Keller U, Buillard C et al. Prévention et dépistage de la maladie coronarienne chez le patient diabétique. *Bulletin des Médecins Suisses* 2000; 81: 2596-2600.
- Troisi RJ, Cowie CC, Harris MI. Diurnal variation in fasting plasma glucose: implications for diagnosis of diabetes in patients examined in the afternoon. *JAMA* 2000; 284: 3157-9.
- Bonvin JL. Insulinothérapie dans le diabète de type 2. *Med Hyg* 2001; 59: 1321-5.
- Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. *N Engl J Med* 2001; 345: 1359-67.
- Yusuf S, Gerstein H, Hoogwerf B, et al. Ramipril and the development of diabetes. *JAMA* 2001; 286: 1882-5.
- American Diabetes Association: Standards of medical care for patients with diabetes mellitus (Position Statement). *Diabetes Care* 2001; 24 (Suppl.1): S33-S43.
- American Diabetes Association: clinical practice recommendations 2002. *Diabetes Care* 2002; 25 (Suppl. 1): S1-S147.
- American Diabetes Association and National Institute of Diabetes, Digestive and Kidney Disease. The prevention or delay of type 2 diabetes (Position statement). *Diabetes Care* 2002; 25: 724-9.
- Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. *Diabetes* 2002; 51: 2796-803.
- Chiasson JL, Josse RG, Gomis R et al. STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus. The STOP-NIDDM randomised trial. *Lancet* 2002; 359: 2072-7.
- Diabetes Preventive Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 2002; 346: 393-403.
- Nathan DM. Initial management of glycemia in type 2 diabetes mellitus. *N Engl J Med* 2002; 347: 1342-9.
- American Diabetes Association: Aspirin therapy in diabetes (Position Statement). *Diabetes Care* 2003; 26 (Suppl. 1): S87-S88.
- American Diabetes Association: Diabetic nephropathy (Position Statement). *Diabetes Care* 2003; 26 (Suppl. 1): S94-S98.
- American Diabetes Association: Management of dyslipidemia in adults with diabetes (Position Statement). *Diabetes Care* 2003; 26 (Suppl. 1): S83-86.
- American Diabetes Association: Standards of medical care for patients with diabetes mellitus (Position Statement). *Diabetes Care* 2003; 26 (Suppl. 1): S33-S50.
- American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. *Diabetes Care* 2003; 26 (Suppl. 1): S5-S20.
- American Diabetes Association: Treatment of hypertension in adults with diabetes (Position Statement). *Diabetes Care* 2003; 26 (Suppl. 1): S80-S82.
- Barnett AH. A review of basal insulins. *Diabet Med* 2003; 20: 873-85.
- Schwab S, Stuer S, Müller B et al. Orale Antidiabetika heute - Substanzen, Indikationen, Perspektiven. *Schweiz Med Forum* 2005; 5: 993-9.
- Amori RE, Lau J, Pittas AG. Efficacy and Safety of Incretin Therapy in Type 2 Diabetes Systematic Review and Meta-analysis. *JAMA* 2007; 298: 194-206.
- Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-Receptor Antagonist in Type 2 Diabetes Mellitus. *N Engl J Med* 2007; 356: 1517-26.
- Holman RR, Thorne KI Farmer AJ et al. Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes. *N Engl J Med* 2007; 357: 1716-30.
- Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 2014; 37 (Suppl 1): S81-S90.
- Delrete S, Coutaz M. Diabète: cibles glycémiques au grand âge et surtraitements. *Rev Med Suisse* 2016; 12: 461-466.
- Lamine F, Lalubin F, Pitteloud N et al. Chronic kidney disease in type 2 diabetic patients followed-up by primary care physicians in Switzerland: prevalence and prescription of antidiabetic drugs. *Swiss Med Wkly* 2016; 146:w14282.
- Standards of Medical Care in Diabetes-2016: Summary of Revisions. *Diabetes Care* 2016; 39 Suppl 1:S4-5.
- Classification and Diagnosis of Diabetes. *Diabetes Care* 2017; 40(Suppl 1): S11-S24.
- Matthew C. Riddle, MD et al. American Diabetes Association Standards of Medical Care in Diabetes - 2018. *Diabetes Care* 2018; 41, Suppl 1: S1-S159.
- Qaseem A, Wilt TJ, Kansagara D et al. Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians. *Ann Intern Med* 2018; 168:569-76.
- Cosentino F, Grant PJ, Aboyans V et al. The Task

Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal 2020; 41: 255-323.

Diabète gestationnel

Horsch A, Gross J, Jornayvaz FR et al. Diabète gestationnel – quelles sont les approches non médicales ? Rev Med Suisse 2016; 1089-1091. Standards of Medical Care in Diabetes-2016: Summary of Revisions. Diabetes Care 2016; 39 Suppl 1:S4-5.

Acidocétose diabétique, hyperosmol.

Delaney MF, Zisman A, Kettyle WM. Diabetic ketoacidosis and hyperglycemic hyperosmolar nonketotic syndrome. Endocrinol Metab Clin North Am 2000; 29: 683-705.

American Diabetes Association. Hyperglycemic crises in patients with diabetes mellitus. Diabetes Care 2001; 19: 82-90.

Kitabchi AE, Umpierrez GE, Murphy MB, et al. Management of hyperglycemic crises in patients with diabetes. Diabetes Care 2001; 24: 131-53.

Magee MF, Bhatt BA. Management of decompensated diabetes. Diabetic ketoacidosis and hyperglycemic hyperosmolar syndrome. Crit Care Med 2001; 17: 75-106.

American Diabetes Association. Hyperglycemic crisis in patients with diabetes mellitus. Diabetes Care 2003; 26 (Suppl. 1): S109-S117.

Kitabchi AE, Umpierrez GE, Murphy MB, et al. Hyperglycemic crises in adult patients with diabetes: a consensus statement from the American Diabetes Association. Diabetes Care 2006; 29: 2739-48.

Kitabschi AE, Umpierrez GE, Miles JM et al. Hyperglycemic Crises in Adult Patients with Diabetes. Diabetes Care 2009; 32: 1335-43.

Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2014; 37 (Suppl 1): S81-S90.

Standards of Medical Care in Diabetes - 2014.

Diabetes Care 2014; 37 (Suppl 1): S14-S80.

Syndrome des ovaires polykystiques (POCS)

Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41-7.

Steering Committee of the National Institutes of Health Evidence-Based Methodology Workshop on Polycystic Ovary Syndrome. Evidence-based Methodology Workshop on Polycystic Ovary Syndrome. Final Report. <https://prevention.nih.gov/docs/programs/pcos/FinalReport.pdf> (National Institute of Health, Bethesda, MD, USA, 2012).

Von Wolff M. Das PCO-Syndrom: Management in der Praxis Differenzialdiagnostik und Therapie. Gynäkologie 2012;1:9-15.

Dewailly D. Diagnostic criteria for PCOS: Is there

a need for a rethink? Best Pract Res Clin Obstet Gynaecol 2016; 37: 5-11.

Draft Summary and Recommendations of International Evidenced-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. 2018. http://pcos-cre.edu.au/wp-content/uploads/2018/02/PCOS-guideline-summary-and-recommendations_PC-DRAFT_FINAL-V2-050218-1.pdf (accessed on 28 October 2018).

Aswini R, Jayapalan S. Modified Ferriman-Gallwey Score in Hirsutism and its Association with Metabolic Syndrome. Int J Trichology 2017;9:7-13.

Lie Fong S, Laven JSE, Duhamel A et al. Polycystic ovarian morphology and the diagnosis of polycystic ovary syndrome: redefining threshold levels for follicle count and serum anti-Müllerian hormone using cluster analysis. Hum Reprod 2017; 32: 1723-31.

Casadei L, Fanisio F, Sorge RP et al. The diagnosis of PCOS in young infertile women according to different diagnostic criteria: the role of serum anti-Müllerian hormone. Arch Gynecol Obstet 2018; 298: 207-15.

Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol 2018; 14: 270-84.

Teede HJ, Misso ML, Costello MF et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod 2018;33:1602-18.

Diabète insipide — Diabetes insipidus

Miller M, Dalakos T, Moses AM et al. Recognition of partial defects in antidiuretic hormone secretion. Ann Intern Med 1970; 73: 721-9.

Vokes TJ, Robertson GL. Disorders of antidiuretic hormone. Endocrinol Metabol North Am 1988; 17: 281-99.

Fujii T, Kojima S, Imanishi M, et al. Different mechanisms of polyuria and natriuresis associated with paroxysmal supraventricular tachycardia. Am J Cardiol 1991; 68: 343-8.

Blevins LS, Wand GS. Diabetes insipidus. Crit Care Med 1992; 20: 69-79.

Buonocore CM, Robinson AG. The diagnosis and management of diabetes insipidus during medical emergencies. Endocrinol Metab Clin North Am 1993; 22: 411-23.

Kumar S, Berl T. Sodium. Lancet 1998; 352: 220-8.

Maghanie M, Cosi G, Genovese E, et al. Central diabetes insipidus in children and young adults. N Engl J Med 2000; 343: 998-1007.

Rose BD, Post TW. Clinical physiology of acid-base and electrolyte disorders, 5th edition 2001; McGraw-Hill, New York: p. 754-8.

Hypoglycémie

Marks V, Teale JD. Investigation of hypoglycemia. Clin Endocrinol 1996; 44: 133-6.

Service JF. Hypoglycemic Disorders. N Engl J Med 1995; 332: 1144-52.

Dizon AM, Kowalsky S, Hoogwerf BJ. Neurogly-

- copenic and other symptoms in patients with insulinoma. Am J Med 1999; 106: 307-10.
- Service FJ. Classification of hypoglycemic disorders. Endocrinol Metab Clin North Am 1999; 28: 501-17.
- Sinnvolle Anwendung endokrinologischer Tests. Christ-Crain M, Schild U, Müller B. Schweiz Med Forum 2004; 4: 1113-9.
- Hirsch IB. Insulin Analogues. N Engl J Med 2005; 352: 174-83.

Axe hypothalamo-hypophysaire

- Livanou T, Ferriman D, James VH. Recovery of hypothalamo-pituitary-adrenal function after corticoid therapy. Lancet 1967;2: 856-9.
- Esteban NV, Loughlin T, Yerger AL, et al. Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. J Clin Endocrinol Metabol 1991; 72: 39-45.
- Service FJ, O'Brian PC, Kao PC, et al. C-peptide suppression test: effects of gender, age, and body mass index; implications for the diagnosis of insulinoma. J Clin Endocrinol Metab 1992; 74: 204-10.
- Grinspoon SK, Biller BM. Clinical review 62 : Laboratory assessment of adrenal insufficiency. J Clin Endocrinol Metabol 1994; 79: 923-31.
- Trainer PJ, Besser M. The Bart's endocrine protocols. Churchill Livingstone, 1995.
- Glowniak JV, Loriaux DL. A double-blind study of perioperative steroid requirements in secondary adrenal insufficiency. Surgery 1997; 121: 123-9.
- Bangar V, Clayton RN. How reliable is the short synacthen test for the investigation of the hypothalamic-pituitary-adrenal axis? Eur J Endocrinol 1998; 139: 580-3
- Vollenweider P, Waeber G. Stratégie thérapeutique lors d'un sevrage aux glucocorticoïdes. Med Hyg 2001; 59: 366-73.
- Cooper M, Stewart P. Corticosteroid insufficiency in acutely ill patients. N Engl J Med 2003; 348: 727-734.

Insuffisance surrenalienne

- Werbel SS, Ober KP. Acute adrenal insufficiency. Endocrinol Metab Clin North Am 1993; 22: 303-28.
- Howlett TA. An assessment of optimal hydrocortisone replacement therapy. Clin Endocrinol 1997; 46: 263-8.
- Dickstein G. The assessment of the hypothalamo-pituitary-adrenal axis in pituitary disease: are there short cuts? J Endocrinol Invest 2003; 26: 25-30.

Syndrome polyglandulaire autoimmun

- Leshin M. Polyglandular autoimmune syndromes. Am J Med Sci 1985; 290: 77.
- Neufeld M, Maclarek NK, Blizzard RM. Two types of autoimmune Addison's disease associated with different polyglandular autoimmune (PGA) syndromes. Medicine (Baltimore) 1981; 60: 355.

Tumeurs neuroendocriniennes - NET

- Lamberts SW. Octreotide. N Engl J Med 1996; 334: 246-54.

- Bissonnette RT. Fatal carcinoid crisis after percutaneous fine-needle biopsy of hepatic metastasis: case report and literature review. Radiology 1990; 174: 752-2.
- Schupak KD. The role of radiation therapy in the treatment of locally unresectable or metastatic carcinoid tumors. Int J Radiat Oncol Biol Phys 1991; 20: 489-95.
- Gibril F. Comparative analysis of diagnostic techniques for localization of gastrointestinal neuroendocrine tumors. Yale J Biol Med 1997; 70: 509-22.

- Modlin IM. An analysis of 8305 cases of carcinoid tumors. Cancer 1997; 79: 813-29.
- Caplin ME, Buscombe JR, Hilsdon AJ, et al. Carcinoid tumor. Lancet 1998; 352: 799-805.
- Nuttall KL, Pingree SS. The incidence of elevations in urine 5-hydroxyindoleacetic acid. Ann Clin Sci 1998; 28: 167-74.
- Pirkle RA. Usefulness of chromogranin A as marker for detection of relapses of carcinoid tumors. Clin Chem Lab Med 1998; 36: 837-40.
- Wullbrand U. Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumors. Eur J Clin Invest 1998; 28: 1038-49.
- Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med 1999; 340: 858-68.
- Virgolini I. In- and Y-Dota-Ianreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 2002; 32: 148-55.

- Metz DC. Endocrine Tumors of the Gastrointestinal Tract and Pancreas. Edinburgh: Saunders, 2003: p. 678-719.
- Moeller JE. Factors associated with progression of carcinoid heart disease. N Engl J Med 2003; 348: 1005-15.

- Oberg K, Astrup L, Eriksson B, et al. on behalf of the Nordic NE Tumour Group Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part ii—specific to tumour types. Acta Oncol 2004; 43: 626-36.

- O'Toole D, Grossman A, Gross D et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers. Neuroendocrinology 2009;90:194-202.
- Klimstra D, Modlin I, Coppola D.: The pathologic classification of neuroendocrine tumors. Pancreas 2010; 39: 707-12.

- Kocha W, Maroun J, Wong R. Consensus recommendations for the diagnosis and management of well-differentiated gastroenterohepatic neuroendocrine tumours: a revised statement from a Canadian National Expert Group. Curr Oncol 2010; 17: 49-64.

- Ramage JK, Ahmed A, Ardill J et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut 2012; 61: 6-32.

Hypercorticisme (CUSHING)

- Liddle GW. Test of pituitary-adrenal suppressibility in the diagnosis of Cushing's syndrome. J Clin Endocrinol Metabol 1960; 20: 1539-90.
- Crapo L. Cushing's syndrome: a review of diagnostic tests. Metabolism 1979; 28: 955-77.

- Tyrell JB, Findling JW, Aron DC, et al. An overnight high-dose Dexamethasone suppression test for rapid differential diagnosis of Cushing's syndrome. *Ann Int Med* 1986; 104: 180-6.
- Kaye TB, Crapo LC. The Cushing syndrome: an update on diagnostic tests. *Ann Intern Med* 1990; 112: 434-44.
- Esteban NV, Loughlin T, et al. Daily cortisol production rate in man determined by stable dilution/mass spectrometry. *J Clin Endocrinol Metab* 1991; 71: 39-45.
- Oelkers W. Adrenal insufficiency. *N Engl J Med* 1996; 335: 1206-12.
- Meier CA, Biller BMK. Clinical and biochemical evaluation of Cushing's syndrome. *Endocrinol Metab Clin North Am* 1997; 26: 741-61.
- Newell-Price J, Trainer P, Besser M, et al. The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's state. *Endocr Rev* 1998; 19: 647-72.
- Simon S, Meier CA. Diagnostic du syndrome de Cushing. *Med Hyg* 2001; 59: 358-62.
- Arnaldi G, Angeli A, Atkinson AB, et al. Diagnosis and Complications of Cushing's Syndrome: A Consensus Statement. *J Clin Endocrinol Metabol* 2003; 88: 593-602.
- Newell-Price J, Bertagna X, Grossman AB, et al. Cushing's syndrome. *Lancet* 2006; 367: 1605-17.

Hyperaldostéronisme

- Kaplan NM. (ed). In: Kaplan NM (ed). *Clinical Hypertension. Primary aldosteronism*. Baltimore: Williams&Wilkins, 1994; 389-408.
- Young WF, Stanson AW, Thompson GB, et al. Role for adrenal venous sampling in primary aldosteronism. *Surgery* 2004; 136: 1227-35.
- Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. *J Am Coll Cardiol* 2005; 45: 1243.
- Mulatero P, Milan A, Fallo F, et al. Comparison of confirmatory tests for the diagnosis of primary aldosteronism. *J Clin Endocrinol Metab* 2006; 91: 2618-23.
- Rossi GP, Bernini G, Caliumi C, et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. *J Am Coll Cardiol* 2006; 48: 2293-300.
- Fallo F, Della Mea P, Sonino N, et al. Adiponectin and insulin sensitivity in primary aldosteronism. *Am J Hypertens* 2007; 20: 855-61.
- Bernini G, Galetta F, Franzoni F, et al. Arterial stiffness, intima-media thickness and carotid artery fibrosis in patients with primary aldosteronism. *J Hypertens* 2008; 26: 2399-405.
- Catena C, Colussi G, Nadalini E, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. *Arch Intern Med* 2008; 168: 80-5.
- Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism : An endocrine society clinical practice guideline. *J Clin Endocrinol Metab* 2008; 93: 3266-81.

Rossi GP, Bolognesi M, Rizzoni D, et al. Vascular

- remodeling and duration of hypertension predict outcome of adrenalectomy in primary aldosteronism patients. *Hypertension* 2008; 51: 1366-71.
- Tsioufis C, Tsiaichris D, Dimitriadis K, et al. Myocardial and aortic stiffening in the early course of primary aldosteronism. *Clin Cardiol* 2008; 31: 431-6.
- Kempers MJ, Lenders JW, van Outhoudsen L, et al. Systematic review : Diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. *Ann Intern Med* 2009; 151: 329-37.
- Sowers JR, Whaley-Connell A, Epstein M. Narrative review : The emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. *Ann Intern Med* 2009; 150: 776-83.

Staermose S, Marwick TH, Gordon RD, et al. Elevated serum interleukin 6 levels in normotensive individuals with familial hyperaldosteronism type 1. *Hypertension* 2009; 53:e31-2.

Tsuchiya K, Yoshimoto T, Hirata Y. Endothelial dysfunction is related to aldosterone excess and raised blood pressure. *Endocr J* 2009; 56: 553-9.

Mulatero P, Monticone S, Bertello C, et al. Evaluation of primary aldosteronism. *Curr Opin Endocrinol Diabetes Obes* 2010; 17: 188-93.

Rossi GP. Prevalence and diagnosis of primary aldosteronism. *Curr Hypertens Rep* 2010; 12: 342-8.

Du Caillar G, Fesler P, Ribstein J, Mimran A. Dietary sodium, aldosterone, and left ventricular mass changes during long-term inhibition of the renin-angiotensin system. *Hypertension* 2010; 56: 865-70.

Briet M, Schiffrin EL. The role of aldosterone in the metabolic syndrome. *Curr Hypertens Rep* 2011; 13: 163-72.

Phéochromocytome

Plouin PF, et al. Le dépistage du phéochromocytome: chez quels hypertendus ? Etude sémiologique chez 2585 hypertendus dont 11 ayant un phéochromocytome. *Nouvelle Presse Méd* 1981; 10: 869-72.

Feldman JM. Falsely elevated urinary excretion of catecholamines and metanephrines in patients receiving labetalol therapy. *J Clin Pharmacol* 1987; 27: 288-92.

Shapiro B, Eig LM. Management of pheochromocytoma. *Endocrinol Metab Clin North Am* 1989; 18: 443-81

Bravo EL. Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma. *Endocrine Rev* 1994; 15: 356-68.

Kaplan NM. (ed). In: *Clinical Hypertension. Pheochromocytoma*. Baltimore: Williams & Wilkins, 1994; 367-87.

Gomez F. La recherche d'un phéochromocytome chez le patient hypertendu: indication et méthode. *Med Hyg* 1999; 57: 294-7.

Tumeur neuroendocrinienne: NEN/NET/NEC

Sorbye H, et al. Predictive and prognostic factors for treatment and survival in 305 patients with

- advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. *Ann Oncol* 2013; 24: 152-60.
- Basturk O, et al. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogeneous and includes both well differentiated and poorly differentiated neoplasms. *Am J Surg Pathol* 2015; 39: 683-90.
- Ramage JK, De Herder WW, Delle Fave G, et al. ENETS Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms. *Neuroendocrinology* 2016; 103: 139-43.
- Dasari A, et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. *JAMA Oncol* 2017; 3: 1335-1342.
- Kim JY, Hong SM, Ro JY, Recent updates on grading and classification of neuroendocrine tumors. *Ann Diagn Pathol* 2017; 29: 11-16.
- Lloyd RV, Osamura RY, Klöppel G, Rosai J (Eds). WHO Classification of Tumours of Endocrine Organs, 4th ed, IARC Press, Lyon 2017. p.211.
- Alexander Siebenhäuser A, Morell B, Burger IA, et al. Neuroendocrine Tumoren. *Schweiz Med Forum* 2019; 19: 378-84.
- Klimstra DS, Kloppel G, La Rosa S, Rindi G. Classification of neuroendocrine neoplasms of the digestive system. In: WHO Classification of Tumours: Digestive System Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), International Agency for Research on Cancer, Lyon 2019. p.16.
- ### Osteoporose - Ostéoporose
- Gallagher JC. Pathophysiology of osteoporosis. *Semin Nephrol* 1992; 12: 109-15.
- Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. *Ann Intern Med* 1992; 117: 1-9.
- Felson DT, Zhang Y, Hannan MT, et al. The effect of postmenopausal estrogen therapy on bone density in elderly women. *N Engl J Med* 1993; 329: 1141-6.
- Meunier PJ. Is steroid-induced osteoporosis preventable? *N Engl J Med* 1993; 328: 1781-2 et 1745-52 (Comment).
- Peck WA, et al. Consensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosis. *Am J Med* 1993; 94: 646-50.
- Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report. *Osteoporosis Int* 1994; 4: 368-81.
- Gambert SR, Schultz BM, Hamdy RC. Osteoporosis. Clinical features, prevention and treatment. *Endocrinol Metab Clin North Am* 1995; 24: 317-71.
- Chesnut CH, et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. *Am J Med* 1995; 99: 144-52.
- Liberman UA, Weiss ST, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis treatment Study Group. *N Engl J Med* 1995; 333: 1437-43.
- Reginster JY, Derroisy R, Lecart MP, et al. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss. *Am J Med* 1995; 98: 452-8.
- Osteoporose: Richtlinien der Diagnostik-Prävention-Behandlung. Schweizerische Vereinigung gegen die Osteoporose SVGO; 1996.
- Ziegler R. Osteoporosis - diagnosis and therapy. *Med Klin* 1996; 91 (Suppl.1): 29-33.
- Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. *N Engl J Med* 1997; 337: 670-6.
- Delmas PD, Bjarnason NH, Mitak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women, *N Engl J Med* 1997; 337: 1641-7.
- Delmas PD, Meunier PJ. The management of Paget's disease of bone. *N Engl J Med* 1997; 336: 558-66.
- Kanis JA, Delmas P, Burckhardt P, et al. Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. *Osteoporos Int* 1997; 7: 390-406.
- Hosking D, Chilvers CE, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early postmenopausal intervention cohort study group. *N Engl J Med* 1998; 338: 485-92.
- Seibel MJ. Biochemische Marker des Knochenstoffwechsels, klinische Wertigkeit in der Praxis. *Ther Umsch* 1998; 55: 676-84.
- Kraenzlin ME, Rizzoli R. Abklärung der Osteoporose. *Schweiz Ärztezeitung* 1999; 80: 536-543.
- Lippuner K, Casez J.-P, Jaeger Ph. L'approche en trois étapes du diagnostic de l'ostéoporose. Modèle d'un screening à large échelle de l'ostéoporose postménopausique. *Med Hyg* 1999; 57: 520-4.
- Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis Alendronate Once-Weekly Study Group. *Aging (Milano)* 2000; 12: 1-12.
- Tonino RP, Meunier PJ, Emkey R, et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. *J Clin Endocrinol Metab* 2000; 85: 3109-15.
- Wirthner D, De Grandi P. Place des SERM (selective estrogen receptor modulators) dans la substitution hormonale postménopausique. *Med Hyg* 2000; 58: 1677-81.
- Black DM, Steinbuch M, Palermo L, et al. An Assessment tool for predicting fracture risk in postmenopausal women. *Osteoporos Int* 2001; 12: 519-28.
- Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a

- fracture. *JAMA* 2001; 285: 320-3.
- NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. *JAMA* 2001; 285: 785-95.
- Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. *N Engl J Med* 2004; 350: 459-8.
- Lawrence G, Raisz. Screening for Osteoporosis. *N Engl J Med* 2005; 353:164-171.
- Whyte MP. Paget's Disease of Bone. *N Engl J Med* 2006; 355: 593-600.
- Canalis E, Giustina A, Bilezikian JP. Mechanisms of Anabolic Therapies for Osteoporosis. *N Engl J Med* 2007; 357: 357:905-916.
- Kanis JA, Burlet N, Cooper C, Reginster J-Y, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. *Osteoporos Int* 2008; 19: 385-97.
- Kearns AE, Khosla S, Kostenuik P. RANKL and OPG regulation of bone remodeling in health and disease. *Endocr Rev* 2008; 29: 155-92.
- National Osteoporosis Foundation (NOF). Clinician's guide to prevention and treatment of osteoporosis. www.nof.org. 2008.
- Bonjour J-P, Kraenzlin ME, Rajzbaum G, et al. Ostéoporose: évaluation du risque fracturaire absolu par le questionnaire OMSFRAX. *Reprod Hum Horm* 2009; 12: 46-53.
- Compston J, Cooper A, Cooper C, et al. Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. *Maturitas* 2009; 62: 105-8.
- Cummings SR, Martin JS, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. *N Engl J Med* 2009; 361: 756-65.
- Dachverband Osteologie. DVO-Leitlinie 2009 zur Prophylaxe, Diagnostik und Therapie der Osteoporose bei Erwachsenen. www.dv-osteologie.org. 2009.
- Kanis JA, Oden A, Johansson H, et al. FRAX® and its applications to clinical practice. *Bone*. 2009; 44:734-43.
- Lewiecki EM, Watts NB. New guidelines for the prevention and treatment of osteoporosis. *South Med J* 2009; 102: 175-9.
- Lippuner K, Johansson H, Kanis JA, et al. Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women. *Osteoporos Int* 2009; 20: 1131-40.
- Smith MR, Egerdie B, Toriz NH, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. *N Engl J Med* 2009; 361: 745-55.
- Osteoporose: Prävention, Diagnostik und Therapie. Empfehlungen 2010 Schweizerische Vereinigung gegen Osteoporose (SVGO). www.SVGO.ch. 2010.
- Padhi D, Jang G, Stouch B, et al. Single-dose, placebocontrolled, randomized study of AMG 785, a sclerostin monoclonal antibody. *J Bone Miner Res*. 2010; epub.
- Rizzoli R, Ammann P, Birkhäuser MH, et al. Osteoporose: von der osteodensitometrischen Diagnose zur Evaluation des absoluten Frakturrisikos. *Schweiz Med Forum* 2010; 10: 111-3.
- Kraenzlin ME, Meier Chr. Neue Wege in der Diagnostik und Therapie der Osteoporose. *Schweiz Med Forum* 2011; 11: 25-28.
- NOF's Clinician's Guide to Prevention and Treatment of Osteoporosis. <http://nof.org/files/nof/public/content/file/344/upload/159.pdf>, accessed November 28, 2012.
- Watts NB, Adler RA, Bilezikian JP, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 2012; 97:1802.
- Lehmann Th, Aeberli D, Häuselmann HJ. Prédition du risque fracturaire - pas uniquement une question de densité osseuse. *Forum Med Suisse* 2012; 13: 913-6.
- Adler RA, El-Hajj Fuleihan G, Bauer DC et al. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. *J Bone Miner Res* 2016; 31: 16-35.
- A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass Gains. Everts-Graber J, Reichenbach S, Ziswiler HR et al. *J Bone Miner Res* 2020; 35: 1207-15.
- ### Osteomalacie
- Bingham CT, Fitzpatrick LA. NMoninvaice testing in the diagnosis of osteomalacia. *Am J Med* 1993; 95: 519-23.
- Marie P, Mirav L. Ostéomalacées. In: Kuntz D (ed). Maladies Métaboliques Osseuses de l'Adulte. Médecine Sciences Flammarion. Paris; 1996: 218-33.
- ### Néoplasie endocrine multiple (NEM)
- Wolfe MM, Jensen RT. Zollinger-Ellison syndrome. *N Engl J Med* 1987; 317: 1200-9.
- Pipeleers-Marichal M, Somers G, Willems G, et al. Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and the Zollinger-Ellison syndrome. *N Engl J Med* 1990; 322: 723-7.
- Jensen RT, Fraker DL. Zollinger-Ellison syndrome. *JAMA* 1994; 271: 1429-35.
- Members of Nordic Ne Tumour Group. Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part II—Specific NE Tumour Types. *Acta Oncol* 2004;43: 626-36.
- Aluri V, Dillon JS. Biochemical Testing in Neuroendocrine Tumors. *Endocrinol Metab Clin North Am*. 2017;46:669-677.
- Kleinmuntz D, Plitzko G, Wieland Ch. Neuroendokrine Tumoren der Lunge. *Schweiz Med Forum* 2016; 16: 292-8.
- Klimstra DS, Kloppel G, La Rosa S, Rindi G. Classification of neuroendocrine neoplasms of the digestive system. In: WHO Classification of

Tumours: Digestive System Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), International Agency for Research on Cancer, Lyon 2019. p.16.

Thyroïde

Horvath E, Majlis S, Rossi R, et al. An ultrasonogram reporting system for thyroid nodules stratifying cancer risk for clinical management. *J Clin Endocrinol Metab* 2009; 94: 1748-51.

Hyperthyroïdie

Surks MI, Chopra IJ, Mariash CN, et al. American thyroid association guidelines for use of laboratory tests in thyroid disorders. *JAMA* 1990; 263: 1529-32.

Nordin H, Gallo AM, Ladefoged SD, et al. The effects of propranolol and verapamil on hyperthyroid heart symptoms and function, assessed by systolic time intervals. *Acta Endocrinol (Copenh)* 1993; 128: 297-300.

Franklyn JA. The management of hyperthyroidism. *N Engl J Med* 1994; 330: 1731-8.

Singer PA, Cooper DA, Levy EG, et al. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. *JAMA* 1995; 273: 808-12.

Weetman AP. Graves' disease. *N Engl J Med* 2000; 343: 1236-48.

Portmann L. Approches thérapeutiques de l'hyperthyroïdie. *Med Hyg* 2001; 59: 350-6.

Cooper DS. Subclinical Hyperthyroidism. *N Engl J Med* 2001; 345: 260-5.

Weetman AP. Graves'disease. *N Engl J Med* 2001; 235: 1236-48.

Fajfr R, Müller B, Diem P. Hyperhyreose - Abklärung und Therapie. *Schweiz Forum* 2003; 5: 103-8.

Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. *JAMA* 2004; 291: 228-38.

Hypothyroïdie

Staub JJ, Althaus BU, Engler H et al. Spectrum of subclinical and overt hypothyroidism: effect on thyrotropin, prolactin, and thyroid reserve, and metabolic impact on peripheral target tissues. *Am J Med* 1992; 92: 631-42.

Zulewski H, et al. Estimation of tissue hypothyroidism by a new clinical score: Evaluation of patients with various grades of hypothyroidism and controls. *J Clin Endocrinol Metab* 1997; 82: 771-76.

Zulewski H, Muller B, Exer P, et al. Estimation of tissue hypothyroidism by a new clinical score: evaluation of patients with various grades of hypothyroidism and controls. *J Clin Endocrinol Metab* 1997; 82: 771-6.

Zulewski H, Siggelkow H, Walden C, et al. Evaluation of procollagen III peptide as a marker of tissue hyperthyroidism in long-term treated women with TSH suppressive doses of thyroxine. *Exp Clin Endocrinol Diabetes* 1999; 107: 190-4.

Toft AD. Subclinical Hypothyroidism. *N Engl J Med* 2001; 345: 512-6.

Col NF, Surks MI, Daniels GH. Subclinical thyroid

disease: clinical applications. *JAMA* 2004; 291: 239-43.

Surks MI, Ortiz E, Daniels GH et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. *JAMA* 2004; 291: 228-38.

Thynne TR, Doogue MP. A dose of paracetamol for the levthyroxine absorption test. *Clin Endocrinol (Oxf)*. 2013; 78: 968-9.

Peeters RP. Subclinical Hypothyroidism. *NEJM* 2017; 376: 256-65

Thyroïdite de HASHIMOTO

Dyan CM, Daniels GH. Chronic autoimmune thyroiditis. *N Engl J Med* 1996; 335: 99-107.

Nodules thyroïdiens

American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. *Thyroid* 2009; 19:1167.

Durante C, Costante G, Lucisano G, et al. The natural history of benign thyroid nodules. *JAMA* 2015; 313: 926-35.

Crise thyréotoxique - Thyroid storm

Burch HB, Wartofsky L. Life-threatening thyrotoxicosis. Thyroid storm. *Endocrinol Metab Clin North Am* 1993; 22: 263.

Porphyrie

Betancor P. Patología del metabolismo de las porfirinas. In: Rodés J, et al. (eds.). *El Manual de Medicina*. Masson, S.A, 1993, p: 1212-20.

Fauci A, Braunwald E, (eds.) et al. In: Harrison: Principles of Internal Medicine. 1998 Mc Graw Hill.

Cholestérol - Cholesterin - Dyslipidämie Dyslipidémie - Hypercholesterinämie

Jestra JA, Kromhout D, van der Schouw YT et al. Effect size estimates of lifestyle and dietary changes on all-cause mortality in coronary artery disease patients: a systematic review. *Circulation*. 2005; 112: 924-34.

Reiner Z, Catapano AL, De Backer G, Graham I, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). *Eur Heart J* 2011; 32: 1769-818.

Brun N, Rodondi N. [How to deal with familial dyslipidemia in clinical practice?]. *Rev Med Suisse* 2012; 8: 494-6, 8-500.

Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG. Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. *J Clin Endocrinol Metab*. 2012; 97: 3956-64.

Anderson TJ, Grégoire J, Hegele RA et al. 2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascu-

- lar Disease in the Adult. *Can J Cardiol* 2013;29:151-67.
- Goff DC, Jr., LloydJones DM, Bennett G, Coady S, D'Agostino RB, Sr., Gibbons R, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation* November 12, 2013.
[http://circ.ahajournals.org/content/early/2013/11/11/01.cir.0000437741.48606.98.citation](http://circ.ahajournals.org/content/early/2013/11/11/01.cir.0000437741.48606.98)
- Kokkinos PF, Faselis C, Myers J, Panagiotakos D, Doumas M. Interactive effects of fitness and statin treatment on mortality risk in veterans with dyslipidaemia: a cohort study. *Lancet* 2013; 381: 394-9.
- Stone NJ, Robinson J, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. November 12, 2013.
[http://circ.ahajournals.org/content/early/2013/11/11/01.cir.0000437738.63853.7a.citation](http://circ.ahajournals.org/content/early/2013/11/11/01.cir.0000437738.63853.7a)
- Ioannidis JP. More Than a Billion People Taking Statins? Potential Implications of the New Cardiovascular Guidelines. *JAMA* 2014; 311: 463-4.
- Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. *Lancet* 2013; 382: 1762-5.
- Nanchen D, von Eckardstein A., Riesen WF, et al. im Namen der Schweizer Arbeitsgruppe Lipide und Atherosklerose (AGLA). Cholesterin management in der kardiovaskulären Risikoprävention: amerikanische Guidelines 2013 Stellungnahme der Schweizer Arbeitsgruppe Lipide und Atherosklerose (AGLA). *Schweiz Med Forum* 2014; 14: 378-381.
- Yates T, Haffner SM, Schulte PJ, et al. Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis. *Lancet* 2014; 383: 1059-66.
- Anderson TJ, Grigoire J, Pearson GJ et al. 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. *Can J Cardiol* 2016; 32: 1263e1282.
- Aubert C-E., Gencer B. Rodondi N. Recommandations de prise en charge des dyslipidémies en 2016 en Suisse. *Rev Med Suisse* 2016; 12: 430-4.
- Aubert C-E., Gencer B. Rodondi N. Dyslipidémies au cabinet médical. Primary Care 2017; 17: 250-3.
- Mach F, Baigent C, Catapano AL et al. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Eur Heart J* 2020; 41: 111-88.

Obésité

- Ireton-Jones CS, Turner WW Jr. Actual or ideal body weight: which should be used to predict energy expenditure? *J Am Diet Assoc* 1991; 91: 193-5.
- Physical status: the use and interpretation of anthropometry: report of a WHO expert committee. *WHO Tech Rep Ser* 1995; 854: 1-452.
- Björntorp P. Obesity. *Lancet* 1997; 350: 423-6.
- International Obesity Task Force (IOTF). *Obesity: preventing and managing the global epidemic. Report of a WHO consultation on obesity*. Geneva, 3-5 June, 1997 (WHO/NUT/NCD/97.2).
- Lean ME. Silbutamine – a review of clinical efficacy. *Int J Obes Relat Metab Disord* 1997; 21(Suppl. 1): S30-6; discussion S37-9.
- Seidel JC, Rissanen AM. Time trends in the worldwide prevalence of obesity. In: Bray GA, Bouchard C, James WPT (eds.). *Handbook of obesity*. New York: Marcel Dekker 1998, p. 79-91.
- Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. *Lancet* 1998; 352: 167-73.
- Stevens J, Cai J, Pamuk ER, et al. The effect of age on the association between body-mass index and mortality. *N Engl J Med* 1998; 338: 1-7.
- Calle EE, Thun MJ, Petrelli JM, et al. Body-mass index and mortality in a prospective cohort on U.S. adults. *N Engl J Med* 1999; 341: 1097-1105.
- Davidson MH, Hauptmann J, Di Girolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. *JAMA* 1999; 281: 235-42.
- Golay A, et al. Konsensus über die Behandlung der Adipositas in der Schweiz 1999. *Schweiz Med Wschr* 1999; 129 (Suppl.114): 4S-20S.
- Golay A, et al. Consensus sur le traitement de l'obésité en Suisse 1999. *Schweiz Med Wschr* 1999; 129 (Suppl.114): 21S-36S.
- Wirth A, Krause J. Long-term weight loss with sibutramine: a randomized controlled trial. *JAMA* 2001; 286: 1331-9.
- Deitel M, Shikora SA. The development of the surgical treatment of morbid obesity. *J Am Coll Nutr* 2002; 21: 365-71.
- Yanovski SZ, Yanovski JA. Obesity. *N Engl J Med* 2002; 346: 591-602.
- Pi-Sunyer X, Astrup A, Fujioka K et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. *NEJM* 2015; 373: 11-22.
- O'Brian PE, Dixon JB. Weight loss early and late complications - the international experience. *Am J Surg* 2003; 184: 42S-45S.

Syndrome des ovaires polykystiques

- Stein IF, Leventhal ML. Amenorrhoea associated with bilateral polycystic ovaries. *Am J Obstet Gynecol* 1935; 29: 181-91.
- Waldstreicher J. Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence for partial

- gonadotroph desensitization. *J Clin Endocrinol Metab* 1988; 66: 165-72.
- Knochenhauer E. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. *J Clin Endocrinol Metab* 1998; 83: 3078-82.
- Diamanti-Kandarakis E. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. *J Clin Endocrinol Metab* 1999; 84: 4006-11.
- Ehrmann DA. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. *Diabetes care* 1999; 22: 141-6.
- Legro RS. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. *J Clin Endocrinol Metab* 1999; 84: 165-9.
- Azziz R. Family history as a risk factor for the polycystic ovary syndrome. *J Pediatr Endocrinol Metab* 2000; 13: 1303-6.
- Azziz R. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. *J Clin Endocrinol Metab* 2001; 86: 1626-32.
- Fogel RB. Increased prevalence of obstructive sleep apnea and daytime sleepiness: role of insulin resistance. *J Clin Endocrinol Metab* 2001; 86: 1175-80.
- Hardiman P. Polycystic ovary syndrome and endometrial carcinoma. *Lancet* 2003; 362:1082 / Balen A. Polycystic ovary syndrome and cancer. *Hum Reprod Update* 2001; 7: 522-5.
- Gopal M. The role of obesity in the increased prevalence of obstructive sleep apnea syndrome in patients with polycystic ovary syndrome. *Sleep Med* 2002; 3: 401-4.
- Glueck CJ. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. *Metabolism* 2003; 52: 908-15.
- Ehrmann DA. Polycystic Ovary Syndrome. *N Engl J Med* 2005; 352: 1223-36.
- Syndrome métabolique**
- Weisser B, Locher R, Vetter W. The metabolic syndrome: common etiology fo distinct cardiovascular risk factors. *Schweiz Rundsch Med Prax* 1993; 82: 1339-43.
- Zimmet P, Boyko EJ, Collier GR, et al. Etiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance, and other players. *Ann NY Acad Sci* 1999; 892: 25-44.
- Meigs JB, Mittleman MA, Nathan DM, et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis, The Framingham offspring study. *JAMA* 2000; 283: 221-8.
- Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. *Diabetes Care* 2001; 24: 683-9.
- Ramos F, Baglivio HP, Ramirez AJ, et al. The metabolic syndrome and related cardiovascular risk. *Curr Hypertens Rep* 2001; 3: 100-6.
- Ford ES, Wayne HG, Dietz WH, et al. Prevalence of the metabolic syndrome amoung US adult. *JAMA* 2002; 287: 356-9.
- Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. *JAMA* 2002; 288: 2799-16.
- National Cholesterol Education Program. Third report of the national cholesterol education program (NCEP). Expert panel on detection, evaluation, and treatment of hight blood cholesterol in adults (Adult Treatment Panel III). Final report: National Publication No.- 02-5215, september 2002 (www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf). And: Executive summary, National Publication No.- 01-3670, mai 2001 (www.nhlbi.nih.gov/guidelines/cholesterol/atp3xsum.pdf).
- Keller KB, Lemberg L. Obesity and the metabolic syndrome. *Am J Crit Care* 2003; 12: 167-70.
- Meigs JB. The metabolic syndrome. *BMJ* 2003; 327: 61-2.
- American Diabetes association. Screening for type 2 diabetes. *Diabetes Care* 2004; 27 (Suppl 1):S11-S14.
- Hypercholestérolémie - Dyslipidémie**
- Hypercholesterinämie - Dislipidämie**
- Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the scandinavian simvastatin survival study (4S). *Lancet* 1994; 344: 1383-9.
- Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events (CARE) trial investigators. *N Engl J Med* 1996; 335: 1001-9.
- Herd JA, Ballantyne CM, Farmer JA, et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations lipoprotein and coronary atherosclerosis study. *Am J Cardiol* 1997; 80: 278-86.
- Pyorala K, Pederson TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the scandinavian simvastatin survival study (4S). *Diabetes Care* 1997; 20: 614-20.
- Haffner SM. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N Engl J Med* 1998; 339: 229-34.
- Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). *Circulation* 1998; 97: 1440-5.
- Recommendations of the Second Joint Task Force of European and other Societies on coronary Prevention. Prevention of coronary heart disease in clinical practice. *Eur Heart J* 1998; 19: 1434-1503.

- The long-term intervention with pravastatin in ischaemic disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. *N Engl J Med* 1998; 339: 1349-57.
- Familial hypercholesterolemia (FH): report of a second WHO consultation, Geneva, 4 September 1998. World Health Organization, p. 13, 1998.
- Société Suisse de Cardiologie, Groupe de travail Lipides et Athérosclérose. Recommandations 1999 pour l'indication au traitement du facteur de risque " cholestérol ". *Schweiz Ärztezeitung* 1999; 80: 544-8.
- Lauer MS. Aspirin for primary prevention of coronary events. *N Engl J Med* 2002; 346: 1468-74.
- Management of dyslipidemia in adults with diabetes. *Diabetes Care* 2002; 25: Suppl. 1: S74-S77.
- National Cholesterol Education Program. Third report of the national cholesterol education program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). National Publication No.- 02-5215, september 2002 (www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf).
- Sudhop T, Lutjohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. *Circulation* 2002; 106: 1943-8.
- Sudhop T, von Bergmann K. Cholesterol absorption inhibitors for the treatment of hypercholesterolemia. *Drugs* 2002; 62: 2333-7.
- De Backer G, Ambrosini E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice. *Eur Heart J* 2003; 24: 1601-10.
- Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. *N Engl J Med* 2004; 350: 1505-15.
- International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Acces sept 2005 (consensus 14 april 2005, Berlin) y Rev Panam Salud Publica 2005; 18: 451-4.
- The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-Dose Atorvastatin after Stroke or Transient Ischemic Attack. *N Engl J Med* 2006; 355: 549-59.
- Barter Ph, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. Treating to New Targets Investigators. *N Engl J Med* 2007; 357: 1301-10.
- Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. *Eur J Cardiol* 2013; 34: 3478-3490a.
- Benn M, Watts GF, Tybjærg-Hansen A et al. Mutations causative of familial hypercholesterolemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. *Eur Heart J* 2016; 37: 1384-94.
- Catapano AL, Graham I, De Backer G, Wiklund O et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. *Eur Heart J* 2016; 37: 2999-3058.
- Schöb M, Müller P, Gert Y et al. Familiäre Hypercholesterinämie – Diagnose und Therapie Diagnosis and Treatment of Familial Hypercholesterolemia. *Praxis* 2018; 107: 1345-53.
- Grundy SM, Stone NJ, Bailey AL et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/A GS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation* 2019; 139: e1046.
- Mach F, Baigent C, Catapano AL et al. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Eur Heart J* 2020; 41: 111-88.
- Riesen W, Kaiser W, Gallino A et al. Neue ESC/EAS-Dyslipidämie- Guidelines. *Schweiz Med Forum* 2020;20:140-8.
- PCSK9**
- Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. *New Engl J Med* 2012; 367: 1891-900.
- Vogel RA. PCSK9 inhibition : The next statin ? . *J Am Coll Cardiol* 2012; 59: 2354-5.
- Raal FJ, Honarpour N, Blom DJ, et al; TESLA Investigators. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. *Lancet*. 2015; 385: 341-50.
- Raal FJ, Stein EA, Dufour R, et al.; RUTHERFORD-2 Investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. *Lancet*. 2015; 385:331-4.
- Raal FJ, Giugliano RP, Sabatino MS, et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. *J Am Coll Cardiol* 2014; 63:1278-88.
- Nutrition**
- A.S.P.E.N. Board of Directors. Guidelines for the use of enteral nutrition in the adult patient. *JPN* 1987; 11: 435-9.
- Rodés J, Aguirre A, Arroyo V, et al. (eds.). Valores nutrivos. El Manual de Medicina. Masson, 1993, p: 3335-41.

Hyperparathyroïdie

NIH Consensus development conference statement: diagnosis and management of asymptomatic primary hyperparathyroidism. Ann Intern Med 1991; 114: 593-7.

Niederle B, Stamm L, Längle F, et al. Primary hyperparathyroidism in Austria. Results of an 8-year prospective study. World J Surg 1992; 16: 777-83.

Pattou F, Huglo D, Proye C. Radionuclide scanning in parathyroid disease. Br J Surg 1998; 85: 1605-16.

Marcus R. Diagnosis and treatment of hyperparathyroidism. Rev Endocr Metab Disord 2000; 1: 247-52.

Kearns AE, Thompson GB. Medical and surgical management of hyperparathyroidism. Mayo Clin Proc 2002; 77: 87-91.

Bilezikian JP, Bandeira L, Khan A, et al. Hyperparathyroidism. Lancet 2018; 391: 168-78.

patient have acute meningitis? JAMA 1999; 282: 175-81.

Troillet N, Rohner P, Raeber R, et al. Épidémiologie et prévention des infections dues à *Neisseria meningitidis*. Bull Med Suisse 1999; 80: 1375-9.

Apicella MA, *Neisseria meningitidis*. In: GL, Bennett JE, Dolin R (eds). Principles and practice of infectious diseases. 5th edition New York: Churchill Livingstone 2000.

Hasbun R, Abrahams J, Jekel J, et al. Computed tomography of the head before lumbar puncture in adults with suspected meningitis. N Engl J Med 2001; 345: 1727-33.

De Gans J, Van de Beek D. Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002; 347: 1549-56.

Thi Hoang Mai N, Thi Hong Chau T, Thwaites G, et al. Dexamethasone in Vietnamese Adolescents and Adults with Bacterial Meningitis. N Engl J Med 2007; 357: 2431-40.

INFECTIOLOGIE - INFEKTIROLOGIE

Ménigrite - Meningitis

Glauser MP. Recommandations pour la prévention de la dissémination des méningococcies. Schweiz Aerztezeitung 1982; 63: 279-81.

Quagliarello VJ, Scheld WM. Bacterial meningitis: pathogenesis, pathophysiology, and progress. N Engl J Med 1992; 327: 864-72.

Durand ML, Calderwood SB, Weber DJ, et al. Acute bacterial meningitis in adults: a review of 493 episodes. N Engl J Med 1993; 328: 21-8.

Lepow ML. Meningococcal vaccines. In: Plotkin SA, Mortimer EA (eds). Vaccines. 2nd edition Philadelphia: WB Saunders Company 1994, p: 503-15.

Office fédéral de la santé publique. Maladies méningococciques invasives en Suisse 1988-1994. Bull OFSP 1995; 50: 5-11.

Garner JS, and the Hospital Infection Control Practices Advisory Committee. Guideline for isolation precautions in hospitals. Am J Infect Control 1996; 24: 24-52.

Centers for Disease Control and Prevention. Control and prevention of meningococcal disease and control and prevention of serogroup C meningococcal disease: evaluation and management of suspected outbreaks.

Recommendations of the Advisory Committee on Immunization Practices. MMWR 1997; 46: 1-21.

Jafari HS, Perkins BA, Wenger JD. Control and prevention of meningococcal disease: recommendations of the advisory committee of immunization practices (ACIP). MMWR 1997; 46, RR-5: 1-11.

Quagliarello VJ, Scheld WM. Treatment of bacterial meningitis. N Engl J Med 1997; 336: 708-16.

Aronin SI, et al. Community-acquired bacterial meningitis: risk stratification for adverse clinical outcome and effect of antibiotic timing. Ann Intern Med 1998; 129: 862-9.

Attia J, Hatala R, Cook DJ, et al. Does this adult

État fébrile - Fieber - Status febrilis

Mackowiak PA, LeMaistre CF. Drug fever: a critical appraisal of conventional concepts. Ann Intern Med 1987; 106: 728-33.

Strickland TG. Fever in travelers. In: Strickland TG. (ed.): Hunter's Tropical Medicine. Philadelphia: WB Saunders, 1991; 1023-31.

Wyngaarden JB, Smith LH, Bennet JC. (eds.). Cecil, Textbook of Medicine. W.B. Saunders Company 1992.

Humar A, Keystone J. Evaluating fever in travelers returning from tropical countries. BMJ 1996; 312: 953-6.

Norman DC, et al. Fever in the elderly. Infect Dis Clin North Am 1996; 10: 93-9.

Fauci A, Braunwald E, (eds.) et al. In: Harrison: Principles of Internal Medicine. 1998 Mc Graw Hill.

Magill AJ. Fever in the returned traveler. Infect Dis Clin North Am 1998; 12: 445-69.

Fièvre d'origine indéterminée (FEO)

NET:

- www.fevertravel.ch
 - www.safetravel.ch
- Petersdorf RG, Beeson PB. Fever of unexplained origin. Medicine 1961; 40: 1-30.
- Jacoby GA, Swartz MN. Fever of undetermined origin. N Engl J Med 1973; 289: 1407-10
- Petersdorf RG. Fever of unknown origin. An old friend revisited. Arch Intern Med 1992; 152: 21-2.
- Schneider-Gilg A. Unklarer Status Febrilis. Praxis 1986; 75: 651-5.
- Cunha BA. Fever of unknown origin. Infect Dis Clin North Am 1996; 10: 111-27.
- Arnow PM, Flaherty JP. Fever of unknown origin. Lancet 1997; 350: 575-80.
- Hirschmann JV. Fever of unknown origin in adults. Clin Infect Dis 1997; 24: 291-302.

Neutropénie fébrile - Neutropenie & Fieber

Imunocompromised Host Society. The design, analysis and reporting of clinical trials on the empirical antibiotic management of the neutro-

- penic patient. *J Inf Dis* 1990; 161: 397-401.
- Cometta A, Calandra T, Gaya H, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. *Antimicrob Agents Chemother* 1996; 40: 1108-15.
- Hughes WT, Armstrong D, Bodey GP, et al. Guidelines from the infectious diseases society of America. 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. *Clin Infect Dis* 1997; 25: 551-73.
- Harten P, et al. Febrile neutropenia: practical aspects. *Med Klin* 1998; 93: 598-611.
- Kern WV, Cometta A, De Bock R, et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. *N Engl J Med* 1999; 341: 312-18.
- Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. *N Engl J Med* 1999; 340: 764-71.
- Klastersky J, Paesmans M, Rubenstein EB, et al. Te multinatioal association for supportive care in cancer risk index: a multinational scoring system for identify low-risk febrile neutropenic cancer patients. *J Clin Oncol* 2000; 18: 3038-51.
- Corey L, Boeckh M. Persistant fever in patients with neutropenia. *N Engl J Med* 2002; 346: 222-4.
- Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. *Clin Infect Dis* 2002; 34: 730-51.
- Walsh TJ, Pappas P, Winston D, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. *N Engl J Med* 2002; 346: 225-34.
- Flückiger U, Marchetti O, Bille J, et al. Treatment options of invasive fungal infections in adults. *Swiss Med Wkly* 2006; 136:447-463.
- Tuberkulose - Tuberkulose (TB)**
- NET: www.who.int
 NET: www.tbinfo.ch
https://www.tbinfo.ch/fileadmin/user_upload/1wissenschaftszentrum/Publikationen/Handbuch_Tuberkulose/Handbuch_TB_DE_16_05_19.pdf
- Shaw JB, Wynn-Williams N. Infectivity of pulmonary tuberculosis in relation to sputum status. *Am Rev Tuberc* 1954; 69: 724-32.
- Meijer J, Barnett GD, Kubik A, Styblo K. Identification of sources of infection. *Bull Int Union Tuberc* 1971; 45:5-50.
- Grzybowski S, Barnett GD, Styblo K. Contacts of cases of active pulmonary tuberculosis. *Bull Int Union Tuberc* 1975;50:90-106.
- Kopanoff DE, Snider DE, Caras GJ. Isoniazid-related hepatitis. *Am Rev Respir Dis* 1978; 117: 991-1001.
- Cauthen GM, Pio A, ten Dam HG. Annual risk of infection. World Health Organization Document 1988;WHO/TB/88.154:1-34.
- Rieder HL, Zimmermann H, Zwahlen M, Billo NE. Epidemiologie der Tuberkulose in der Schweiz. *Schweiz Rundschau Med Praxis* 1990; 79: 675-9.
- Association suisse contre la tuberculose et les maladies pulmonaires. Lignes directrices pour la chimiothérapie préventive de l'infection tuberculeuse. *Bull OFSP* 1991; 23: 38-9.
- Snider DE Jr, Caras GJ. Isoniazid-associated hepatitis deaths: a review of available information. *Am Rev Respir Dis* 1992; 145:494-7.
- Winters R.A., Murray H.W. Malaria - The Mime Revisited: Fifteen More Years of Experience at a New York City Teaching Hospital. *The American Journal of Medicine*. 1992; 93: 243-6.
- Veen J. Microepidemics of tuberculosis: the stone-in-the-pond principle. *Tuber Lung Dis* 1992;73:73-6.
- Association suisse contre la tuberculose et les maladies pulmonaires. Lignes directrices concernant la prévention de la tuberculose dans le cadre professionnel. *Bull OFSP* 1993; annexe 3: 31-6.
- Iseman MD. Treatment of multidrug-resistant tuberculosis. *N Engl J Med* 1993; 329: 784-791.
- American Thoracic Society, CDC and Prevention. Treatment of tuberculosis and tuberculosis infection in adults and children. *Am J Respir Crit Care Med* 1994; 149: 1359-74.
- Brewer MA, Edwards KM, Palmer PS, Hinson HP. Bacille Calmette Guerin immunization in normal healthy adults. *J Infect Dis* 1994; 170:476-9.
- Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. *JAMA* 1994; 271: 698-702.
- International Union Against Tuberculosis and Lung Disease. Criteria for discontinuation of vaccination programmes using Bacille Calmette-Guerin (BCG) in countries with a low prevalence of tuberculosis. A statement of the International Union Against Tuberculosis and Lung Disease. *Tuber Lung Dis* 1994; 75:179-80.
- Rieder HL, Zellweger JP, Ravaglione MC, Keizer ST, Migliori GB. Tuberculosis control in Europe and international migration. Report of a European Task Force. *Eur Respir J* 1994; 7: 1545-53.
- Standards Committee, Canadian Thoracic Society. Essential of tuberculosis control for the practising physician. *Can Med Assoc J* 1994; 150: 1561-71.
- Schalcher C, Brändli O, Beran J, Gaze H, Howald H, Tschopp JM. Tuberkulintests bei Schulabgängern in den Kantonen Bern, Neuenburg und Wallis 1992/1993. *Schweiz Med Wochenschr* 1995; 125:796-801.
- World Health Organization. Global tuberculosis programme and global programme on vaccines. Statement on BCG revaccination for the prevention of tuberculosis. *WHO Wkly Epidemiol Rec* 1995; 70: 229-31.
- Association suisse contre la tuberculose et les maladies pulmonaires. Lignes directrices pour le traitement de la tuberculose. *Bull OFSP*

- 1996; 16: 9-13.
- Sudre P, Rieder H, Bassetti S, Hirscher BJ, Leidergerber B, Malvy D, Swiss HIV Cohort Study. Infection VIH, tuberculose et test tuberculinique en Suisse. Schweiz Med Wochenschr 1996; 126: 2007-12.
- White NJ. The treatment of malaria. N Engl J Med 1996; 335:800-6.
- Richtlinien für den Tuberkulintest. Bull BAG 1997;13-14.
- Association suisse contre la tuberculose et les maladies pulmonaires ASTP Société suisse de pneumologie SSP. Lignes directrices concernant le test tuberculinique. Bull OFSP 1997; 16: 13-14.
- Behr MA, Hopewell PC, Paz A, Kawamura LM, Schechter GF, Small PM. Predictive value of contact investigation for identifying recent transmission of mycobacterium tuberculosis. Am J Respir Crit Care Med 1998; 158: 465-9.
- Maher D, Chaulet P, Spinaci S, Harries A. Global Tuberculosis Programme World Health Organization Geneva, Switzerland, 1998, p 1-81.[<http://www.who.int>]
- Markwalder K., Hatz C. Malaria-Therapie 1998. Schweiz Med Wochenschr 1998; 128: 1313-27.
- Trnka L, Dankova D, Zitova J, et al. Survey of BCG vaccination policy in Europe: 1994-96. Bull World Health Organ 1998; 76:85-91.
- Standards Committee (Tuberculosis), Canadian Thoracic Society. Canadian tuberculosis standards. 3rd ed. Ottawa: Canadian Lung Association, 1998.
- Soccal PM, Rochat Th. Diagnostic de tuberculose. Med Hyg 1998; 56: 2336-41.
- Bundesamt für Gesundheit. Infektionskrankheiten in der Schweiz 1997. Tuberkulose. Bull BAG/OFSP 1999; 34-7.
- ERS TASK FORCE.Tuberculosis management in Europe.Eur Respir J 1999; 14: 978-92.
- Havlir DV, Barnes PF. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1999;340:367-73.
- Del Castillo OD, Penefiel CM, Alvarez GF, Soto Campos JG, Calderon OE, et al. Investigation of tuberculosis contacts in a nonhospital pneumonia practice. Eur J Clin Microbiol Infect Dis 1999; 18: 790-5.
- American Thoracic Society, Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161: S221-S247.
- American Thoracic Society, CDC and prevention. Diagnostic standards and classification of tuberculosis in adults and children. Am J Resp Crit Care Med 2000; 161: 1376-95.
- Hopewell PC. Targeting tuberculosis prevention. Am J Respir Crit Care Med 2000; 162: 2017-8.
- Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR 2000; 49 (N° RR-6).
- Chin DP, Crane CM, Diul MY, Sun SJ, Agraz R, et al. Spread of mycobacterium tuberculosis in a community implementing recommended ele-
- ments of tuberculosis control. JAMA 2000; 283: 2968-74.
- Marks SM, Taylor Z, Qualls NL, Shrestha-Kuwa-hara RJ, Wilce MA, Nguyen CH. Outcomes of contact investigations of infectious tuberculosis patients. Am J Respir Crit Care Med. 2000; 162: 2033-8.
- Rieder HL. Epidemiologic basis of tuberculosis control. 1 ed. International Union Against Tuberculosis and Lung Disease, Paris, 1999; 1-162.
- Bundesamt für Gesundheit. Tuberkulose in der Schweiz: 1995 bis 1998. Bull BAG/OFSP 2000;1:8-11.
- World Health Organisation. Severe Falciparum Malaria. Trans R Soc Trop Med Hyg 2000; 94 (S1): 1-90.
- American Thoracic Society, Centers for Disease Control and Prevention. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations - United States 2001. Am J Respir Crit Care Med 2001; 164: 1319-20.
- Hatz C. Clinical Treatment of Malaria in Returned Travelers. In: Schlagenhauf P. (Hrsg). Travelers' Malaria. BC Decker, Hamilton - London 2001; 431-45.
- Keane J, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-104.
- Lalvani A, Pathan AA, McShane H, et al. Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Am J Respir Crit Care Med 2001; 163: 824-8.
- Lalvani A, Pathan AA, Durkan H, et al. Enhanced contact tracing and spatial tracking of mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Lancet 2001; 357: 2017-21.
- Rieder HL. Risk of travel-associated tuberculosis. Clin Infect Dis 2001; 33: 1393-6.
- World Health Organization. BCG in immunization programmes. Wkly Epidemiol Rec 2001;76:33-9.
- Broekmans JF, Migliori GB, Rieder HL, Lees J, Ruutu P, et al. European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNVC) Working Group. Eur Respir J 2002; 19: 765-75.
- Wang L, Turner MO, Elwood RK, Schulzer M, Fitzgerald JM. A meta-analysis of the effect of bacille Calmette Guerin vaccination on tuberculin skin test measurements. Thorax 2002;57:804-9.
- American Thoracic Society, CDC, and infectious disease of America. Treatment of tuberculosis. MMWR 2003; 52 (N° RR-11).
- Barnes PF, Cave MD. Molecular epidemiology of tuberculosis. N Engl J Med 2003; 349: 1149-56.
- Lalvani A. Spotting latent infection: the path to better tuberculosis control Thorax 2003; 58:916-8.

- Pai M, Riley LW, Colford JM. Interferon-g assays in the immunodiagnosis of tuberculosis: a systematic review. *Lancet Infect Dis* 2004;4:761-76.
- Whitty CJ, Laloo D, Ustianowski A. Malaria: an update on treatment of adults in non-endemic countries. *BMJ* 2006; 333: 241-5.
- Genton B. Malaria: Prophylaxe und Therapie - ist die Mefloquin-Ära vorbei? *Schweiz Med Forum* 2001; 1: 337-44.
- Erkens CG, Kamphorst M, Abubakar I, et al. Tuberculosis contact investigation in low prevalence countries: a European consensus. *Eur Respir J* 2010; 36: 925-49.
- Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society / Centers for Disease Control and Prevention / Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. *Clin Infect Dis* 2016; 63: 853-67.
- World Health Organization. Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update. WHO / HTM / TB / 2017.05
- Bernhard S, Büttcher M, Heininger U, et al. Guidance for testing and preventing infections and updating immunisations in asymptomatic refugee children and adolescents in Switzerland. *Paediatrica* 2016; 27: 1-8.
- World Health Organization. Rapid communication: key changes to treatment of multidrug and rifampicin-resistant tuberculosis (MDR / RR-TB). WHO / CDS / TB / 2018.18
- World Health Organization. Global tuberculosis report 2018. World Health Organization Document 2018; WHO / CDS / TB / 2018.20
- World Health Organization. WHO treatment guidelines for isoniazid-resistant tuberculosis. Supplement to the WHO treatment guidelines for drug-resistant tuberculosis. WHO / CDS / TB / 2018.7
- Borreliose (LYME-disease)**
- Steere AC, Batsford WP, Weinberg M, et al. Lyme carditis: cardiac abnormalities of Lyme disease. *Ann Intern Med* 1980; 93: 8-16.
- Burgdorfer W, Barbour AG, Hayes SF, et al. Lyme disease - a tick-borne spirochetosis ? *Science* 1982; 216: 1317-9.
- Steere AC. Lyme disease. *N Engl J Med* 1989; 321: 586-96.
- Logigan EL, Kaplan RF, Steere AC. Chronic neurologic manifestations of Lyme disease. *N Engl J Med* 1990; 323:1438-44.
- Rahn DW. Lyme disease: clinical manifestations, diagnosis, and treatment. *Semin Arthritis Rheum* 1991; 20: 201-18.
- Rahn DW, Malawista SE. Lyme disease. *Ann Intern Med* 1991; 114: 472-81.
- Fallon BA, et al. Lyme disease: a neuropsychiatric illness. *Am J Psychiatry* 1994; 151:1571-83.
- Stanek G, O'Connell S, Cimmino M, et al. European Union Concerted Action on Risk Assessment in Lyme Borreliosis: Clinical case definitions for Lyme borreliosis. *Wien Klin Wo chenschr* 1996; 108: 741-7.
- Centers for Disease Control and Prevention. Case definitions for infectious conditions under public health surveillance. MMWR Recomm Rep 1997; 46: 1-55.
- Dattwyler RJ, Luft BJ, Kunkel MJ, et al. Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease. *N Engl J Med* 1997; 337: 289-94.
- Tugwell P, Dennis D, Weinstein A, et al. Laboratory evaluation in the diagnosis of Lyme disease. *Ann Intern Med* 1997; 127: 1109-23.
- Nahimana I, Praz G, Francioli P. Borréliose de Lyme: actualités. *Rev Med Suisse Rom* 2000; 120: 31-7.
- Wormser GP, Nadelman RB, Dattwyler RJ, et al. Practice guidelines for the treatment of Lyme disease. *Clin Infect Dis* 2000; 31 (Suppl. 1): S1-14.
- Klempern MS, Hu LT, Evans J, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. *N Engl J Med* 2001; 345: 85-92.
- Nadelman RB, Nowakowski J, Fish D, et al. Prophylaxis with single-dose Doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. *N Engl J Med* 2001; 345: 79-84.
- Shapiro AE. Doxycycline for tick bites - nor for everyone. *N Engl J Med* 2001; 345: 133-4.
- Steere AC. Lyme disease. *N Engl J Med* 2001; 345: 115-125.
- Kaplan RF, Trevino RP, Johnson GM, et al. Cognitive function in post-treatment Lyme disease: Do additional antibiotics help ? *Neurology* 2003; 60: 1916-22.
- Krupp LB, Hyman LG, Grimson R, et al. Study and treatment of post-Lyme disease (STOP-LD): A randomized double masked clinical trial. *Neurology* 2003; 60: 1923-30.
- Wormser GP, Ramanthan R, Nowakowski J, et al. Duration of antibiotic therapy for early Lyme disease. A randomized, double-blind, placebo-controlled trial. *Ann Intern Med* 2003; 138: 697-704.
- Evison J, Aebi C, Francioli P et al. Borréliose de Lyme. *Rev Med Suisse* 2006; 2: 919-24 (1 part) et 925.34 (2nd part) et 935-40 (third part).
- Lienhard R. Quelle est l'utilité de la sérologie de Lyme? *Rev Med Suisse* 2015; 11: 1830-4.
- Salmonellose**
- Aserkoff B, Bennett JV. Effect of antibiotic therapy in acute salmonellosis on the fecal excretion of salmonellae. *N Engl J Med* 1969; 281: 636-40.
- Goldberg MB, Rubin RH. The spectrum of salmonella infection. *Infect Dis Clin North Am* 1988; 2: 571-98.
- Wistrom J, Jertborn M, Ekwall E, et al. Empiric treatment of acute diarrheal disease with norfloxacin: a randomized placebo controlled study. Swedish study group. *Ann Intern Med* 1992; 117: 202-8.
- Rowe B, Ward LR, Threlfall EJ. Multidrug-resistant *Salmonella typhi*: a worldwide epidemic. *Clin Infect Dis* 1997; 24 (Suppl.1): S106-9.
- Mandell GL. Principles and Practice of Infectious

- diseases. 5th edition Churchill Livingstone. 2000.
- Oehri I, Frei R, Sponagel L et al. Salmonellosen. Schweiz Med Forum 2005; 5: 1000-7.
- Endocardite**
- Von Reyn CF, Levy BS, Arbeit RD, et al. Infective endocarditis: an analysis based on strict case definitions. Ann Intern Med 1981; 94: 505-18.
- Durack DT, Lukes AS, Bright DK, et al. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Am J Med 1994; 96: 200-9.
- Wilson WR, Karchmer AW, Dajani AS, et al. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci and HACEK microorganisms. JAMA 1995; 274: 1706-13.
- Dajani AS, Taubert KA, Wilson W, et al. Prevention of bacterial endocarditis. Recommendations by the American Heart Association. JAMA 1997; 277:1794-1801.
- Bayer AS, Bolger AF, Taubert KA, et al. Diagnosis and management of infective endocarditis and its complications. Circulation 1998; 98: 2936-48.
- Little J. The American Heart Association's guidelines for the prevention of bacterial endocarditis: a critical review. Gen Dent 1998; 46: 508-15.
- Moreillon P, for the Swiss working group for endocarditis prophylaxis. Schweiz Med Wochenschr 2000; 130: 1013-26.
- Mylonakis E, Calderwood SB. Infective endocarditis in adults. N Engl J Med 2001; 345: 1318-30.
- Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC Guidelines for the management of infective endocarditis. The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Eur Heart J 2015; 36: 3075-3123.
- Legionella pneumophila**
- Fraser DW, Tsai TR, Orenstein W, et al: Legionnaires' disease: description of an epidemic of pneumonia, N Engl J Med 1977; 297: 1189-97.
- Edelstein PH. Legionnaires' disease. Clin Infect Dis 1993; 16: 741-9.
- Plouffe JF, File TM, Breimann RF. Reevaluation of the definition of Legionnaire's disease: use of the urinary antigen assay. Clin Infect Dis 1995; 20: 1286-91.
- Stout JE, Yu VL. Legionellosis. N Engl J Med 1997; 337: 682-7.
- Gilbert DN, Moellering RC, Sande MA. The Sandford Guide to antimicrobial therapy; 2003.
- Listeria monocytogenes**
- Bula CJ, Bille J, Glässer MP. An epidemic of food-borne Listeriosis in western Switzerland: description of 57 cases involving adults. Clin Infect Dis 1995; 20: 66-72.
- Siztwick FS, Purich DL. Intracellular pathogenesis of Listeriosis. N Engl J Med 1996; 334: 770-6.
- Calder JAM. Listeria meningitis in adults. Lancet 1997; 350: 307.
- Dalten CG, Austin CC, Sobel J, et al. An outbreak of gastroenteritis and fever due to Listeria monocytogenes in milk. N Engl J Med 1997; 336: 100-5.
- Lorber B. Listeriosis. Clin Infect Dis 1997; 24: 1-11.
- Schuchat A, Robinson K, Wenger JD, et al. Bacterial meningitis in the United States in 1995. N Engl J Med 1997; 337: 970-6.
- Mylonakis E, Hohmann EL, Calderwood SB. Central nervous system infection with Listeria monocytogenes. 33 years' experience at a general hospital and review of 776 episodes from the literature. Medicine (Baltimore). 1998; 77: 313-36.vioe
- Lorber B. Listeria monocytogenes. In: Principles and Practice of Infectious Diseases. 5th ed. Mandell GL, et al. Churchill Livingstone, Philadelphia 2000; p. 2208.
- Mylonakis E, Paliou M, Hohmann EL, et al. Listeriosis during pregnancy: a case series and review of 222 cases. Medicine (Baltimore) 2002; 81: 260-9.
- Hof H. An update on the medical management of listeriosis. Expert Opin Pharmacother 2004; 5: 1727-35.
- Ooi ST, Lorber B. Gastroenteritis due to Listeria monocytogenes. Clin Infect Dis 2005; 40: 1327-32.
- Brouwer MC, van de Beek D, Heckenberg SG. Community-acquired Listeria monocytogenes meningitis in adults. Clin Infect Dis 2006; 43: 1233-8.
- Brucellose**
- Falagas ME, Bliziotis IA. Quinolones for Treatment of Human Brucellosis: Critical Review of the Evidence from Microbiological and Clinical Studies. Antimicrob Agents Chemother 2006; 50: 22-23.
- Roushan MRH, Mohraz M, Hajiahmadi M, et al. Efficacy of Gentamicin plus Doxycycline versus Streptomycin plus Doxycycline in the Treatment of Brucellosis in Humans. Clinical Infectious Diseases 2006; 42: 1075-80.
- Maladie de griffes de chat**
- Holley HP. Successful treatment of cat-scratch disease with ciprofloxacin. JAMA 1991; 265: 1563-5.
- Margileth AM. Antibiotic therapy for cat-scratch disease: clinical study of therapeutic outcome in 268 patients and a review of the literature. Pediatr Infect Dis J 1992; 11: 474-8.
- Bass JW, Freitas BC, Freitas AD. Prospective randomized double-blind placebo-controlled evaluation of azithromycin for treatment of cat-scratch disease. Pediatr Infect Dis J 1998; 17: 447-52.
- Chia JK, Nakata MM, Lami JL, et al. Azithromycin for the treatment of cat-scratch disease. Clin Infect Dis 1998; 26: 193-4.
- Morsure d'animaux et d'humains - Bisswunden**
- Stucker FJ, Shaw GY, Boyd S, et al. Management of animal and human bites in the head and

- neck. Arch Otolaryngol Head Neck Surg 1990; 116: 789-93.
- Weber DH, Ganson AR. Infections resulting from animal bites. Infect Dis Clin North Am 1991; 5: 663-80.
- Goldstein EJC. Bite wounds and infection. Clin Infect Dis 1992; 14: 633-8.
- Klein NC, Cunha BA. *Pasteurella multocida* pneumonia. Semin Respir Infect 1997; 12: 54-6.
- Fleisher GR. The management of bite wounds. NEJM 1999; 340:138-40.
- Talan DA, Citron DM, Abrahamian FM, et al. Bacteriologic analysis of infected dog and cat bites. N Engl J Med 1999; 340: 85-92.
- Medeiros I, Saconato H. Antibiotic prophylaxis for mammalian bites. Cochrane Database Syst Rev 2001; 2: CD001738.
- Green BT, Ramsey KM, Nolan PE. *Pasteurella multocida* meningitis: case report and review of the last 11 years. Scand J Infect Dis 2002; 34: 213-7.
- Gilbert DN, Moellering RC, Sande MA. The Sandford Guide to antimicrobial therapy; 2003.
- Broder J, Jerrard D, Olshaker J, et al. Low risk of infection in selected human bites treated without antibiotics. Am J Emerg Med 2004; 22: 10-13.
- Taplitz RA. Managing bite wounds: current recommended antibiotics for treatment and prophylaxis. Postgrad Med 2004; 116: 49-59.
- Prä- und postexpositionelle Tollwutprophylaxe beim Menschen. Schweizerische Bundesamt für Gesundheitswesen 01.07.2004.
- Oehler RL, Velez AP, Mizrachi M et al. Bite-related and septic syndromes caused by cats and dogs. Lancet Infect Dis 2009; 9: 439-47.
- Eigenmann K, Vogt M. Was tun bei Bissverletzungen? Schweiz Med Forum 2015; 15: 172-6.
- Clostridium difficile**
- Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994; 330: 257-62.
- Blossom DB, McDonald CL. The Challenges Posed by Reemerging Clostridium difficile Infection. Clin Infect Dis 2007; 45: 222-7.
- Neal MD, Alverdy JC, Hall DE, et al. Diverting loop ileostomy and colonic lavage: An alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann Surg 2011;254:423-7; discussion 427-9.
- Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. NEJM 2011; 364: 422-31.
- Cornely OA. Current and emerging management options for Clostridium difficile infection: What is the role of fidaxomicin? Clin Microbiol Infect 2012;18 (Suppl. 6):28-35
- Cohen SH, Gerdin ND, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31: 431-55.
- Smits LP, Bouter KE, de Vos WM, et al. Therapeutic potential of fecal microbiota transplantation. Gastroenterology 2013; 145: 946-53.
- van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. NEJM 2013; 368: 407-15.
- Debast SB, Bauer MP, Kuijper EJ, and The Committee European Society of Clinical Microbiology and
- Infectious Diseases (ESCMID): Update of the treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2014;20(Suppl. 2): 1-26.
- Glé O, Clerc D, Giulieri S et al. Prise en charge de la colite à Clostridium difficile. Rev Med Suisse 2014; 10: 1309-13.
- Syphilis**
- Larsen SA, Steiner BM, Rudolph AH. Laboratory diagnosis and interpretation of tests for syphilis. Clin Microbiol Rev 1995; 8: 1-21.
- Young H. Syphilis. Serology. Dermatol Clin. 1998; 16: 691-8.
- Peeling RW, Ye H. Diagnostic tools for preventing and managing maternal and congenital syphilis: an overview. Bulletin of the World Health Organization 2004; 82: 439-46.
- Itin P, Bosshard PP, Toutous Trellu L, Schmidt AJ, Vernazza P, Tarr Ph et al. Syphilis: Diagnostik und Behandlung. Schweiz Med Forum 2015;15:459.
- MRSA / MSSA -- SASM / SARM**
- Boyce JM. Methicillin-resistant Staphylococcus aureus. Detection, epidemiology, and control measures. Infect Dis Clin North Am 1989; 3: 901-13.
- Mulligan ME, et al. Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management. Am J Med 1993; 94: 313-28.
- Sanford MD, Widmer AF et al. Efficient detection and long-term persistence of carriage of methicillin-resistant S. aureus. Clin Infect Dis 1994; 19: 1123-8.
- Working party Report: Revised guidelines for the control of methicillin-resistant Staphylococcus aureus infection in hospital. J of Hosp Infection 1998; 39: 253-90.
- Mandell, Douglas, and Bennett's. Principles and Practice of infectious diseases. Churchill Livingstone 5th ed, 2000.
- Oliveira DC, Tomasz A, de Lencastre H. Secrets of success of a human pathogen: molecular evolution of pandemic clones of methicillin-resistant Staphylococcus aureus. Lancet Infect Dis. 2002; 2: 180-9.
- Wunderling RG, Rello J, Cammarata SK, et al. Linezolid vs vancomycin: analysis of the double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124: 1789-97.
- Lee MC, Rios AM, Aten MF, et al. Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus. Pe-

- diatr Infect Des J 2004; 23: 123-7.
- Harbarth S, Francois P, Schrenzel J et al. Community-associated methicillin-resistant *Staphylococcus aureus*. Emerg Infect Dis 2005; 11: 962-5.
- Zimmerli W. Infektiologie: Der ambulant erworbene methicillinresistente *Staphylococcus aureus* (CA-MRSA). Schweiz Med Forum 2005; 5: 1285-7.
- Gorwitz RJ, Jernigan DB, Powers HJ, et al. Strategies for clinical management of MRSA in the community: summary of an experts' meeting convened by the CDC. March 2006. www.cdc.gov/ncidod/dhqp/pdf/ar/CAMRSA_Exp_MtgStrategies.pdf
- Daum RS. Skin an doft-itissue infections caused by Methicillin-resistant *Staphylococcus aureus*. N Engl J Med 2007; 357: 380-90.
- Malaria (paludisme)**
- INTERNET:
- www.safetravel.ch and NET: cdc.com
 - [www.sti-ch \(= schweiz. Tropeninstitut\)](http://www.sti-ch). Notfallnummer: 061/284.81.44
 - www.hc-sc.gc.ca/phpb-dgspsp/publicat/ccdr-rmtc/97vol23/23s5/index_f.html
- Markwalder K., Hatz C. Malaria-Therapie 1998. Schweiz Med Wochenschr 1998; 128: 13-27.
- Warrell DA, Molyneux ME, Beales PF. Severe and complicated malaria. WHO malaria action programme. Trans R Soc Trop Med Hyg 1990; 84 (Suppl. 2): 1-65.
- Winters R.A., Murray H.W. Malaria - The Mite Revisited: Fifteen More Years of Experience at a New York City Teaching Hospital. The American Journal of Medicine. 1992; 93: 243-6.
- Gilles HM, Warrel DA. Bruce-Chwatt's Essential of Malariaiology.. Edward Arnold, 1993.
- Recommendations canadiennes pour la prévention et le traitement du paludisme (malaria) chez les voyageurs internationaux 1995. Rélevé des maladies transmissibles au Canada, RMTC 1995, volume 21S3, octobre.
- Swenson JE, MacLean JD, Gyorkos TW, et al. Imported malaria. Clinical presentation and examination of symptomatic travelers. Arch Intern Med 1995; 155: 861-8.
- Office fédéral de la santé publique, Division Épidémiologie et maladies infectieuses - Guide méthodologique des maladies transmissibles - Janvier 1996.
- White NJ. The treatment of malaria. N Engl J Med 1996; 335: 800-6.
- Recommendations canadiennes pour la prévention et le traitement du paludisme (malaria) chez les voyageurs internationaux 1997. Rélevé des maladies transmissibles au Canada, RMTC (www.hc-sc.gc.ca/phpb-dgspsp/publicat/ccdr-rmtc/97vol23/23s5/index_f.html).
- Warrell DA. Cerebral malaria: clinical features, pathophysiology and treatment. Ann Trop Med Parasitol 1997; 91: 875-84.
- Newton CR, Taylor TE, Whitten RO. Pathophysiology of fatal falciparum malaria in African children. Am Trop Med Hyg 1998; 58: 673-83.
- Genton B. Tests rapides pour le diagnostic des maladies tropicales. Med Hyg 1999; 57: 1120-6.
- Warrell DA. The management of severe malaria. Parasitology 1999; 41: 287-94.
- Mandell GL. Principles and Practice of Infectious diseases. 5th edition Churchill Livingstone 2000.
- World Health Organisation. Severe Falciparum Malaria. Trans R Soc Trop Med Hyg 2000; 94 (SI): 1-90
- Genton B. Malaria: Prophylaxe und Therapie - Ist die Mefloquin-Aera vorbei? Schweiz Med Forum 2001; 1: 337-44.
- Hatz C. Clinical Treatment of Malaria in Returned Travelers. In: Schlagenhauf P. (Hrsg). Travelers' Malaria. BC Decker, Hamilton - London 2001; 431-445.
- D'Acremont V et al. Treatment of imported malaria in an ambulatory setting: prospective study. BMJ. 2002; 324: 875-7.
- D'Acremont V, Burnand B, Ambresin AE, Genton B. Practice guidelines for evaluation of fever in returning travelers and migrants. J.Travel Med. 2003;10:S25-S52.
- Whitty CJ, Laloo D, Ustianowski A. Malaria: an update on treatment of adults in non-endemic countries. BMJ 2006; 333: 241-5.
- SIDA / AIDS, virostatiques**
- Société canadienne (1-800-499-1986)
- INTERNET:
- www.cdnais.ca
 - www.hivnet.ch
- Krawczynski K, Alter MJ, Tankersley DL, et al. Effect of immune globulin on the prevention of experimental hepatitis C virus infection. J Infect Dis 1996; 173: 822-8.
- Owens DK, Holodniy M, Garber AM, et al. Polymerase chain reaction for the diagnosis of HIV infection in adults. A meta-analysis with recommendations for clinical practice and study design. Ann Intern Med 1996; 124: 803-15.
- Bush MP, Satten GA. Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure. Am J Med 1997; 102: 117-26.
- Office fédéral de la santé publique (OFSP). 22.12.1997.
- Bulletin de l'Office fédéral de la santé publique (OFSP). Expositions à du sang en milieu professionnel et traitement prophylactique post-expositionnel en Suisse jusqu'à fin 1996. Bulletin de l'OFSP 1998; 27: 14-19.
- CDC: Public health service guidelines for the management of health-care worker exposures to HIV and recommendations for postexposure prophylaxis. MMWR 1998; 47: 1-31.
- Hirschel B, Kaiser L. (eds.). In: Le Sida. Guide du praticien - Diagnostic, traitement, prise en charge. M&H, 1998.
- Jost M et al. Prévention des maladies infectieuses transmises par voie sanguine dans le secteur sanitaire. SUVA 1998; 2869/30.f.
- Bulletin de l'Office fédéral de la santé publique (OFSP). Nouveautés dans le diagnostic de l'infection par le VIH et complément au "concept de test VIH". OFSP 1998; 29 novembre 1999.

- 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with Human Immunodeficiency Virus.
- USPHS/IDSA Prevention of Opportunistic Infections Working Group. Infectious Diseases Society of American. Ann Intern Med 1999; 131: 873-908.
- 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA). MMWR 1999; 48 (RR-10): 1-59, 61-6.
- Bürkisser P, Spertini F. Test de diagnostic et de suivi de l'infection par le VIH: progrès récents. Med Hyg 1999; 57: 867-71.
- Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 1999; 282: 2220-6.
- Rime Dubey B, Telenti A, Francioli P. Prise en charge des expositions professionnelles à du sang ou à d'autres liquides biologiques contaminés par les hépatites B et C et le VIH. Rev Med Suisse Rom 1999; 119: 587-92.
- Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 2000; 283: 381-90.
- Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283: 74-80.
- Whitcup SM. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. JAMA 2000; 283: 653-7.
- 1999 USPHS/IDSA Guidelines for the prevention of opportunistic infections in persons infected with HIV: part I. Prevention of exposure. Am Fam Physician 2000; 61: 163-74.
- 1999 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with HIV: Part II. Prevention of the first episode of disease. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention. U.S. Public Health Service/Infectious Diseases Society of America. Am Fam Physician 2000; 61: 441-2, 445-9, 453-4.
- 1999 USPHS/IDSA Guidelines for the prevention of opportunistic infections in persons infected with HIV: Part III. Prevention of disease recurrence. United States Public Health Service/Infectious Diseases Society of America. Am Fam Physician 2000; 61: 771-8, 780, 785.
- Bassetti S, Battegay M, Sudre P. Access to antiretroviral therapy. JAMA 2000; 283: 883-4; discussion 884.
- Flepp M, Jost J, Hirscher B, et al. Subkommission Klinik (SKK) der Eidg. Kommission für AIDS-Fragen (EKAf): Empfehlungen zur antiretroviralen HIV-Therapie 2001. Bulletin, des Bundesamtes für Gesundheit 2000; 51: 994-1000.
- Gallant JE. Strategies for long-term success in the treatment of HIV infection. JAMA 2000; 283: 1329-34.
- Hirsch MS, Brun-Vezinet F, D'Aquila RT, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA 2000; 283: 2417-26.
- Kovacs JA, Masur H. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N Engl J Med 2000; 342: 1416-29.
- Ledergerber B, Egger M, Telenti A. AIDS-Related opportunistic illness and potent antiretroviral therapy. JAMA 2000; 283: 2653-4.
- Furrer H. Behandlung und Prävention der wichtigsten HIV-assoziierten Infektionen. Schweiz Med Forum 2001; 1: 605-12.
- Tillmann HL, Heiken H, Knapik-Botor A, et al. Infection with GB virus reduced mortality among HIV-infected patients. N Engl J Med 2001; 345: 715-24.
- Updated U.S. Public Health Service Guidelines for the management of occupational exposures to HBV, HCV and HIV and recommendations for postexposure prophylaxis. MMWR 2001; 58 (RR-11): 1-52.
- Xiang J, Wunschmann S, Diekema D, et al. Effect of coinfection with GB virus C on survival among patients with HIV infection. N Engl J Med 2001; 345: 707-14.
- Guidelines for the use of antiretroviral agents in HIV-1-infected adults. MMWR 2003; July 14.
- Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 345: 2293-303.
- Benson CA, Kaplan JE, Masur H, Pau A, Holmes KK. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR Recomm Rep 2004; 53: 1-112.
- Gulick RM, J. Ribaud HJ, Shikuma CM, et al. Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 Infection. New Engl J Med 2004; 350: 1850-61.
- Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006; 296: 827-43.

Herpès: HSV, VZV-Zoster, EBV, CMV

- Corey L, Nahmias AJ, Guinan ME, et al. A trial of topical acyclovir in genital herpes simplex virus infections. NEJM 1982; 306: 1313-9.
- Ragozzino MW, Melton LJ, III, Kurland LT, Chu CP, Perry HO. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore) 1982; 61: 310-6.
- Andersson J, Ernberg I. Management of Epstein-Barr virus infections. Am J Med 1988; 85: 107-15.
- Haake DA, Zakowski PC, Haake DL, et al. Early treatment with acyclovir for varicella pneumonia

- in otherwise healthy adults: retrospective controlled study and review. *Rev Infect Dis* 1990; 12: 788-98.
- Orenl, Sobel JD. Human herpesvirus type 6: review. *Clin Infect Dis* 1992; 14: 741-6.
- Reusser P, Gambertoglio JG, Lilleby K, et al. Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogenic marrow transplant recipients. *J Infect Dis* 1992; 166: 303-310.
- Wallach MR, et al. Treatment of adult varicella with oral acyclovir. A randomized placebo-controlled trial. *Ann Intern Med* 1992; 117: 358-63.
- Rooney JF, et al. Oral acyclovir to suppress frequently recurrent herpes labialis: A double-blind placebo-controlled trial. *Ann Intern Med* 1993; 118: 268-72.
- Wood MJ, et al. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. *N Engl J Med* 1994; 330: 896-900.
- Kost RG, Strauss St. Postherpetic neuralgia – pathogenesis, treatment and prevention. *N Engl J Med* 1996; 335: 32-42.
- Whiteley RJ, Weiss H, Gnann JW Jr, et al. Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. *Ann Intern Med* 1996; 125: 831-2.
- Jackson JL, Gibbons R, Meyer G, et al. The effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia. A meta-analysis. *Arch Intern Med* 1997; 157: 909-12.
- Reitano M, Tyring S, Lang W, et al. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. *J Infect Dis* 1998; 178: 603-10.
- Rowbotham M, Harden N, Stacey B. Gabapentin for the treatment of postherpetic neuralgia. *JAMA*, 1998; 280: 1837-42.
- Whiteley RJ, Kimberlin DW, Roizman B. Herpes simplex virus. *Clin Infect Dis* 1998; 26: 541-55.
- Reusser P. Management of viral infections. In: Klasterky J, Schimpff SC, Senn H-J, eds. *Supportive care in cancer: A handbook for oncologists*. 2nd ed. New York: Marcel Dekker, 1999: 87-112.
- Cathomas G. Human herpes virus 8: a new virus discloses its face. *Virchows Arch* 2000; 436: 195-206.
- Furuta Y, Ohtani F, Kawabata H, et al. High prevalence of varicella-zoster virus reactivation in herpes simplex virus-seronegative patients with acute peripheral facial palsy. *Clin Infect Dis* 2000; 30: 529-33.
- Helgason S, Petursson G, Guðmundsson S, Sigurdsson JA. Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up. *BMJ* 2000; 321: 794-6.
- Reusser P. Antiviral therapy: Current opinions and challenges. *Schweiz Med Wschr* 2000; 130: 101-12.
- Schmader K. Herpes zoster in older adults. *Clin Infect Dis* 2001; 32: 1481-6.
- Wald A, Langenberg AG, Link K, et al. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women. *JAMA* 2001; 285: 3100-6.
- Gnann JW, Whiteley. Herpes Zoster. *N Engl J Med* 2002; 347: 340-6.
- Raschilas F, Wolff M, Delatour F, et al. Outcome of and prognostic factors for herpes simplex encephalitis in adults patients: results of a multicenter study. *Clin Infect Dis* 2002; 35: 254-60.
- Hjalgrim H, Askling J, Rostgaard K, et al. Characteristics of Hodgkin's lymphoma after infectious mononucleosis, *N Engl J Med* 2003; 349: 1324-32.
- Swiss Herpes Management Forum. Schweizer Empfehlungen für das Management des Herpes genitalis und Herpes-simplex-Virus Infektion des Neugeborenen. *Schweiz Ärztezeitung* 2005; 86: 780-92.
- Meylan P, Kempf W, Gerber S, et al. Recommandations suisses pour la prise en charge des infections dues au virus de la varicelle-zoster. *Forum Med Suisse* 2007; 7: 895-905.
- Lautenschlager S. Herpes-simplex-Infektionen der Haut. *Schweiz Med Forum* 2013; 13:703-8.
- Buvelet H, Lebowitz D, Huttner B, et al. Infection par le virus Varicella zoster chez l'adulte : au-delà du zona ? *Rev Med Suisse* 2016; 12: 738-43.
- Surber J, Hunziker M, Navarria I, et al. Genitalherpes – Update 2020 für die Praxis. *Primary Hosp Care – Allg Innere Med* 2020; 20: 100-104.

EPSTEIN-BARR virus - Mononukleose

- Aldrete JS. Spontaneous rupture of the spleen in patients with infectious mononucleosis. *Mayo Clin Proc* 1992; 67: 910-2.
- Robert-Gangneux F, Dardé ML. Epidemiology and diagnostic strategies for toxoplasmosis. *Clin Microbiol Rev* 2012; 25: 264-96.
- Anonymous. Concept suisse de test VIH: récapitulatif actualisé. *Bulletin OFSP* 2013;6:6-14.
- Valin N. Conduite à tenir devant un syndrome mononucléosique. *EMC Maladies Infectieuses* 2014; 11: 1-5.
- Lennon P, Crotty M, Fenton JE. Infectious mononucleosis. *BMJ* 2015; 350: h1825.
- De Paor M, O'Brien K, Fahey T, et al. Antiviral agents for infectious mononucleosis (glandular fever). *Cochrane Database Syst Rev* 2016;12:CD011487.
- Dumoulin A, Eyer M. Causes fréquentes de mononucléose infectieuse. *Rev Med Suisse* 2018; 14: 1799-802.
- Sonderegger J, Karrer U, Huber B, et al. Infektiöse Mononukleose: Update für die Praxis. *Praxis* 2021 in press.

Tétanos

NET: www.bag.admin.ch

- Ahmadsyah I, Salim A. Treatment of tetanus: an open study to compare the efficacy of procaine penicillin and metronidazole. *Br Med J* 1985; 291: 648-50.
- Sun KO, Chan YW, Cheung RT, et al. Management of tetanus: a review of 18 cases. *J R Soc*

Med 1994; 87: 135-7.
Sanford J. Tetanus – Forgotten but not gone. N Engl J Med 1995; 332: 812.
Mandell GL. Principles and Practice of Infectious diseases. 5th edition Churchill Livingstone. 2000.

Rage

Centers for Disease Control and Prevention. Human rabies prevention - United States, 1999. Recommendations for the advisory committee on immunization practices (ACIP). Morb Mortal Wkly Rep 1998; 48 (RR-1): 1-21.

Diphthérie

Wilson AP. Treatment of infection caused by toxicogenic and non-toxigenic strains of Corynebacterium diphtheriae. J Antimicrob Chemoth 1995; 35: 717-20.

Vaccins:

Grippe

Tétanos

Pneumocoque

Hépatites

NET: www.cdc.gov/disease/flu/weekly.htm

NET: www.influenza.ch (centre de grippe national, Genève)

INFLUENZA

Nichol KL, Margolis KL, Wuorenma J, et al. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994; 331: 778-84.

Nichol KL, Lind A, Margolis KL, et al. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med 1995; 333: 889-93.

Recommendations pour la prévention de la grippe. Office fédéral de la santé publique. Bulletin OFSP, Suppl. XIII, août 1996.

Magnenat JL. Vaccins anti-grippal et anti-pneumococcique chez la personne âgée. Med Hyg 1997; 55: 977-80.

Bulletin de l'OFSP. Une nouvelle possibilité de traiter les infections par le virus grippal. Bulletin 44/99, OFSP 1 novembre 1999.

Bundesamt für Gesundheit, Arbeitsgruppe Influenza, Schweizerische Kommission für Impffragen. Empfehlung zur Grippeprävention, in: Bundesamt für Gesundheit, ed. Infektionskrankheiten. Diagnose und Bekämpfung. Bern: Bundesamt für Gesundheit, Suppl. XIII; 2000.

Wenzel RP. Expanding the treatment options for influenza. JAMA 2000; 283: 1057-9.

Bundesamt für Gesundheit, Arbeitsgruppe Influenza, Schweizerische Kommission für Impffragen. Empfehlung zur Grippeprävention, in: Bundesamt für Gesundheit, ed. Infektionskrankheiten. Diagnose und Bekämpfung. Bern: Bundesamt für Gesundheit, Suppl. XIII;

2000. European Influenza Surveillance Scheme. Low and decreasing levels of influenza activity in Europe. 15 April 2005: 151.

Brief der EKIF an die Kantonsärzte vom 14. Juni 2006

EVM statement: Influenza vaccine supply for the

2006/7 season: low yield of recommended strain may lead to delivery delays. 9. Juni 2006 World Health Organization. Recommended composition of influenza virus vaccines for use in the 2006-2007 influenza season. Weekly epidemiological record No.9, 2006; 81: 82.

COVID-19

Morgan RJM, Williams F, Wright MM. An early warning scoring system for detecting developing critical illness. Clin Intens Care 1997; 8: 100.

Beigel JH, Tomashek KM, Dodd LE et al. Remdesivir for the Treatment of Covid-19 — Final Report NEJM 2020 Oct 8;NEJMoa2007764. Cochrane Database Syst Rev. 2020;9:CD013639. Epub 2020 Sep 30.

Goyal P, Choi JJ, Pinheiro L e al. Clinical Characteristics of Covid-19 in New York City. NEJM 2020; 382: 2372-2374.

He J, GuoY, Mao R et al. Proportion of asymptomatic coronavirus disease 2019: A systematic review and meta-analysis. J Med Virol 2020 Jul 21;10.1002/jmv.26326

Ilaria Liguoro I, Pilotto C, Bonanni M et al. SARS-CoV-2 infection in children and newborns: a systematic review. Eur J Pediatr 2020; 179: 1029-46.

Kucirka LM, Lauer SA, Laeyendecker O et al. Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since Exposure. Ann Intern Med 2020; 173: 262-267.

Lauer SA, Grantz KH, Bi Q et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med 2020; 172: 577-82.

Leismann DE, Ronner L, Pinotti R et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes Lancet [https://doi.org/10.1016/S2213-2600\(20\)30404-5](https://doi.org/10.1016/S2213-2600(20)30404-5)

Li L, Zhang W, Hu Y et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA 2020; 324: 460-470.

Petrilli Ch, Jones SA, Yang J et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ 2020;369:m1966.

Wang B, Ruobao L, Zhong L et al. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging 2020; 12: 6049-57.

Wang D, Hu B, Hu C et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020; 323:1061-1069

Wong HYF, Lam HYS, Ho-Tung Fong A et al. Frequency and Distribution of Chest Radiographic Findings in Patients Positive for COVID-19. Ra-

- diology 2020; 296: E72-E78.
- Pan Y, Zhang D, Yang P et al. Viral load of SARS-CoV-2 in clinical samples. Lancet Infect Dis 2020; 20: 411-412
- RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. NEJM 2020 July 17, DOI: 10.1056/NEJMoa2021436.
- ### TETANOS
- Weinstein L. Tetanus. N Engl J Med 1974; 289: 1293-6.
- Centers for disease control. Diphtheria, tetanus, and pertussis; recommendations for vaccine se and other preventive measures: recommendations of the immunization practices advisory committee (ACIP). MMWR 1991; 40: 1-28.
- ### PNEUMOCOQUE
- Butler JC, Breiman RF, Campbell JF, et al. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 1993; 270: 1826-31.
- Farr BM, Johnston L, Cobb DK, et al. Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study. Arch Intern Med 1995; 155: 2336-40.
- Konradsen HB. Quantity and avidity of pneumococcal antibodies before and up to 5 years after pneumococcal vaccination of elderly persons. Clin Infect Dis 1995; 21: 616-20.
- Magnenat JL. Vaccins anti-grippal et anti-pneumococcique chez la personne âgée. Med Hyg 1997; 55: 977-80.
- Nuorti PJ, Butler JC, Breiman RF. Prevention of pneumococcal disease: recommendations of the advisory committee on immunization practices (ACIP). MMWR 1997; 46, RR-8: 1-24.
- Ketterer JP, Rochat Th. Vaccin anti-pneumococcique. Med Hyg 1999; 57: 2329-33.
- Mühlemann K, Francioli P, et al. Prévention des infections à pneumocoques par la vaccination. Schweiz Aerztezeitung 2000; 81: 561-7.
- Prevention and control of influenza: Recommendations of the advisory committee on immunization practices (ACIP). MMWR 2000; 49, RR-03: 1-38.
- ### Pharyngite aiguë / RAA
- NET: www.idsociety.org
- Gerber MA. Comparison of throat cultures and rapid strep tests for diagnosis of streptococcal pharyngitis. Pediatr Infect Dis J 1989; 8: 820-4.
- Guidelines for the diagnosis of rheumatic fever. Jones Criteria, 1992 update. Special Writing Group of the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young of the American Heart Association. JAMA 1992; 268: 2069.
- Djani AS, Ayoub E, Bierman FZ, et al. Guidelines for the diagnosis of rheumatic fever: Jones criteria, updated 1993. Circulation 1993; 87: 302-7.
- Bisno AL, Gerber MA, Gwaltney JM, et al. Diagnosis and management of group A streptococcal pharyngitis; A practice guideline. Clin Infect Dis 1997; 25: 574-583.
- Nadal D, Weber R. Diagnose und Therapie der akuten Tonsillo-pharyngitis durch Gruppe A beta-hämolsierende Streptokokken. Schweiz Ärztezeitung 1999; 80: 599-601; version française p: 602-4.
- Zwart S, Sachs AP, Ruijs GJ, et al. Penicillin for acute sore throat: randomised double blind trial of seven days versus three days treatment or placebo in adults. BMJ 2000; 320: 150-4.
- Bisno AL, Gerber MA, Gwaltney JM, et al. Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. Clin Infect Dis 2002; 25: 113-25.
- Perrier P, Jones Criteria Working Group. Proceedings of the Jones Criteria workshop. Circulation 2002; 106: 2521.
- Gilbert DN, Moellering RC, Sande MA. The Sanford Guide to antimicrobial therapy; 2003.
- Gewitz MH, Baltimore RS, Tani LY, Sable CA et al. Revision of the Jones Criteria for the diagnosis of acute rheumatic fever in the era of Doppler echocardiography: a scientific statement from the American Heart Association. Circulation 2015; 131: 1806-18.
- ### Candidose
- Graybill JR, Vasquez J, Darouiche RO, et al. Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in hiv/aids patients. Am J Med 1988; 104: 33-9.
- Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994; 331: 1325-30.
- Fisher JF, Newman CL, Sobel JD. Yeast in the urine: solutions for a budding problem. Clin Infect Dis 1995; 20: 183-9.
- Nguyen MH, Peacock JE Jr, Tanner DC, et al. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med 1995; 155: 2429-35.
- Witt MD, Lewis RJ, Larsen RA, et al. Identification of patients with acute aids-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing. Clin Infect Dis 1996; 22: 322-8.
- Edwards JE, et al. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis 1997; 25: 43-59.
- Sobel JD. Vaginitis. N Engl J Med 1997; 337: 1896-1903.
- Van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med 1997; 337: 15-21.
- Denning DW. Invasive aspergillosis. Clin Infect Dis. 1998; 26: 781-5.
- Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26: 1383-96.
- Francis P, Walsh TJ. Evolving role of flucytosine

- in immunocompromized patients: new insights into safety, pharmacokinetics and antifungal therapy. *Clin Infect Dis* 1999; 16: 1-9.
- Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. *N Engl J Med* 1999; 340: 764-71.
- Fisher JF. Candiduria: when and how to treat it. *Curr Infect Dis Rep* 2000; 2: 523-30.
- Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. *Clin Infect Dis* 2000; 30: 662-78.
- Lundstrom T, Sobel J. Nosocomial candiduria: a review. *Clin Infect Dis* 2001; 32: 1602-7.
- Mora-Duarte J et al. Comparison of Caspofungin and Amphotericin B for invasive Candidiasis. *New Engl J Med* 2002; 347: 2020-9.
- Kullberg BJ, Pappas P, Ruhnke M et al. Voriconazole compared with a strategy of amphotericin B followed by fluconazole of candidaemia in non-neutropenic patients. Abstract O245, 14th ECCMID, Prague, May 1-4, 2004
- Infection urinaire — HWI (Harnwegsinfekt)**
Pyélonéphrite — Pyelonephritis
Prostatite/Epididymite
Prostatitis/Epididymitis
- Warren JW, Tenney JH, Hoopes JM, et al. A prospective microbiologic study of bacteriuria in patients with chronic indwelling urethral catheters. *J Infect Dis* 1982; 146: 719-23.
- Wong ES, McEvitt M, Running K, et al. Management of recurrent urinary tract infections with patient-administered single-dose therapy. *Ann Intern Med* 1985; 102: 302-7.
- Schaeffer AJ. Catheter-associated bacteriuria. *Urol Clin North Am* 1986; 13: 735-47.
- Warren JW. Catheter-associated urinary tract infections. *Infect Dis Clin North Am* 1987; 1: 823-54.
- Pezzlo M. Detection of urinary tract infections by rapid methods. *Clin Microbiol Rev* 1988; 2: 268-80.
- Dickinson GM, Bisno AL. Infections associated with indwelling devices: concept of pathogenesis; infection associated with intravascular devices. *Antimicrob Agents Chemother* 1989; 33: 597-607.
- Lipsky BA. Urinary tract infections in men: epidemiology, pathophysiology, diagnosis, and treatment. *Ann Intern Med* 1989; 110: 138-50.
- Stapleton A, Latham RH, Johnson C, Stamm WE. Postcoital antimicrobial prophylaxis for recurrent urinary tract infection: a randomized, double-blind, placebo-controlled trial. *JAMA* 1990; 264: 703-6.
- Pappas PG. Laboratory in the diagnosis and management of urinary tract infections. *Med Clin North Am* 1991; 75: 313-25.
- Humbert G. French consensus on antibiotherapy of urinary tract infections. The French Society for Infectious Diseases. *Infection* 1992; 20 (Suppl 3): S171-2.
- Neu HC. Urinary tract infections. *Am J Med* 1992; 92(Suppl.4A): 63S-70S.
- Rubin RH, Shapiro ED, Andriole VT, et al. Evaluation of new anti-infective drugs for the treatment of urinary tract infection. *Clin Infect Dis* 1992; 15 (Suppl.1): S216-S27.
- Stamm WE, Hooton TM. Management of urinary tract infections in adults. *N Engl J Med* 1993; 329: 1328-34.
- Hatton J, Hughes M, Raymond Ch. Management of bacterial urinary tract infections in adults. *Ann Pharmacother*. 1994; 28: 1264-72.
- Lipsky BA. Prostatitis and urinary tract infection in men: what's new; what's true? *Am J Med* 1999; 106: 327-34.
- Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. *Clin Infect Dis* 2000; 30: 662-78.
- Tambayah PA, Maki DG. Catheter-associated urinary tract infection is rarely symptomatic: a prospective study of 1,497 catheterized patients. *Arch Intern Med* 2000; 160: 678-82.
- Gilbert DN, Moellering RC, Sande MA. The Sanford Guide to antimicrobial therapy; 2003.
- Hooton TM, Scholes D, Gupta K et al. Amoxicillin-Clavulanate vs Ciprofloxacin for the Treatment of Uncomplicated Cystitis in Women. A Randomized Trial. *JAMA* 2005; 293: 949-955.
- Mandell, Douglas, Bennett's Principles and Practices of Infectious Diseases. Sixth Edition 2005.
- Nicolle LE, Bradley S, Colgan R, et al. American guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. *Clin Infect Dis* 2005;40: 643-54.
- Naber KG, Bishop MC, Bjerklund-Johansen TE et al. Guidelines on The Management of Urinary and Male Genital Tract Infections. European Association of Urology 2006.
- Janet Peterson, Simrati Kaul, Mohammed Khasab et al. A Double-Blind, Randomized Comparison of Levofloxacin 750 mg Once-Daily for Five Days With Ciprofloxacin 400/500 mg Twice-Daily for 10 Days for the Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis. *Urology* 2008; 17-22. © 2008 Elsevier Inc.
- Splénectomie**
- Ruben FL, Hankins WA, Zeigler Z. Antibody responses to meningococcal polysaccharide vaccine in adults without a spleen. *N Engl J Med* 1983; 299: 115-21.
- McMullin M, Johnston G. Long term management of patients after splenectomy. *BMJ* 1993; 307: 1372-3.
- Waghorn DJ. Prevention of post-splenectomy sepsis. *Lancet* 1993; 341: 248.
- British committee for standard in haematology, clinical haematology task force. Guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen. *BMJ* 1996; 312: 430-4.
- Genne D. Recommandations pour la prévention et le traitement des infections chez les patients splénectomisés ou souffrant d'une rate non fonctionnelle. *Med Hyg* 2001; 59: 2306-10.
- Anthrax**
- INTERNET: <http://www.bt.cdc.gov>.
- La Force FM. Anthrax. *Clin Infect Dis* 1994; 19:

1009-14.

Centers for Disease Control, and Prevention. Bio-terroism alleging use of anthrax and interim guidelines for management: United States, 1998. *Morb Mortal Wkly Rep* 1999; 48: 69-74.

Dixom TC, Meselson M, Guillemin J, et al. Anthrax. *N Engl J Med* 1999; 341: 815-26.

Ingleby TV, Henderson DA, Bartlett JG, et al. Anthrax as a biological and public health management. Working group on civilian biodefense. *JAMA* 1999; 283: 1735-45. [Erratum: *JAMA* 2000; 283: 1963]

Shafazand S, Doyle R, Ruoss S, et al. Inhalational Anthrax. Epidemiology, Diagnosis, and Management. *Chest* 1999; 116: 1369-76.

Swartz AN. Recognition and management of anthrax - an update. *N Engl J Med* 2001; 345: 1621-6.

Infection de cathéter

Bryant JK, Strand CL. Reliability of blood cultures collected from intravascular catheter versus veinpuncture. *Am J Clin Pathol* 1987; 88: 113-6.

Mansfield PF, Hohn DC, Fornage BD, et al. Complications and failures of subclavian-vein catheterization. *N Engl J Med* 1994; 331: 1735-8.

Raad I. Intravascular-catheter-related infections. *Lancet* 1998; 351: 893-8.

McKinley S, Mackenzie A, Finfer S, et al. Incidence and predictors of central venous catheter related infection in intensive care patients. *Anesthes Intensive Care* 1999; 27: 164-9.

Merrel LA, Farr BM, Sherertz RJ, Raad II, et al. Guidelines for the management of intravascular catheter-related infections. *Clin Infect Dis* 2001; 32: 1249-72.

Merrey J, De Jonghe B, Golliot F, et al. Complications of femoral and subclavian venous catheterization in critically ill patients. *JAMA* 2001; 286: 700-7.

O'Grady NP, Alexander m, Dellinger EP, et al. Guidelines for prevention of intravascular catheter-related infections. *Clin Infect Dis* 2002; 35: 1281-307.

O'Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. *MMWR Recomm Rep* 2002; 51(RR-10): 1-29.

McGee DC, Gould MK. Preventing complications of central venous catheterization. *N Engl J Med* 2003; 348: 1123-33.

Ostéomyélite

Walvogel FA, Vasey H. Osteomyelitis: the past decade. *N Engl J Med* 1980; 303: 360-70.

Lew DP, Walvogel FA. Osteomyelitis. *N Engl J Med* 1997; 336: 999-1007.

Fernandez M, Carroll CL, Baker CJ. Discitis and vertebral osteomyelitis in children: a 18-year review. *Pediatrics* 2000; 105: 1299-304.

McHenry MC, Easley KA, Locker GA. Vertebral osteomyelitis: long term outcome for 253 patients from 7 Cleveland-area hospitals. *Clin Infect Dis* 2002; 34: 1342-50.

Gilbert DN, Moellering RC, Sande MA. The Sand-

ford Guide to antimicrobial therapy; 2003.

Lee MV, Minotti A. Acute vertebral osteomyelitis. *N Engl J Med* 2003; 349: 2525.

Tice AD, Hoaglund PA, Shoulz DA. Outcomes of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy. *Am J Med* 2003; 114: 723-8.

Chlamydia trachomatis

Kälin U, Lauper U, Lautenschlager S. Urethritis. Erregerspektrum, Abklärung und Therapie Teil 1. *Swiss Med Forum* 2009; 9: 101-4.

Kälin U, Lauper U, Lautenschlager S. Urethritis. Erregerspektrum, Abklärung und Therapie Teil 2. *Swiss Med Forum* 2009; 9: 121-4.

Oakeshott P, Kerry S, Aghaizu A, et al. Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (prevention of pelvic infection) trial. *BMJ*. 2010;340:c1642.

Bundesamt für Gesundheit BAG – 2011. Sex unter Männern: Für eine bessere sexuelle Gesundheit 2012.

<https://www.bag.admin.ch/bag/de/home/service/publikationen/broschueren/publikationen-uebertragbare-krankheiten/maenner-sex.html>

Dize L, Agreda P, Quinn N, Barnes MR, Hsieh Y-H, Gaydos CA. Comparison of self-obtained penile-meatal swabs to urine for the detection of *C. trachomatis*, *N. gonorrhoeae* and *T. vaginalis*. *Sex Transm Infect* 2012; 89: 305-7.

Rekart ML, Gilbert M, Meza R, et al. Chlamydia public health programs and the epidemiology of pelvic inflammatory disease and ectopic pregnancy. *J Infect Dis* 2012; 207: 30-8.

Testing for Chlamydia trachomatis: time trends in positivity rates in the canton of Basel-Stadt, Switzerland. *Epidemiology and Infection* 2012; 141: 1953.

Papp JR, Schachter J, Gaydos CA, Van Der Pol B. Recommendations for the Laboratory-Based Detection of Chlamydia trachomatis and *Neisseria gonorrhoeae* – 2014. *MMWR – Recommendations and Reports* 2014; 63: 1-19.

Bally F, Quach A, Greub G, et al. Opportunistic testing for urogenital infection with Chlamydia trachomatis in south-western Switzerland, 2012: a feasibility study. *Euro Surveill* 2015; 20: 21051.

Geisler WM, Uniyal A, Lee JY, et al. Azithromycin versus Doxycycline for Urogenital Chlamydia trachomatis Infection. *N Engl J Med* 2015; 373: 2512-21.

Lanjouw E, Ouburg S, de Vries HJ, Stary A, Radcliffe K, Unemo M. 2015 European guideline on the management of Chlamydia trachomatis infections. *Int J STD AIDS* 2015; 27: 333-48.

Moore MS, Golden MR, Scholes D, Kerani RP. Assessing Trends in Chlamydia Positivity and Gonorrhea Incidence and Their Associations With the Incidence of Pelvic Inflammatory Disease and Ectopic Pregnancy in Washington State, 1988–2010. *Sex Transm Dis* 2015; 43: 2-8.

Nwokolo NC, Dragovic B, Patel S, Tong CYW, Barker G, Radcliffe K. 2015 UK national guideline for the management of infection with Chla-

- mydia trachomatis. Int J STD AIDS 2015; 27: 251–67.
- Prevention ECDC. Scientific advice: Guidance on chlamydia control in Europe. 2015. <https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/chlamydia-control-europe-guidance.pdf>
- Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64: 1–137.
- Bundesamt für Gesundheit BAG. HIV, Syphilis, Gonorrhoe und Chlamydiose in der Schweiz im Jahr 2015: eine epidemiologische Übersicht. BAG Bulletin 2016; 12-3.
- Dize L, Barnes P, Barnes M, et al. Performance of self-collected penile-meatal swabs compared to clinician-collected urethral swabs for the detection of Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium by nucleic acid amplification assays. Diagn Microbiol Infect Dis 2016; 86: 131–5.
- Price MJ, Ades AE, Soldan K, et al. The natural history of Chlamydia trachomatis infection in women: a multi-parameter evidence synthesis. Health Technol Assess 2016; 20: 1–250.
- Berry L, Stanley B. Comparison of self-collected meatal swabs with urine specimens for the diagnosis of Chlamydia trachomatis and Neisseria gonorrhoeae in men. J Med Microbiol 2017; 66: 134–6.
- Notter J, Frey Tirri B, Bally F et al. Sexuell übertragene Infektionen mit Chlamydia trachomatis. Schweiz Med Forum 2017; 11: 705–711.
- ## HÉMATOLOGIE - Hämatoologie
- INTERNET: www.2bib.ch/hemato.pdf
- Schmidt PM: Bases physiopathologiques en hématologie générale, v. 8.0, 2005
- ### Anémie - Anämie – Eisenmangelanämie
- Ganzoni AM. Eisen-Dextran intravenös: therapeutische und experimentelle Möglichkeiten. Schweiz Med Wochenschr 1970; 100: 301-3.
- Healton B, Savage D, Brust JCM et al. Neurologic aspects of cobalamin deficiency. Medicine 1991; 70: 229-44.
- Guyatt GH, Oxman AD, Ali M, et al. Laboratory diagnosis of iron-deficiency anemia: an overview. J Gen Intern Med 1992; 7: 145-53.
- Lee R, et al (eds). Clinical hematology. 1993, Lea & Febiger.
- Stalder M. Une anémie peut en cacher une autre. Rev Med Suisse Rom 1913; 113: 1019-23.
- Beris P, Tobler A. Diagnostic de l'anémie. Med Hyg 1997; 55: 1812-6.
- Ruedin P. Traitement de l'anémie liée à l'insuffisance rénale chronique. Med Hyg 1998; 56: 2081-4.
- Olivieri NF. The beta-thalassemias. N Engl J Med 1999; 341: 99-109. [Erratum: N Engl J Med 1999; 341: 1407].
- Bernini LF, Harteveld CL. Alpha-thalassæmia. Baillieres Clin Haematol 1998; 11: 53-90.
- ### Fer - Eisen
- Working group on fortification of salt with iron: Use of common salt fortified with iron in the control and prevention of anemia – a collaborative study. Am J Clin Nutr 1982; 35: 1442.
- Crosby WH, O'Neil-Cutting MA. A small-dose iron tolerance test as an indicator of mild iron deficiency. JAMA 1984; 251: 1986-7.
- Wallach J. Interpretation of Diagnostic Tests. Little Brown, 1996.
- Hoffman R. Hematology Basic Principles & Practice. Mosby 1999, p: 417.
- ### **Surchage en fer - Eisenüberlastung**
- Kirk, P., et al., Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 2009; 120: 1961-8.
- Wood, J.C., Guidelines for quantifying iron overload. Hematology Am Soc Hematol Educ Program 2014: 2014: 210-5.
- Ogilvie, C., et al., Improved detection of hereditary haemochromatosis. J Clin Pathol 2015; 68: 218-21.
- Coates, T.D., et al., Management of iron overload in hemoglobinopathies: what is the appropriate target iron level? Ann N Y Acad Sci 2016; 1368: 95-106.
- Cullis, J.O., et al., Investigation and management of a raised serum ferritin. Br J Haematol 2018; 181: 331-340.
- Fitzsimons, E.J., et al., Diagnosis and therapy of genetic haemochromatosis (review and 2017 update). Br J Haematol 2018; 181: 293-303.
- ### **Électrophorèse (protéines)**
- Merino J. Patología del metabolismo de las proteínas y los aminoácidos. In: Rodés J, et al. (eds.). El Manual de Medicina. Masson, 1993. p: 1193-6.
- ### **Transfusions sanguines**
- Consensus conference: perioperative red blood cell transfusion. JAMA 1988; 260: 2700-3.
- American College of Physicians. Practice strategies for elective red blood cell transfusion. Ann Intern Med 1992; 116: 403-6.
- Expert Working Group. Guidelines for red blood cell and plasma transfusions for adults and children. Can med Assoc J 1997; 156 (Suppl 11): S1-24.
- Hebert PC, Wells G, Martin C, et al. Canadian survey of transfusion practices in critically ill patients. Crit Care Med 1998; 26: 482-7.
- Ely EW, Bernard GR. Transfusions in critically ill patients. N Engl J Med 1999; 340: 467-8.
- Goodnough LT, Brecher ME, Kanter MH et al. Transfusion medicine - blood transfusion. N Engl J Med 1999; 340: 438-47.
- Hebert PC, Wells G, Blajcjam MA, et al. Transfusion requirements in critical care: a multicentre randomized controlled clinical trial. N Engl J Med 1999 ;340: 409-17.
- Goodnough LT, Bach RG. Anemia, Transfusion, and mortality. N Engl J Med 2001; 345: 1272-4.
- Wu WC, Rathore SS, Wang Y, et al. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med 2001; 345: 230-6.
- Agence française de sécurité sanitaire des pro-

- duits de santé. Transfusion de globules rouges homologues: produits, indications, alternatives. Méthode générale et recommandations. Transfusion clinique et biologiques 2002; 9: 333-56.
- Nguyen BV, Bota DP, Melot C, et al. Time course of hemoglobin concentrations in nonbleeding intensive care unit patients. Crit Care Med 2003; 31: 406-10.
- Chiaroni J, Legrand D, Dettori I, Ferrera V. Analysis of ABO discrepancies occurring in 35 French hospitals. Transfusion 2004; 44: 860-4.
- Brecher ME, Hay SM. Bacterial contamination of blood components. Clin Microbiol Rev 2005; 18: 195-204.
- Goodnough LT. Risks of blood transfusion. Anesthésiol Clin North America 2005; 23: 241-52.
- Toy P, Popovsky M, Abraham E, et al. Transfusion-related acute lung injury: Definition and review. Critical Care Medicine 2005; 33: 721-6.
- Myéloïme multiple, MGUS**
- Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975; 36: 842-54.
- Durie BG. Staging and kinetics of multiple myeloma. Sem Oncol 1986; 13: 300-9.
- Kyle RA. Multiple myeloma. An update on diagnosis and management. Acta Oncol 1990; 29: 1-8.
- Durie BGM. Staging and kinetics of multiple myeloma. In: Wiernik Ph, et al. (eds.), Neoplastic diseases of the blood. New York, NY, Churchill Livingstone 1991, p: 439-52.
- Kyle RA. Diagnostic criteria of multiple myeloma. Hematol Oncol Clin North Am 1992; 6: 347-58.
- Riedel DA, Pottern LM. The epidemiology of multiple myeloma. Hematol Oncol Clin North Am, 1992; 6: 225-47.
- Bladé J. Gammopathías monoclonales. In: Rodés J, et. al. (eds.). El Manual de Medicina. Masson, S.A., 1993. p: 1834.
- Kyle RA. «Benign» monoclonal gammopathy - after 20 to 35 years of follow-up. Myo Clin Proc 1993; 68: 26-36.
- Roux C, Ravaud P, Cohen-Solal M, et al. Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma. Bone 1993; 15: 41-9.
- Kyle RA. Monoclonal gammopathy of undetermined significance. Blood Rev 1994; 8: 135-41.
- Sukpanichnant S, Cousar JB, Leelasiri A, et al. Diagnostic criteria and histologic grading in multiple myeloma: histologic and immunohistologic analysis of 176 cases with clinical correlation. Hum Pathol 1994; 25: 308-18.
- Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med 1997; 336: 1657-64.
- Zulian GB. Multiple myeloma: clinical evaluation of plasma cell lymphoproliferative disorders and initial management. Semin Hematol 1997; 34(Suppl.1): 29-39.
- Major PP, Lipton A, Berenson J, et al. Oral bisphosphonates: a review of clinical use in patients with bone metastases. Cancer 2000; 88: 6-14.
- Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002; 48: 1437-44.
- Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346: 564-9.
- The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorder: report of the International Myeloma Working Group. Br J Hematol 2003, 121:749-57.
- Child JA, Gareth JM, Faith ED, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-83.
- International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-57.
- Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Melton LJ III. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later. Mayo Clin Proc 2004; 79: 859-66.
- Griep PhR, San Miguel J, Durie BGM et al. International Staging System for Multiple Myeloma. J of Clin Oncology 2005; 3: 3412-20.
- Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005; 106: 812-17.
- Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006; 354: 1362-9.
- Polycythaemia vera (VAQUEZ-OSLER)**
- Silverstein MN, Pettitt RM, Solberg LA Jr, et al. Anagrelide: a new drug for treating thrombocytosis. N Engl J Med 1988; 318: 1292-4.
- Cervantes F. Eritrocitosis y policitemia. In: Rodés J, et. al. (eds.). El Manual de Medicina. Masson, S.A., 1993. p: 1776-80.
- Rognon R, Piguet D, Mégevand M, Kaeser P. Polyglobulies secondaires: le rôle de l'érythropoïétine. Rev Med Suisse Rom 1993; 113: 865-71.
- Pearson TC, Messiney M. The Diagnostic Criteria of Polycythaemia Rubra Vera. Leukemia and Lymphoma 1996; 22 (Suppl. 1): 87-93.
- Michiels JJ, Juvonen E. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group. Semin Thromb Hemost 1997; 23: 339-47.
- Pettitt RM, Silverstein MN, Petrone ME. Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders. Semin Hematol 1997; 34: 51-4.
- Messiney M, Pearson TC. Diagnosis of Polycy-

- thaemia. *J Clin Pathol* 1998; 51: 1-4.
- Landolfi R, Marchiolo R, Kutt J, et al. Efficacy and safety on low-dose Asprin in polycythemia vera. *N Engl J Med* 2004; 350: 114-24.
- Thrombocytose essentielle**
- Michiels JJ, Juvonen E. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group. *Semin Thromb Hemost* 1997; 23: 339-47.
- Thiele J, Kvasnicka HM. Chronic myeloproliferative disorders. The new WHO classification. *Pan�ologe* 2001; 22: 429-43.
- Harrison CN, Path MRC, Campbell PJ et al. Hydroxyurea Compared with Anagrelide in High-Risk Essential Thrombocythemia. *N Engl J Med* 2005; 353:33-45.
- Tefferi A, Thiele J, Orazi A, Kvasnicka HM et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. *Blood* 2007; 8 may.
- Thrombozytopenie – Thrombozytose**
- Thrombopénie – Thrombocytose**
- Fauci A, Braunwald E, (eds.) et al. In: Harrison: Principles of Internal Medicine. 1998 Mc Graw Hill.
- Arepally GM, Ortell TL. Heparin-induced thrombocytopenia. *N Engl J Med* 2006; 355: 809-17.
- Aster RH, Bougie D. Drug-induced immune thrombocytopenia. *N Engl J Med* 2007; 357: 580-7.
- Warkentin TE, Pai M, Linkins LA. Direct oral anti-coagulants for treatment of HIT: update of Hamilton experience and literature review. *Blood* 2017 31; 130:1104-1113.
- Provan D et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. *Blood Adv* 2019, 3: 3780-3817
- Thrombotische Mikroangiopathie, Thrombotisch thrombozytopenische Purpura**
- Kremer Hovinga JA, Coppo P, Lämmle B., Moake JL, Miyata T, Vanhoorelbeke K. Thrombotic thrombocytopenic purpura. *Nat Rev Dis Primers* 2017; 3:17020
- Thrombopénie induite par l'héparine (TIH)**
- Arepally GM. Heparin-induced thrombocytopenia. *Blood*. 2017;129(21):2864-72.
- Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. *NEJM* 2001; 344: 1286-92.
- Warkentin TE, Kelton JG. Delayed-onset heparin-induced thrombocytopenia and thrombosis. *Ann Intern Med* 2001; 35: 502-6.
- Lubenow N, Kempf R, Eichner A, Eichler P, Carlsson LE, Greinacher A. Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. *Chest* 2002; 122: 37-42.
- Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. *Br J Haematology* 2003; 121: 535-55.
- Pouplard C, May MA, Regina S, Marchand M, Fusciani J, Gruel Y. Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies. *Br J Haematol* 2005; 128: 837-41.
- Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. *Br J Haematol* 2003; 121: 535-55.
- Levine RL, Hursting MJ, McCollum D. Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction. *Chest* 2006; 129: 1167-75.
- Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. *J Thrombosis and Haemostasis* 2006; 4: 759-765.
- Levi M. Disseminated intravascular coagulation in cancer patients. *Best Pract Res Clin Haematol* 2009; 22: 129-36.
- Shepherd MF, Jacobsen JM, Rosborough TK. Argatroban therapy using enzymatic anti-factor IIa monitoring. *The Annals of pharmacotherapy* 2011; 45: 422-3.
- Tun NM, Bo ZM, Ahluwalia M, Guevara E, Villani GM. A rare case of intracerebral hemorrhage complicating heparin-induced thrombocytopenia with thrombosis: a clinical dilemma ameliorated by novel use of plasmapheresis. *Int J Hematol* 2012; 96: 513-5.
- Levi M, van der Poll T. Disseminated intravascular coagulation: a review for the internist. *Intern Emerg Med* 2013; 8: 23-32.
- Colucci G, Nagler M, Klaus N, Conte T, Giabbani E, Alberio L. Practical guidelines for argatroban and bivalirudine in patients with heparin-induced thrombocytopenia. *J Transl Sci* 2015; 1: 37-42.
- Iluonakhamhe E, Ibekwe O, Samuel S, Zakaria A. Plasmapheresis may be an option in urgent management of heparin-induced thrombocytopenia in the setting of acute intracerebral hemorrhage. *Neurocrit Care*. 2015; 22:140-5.
- Linkins LA et al.: Combination of 4Ts score and PF4/H-PaGIA for diagnosis and management of heparin-induced thrombocytopenia: prospective cohort study. *Blood* 2015; 126: 597-603.
- Tardy-Poncet B, Nguyen P, Thiranos JC, Morange PE, Biron-Andreani C, Gruel Y, et al. Argatroban in the management of heparin-induced thrombocytopenia: a multicenter clinical trial. *Crit Care* 2015; 19: 396.
- Thachil J, falanga A, levi M, liebman H, Di nisio M. Management of cancer-associated disseminated intravascular coagulation: guidance from the SSC of the ISTH. *J Thromb Haemost* 2015; 13: 671-5.
- Tvito A, Bakchoul T, Rowe JM, Greinacher A, Ganzel C. Severe and persistent heparin-induced thrombocytopenia despite fondaparinux treatment. *Am J Hematol* 2015; 90: 675-8.
- Levi M. Management of cancer-associated disseminated intravascular coagulation. *Thromb Res* 2016; 140 Suppl 1: S66-70.

Nagler M, Bakchoul T. Clinical and laboratory tests for the diagnosis of heparin-induced thrombocytopenia. *Thromb Haemost* 2016; 116: 823-34.

Nagler M, et al. Diagnostic value of immunoassays for heparin-induced thrombocytopenia: a systematic review and meta-analysis. *Blood* 2016; 127: 546-57.

Falanga A, Russo I, Milesi V et al. Mechanisms and risk factors of thrombosis in cancer. *Crit Rev Oncol Hematol* 2017; 118: 79-83.

Lei BZ, Shatzel JJ, Sendowski M. Rapid and durable response to intravenous immunoglobulin in delayed heparin-induced thrombocytopenia: a case report. *Transfusion* 2017; 57: 919-23.

Padmanabhan A, Jones CG, Pechauer SM et al. IVIg for Treatment of Severe Refractory Heparin-Induced Thrombocytopenia. *Chest* 2017; 152: 478-85.

Warkentin TE, Pai M, Linkins LA. Direct oral anti-coagulants for treatment of HIT: update of Hamilton experience and literature review. *Blood* 2017 31; 130: 1104-1113.

Coagulation sanguine

Van Wynsberghe D, Noback CR, Carola R. (eds.). *Human Anatomy and Physiology*. McGraw-Hill, 1995.

Wallach J. *Interpretation of Diagnostic Tests*. Little Brown, 1996.

Gavillet M, Angelillo-Scherrer A. Quantification of the anticoagulatory effect of novel anticoagulants and management of emergencies. *Cardiovasc Med* 2012; 15: 170-9.

Hémophilie,

Maladie de Von WILLEBRAND

Sadler JE, Davie EW. Hemophilia A, hemophilia B, and von Willebrand's disease. In: *The molecular basis of blood diseases*. G Stamatoyanopoulos et al (eds.). Philadelphia, Saunders 1987; p: 575-630.

Beutler E, Lichtmann MA, Coller TJ, et al. (eds.). In: *Williams Hematology*, Fifth Edition 1995, McGraw Hill, p: 1413-29, and p: 1458-80.

Pier MM. Treatment of von Willebrand's Disease. *N Engl N Med* 2004; 351: 683-94.

Sadler JE, Budde U, Eikenboom JCJ et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. *J Thromb Haemost* 2006;4:2103-14.

James PD, Connell NT, Amer B et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. *Blood Adv* 2021; 5: 280-300.

Purpura (voir «INVESTI-MÉD»)

Kitchens CS. The purpuric disorders. *Semin Thromb Hemost* 1984; 10: 173-89.

Hoffbrand AV, Petit JE. *Essential Haematology*. Blackwell Scientific Publications, 1993.

George JN, El-Harake MA, Raskob GE. Chronic idiopathic thrombocytopenic purpura. *N Engl J Med* 1994, 331: 1207-11.

Varet B. *Le livre de l'intérite: hématologie*. Médecine-Sciences. Flammarion, 1997.

Eldor A. Thrombotic thrombocytopenic purpura: diagnosis, pathogenesis and modern therapy. *Baillière's Clinical Haematology*, 1998; 11: 475-95.

Fauci A, Braunwald E, (eds.) et al. In: *Harrison: Principles of Internal Medicine*. 1998 Mc Graw Hill.

Gillis S, Eldor A. Immune thrombocytopenic purpura in adults: clinical aspects. *Baillière's Clinical Haematology*, 1998; 11: 361-72.

Provan D, Chisholm M, Duncombe AS, et al. *Oxford Handbook of Clinical Haematology*, Oxford University Press, 1998.

Pallister CJ. *Haematology (Biomedical Sciences Explained)*. Butterworth-Heinemann, 1999.

Cines DB, Blanchette VS. Immune thrombocytopenic purpura. *N Engl J Med* 2002; 346: 995-1008.

Cheng Y, Wong RSM, Soo YOY, et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. *N Engl J Med* 2002; 349: 831-6.

CIVD - DIC Disseminierte intravasale Gerinn.

Colman R, Robboy S, Minna J. Disseminated intravascular coagulation (DIC): an approach. *Am J Med* 1972; 52: 679-87.

Fenstein D. Diagnosis and management of disseminated intravascular coagulation: the role of heparin therapy. *Blood* 1982; 60: 284-7.

Bick RL. Disseminated intravascular coagulation. *Hem Onc Clin North Am* 1992; 6: 1259-81.

Williams E. Disseminated intravascular coagulation. In: Loscalzo J, Schafer A (eds.). *Thrombosis and hemorrhage*. Blackwell Science 1994, pp. 921-44.

Baglin T. Disseminated intravascular coagulation: diagnosis and treatment. *BMJ* 1996; 312: 683-7.

Boneu B. Disseminated intravascular coagulation. Etiology, diagnosis. *Rev Prat* 1997; 47:215-8.

Levi M, Ten Cate H. Current concepts: disseminated intravascular coagulation. *N Engl J Med* 1999; 341: 586-92.

Erez O, Mastrolia SA, Thachil J. Disseminated intravascular coagulation in pregnancy: insights in pathophysiology, diagnosis and management. *Am J Obstet Gynecol* 2015; 213: 452-63.

Erez O. Disseminated intravascular coagulation in pregnancy – Clinical phenotypes and diagnostic scores. *Thrombosis Research* 2017; 151(Suppl. 1): S56–S60.

Thrombophilie

Syndrome anti-phospholipides

Asherson RA, Chan JKH, Harris EN, et al. Anti-cardiolipin antibody, recurrent thrombosis, and Warfarin withdrawal. *Ann Rheum Dis* 1985; 44: 823-5.

Hughes GRV, Harris NN, Gharavi AE. The anti-cardiolipin syndrome. *J Rheum* 1986; 13: 486-9.

Mackworth-Young CG, Loizou S, Walport MJ. Primary antiphospholipid syndrome: features of patients with raised anticardiolipin antibodies and no other disorder. *Ann Rheum Dis* 1989; 48: 362-7.

- Brandt TJ, Triplett DA, Alving B, et al. Criteria for the diagnosis of lupus anticoagulants: an update. *Thromb Haemost* 1995; 74: 1185-90.
- Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. *N Engl J Med* 1995; 332: 993-7.
- Ginsberg JS, Wells PS, Brill-Edwards P, et al. Antiphospholipid antibodies and venous thromboembolism. *Blood* 1995; 10: 3685-91.
- Cavenagh JD, Colvin BT. Guidelines for the management of thrombophilia. *Postgrad Med J* 1996; 72: 87-94.
- Price DT, Ridker PM. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. *Ann Intern Med* 1997; 127: 895-903.
- Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. *Arthritis Rheum* 1999; 42: 1309-11.
- Graves M. Antiphospholipid antibodies and thrombosis. *Lancet* 1999; 353: 1348-53.
- Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. *N Engl J Med* 2002; 346: 752-63.
- Crowther MA, Ginsberg JS, Math JJ, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with antiphospholipid antibody syndrome. *N Engl J Med* 2003; 349: 1133-8.
- Weitz JL, Lensing AWA, Prins MH, et al. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. *N Engl J Med*. 2017; 376: 1211-22.

Hémopathies malignes

- INTERNET: www.2bib.ch/hemato.pdf
- Schmidt PM: Bases physiopathologiques en hématologie générale, v. 8.0, 2005 (p. 94-152 et 166)
- Jaffe ES, Harris NL, Stein H, et al (ed.). Tumors of haematopoietics and lymphoid tissues. World Health Organization classification of tumors. Pathology and genetics. IARC Press, 2001 (351 pages).

Syndromes myélodysplasiques (SMD)

- Aul C, Gattermann N and Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. *British journal of haematology* 1992; 82: 358-367. 1992/10/01.

Myélofibrose

- Tefferi A. Myelofibrosis with myeloid metaplasia. *NEJM* 2000; 342: 1255-65.
- Barosi G, Hoffman R. Idiopathic myelofibrosis. *Semin Hematol* 2005; 42: 248-58.
- Mehta J, Wang H, Iqbal SU, et al. Epidemiology of myeloproliferative neoplasms in the United States. *Leukemia & lymphoma* 2014; 55: 595-600.
- Tefferi A. Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management. *American journal of hematology* 2014; 89: 915-

925.

- Tefferi A and Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology* 2011; 29: 573-82.

Drépanocytose (anémie falciforme)

- Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease: rates and risk factors. *N Engl J Med* 1991; 325: 11-6.
- Brookoff D, Polomano R. Treating sickle cell pain like cancer pain. *Ann Intern Med* 1992; 116: 364-8.
- Wayne AS, Kevy SV, Nathan DG. Transfusion management of sickle cell disease. *Blood* 1993; 81: 1109-23.
- Carache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. *N Engl J Med* 1995; 332: 1317-22.
- Vichinsky EP, Haberkern CM, Neumayr L, et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. *N Engl J Med* 1995; 333: 206-13.
- Stuart MJ, Setty BN. Sickle cell acute chest syndrome: pathogenesis and rationale for treatment. *Blood* 1999; 94: 1555-60.
- Ballas SK. Sickle cell disease: current clinical management. *Semin Hematol* 2001; 38: 307-14.
- Stuart MJ, Setty BN. Acute chest syndrome of sickle cell disease: new light on an old problem. *Curr Opin Hematol* 2001; 8: 111-22.
- Ballas SK. Sickle cell anaemia: progress in pathogenesis and treatment. *Drugs* 2002; 62: 1143-72.

Oncologie - Onkologie

www.cancer.gov/cancertopics

Cancer colo-rectal

- Van Gossum A, Miguel Munoz Navas M, Fernandez-Urien I, et al. Capsule Endoscopy versus Colonoscopy for the Detection of Polyps and Cancer. *N Engl J Med* 2009; 361: 264-70.

CA mammaire

ces références sont en cours

Schildrüsen-CA

- Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid* 2016; 26: 1-133.

Cancer des testicules - Hodentumor

- International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. *J Clin Oncol* 1997; 15:594-603.

Lymphome HODGKIN et non-HODGKIN

- Rosenberg SA. Validity of the Ann Arbor staging classification for the non-Hodgkin's lymphomas. *Cancer Treat Rep* 1977; 61: 1023-7.
- A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. *N Engl J Med* 1993; 329: 987-94.
- Chronisch lymphastische Leukämie (CLL)**
- Rai, K.R., Sawitsky, A., Cronkite, E.P., Chanana, A.D., Levy, R.N., Pasternack, B.S.. Clinical staging of chronic lymphocytic leukemia. *Blood* 1975; 46: 219-234.
- Binet, JL, Leporrier M, Dighiero G et al. A Clinical staging system for chronic lymphocytic leukemia. *Cancer* 1977; 40: 855-864.
- Binet, J.L., et al., A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. *Cancer* 1981; 48: 198-206.

CA prostatique - Prostata-CA

D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. *JAMA* 1998; 280: 969-74.

Syndrome veine cave supérieure

Wilson LD, Detterbeck FC, Yahalom J. Clinical practice. Superior vena cava syndrome with malignant causes. *N Engl J Med* 2007; 356: 1862-9.

Giome

Brouland JP, Hottinger AF. Nouvelle classification OMS 2016 des gliomes: quels changements ? *Rev Med Suisse* 2017; 13: 1805-9.

WHO Classification of Tumours of the Central Nervous System, 4th ed, Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (Eds), IARC, Lyon 2016.

Melanom - Mélanome

Grob JJ, Bonerandi JJ. The "ugly duckling" sign: identification of the common characteristics of nevi in an individual as a basis for melanoma screening. *Arch Dermatol* 1998; 134: 103-4.

Abbas NR, Shaw HM, Rigel DS, et al. Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. *JAMA* 2004; 292: 2771-76.

Gershenwald JE, Scolyer R, Hess KR et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. *CA Cancer J Clin* 2017; 67: 472-92.

DERMATOLOGIE

Textbook

Saurat JH. Dermatologie et maladies sexuellement transmissibles. Masson 1999.

www.kopflaus.ch

Lebwohl M. et al. Therapy for head lice based on life cycle, resistance, and safety considerations. *Pediatrics* 2007; 119: 965-74.

Livedo reticularis

- Frances C, Niang S, Laffitte E, et al. Dermatologic manifestations of the antiphospholipid syndrome: two hundred consecutive cases. *Arthritis Rheum* 2005; 52: 1785-93.
- Gibbs MB, English JC, Zirwas MJ. Livedo reticularis: an update. *J Am Acad Dermatol* 2005; 52: 1009-19.
- Herrero C, Guilbert A, Mascaro-Galy JM. Diagnosis and treatment of livedo reticularis on the legs. *Actas Dermosifiliogr* 2008; 99: 598-607.
- Kroshinsky D, Stone JH, Bloch DB, Sepehr A. Case records of the Massachusetts General Hospital. Case 5-2009. A 47-year-old woman with a rash and numbness and pain in the legs. *NEJM* 2009; 360: 711-20.
- Coattrener Y, Terrani I, Spoerl D. Le livedo: physiopathologie et diagnostic. *Rev Med Suisse* 2018; 14: 746-50.

Dermatite atopique=Eczéma atopique

- Hannifin J.M et al. *Acta Dermatovener* 1980; 92: 44.
- Williams H.C, Jburney PG, Hay RJ et al. The U.K. working Party's diagnostic criteria for atopic dermatitis. *Br J Dermatol* 1994; 131: 383-96.
- Lucky AW, Leach AD, Laskarzewski P et al. Use of an emollient as a steroid-sparing agent in the treatment of mild to moderate atopic dermatitis in children. *Pediatr Dermatol* 1997; 14: 321-4.
- Kang S, Lucky AW, Pariser D, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. *J Am Acad Dermatol* 2001; 44 (Suppl 1):S58-64.
- Devillers, ACA, de Waard-van der Spek F.B., Mulder PGH et al. Treatment of Refractory Atopic Dermatitis Using "Wet-Wrap" Dressings and Diluted Corticosteroids: Results of Standardized Treatment in both Children and Adults. *Dermatology* 2002; 204: 50-55.
- Williams H. New treatment for atopic dermatitis. *BMJ* 2003; 324: 1533-4.
- Leung DY, Bieber T. Atopic dermatitis. *Lancet* 2003; 361: 151-60.

Hanfin JM, Cooper KD, Ho VC et al. Guidelines of care for atopic dermatitis, developed in accordance with the AAD. *J Am Acad Dermatol* 2004; 50: 391-404.

Illi S, von Mutius E, Lau S, et al. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. *J Allergy Clin Immunol* 2004; 113: 925-31.

Luger TA, Tahfa M, Folwster-Holst R, et al. Long-term safety and tolerability of pimecrolimus cream 0.1 % and topical corticosteroids in adults with moderate to severe atopic dermatitis. *J Dermatol Treat* 2004; 15:169-78.

National Institute for Clinical Excellence. Final appraisal determination: tacrolimus and pimecrolimus for atopic eczema.

www.nice.org.uk/pdf/P&T_FAD.pdf

Williams HC. Atopic dermatitis. *N Engl J Med* 2005; 352: 2314-24.

Gale

Delisle BR. La gale humaine. *Le Médecin du Québec* 1998; 33, 59-60.

- Bigby M. A systematic review of the treatment of scabies. *Arch Dermatol* 2000; 136: 387-9.
- Del Giudice P. Ivermectin in scabies. *Curr Opin Infect Dis* 2002; 15: 123-6.
- Elston DM. Controversies concerning the treatment of lice and scabies. *J Am Acad Dermatol* 2002; 46: 794-6.
- Leone PA. Scabies and pediculosis pubis: an update of treatment regimens and general review. *Clin Infect Dis* 2007; 44 (Suppl 3): S153-9.
- Psoriasis**
- Greaves MW, Weinstein GD. Treatment of psoriasis. *N Engl J Med* 1995; 332: 581-9.
- Nickoloff BJ, Wrone-Smith T. Superantigens, autoantigens, and pathogenic T cells in psoriasis. *J Invest Dermatol* 1998; 110: 459-60.
- Drew GS. Psoriasis. *Prim Care* 2000; 27: 385-406.
- Ashcroft DM, Li Wan Po A, Griffiths CE. Therapeutic strategies for psoriasis. *J Clin Pharm Ther* 2000; 25: 1-10.
- Granstein RD. New treatments for psoriasis. *N Engl J Med* 2001; 345: 284-7.
- Heydendaal VMR, Spuls P, Cipriani RC, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. *N Engl J Med* 2003; 349: 658-65.
- Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. *N Engl J Med* 2003; 349: 2014-22.
- Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. *Nature* 2007; 445: 866-73.
- Stern RS. Psoralen and ultraviolet a light therapy for psoriasis. *N Engl J Med* 2007; 357: 682-90.
- Erysipèle (cellulite) - fasciite**
- Leppard BJ, Seal DV, Colman G, et al. The value of bacteriology and serology in the diagnosis of cellulite end erysipelas. *Br J Dermatol* 1985; 112: 559-67.
- Hock EW 3d, Hooton TM, Horton CA, et al. Microbiologic evaluation of cutaneous cellulitis in adults. *Arch Intern Med* 1986; 146: 295-7.
- Duvanel T, Auckenthaler R, Rohner P, et al. Quantitative cultures of biopsy specimens from cutaneous cellulitis. *Arch Intern Med* 1989; 149: 239-6.
- Chartier C, Grosshans E. Erysipelas. *Int J Dermatol* 1990; 29: 459-67.
- Sjöblom AC, Eriksson B, Jorup-Rönstrom C, et al. Antibiotic prophylaxis in recurrent erysipelas. *Infection* 1993; 21: 390-3.
- Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. *N Engl J Med* 1996; 334: 240-5.
- Eriksson B, Jorup-Rönstrom C, Karkonen K, et al. Erysipelas: clinical and bacteriologic spectrum and serological aspects. *Clin Infect Dis* 1996; 23: 1091-8.
- Dan M, Heller K, Shapira I, et al. Incidence of erysipelas following venectomy for coronary artery bypass surgery. *Infection* 1987; 15: 107-8.
- Mertz KR, Baddur LM, Bell JL, et al. Breast cellulitis following breast conservation therapy: a novel complication of medical progress. *Clin Infect Dis* 1998; 26: 481-6.
- Dupuy A, Benchikhi H, Roujeau JC, et al. Risk factors for erysipelas of the leg (cellulitis): case-control study. *BMJ* 1999; 318: 1591-4.
- Perl B, Gottehrer NP, Raveh D, et al. Cost-effectiveness of blood cultures for adult patients with cellulitis. *Clin Infect Dis* 1999; 29: 1483-8.
- Mandell GL. Principles and Practice of Infectious Diseases. 5th edition. Churchill Livingstone 2000.
- Gottlieb T, Atkins BL, Shaw DR. Soft tissue, bone and joint infections. *Med J Aust* 2002; 176: 609-15.
- Bassetti St, Itin P, Flückiger U. Primäre bakterielle Hautinfektion. *Schweiz Med Forum* 2003; 35: 819-7.
- Stevens DL, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. *Clin Infect Dis* 2005; 41: 1373-406.
- Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. *Clin Infect Dis* 2014; 59: 147-59.
- Martinez M, Peponis Th, Hage A, et al. The Role of Computed Tomography in the Diagnosis of Necrotizing Soft Tissue Infections. *World J Surg* (2018) 42:82-87.
- Érythème nouveau**
- Bohn S, Buchner S, Itin P. Erythema nodosum: 112 cases. epidemiology, clinical aspects and histopathology. *Schweiz Med Wochenschr* 1998; 128: 85.
- Cribier B, Caille A, Heidi E, et al. Erythema nodosum and associated disease. A study of 129 cases. *Int J Dermatol* 1998; 37: 667-72.
- Petit A. Erythema nodosum. *Ann Dermatol Venereol* 2001; 128: 167-71.
- Prurit**
- Hagermark O, Wahlgren CF. Treatment itch. *Semin Dermatol* 1995; 14: 320-5.
- Kantor GR, Bernhard JD. Investigation of the pruritic patient in daily practice. *Semin Dermatol* 1995; 14: 290-6.
- Yosipovitch G, David M. The diagnostic and therapeutic approach to idiopathic generalized pruritus. *Int J Dermatol* 1999; 38: 881-7.
- Krajnik M, Zylicz Z. Understanding pruritus in systemic disease. *J Pain Symptom Manage* 2001; 21: 151-68.
- Vitiligo**
- WEB: American Academy of Dermatology (Ed). Public Resources, Patient Education - Vitiligo, American Academy of Dermatology. [Consulté le 1er décembre 2003]. www.aad.org/pamphlets/Vitiligo.html
- Kragballe K. Vitamin D3 analogues. *Dermatol Clin* 1995; 13: 835-9.
- Kieffer MA. Topical vitamin D analogs. *Dermatol Nurs* 2004; 16: 89-90, 93, 100.
- Berneburg M, Rocken M, Benedict F. Phototherapy with narrowband vs broadband UVB. *Acta Derm Venereol* 2005; 85: 98-108.

- Grimes PE. New insights and new therapies in vitiligo. JAMA 2005; 293: 730-5.
- Kostovic K, Pasic A. New treatment modalities for vitiligo: focus on topical immunomodulators. Drugs 2005; 65: 447-9.

Pemphigoïde bulleuse - Pemphigus

- Nousari HC, Anhalt GJ. Pemphigus and bullous pemphigoid. Lancet 1999; 345: 667-75.
- Joly P, Roujeau JC, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002; 346: 321-7.
- Bystrin JC, Rudolph JL. Pemphigus. Lance 2005; 366 :61-73.
- Ehrenberger-Lang A, Leisner A, Rhyner M, et al. Bullöse Erkrankung mit hoher Letalität. Forum 2006; 6: 945-6.
- Joly P, Mouquet H, Rojeau J-C, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2003; 348: 545-52.
- Diaz LA. Rituximab and pemphigus - a therapeutic advance. N Engl J Med 2007; 357: 605-9.

Toxidermies

- Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331: 1272-85.
- Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490-3.
- Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115: 149-53.
- Prins C, Kerdel FA, Padilla RS, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003; 139: 26-32.
- Trent JT, Kirsner RS, Romanelli Pet al. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami Experience. Arch Dermatol 2003; 139:39-43.
- Gottlieb NL, Riskin WG. Complications of local corticosteroid injections. JAMA 1980; 243:1547-8.
- Goldenberg DL, Reed JI. Bacterial arthritis. N Engl J Med 1985; 312: 764-71.
- Gächter A. Der Gelenkinfekt. Inform Arzt 1985; 5:43.
- Baker DG, Schumacher HR. Acute monoarthritis. N Engl J Med 1993; 329: 1013-20.
- American College of Rheumatology ad hoc committee on clinical guidelines. Guidelines for the initial evaluation of the adult patient with acute musculo-skeletal symptoms. Arthritis Rheum 1996; 39: 1-8.
- Schumacher HR Jr. Synovial fluid analysis and synovial biopsy. In: Kelley ED Jr, Ruddy S, Sledge CB, (eds.). Textbook of rheumatology: pp 609-25. Philadelphia, W.B. Saunders 1997.
- Stutz G, Kuster MS, Kleinstück F et al. Arthroscopic management of septic arthritis; stages of infection and results. Knee Surf Sports Taumatol Arthosc 2000; 8: 270-4.
- Gächter A. Der Gelenkinfekt. Inform Arzt 1985; 5:43.
- Stutz G, Kuster MS, Kleinstück F et al. Arthroscopic management of septic arthritis; stages of infection and results. Knee Surf Sports Taumatol Arthosc 2000; 8: 270-4.
- Stutz G, Gächter A. Diagnosis and stage-related therapy of joints infectios. Unfallchirurg 2001; 104: 682-6.
- Buchs N, Vischer TL. Que faire lors d'une arthrite d'apparition récente? Le triage par le laboratoire et l'imagerie. Med Hyg 1999; 57: 595-600.
- Theiler R. Arthrose. Schweiz Med Forum 2002; 23: 555-61.
- Margarett ME, Kohlwes J, Moore D, Bent S. Does this adult patient have septic arthritis? JAMA 2007;297:1478-88.
- Mathews CJ, Weston VC, Jones A, et al. Bacterial septic arthritis in adults. Lancet 2010; 375: 846-55.
- Carpenter CR, Schuur JD, Everett WW et al. Evidence-based diagnostics: adult septic arthritis. Acad Emerg Med 2011;18:781-96.

RHUMATOLOGIE

- INTERNET:
www.arthritis.ca
www.rheuma-net.ch
- Textbooks
 Colvin RB, Bhan AK, McCluskey RT (eds.). Diagnostic Immunopathology. Raven Press 1995.
 Frank MM, Austen KF, Claman HN, Unanue ER (eds.). Samter's Immunologic Disease. Little Brown 1995.
 Kahn MF, Peltier A, Meyer O, Piette JC (eds.). In: Maladies et syndromes systémiques. Paris: Flammarion Médecine-Sciences, 1999.
 Fox RI. Sjogren's syndrome: Current therapies remain inadequate for a common disease. Expert Opin Invest Drugs 2000; 9: 207-16.
 PM Villiger, Seitz M. Rheumatologie in Kürze. Thieme Verlag 2006.

Arthrite/sepétique - Arthritis septische

Thumboo J, O'Duffy JD. A prospective study of the safety of joint and soft tissue aspirations and injections in patients taking warfarin sodium. Arthritis Rheum 1989; 41: 736-9.

Yood RA. Use of gloves for rheumatologic procedures. Arthritis Rheum 1994; 36: 575.

Lemaire V, charbonnier B, Gruel Y, et al. Antiagrégants, anticoagulants et infiltrations: comment faire? Rev Rhum 2002; 69: 8-11.

Arthrite rhumatoïde

- Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
- Weaver A, Caldwell J, Olsen N. et al. Treatement of active rheumatoid arthritis with leflunomide compared to placebo or methotrexate. Arthritis Rheum 1998; 41: S131.

- Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double blind, randomised, multicenter trial. *Lancet* 1999; 353: 259-66.
- Villiger PM, Brühlmann P. Rheumatoide Arthritis. In: Alexander K, et al (eds). Thiemes Innere Medizin. Stuttgart. Thieme Verlag, 1999, pp 1622-31.
- Schellekens GA, Visser H, de Jong BA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. *Arthritis Rheum* 2000; 43: 1901-2.
- Van der Heijde DMFM. Radiographic imaging: the «gold standard» for assessment of disease progression in rheumatoid arthritis. *Rheumatology* 2000; 39 (Suppl 1): 9-16.
- Tremblay JL, Morin F. La polyarthrite rhumatoïde (PAR). *Le Rhumatologue* 2002; 3: 1-8.
- American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis. *Arthritis Rheum* 2002; 46: 328-46.
- Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTL A4 Ig. *N Engl J Med* 2003; 349: 1907-15.
- Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. *N Engl J Med* 2004; 350: 2167-79.
- Lombalgies**
- Bogduk N, McGuirk B. Medical management of acute and chronic low back pain. An evidence-based approach. Amsterdam: Elsevier, 2002.
- Gouipple P, Mulleman D, Paintaud G et al. Can sciatica induced by disc herniation be treated with tumor necrosis factor alpha blockade? *Arthritis Rheum* 2007; 56: 3887-95.
- Younes M, Bejia I, Aguir Z, et al. Prevalence and risk factors of disk-related sciatica in an urban population in Tunisia. *Joint Bone Spine* 2006; 73: 538-42.
- Bouhassira D, Lanteri-Minet M, Attal N et al. Prevalence of chronic pain with neuropathic characteristics in the general population. *Pain* 2008; 136: 380-7.
- Genevay St, Gabay C. Syndrome radiculaire par hernie discale lombaire. *Rev Med Suisse* 2009; 5: 577-81.
- Guzman J, Haldeman S, Carroll LJ et al. Clinical practice implications of the Bone and Joint Decade 2000-2010 Task Force on Neck Pain and Its Associated Disorders: from concepts and findings to recommendations. *Spine (Phila Pa 1976)* 2008; 33 (Suppl): S199.
- Haldeman S, Carroll L, Cassidy JD et al. The Bone and Joint Decade 2000-2010. Task Force on Neck Pain and Its Associated Disorders. Executive Summary. 2008, Lippincott Williams & Wilkins: SPINE Volume 33, Number 4S, S5-S7.
- Hill JC, Whitehurst DGT, Lewis M et al. Comparison of stratified primary care management for low back pain with current best practice (STarT Back): a randomised controlled trial. *Lancet* 2011; 378: 1560-71.
- Genevay S, Chevallier-Ruggeri P, Faundez A. Canal lombaire étroit: clinique, physiopathologie et traitement. *Rev Med Suisse* 2012; 8: 585-9.
- Cohen SP. Epidemiology, diagnosis, and treatment of neck pain. *Mayo Clin Proc* 2015; 90: 284.
- La Cour P, Petersen M. Effects of mindfulness meditation on chronic pain: a randomized controlled trial. *Pain Med* 2015; 16: 641-5.
- Hilton L, Hempel S, Ewing BA et al. Mindfulness Meditation for Chronic Pain: Systematic Review and Meta-analysis. *Ann Behav Med* 2017; 51: 199-213.
- Genevay St, Courvoisier DS, Konstantinou K et al. Clinical classification criteria for radicular pain caused by lumbar disc herniation: the radicular pain caused by disc herniation (RAPIDH) criteria. *Spine Journal* 2017; 17: 1464-71.
- Juch JN, Maas ET, Osteolo RWJG et al. Effect of Radiofrequency Denervation on Pain Intensity among Patients With Chronic Low Back Pain The Mint Randomized Clinical Trials. *JAMA* 2017; 318:68-81.
- Genevay St, Courvoisier DS, Konstantinou K et al. Clinical classification criteria for neurogenic claudication caused by lumbar spinal stenosis. The N-CLASS criteria. *Spine Journal* 2018 (In press).
- Canal lombaire étroit**
- Katz JN, Dalgas M, Stucki G, et al. Degenerative lumbar spinal stenosis. Diagnostic value of the history and physical examination. *Arthritis Rheum* 1995; 38: 1236-41.
- Lohman CM, Tallroth K, Kettunen JA, Lindgren KA. Comparison of radiologic signs and clinical symptoms of spinal stenosis. *Spine* 2006; 31: 1834-40.
- Chad DA. Lumbar spinal stenosis. *Neurol Clin* 2007; 25: 407-18.
- Katz JN, Harris MB. Clinical practice. Lumbar spinal stenosis. *NEJM* 2008; 358: 818-25.
- Watters WC, 3rd, Baisden J, Gilbert TJ, et al. Degenerative lumbar spinal stenosis: an evidence-based clinical guideline for the diagnosis and treatment of degenerative lumbar spinal stenosis. *Spine J* 2008; 8: 305-10.
- Conn A, Buenaventura RM, Datta S, Abdi S, Diwan S. Systematic review of caudal epidural injections in the management of chronic low back pain. *Pain Physician* 2009; 12: 109-35.
- Siebert E, Pruss H, Klingebiel R, Failli V, Einhaupl KM, Schwab JM. Lumbar spinal stenosis: syndrome, diagnostics and treatment. *Nat Rev Neurol* 2009; 5: 392-403.
- Kalichman L, Cole R, Kim DH, et al. Spinal stenosis prevalence and association with symptoms: the Framingham Study. *Spine J* 2009; 9: 545-50.
- Genevay S, Atlas SJ. Lumbar spinal stenosis. *Best Pract Res Clin Rheumatol* 2010; 24: 253-65.
- Suri P, Rainville J, Kalichman L, Katz JN. Does this older adult with lower extremity pain have the clinical syndrome of lumbar spinal stenosis ? *JAMA* 2010; 304: 2628-36.

- Kovacs FM, Urrutia G, Alarcon JD. Surgery versus conservative treatment for symptomatic lumbar spinal stenosis : A systematic review of randomized controlled trials. *Spine (Phila Pa 1976)* 2011; 36: E1335-51.
- Radcliff KE, Rihn J, Hilibrand A, et al. Does the duration of symptoms in patients with spinal stenosis and degenerative spondylolisthesis affect outcomes?: analysis of the Spine Outcomes Research Trial. *Spine (Phila Pa 1976)* 2011;36: 2197-210.
- Genevay S, Chevallier-Ruggeri P, Faundez A. Canal lombaire étroit: clinique, physiopathologie et traitement. *Rev Med Suisse* 2012; 8: 585-9.
- de Schepper EI, Overdevest GM, Suri P, et al. Diagnosis of lumbar spinal stenosis: an updated systematic review of the accuracy of diagnostic tests. *Spine (Phila Pa 1976)* 2013; 38: E469-81.
- Ishimoto Y, Yoshimura N, Muraki S, et al. Associations between radiographic lumbar spinal stenosis and clinical symptoms in the general population: the Wakayama Spine Study. *Osteoarthritis Cartilage* 2013; 21: 783-8.
- Burgstaller JM, Schuffler PJ, Buhmann JM, et al. Is There an Association Between Pain and Magnetic Resonance Imaging Parameters in Patients With Lumbar Spinal Stenosis? *Spine (Phila Pa 1976)* 2016; 41: E1053-62.
- Forsth P, Olafsson G, Carlsson T, et al. A Randomized, Controlled Trial of Fusion Surgery for Lumbar Spinal Stenosis. *NEJM* 2016; 374: 1413-23.
- Tomkins-Lane C, Melloh M, Lurie J, et al. ISSLSS Prize Winner: Consensus on the Clinical Diagnosis of Lumbar Spinal Stenosis: Results of an International Delphi Study. *Spine (Phila Pa 1976)*. 2016; 41: 1239-46.
- Aichmair A, Burgstaller JM, Schwenkglenks M, et al. Cost-effectiveness of conservative versus surgical treatment strategies of lumbar spinal stenosis in the Swiss setting: analysis of the prospective multicenter Lumbar Stenosis Outcome Study (LSOS). *Eur Spine J* 2017; 26: 501-9.
- Bakhsheshian J, Mehta VA, Liu JC. Current Diagnosis and Management of Cervical Spondylopathic Myelopathy. *Global Spine J* 2017; 7:572-86.
- Machado GC, Ferreira PH, Harris IA, et al. Effectiveness of surgery for lumbar spinal stenosis: a systematic review and meta-analysis. *PLoS One* 2015; 10: e0122800.
- ### Cervicalgies
- Alafifi T, Kern R, Fehlings M. Clinical and MRI predictors of outcome after surgical intervention for cervical spondylotic myelopathy. *J Neuroimaging* 2007; 17: 315-22.
- Furlan JC, Kalsi-Ryan S, Kailaya-Vasan A, et al. Functional and clinical outcomes following surgical treatment in patients with cervical spondylotic myelopathy: A prospective study of 81 cases. *J Neurosurg Spine* 2011; 14: 348-55.
- Faundez A, Genevay St. Canal cervical étroit : diagnostic et traitement. *Rev Med Suisse* 2012; 8: 1383-8.
- Côté P, Wong JJ, Sutton D. Management of neck pain and associated disorders: A clinical practice guideline from the Ontario Protocol for Traumatic Injury Management (OPTIMa) Collaboration. *Eur Spine J* 2016; 25: 2000-22.
- Kjaer P, Kongsted A, Hartvigsen J. National clinical guidelines for non-surgical treatment of patients with recent onset neck pain or cervical radiculopathy. *Eur Spine J* 2017; 26: 2242-57.
- ### Canal cervical étroit
- Faundez A, Genevay St. Canal cervical étroit : diagnostic et traitement. *Rev Med Suisse* 2012; 8: 1383-8.
- Côté P, Wong JJ, Sutton D. Management of neck pain and associated disorders: A clinical practice guideline from the Ontario Protocol for Traumatic Injury Management (OPTIMa) Collaboration. *Eur Spine J* 2016; 25: 2000-22.
- Kjaer P, Kongsted A, Hartvigsen J. National clinical guidelines for non-surgical treatment of patients with recent onset neck pain or cervical radiculopathy. *Eur Spine J* 2017; 26: 2242-57.
- ### Cauda equina syndrom - Syndrome de la queue de cheval
- REF: ↗
http://campus.neurochirurgie.fr/IMG/pdf/231_sq_c.pdf
- Lablanc DA, Mitera G, Ford M, Laperriere NJ . A 2011 updated systematic review and clinical practice guideline for the management of malignant extradural spinal cord compression. *Int J Radiat Oncol Biol Phys* 2012; 84: 312-7.
- ### Maladie de STILL de l'adulte
- Cush JJ, Medsger TA, Christy WC, et al. Adult-onset Still's disease. Clinical course and outcome. *Arthritis Rheum* 1987; 30: 186-94.
- Ohta A, Yamaguchi M, Kaneoka H, et al. Adult Still's disease: review of 228 cases from the literature. *J Rheumatol* 1987; 14: 1139-46.
- Bywaters EG. Still's disease in the adult. *Ann Rheum Dis* 1971; 30: 121-33.
- Cush JJ, Medsger TA, Christy WC, et al. Adult-onset Still's disease. Clinical course and outcome. *Arthritis Rheum* 1987; 30: 186-94.
- Schwarz-Eywill M, Heilig B, Bauer H, Breitbart A. Evaluation of serum ferritin as a marker for adult Still's disease activity. *Ann Rheum Dis* 1992; 51: 683-5.
- Yamagushi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still's disease. *J Rheumatol* 1992; 19: 424-30.
- Van Reeth C, Le Moel G, Lasne Y et al. Serum ferritin and isoferritins are tools for diagnosis of active adult Still's disease. *J Rheumatol* 1994; 21: 890-5.
- Zenagi D, De Coninck JP. Atypical presentation of adult Still's disease mimicking acute bacterial endocarditis. *Eur Heart J* 1995; 16: 1448-50.
- Akritidis N, Giannakakis I, Giouglis T. Ferritin levels and response to treatment in patients with Adult Still's disease. *J Rheumatol* 1996; 23: 201-2.
- Kumakura S, Ishikura H, Munemasa S, Adachi T, et al. Adult onset Still's disease associated hemophagocytosis. *J Rheumatol* 1997; 24: 1645-

- 7.
- Nguyen K, Weisman M. Severe sore throat as a presenting symptom of adult onset Still's disease: a case series and review of the literature. *J Rheumatol* 1997; 24: 592-7.
- Klippel J, Dieppe P. *Rheumatology*. 2nd ed. London: Mosby International; 1998.
- Cavagna L, Caporali R, Epis O, et al. Infliximab in the treatment of adult Still's disease refractory to conventional therapy. *Clin Exp Rheumatol* 2001; 19: 329-32.
- Fautrel B, Le Moel G, Saint-Marcoux B, Taupin P, et al. Diagnostic value of ferritin and glycosylated ferritin in adult onset Still's disease. *J Rheumatol* 2001; 28: 322-8.
- Fautrel B, Zing E, Goldmard J-L, et al. Proposal for a New Set of Classification Criteria for Adult-Onset Still Disease. *Medicine* 2002; 1: 194-200.
- Scirè CA, Cavagna L, Perotti C, et al. Diagnostic value of procalcitonin measurement in febrile patients with systemic autoimmune diseases. *Clin Exp Rheumatol* 2006; 24: 123-8.
- Church LD, Cook GP, McDermott MF. Primer : Inflammation and interleukin 1beta in inflammatory disorders. *Nat Clin Pract Rheumatol* 2008; 4: 34-42.
- Kontzias A, Efthimiou P. Adult-onset Still's disease : Pathogenesis, clinical manifestations and therapeutic advances. *Drugs* 2008; 68: 319-37.
- Ribi C. Maladie de Still de l'adulte. *Rev Med Suisse* 2008; 4: 1039-44.
- Gerfaud-Valentin M, Jamilloux Y, Iwaz J et al.: Adult-onset Still's disease. *Autoimmun Rev* 2014; 13: 708-222.
- Jamilloux Y, Gerfaud-Valentin M, Martinon F et al.: Pathogenesis of adult-onset Still's disease: new insights from the juvenile counterpart. *Immunol Res* 2015; 61: 53-62.
- Sfriso P, Priori R, Valesini G et al. Adult-onset Still's disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients. *Clin Rheumatol* 2016; 35: 1683-89.
- Spondyloarthropathies (SPA)**
- Amor B, Dougados M, Miyajawa. Critères de classification des spondylarthropathies. *Rev Rhum* 1990; 57: 85-9.
- Amor B, Dougados M, Listrat V, et al. Evaluation of the Amor criteria for spondylarthritis and European Spondylarthritis Study Group (ESSG). A cross-sectional analysis of 2,228 patients. *Ann Med Intern (Paris)* 1991; 142: 85-9.
- Dougados M, van der Linden S, Juhlin R, et al. The European Spondyloarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. *Arthritis Rheum* 1991; 34: 1218-27.
- Maksymowycz WP, Chou CT, Russell AS. Matching prevalence of peripheral arthritis and acute anterior uveitis in individuals with ankylosing spondylitis. *Ann Rheum Dis* 1995; 54: 128-30.
- Gordman JD, Sack KE, Davis JC, et al. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. *N Engl J Med* 2002; 346: 1349-56.
- Gladman TD, Hellier P, Marchesoni A, et al. CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. *Arthritis Rheum* 2006; 54: 2665-73.
- Rudwaleit M, Metter A, Listing J et al. Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. *Arthritis Rheum* 2006; 54: 569-78.
- Zochling J, van der Heijde D, Dougados M, Braun. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. *Ann Rheum Dis* 2006; 65: 423-32.
- Gladman DD, Mease PJ, Strand , et al. Consensus on a core set of domains for psoriatic arthritis. *J Rheumatol* 2007; 34: 1167-70.
- Rudwaleit M, van der Heijde D, Landewé R et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. *Ann Rheum Dis* 2011; 70: 25-31.
- Van den Berg R, de Hooge M, Rudwaleit M, et al. ASAS modification of the Berlin algorithm for diagnosing axial spondyloarthritis: results from the SPONDYLOArthritis Caught Early (SPACE)-cohort and from the Assessment of SpondyloArthritis international Society (ASAS)-cohort. *Ann Rheum Dis* 2013; 72: 1646-53.
- Spondylarthrite ankylosante - BECHTEREW**
- Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. *Arthritis Rheum* 1984; 27: 361-8.
- Picozzi M, Weber M, Frey RA, et al. Spondylarthrite ankylosante (maladie de Bechterew). *Forum Med Suisse* 2002; 10: 232-7.
- Rudwaleit M, Khan MA, Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? *Arthritis Rheum* 2005; 52: 1000-8.
- Weber U, Kissling O. Morbus Bechterew - neue Therapien, offene Fragen. *Schweiz Med Forum* 2006; 6: 163-71.
- Rudwaleit M, van der Heijde D, Landewé R et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. *Ann Rheum Dis* 2011; 70: 25-31.
- Van den Berg R, de Hooge M, Rudwaleit M, et al. ASAS modification of the Berlin algorithm for diagnosing axial spondyloarthritis: results from the SPONDYLOArthritis Caught Early (SPACE)-cohort and from the Assessment of SpondyloArthritis international Society (ASAS)-cohort. *Ann Rheum Dis* 2013; 72: 1646-53.
- Myopathie inflammatoire idiopathique**
- Mariampillai K, Granger B, Guiguet M et al. Une nouvelle classification des myopathies inflam-

matoires idiopathiques basée sur des manifestations cliniques et les anticorps spécifiques des myosites.

<https://doi.org/10.1016/j.revmed.2017.10.356>

Schmidt J. Current Classification and Management of Inflammatory Myopathies. *J Neuromuscul Dis* 2018; 5: 109-29.

Lundberg IE, de Visser M, Werth VP. Classification of myositis. *Nat Rev Rheumatol*. 2018;14: 269-278.

Polyomyosite - Dermatomyosite

Tanimoto K, Nakano K, Kano S, et al: Classification criteria for polymyositis and dermatomyositis. *J Rheumatol* 1995; 22: 668-74.

Mixed connective tissue disease

Alarcon-Segovia D, Villarreal M. Classification and diagnostic criteria for mixed connective tissue disease. In: Kasukawa R, Sharp GC, eds. Mixed Connective Tissue Disease and Anti-nuclear Antibodies. Amsterdam, Netherlands: Excerpta Media; 1987:33-40. International Congress Series No. 719.

Amigues JM, Cantagrel A, Abbal M, et al. Comparative study of 4 diagnosis criteria sets for mixed connective tissue diseases in patients with anti-RNP antibodies. *J Rheumatol* 1996; 23: 2055-62.

Kahn MF, Appelboom T. Syndrome de Sharp. In: Kahn MF, et al. Ed. Les maladies systémiques, 3rd ed Paris; Flammarion 1991: 545-56.

SJÖGREN

Vitali C, Bombardieri S, Moutsopoulos HM et al. and the European Community Study Group on Diagnostic Criteria for Sjögren's Syndrome, incl. Manthorpe R. Assessment of the European classification criteria for Sjögren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. *Ann Rheum Dis* 1996; 55: 116-21.

R Manthorpe. Sjögren's syndrome criteria. *Ann Rheum Dis* 2002; 61: 482-4.

Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. *Ann Rheum Dis* 2002; 61: 554-8.

Seror R, Ravaud Ph, Bowman S et al. EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome. *Ann Rheum Dis* 2010; 69: 1103-1109.

Shiboski CH, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome: A consensus and data-driven methodology involving three international patient cohorts. *Ann Rheum Dis* 2017; 76: 9-16.

Liapi A, Horisberger A, Spertini F et al. Syndrome de Sjögren : quand le suspecter et comment le confirmer? *Rev Med Suisse* 2016; 12: 698-702.

Aeby M, Maurer B, Distler O. Le syndrome de Sjögren primaire, une maladie systémique: partie 1. *Swiss Med Forum* 2017; 17: 1027-1038.

Aeby M, Maurer B, Distler O. Le syndrome de

Sjögren primaire, une maladie systémique: partie 2. *Swiss Med Forum* 2017; 17: 1063-1066.

Liquide synovial - Synovialflüssigkeit

Cohen AS et al. Synovial Fluid. In: Laboratory Diagnosis in the Rheumatic Disease, 2nd edition, 1975.

Krey PR, Bailen DA. Synovial fluid leukocytosis. *Am J Med* 1979; 67: 436-42.

Eisenberg JM, et al. Usefulness of synovial fluid analysis in the evaluation of joint effusions. Use of threshold analysis and likelihood ratios to assess a diagnostic test. *Arch Intern Med* 1984; 144: 715-9.

Shmerling RH, Delbanco TL. Synovial fluid tests. What should be ordered? *JAMA* 1990; 264: 1009-14.

Goutte - Gicht

Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. *Arthritis Rheum* 1977; 20: 895-900.

Emmerson BT. The management of gout. *N Engl J Med* 1996; 334: 445-51.

Rana SS, Giuliani MJ, Oddis CV, et al. Acute onset of colchicine myoneuropathy in cardiac transplant recipients: case studies of three patients. *Clin Neurol Neurosurg* 1997; 99: 266-70.

Cohen MG, Emmerson BT. Gout. In: *Rheumatology*. Klippel JH, Dieppe PA (eds.). Mosby Philadelphia, 1998, p: 8.14.1-14.

Minghelli G, Seydoux C, Goy JJ, et al. Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients. *Transplantation* 1998; 66: 268-71.

Bardin, T. Fenofibrate and losartan. *Ann Rheum Dis* 2003; 62: 497-498.

Takahashi S, Moriwaki Y, Yamamoto T, et al. Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. *Ann Rheum Dis* 2003; 52: 572.

Khanna D, Fitzgerald JD, Khanna PP et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. *Arthritis Care Res* 2012; 64: 1431-46.

Keenan RT. Safety of urate-lowering therapies: managing the risks to gain the benefits. *Rheum Dis Clin North Am* 2012; 38: 663-80.

Stamp LK, Taylor WJ, Jones PB et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. *Arthritis Rheum* 2012; 64: 2529-36.

Stamp LK, Taylor WJ, Jones PB, Dockerty JL, Drake J et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. *Arthritis Rheum*. 2012; 64: 2529-36.

Moi JHY, Sriranganathan MK, Edwards CJ, Buchbinder R: Lifestyle interventions for acute gout. *Cochrane Database Syst Rev* 2013;1 1: CD010519.

Duskin-Bitan H, Cohen E, Goldberg E et al. The

- degree of asymptomatic hyperuricemia and the risk of gout. A retrospective analysis of a large cohort. Clin Rheumatol 2014; 33: 549-53.
- Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet 2016; 388: 2039-52.
- Forster A, Krebs A. Kristallkrankheiten (Teil 1): Gicht. Swiss Med Forum 2017; 17:387-390.
- Richette P, Doherty M, Pascual E et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2017; 76: 29-42.
- Shekelle PG, Newberry SJ, FitzGerald JD et al. Management of Gout: A Systematic Review in Support of an American College of Physicians Clinical Practice Guideline. Ann Intern Med 2017; 166: 37-51.
- FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken) 2020; 72: 744-760.
- Fibromyalgie-Syndrom**
- Goldenberg DL. Diagnostic and therapeutic challenges of fibromyalgia. Hosp Pract 1989; September 30: 39-52.
- Wolfe F, Smythe HA, Yunus MB, et al. The american college of rheumatology 1990 criteria for the classification of fibromyalgia. Arthritis Rheum, 1990; 33: 160-72.
- Wolfe F, Hawley DJ and Wilson K. The prevalence and meaning of fatigue in rheumatic disease. J.Rheumatol 1996 ;23: 1407-17.
- White KP, Speechley M, Harth M. The London Fibromyalgia Epidemiology Study: comparing the demographic and clinical characteristics in 100 random community cases of fibromyalgia versus controls. J.Rheumatol 1999; 26: 1577-85.
- Kivimaki M, Leino-Arjas P, Virtanen M, et al. Work stress and incidence of newly diagnosed fibromyalgia: prospective cohort study. J Psychosom Res 2004; 57: 417-22.
- Yunus MB. Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes. Semin Arthritis Rheum 2007; 36: 339-56.
- Wang C, Schmid CH, Rones R, et al. A randomized trial of tai chi for fibromyalgia. NEJM 2010; 363: 74354.
- Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res 2010; 62: 600-10.
- Davidson JR, Crawford C, Ives JA and Jonas WB. Homeopathic treatments in psychiatry: a systematic review of randomized placebo-controlled studies. J.Clin Psychiatry 2011; 72: 795-805.
- Häuser W, Kosseva M, Ücayler N, et al. Emotional, physical, and sexual abuse in fibromyalgia syndrome: a systematic review with meta-analysis. Arthritis Care Res 2011; 63: 808-20.
- Verra ML, Angst F, Beck T, et al. Horticultural therapy for patients with chronic musculoskeletal pain: results of a pilot study. Altern Ther Health Med 2012; 18: 42-50.
- Aeschlimann AG, Bachmann ST, Cedraschi C et al. Syndrome fibromyalgique: nouvelles connaissances relatives au diagnostic et au traitement. Partie 1: tableau clinique, contexte de survenue et évolution. Forum Med Suisse 2013; 13: 517-21.
- Aeschlimann AG, Bachmann ST, Cedraschi C et al. Fibromyalgie-Syndrom: neue Erkenntnisse zu Diagnostik und Therapie Teil 2: Praktisches Vorgehen bei Abklärung und Behandlung. Schweiz Med Forum 2013; 13: 541-43.
- C Sommer, Alten R, Bär KJ et al. Drug Therapy of Fibromyalgia Syndrome : Updated Guidelines 2017 and Overview of Systematic Review Articles Schmerz 2017; 31: 274-284.
- Schiltlenwolf M, Eidmann U, Köllner V et al. Multi-modal therapy of fibromyalgia syndrome : Updated guidelines 2017 and overview of systematic review articles. Schmerz 2017; 31: 285-288.
- Syndrome du tunnel carpien**
- Kaplan SJ, Glickel SZ, Eaton RG. Predictive factors in the non-surgical treatment of carpal tunnel syndrome. J Hand Surg 1990; 15: 108.
- Périarthropathie huméroscapulaire**
- Hawkins RJ, Kennedy JC. Impingement syndrome in athletes. Am J Sports Med 1980; 8: 151-8.
- Hedtmann A, Fett H. So-called humeroscapular periarthropathy-calssification and analysis based on 1266 cases. Z Orthop Ihre Grenzgeb 1989; 127: 643-9.
- Sher JS, Uribe JW, Posada A, et al. Abnormal findings on magnetic resonance images of asymptomatic shoulders. J Bone Joint Surg Am 1995; 77: 10-5.
- Würgler CC, Sheikh R, Jost B et al . Periarthropathia humeroscapularis. Schweiz Med Forum 2007; 7: 81-6.
- Bursite**
- Schumacher HR Jr. Synovial fluid analysis and synovial biopsy. In: Kelley ED Jr, Ruddy S, Sledge CB, (eds.). Textbook of rheumatology. Philadelphia, W.B. Saunders 1997.
- Algodystrophie SUDECK - CRPS Komplexes regionales Schermzsyndrom**
- Sudeck P. Über die akute (reflektorische) Knochenatrophie nach Entzündungen und Verletzungen an den Extremitäten und ihre klinischen Erscheinungen. Fortschr Gebiete Roentgenstr 1901; 5: 277-93.
- Kozin F, Genant HK, Beckerman C, et al. The reflex sympathetic dystrophy syndrome II. Roentgenographic and scintigraphic evidence of bilaterality and of periarticular accentuation. Am J Med 1976; 60: 332-38.
- Merskey H, Bogduk N. Complex regional pain syndromes: classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Seattle: IASP Press 1994; 40-3.
- Stanton-Hicks M, Janic W, Hassenbusch S, et al.

- Reflex sympathetic dystrophy: changing concepts and taxonomy. Pain 1995; 63: 127-33.
- Todorovic-Tiranic M, Obradovic V, Han R, et al. Diagnostic approach to reflex sympathetic dystrophy after fracture: radiography or bone scintigraphy? Eur J Nucl Med 1995; 22: 1187-93.
- Adami S, Fossaluzza V, Gatti D, et al. Bisphosphonate therapy of reflex sympathetic dystrophy syndrome. Ann Rheum Dis 1997; 56: 201-4.
- Zollinger PE, Tuinebreijer WE, Kreis RW, et al. Effect of vitamin C on frequency of reflex sympathetic dystrophy in wrist fractures: a randomised trial. Lancet 1999; 354: 2025-8.
- van Hiltens BJ, van de Beek WJ, Hoff JL, et al. Intrathecal baclofen for the treatment of dystonia in patients with reflex sympathetic dystrophy. N Engl J Med 2000; 343: 625-30.
- Kemler MA, Barendse GA, van Kleef M, et al. Spinal cord stimulation in patients with chronic reflex sympathetic dystrophy. N Engl J Med 2000; 343: 618-24.
- Schwartzmann R, Popescu A. Reflex sympathetic dystrophy. Curr Rheumatol Rep 2002; 4: 165-9.
- van de Beek WJT, Schwartzman RJ, van Nes SI, et al. Diagnostic criteria used in studies of reflex sympathetic dystrophy. Neurology 2002; 58: 522-6.
- Harden RN, Bruehl S, Perez RSGM, et al. Validation of proposed diagnostic criteria (the "Budapest Criteria") for Complex Regional Pain Syndrome. Pain 2010; 150: 268-74.
- Roh YH, Lee BK, Noh JH, et al. Factors associated with complex regional pain syndrome type I in patients with surgically treated distal radius fracture. Arch Orthop Trauma Surg 2014; 177-81.
- Hannik MA, Streitberger K, Brunner F, et al. Komplexes regionales Schmerzsyndrom (CRPS) – Teil 1. Schweiz Med Forum 2021; 21: 209-213.
- Osteonecrose aseptique**
- Manning HJ. Nontraumatic necrosis of bone. N Engl J Med 1992; 326: 1473-9.
- Chang C, Greenspan A, Gershwin ME. Osteonecrosis: current perspectives on pathogenesis and treatment. Semin Arthritis Rheum 1993; 23: 47-69.
- Mirzai R, Chang C, Greenspan A, et al. Avascular necrosis. Compr Ther 1998; 24: 251-5.
- Mirzai R, Chang C, Greenspan A, et al. The pathogenesis of osteonecrosis and the relationships to corticosteroids. J Asthma 1999; 36: 77-95.
- Glesby MJ, Hoover DR, Vaamonde CM. Osteonecrosis in patients with human immunodeficiency virus: a case-control study. J Infect Dis 2001; 184: 519-23.
- Miller KD, Masur H, Jones EC, et al. High prevalence of osteonecrosis of the femoral head in HIV-infected adults. Ann Intern Med 2002; 137: 17-25.
- Paranéoplasie - Paraneoplastisches Syndrom**
- John WJ, et al. (eds.). Paraneoplastic syndromes. In: Cancer. Principles and Practice of Oncology. De Vita VT. Lippincott-Raven 1997, p: 2397-2422.
- Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med 2003; 349: 1543-54.
- Amyloïdose**
- Hill GS, Morel-Maroger L, Mery JP, et al. Renal lesions in multiple myeloma: the relationship to associated protein abnormalities. Am J Kidney Dis 1983; 2: 423-38.
- Bukbaum JN, Chuba JV, Hellman GC, et al. Monoclonal immunoglobulin deposition disease: light chain and light and heavy chain deposition diseases and their relation to light chain amyloidosis. Clinical features, immunopathology, and molecular analysis. Ann Intern Med 1990; 112: 455-64.
- Solomon A, Weiss DT, Kattine AA, et al. Nephrotoxic potential of Bence Jones proteins. N Engl J Med 1991; 324: 1845-51.
- Holmgren G, Ericzon BG, Groth CG, et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 1993; 341: 1113-6.
- Skinner M, Lewis WD, Jones LA, et al. Liver transplantation as a treatment for familial amyloidotic polyneuropathy. Ann Intern Med 1994; 120: 133-4.
- Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997; 337: 898-909.
- Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997; 336: 1202-7.
- Kushwhala SS, Fallen JT, Foster V. Restrictive cardiomyopathy. N Engl J Med 1997; 336: 267-76.
- Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349: 583-96.
- Dember LM, Hawkins PN, BP.C. Hazenberg et al. Eprodisate for the Treatment of Renal Disease in AA Amyloidosis. N Engl J Med 2007; 356: 2349-60.
- Jaccard A, Moreau Ph, Leblond V, et al. High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis, N Engl J Med 2007; 357: 1083-93.
- Auto-anticorps - Autoantikörper**
- Tan EM, Robinson CA, Nakamura RM, et al. ANA's in systemic rheumatic disease: Diagnostic significance. Postgrad Med 1985; 78: 141-2, 145-8.
- Love PE, Santoro SA. Antiphospholipid antibodies: Anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Ann Intern Med 1990; 112: 682-98.
- Wallach J. Interpretation of Diagnostic Tests. Little Brown, 1996.
- Collagénose/connectivite/Vaskulites**
- Kollagenose - Vaskulitis**
- Jennette JC, Falk RJ, Andrassi K, et al. Nomen-

- clature of systemic vasculitides. Proposal of an international consensus conference. *Arthritis Rheum* 1994; 37: 187-92.
- Hunder G. Vasculitis: diagnosis and therapy. *Am J Med* 1996; 100 (Suppl. 2A): 37S-45S.
- Lie JT. Classification of histopathological specificity of systemic vasculitis. In: Ansell BM, Bacon PA, Lie JT (eds). *The vasculitides*. London: Chapman & Hall, 1996; 26-36.
- Jennette JC, Falk RJ. Small-vessel vasculitis. *N Engl J Med* 1997; 337: 1512-23.
- Olivieri J, Chizzolini C, Dayer JM. Vasculites: Un défi pour le clinicien. *Med Hyg* 1998; 56: 398-402.
- Michel B, Brühlmann P. Kollagenosen und Vaskulitiden. In: Flasnoecker M, (ed.). *Thiemes Innere Medizin: TIM*. Georg Thieme Verlag, New York, Stuttgart 1999, p. 1632-51.
- Hoffman GS. Classification of systemic vasculitides. *Clin Exp Rheumatol* 1998; 16: 111-5.
- Gross WL, Trabandt A, Reinhold-Keller E. Diagnosis and evaluation of vasculitis. *Rheumatology* 2000; 39: 245-52.
- Weyand CM, Goronzy JJ. Medium- and large-vessel vasculitis. *N Engl J Med* 2003; 349: 160-9.
- Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. *Arthritis Rheum* 2013; 65:1.
- Walsh M, Merkel PA, Peh CA et al. Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. *Trials* 2013; 14: 14-73.

Phénomène de RAYNAUD

- Allen EV, Brown GE. Raynaud's disease: a critical view of minimal requisites for diagnosis. *Am J Med Sci* 1932; 183: 187-200.
- Klukken N, Rabe E. Clinical picture and treatment of the Raynaud syndrome of the upper extremity. *Phlebologie* 1987; 40: 447-54.
- Lally EV. Raynaud's phenomenon. *Curr Opin Rheumatol* 1992; 4: 825-36.
- LeRoy EC, Medsger TA Jr. Raynaud's phenomenon: a proposal for classification. *Clin Exp Rheumatol* 1992; 10: 485-8.
- Bolster MB, Maricq HR, Leff RL. Office evaluation and treatment of Raynaud's phenomenon. *Cleve Clin J Med* 1995; 62: 51-61.
- Roussin A. Raynaud's phenomenon. Therapeutic choices. 3ème édition. Association des pharmaciens du Canada, 2000, chap. 33, p. 285.
- Block JA, Sequeira W. Raynaud's phenomenon. *Lancet* 2001; 357: 2042-48.
- Roussin A. Le phénomène de Raynaud. Mythes et réalités. *Le Clinicien* Nov 2001; 85-95.
- Wigley FM. Raynaud's phenomenon. *N Engl J Med* 2002; 347: 1001-8.

Sclérose systémique - Systemische Sklerose

- Steen VD, Medsger TA, Rodnan GP. D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis. *Ann Intern Med* 1982; 97 :652-9.
- Leroy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. *J Rheumatol* 1988; 15: 202-5.
- Steen VD, Costantino JP, Shapiro AP, et al. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. *Ann Intern Med* 1990; 113 :352-7.

- Medsger TA. Treatment of systemic sclerosis. *Ann Rheum Dis* 1991; 50 (Suppl 4): 877-86.
- Pope J. Treatment of systemic sclerosis. *Curr Opin Rheumatol* 1993; 5: 792-801.
- Sandusky SB, McGuire L, Smith MT, Wigley FM, Haythornthwaite JA. Fatigue: an overlooked determinant of physical function in scleroderma. *Rheumatology (Oxford)* 2009;48:165.
- Roustit M, Blaise S, Allanore Y, Carpenter PH, Caglayan E, Cracowski JL. Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials. *Ann Rheum Dis*. 2013; 72: 1696-99.

- van den Hoogen F, Khanna D, Fransen J et al. EULAR/ACR. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. *Ann Ann Rheum Dis* 2013; 72: 1747-55.

Khanna D, Distler JHW, Sandner P, Distler O. Emerging strategies for treatment of systemic sclerosis. *Journal of Scleroderma and Related Disorders* 2016; 1: 186-93.

Schoenfeld SR, Choi HK, Sayre EC et al. Risk of Pulmonary Embolism and Deep Venous Thrombosis in Systemic Sclerosis: A General Population-Based Study. *Arthritis Care Res* 2016; 68: 246-53.

Da D. Sclérose systémique. *Forum Médical Suisse* 2017; 17: 808-15.

Kowal-Bielecka O, Fransen J, Avouac J et al. Update of EULAR recommendations for the treatment of systemic sclerosis. *Ann Rheum Dis* 2017; 76: 1327-39.

Péritartérite noueuse (PAN)

- Lightfoot RW, Michel AB, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. *Arthritis Rheum* 1990; 33: 1088-93.

Syndrome de TAKAYASU

- Arend WP, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. *Arthritis Rheum* 1990; 33: 1129-34.

- Villiger PM. Large-vessel vasculitis-giant cell and Takayasu arteritis [Article in German] *Internist (Berl)*. 2019 Oct;60(10):1059-1073. doi: 10.1007/s00108-019-00666-2

IgA-Vaskulitis (HENOCHE-SCHÖNLEIN)

- Mills JA, Michel BA, Cloch DA, et al , The American College of Rheumatology 1990: Criteria for the classification of Henoch-Schönlein purpura. *Arthritis Rheum* 1990; 33: 1114-21.

Vasculite leucocytoclasique

Calabrese LH, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of hypersensitivity vasculitis. *Arthritis Rheum* 1990; 33: 1108-13.

Maladie de BUERGER (Thrombangéite oblitrante)

Mozes M, Cahansky G, Deutsch V, et al. The association of arteriosclerosis and Buerger's disease: a clinical and radiological study. *J Cardiovasc Surg* 1970; 11: 52-7.

Shionoya S. Diagnostic criteria of Buerger's disease. *Int J Cardiol* 1998; 66(Suppl.): 243e5.

Maladie de BEHÇET

International study group for Behçet's disease.

Criteria for diagnosis of Behçet's disease. *Lancet* 1990; 335: 1078-80.

Sakane T, Takeno M, Suzuki N, et al. Behcet's disease. *NEJM* 1999; 341: 1284-91.

Gabay C. Syndrome de Behçet. *Rev Med Suisse* 2008; 4: 728-33.

The International Criteria for Behçet's Disease (ICBD): A Collaborative Study of 27 Countries on the Sensitivity and Specificity of the New Criteria. *J Eur Acad Dermatol Venereol* 2014; 28: 338-47.

Villiger RA, Stefanski AL, Grobety V, Adler S, Villiger PM. Behçet's syndrome: clinical presentation and prevalence in Switzerland. *Swiss Med Wkly*. 2019;149:w20072. <https://smw.ch/article/doi/smw.2019.20072>

Syndrome de CHURG-STRAUSS = Granulomatose éosinophilique avec polyangiite (EGPA)

Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. *Am J Pathol* 1951; 27: 277-94.

Franco J, Artes MJ. Pulmonary eosinophilia associated with montelukast. *Thorax* 1999; 54: 558-60.

Green RL, Vayonis AG: Churg-Strauss syndrome after zafirlukast in two patients not receiving systemic steroid treatment. *Lancet* 1999; 353: 725-6.

Guillevin L, Lhote F, Gayraud M: Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. *Medicine (Baltimore)* 1996; 75: 17-28.

Jennette JC, Falk RJ, Andrassy K. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. *Arthritis Rheum* 1994; 37: 187-92.

Masi AT, Hunder GG, Lie JT. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). *Arthritis Rheum* 1990; 33: 1094-100.

Tuggey JM, Hosker HS. Churg-Strauss syndrome associated with montelukast therapy. *Thorax* 2000; 55: 805-6.

Wechsler ME, Finn D, Gunawardena D: Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. *Chest* 2000; 117: 708-13.

Guillevin L, Pagnoux C, Seror R, et al. The Five-Factor Score revisited: assessment of prognosis of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. *Medicine (Baltimore)* 2011; 90:19.

MCTD

Kahn MF, Appelboom T. Syndrom de Sharp. In: *Les maladies systémiques*, 3rd, Kahn MF, Pelletier AP, Meyer O, Piette JC (Eds), Flammarion, Paris 1991. p.545.

Alarcón-Segovia D, Cardiel MH. Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients. *J Rheumatol* 1989;16:328-34.

Lupus érythémateux disséminé (LED)

Tan EM, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1982; 25: 1271-7.

Hess E. Drug related-lupus. *N Engl J Med* 1988; 318: 1460-2.

Love PE, Santoro SA. Antiphospholipid antibodies: Anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. *Ann Intern Med* 1990; 112: 682- 98.

Colvin RB, Bhan AK, McCluskey RT (eds.). *Diagnostic Immunopathology*. Raven Press 1995.

Frank MM, Austen KF, Claman HN, Unanue ER (eds.). *Samter's Immunologic Disease*. Little Brown 1995.

Hochberg M. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis 1997; 40: 1725-34.*

Piette J-Ch, Le Thi Huong D, Amoura Z. Traitement du lupus érythémateux systémique. *Med Hyg* 1999; 57: 908-15.

Aringer M, Costenbader K, Daikh D et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. *Arthritis Rheumatol* 2019; 71: 1400-1412.

Artérite temporelle (HORTON-Arteriitis) / Risenzellarteriitis (RZA) und Polymyalgia rheumatica (PMR)

Bird HA, Esselinckx W, Dixon AS, et al. An evaluation of criteria for polymyalgia rheumatica. *Ann Rheum Dis* 1979; 38: 434-9.

Chuang TY, Hunder GG, Ilstrup DM, et al. Polymyalgia rheumatica: a 10-year epidemiology and clinical study. *Ann Intern Med* 1982; 97: 672-80.

Healey LA. Long-term follow-up of polymyalgia rheumatica: evidence for synovitis. *Semin Arthritis Rheum* 1984; 13: 322-8.

Delecoeuillerie G, Joly P, Cohen de Lara A, et al. Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens. (11 years of survey of 210 patients). *Ann Rheum Dis* 1988; 47: 733-9.

Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the diagnosis of giant cell arteritis. *Arthritis*

- tis Rheum 1990; 33: 1122-8.
- Evans JM, O'Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. Ann Intern Med 1995; 122: 502-7.
- Salvarani C, Gabriel SE, O'Fallon WM, et al. Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota, 1970-1991. Arthritis Rheum 1995; 38: 369-73.
- Salvarani C, Gabriel SE, O'Fallon WM, et al. The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. Ann Intern Med 1995; 123: 192.
- Schmidt WA, Kraft HE, Vorpahl K, et al. Color duplex ultrasonography in the diagnosis of temporal arteritis. N Engl J Med 1997; 337: 1336-42.
- Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998; 339: 292-9.
- Gonzalez-Gay MA, Garcia-Porrúa C, Llorca J, et al.: Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine 2000; 79: 283-92.
- Martinez-Taboada VM, Rodriguez-Valverde V. Polymyalgia rheumatica with normal erythrocyte sedimentation rate: clinical aspects. Clin Exp Rheumatol 2000; 4 (Suppl. 20): S34-37.
- Gerster J.-CH. Polymyalgia rheumatica et maladie de Horton. Med Hyg 2001; 59: 609-12.
- Salvarani C, Cantini F, Boiardi L, et al. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002; 347: 261-71.
- Rahman W, Rahman FZ: Giant cell (temporal) arteritis: an overview and update. Surv Ophthalmol 2005; 50: 415-28.
- Mazlumzadeh M, Hunder GG, Easley KA, et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum 2006; 54: 3310.
- Ness T, Auw-Hedrich C, Schmidt D: Temporal arteritis (giant cell arteritis). Clinical picture, histology, and treatment. Ophthalmologe 2006; 103: 296-301.
- Dasgupta B, Cimmino MA, Maradit Kremers H, et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheum 2012; 64: 943-54 und Ann Rheum Dis 2012; 71: 484-92.
- Christian Dejaco C, Singh YP, Perel P, et al. A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative. 2015 Recommendations for the Management of Polymyalgia Rheumatica. Ann Rheum Dis 2015; 74: 1799-807.
- Villiger PM. Large-vessel vasculitis-giant cell and Takayasu arteritis [Article in German] Internist (Berl). 2019 Oct;60(10):1059-1073.
- plasmic autoantibodies: their immunodiagnostic value in Wegener's granulomatosis. Ann Intern Med 1989; 111: 28-40.
- Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990; 33: 1101-7.
- Hoffman GS, Kerr GS, Leavitt RY. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116: 488-98.
- Weir A, Lipman M, Congleton J. Co-trimoxazole in Wegener's granulomatosis. N Engl J Med 1996; 335: 1769-70.
- De Groot K, Gross WL. Wegener's granulomatosis: disease course, assessment of activity and extent and treatment. Lupus 1998; 7: 285-91.
- Syndrome de GOODPASTURE**
- Rees AJ. Goodpasture's syndrome. In: Lichtenstein LM, Fauci AS. (eds). Current Therapy in Allergy, Immunology, and Rheumatology. Mosby, 1996. p: 120-6.
- Cryoglobulinémie - Kryoglobulinämie**
- Ramos-Casals M, Stone JH, Cid MC, et al. The cryoglobulinaemias. Lancet. 2012; 379: 348-60.
- Tendinopathie Achilles - rupture du tendon**
- Neumayer F, Mouhsine E, Arlettaz Y, et al. A new conservative-dynamic treatment for the acute ruptured Achilles tendon. Arch Orthop Trauma Surg 2010; 130: 363-8.
- Neumayer F, Crevoisier X, Assal M. Diagnostic et traitement de la rupture du tendon d'Achille. Rev Med Suisse 2012; 8: 1490-95.
- Hitz M, Meier S, Huber M. Die ansatzferne Tendinopathie der Achillessehne. Schweiz Med Forum 2018; 18: 654-60.
- Hitz M, Meier S, Huber M. La tendinopathie achiléenne corporéale. Suisse Med Forum 2018; 18: 654-60.
- ORL — HNO**
- Acouphènes - Tinnitus**
- Luxon LM. Tinnitus: its causes, diagnosis, and treatment. BMJ. 1993;306:1490-1491.
- Nondahl DM, Cruickshanks KJ, Wiley TL, et al. Prevalence and 5-year incidence of tinnitus among older adults: the Epidemiology of Hearing Loss Study. J Am Acad Audiol 2002; 13: 323-31.
- Byung In Han, Ho Won Lee, Tae You Kim, et al. Tinnitus: Characteristics, Causes, Mechanisms, and Treatments. J Clin Neurol. 2009; 5: 11-19.
- Tunkel DE, Bauer CA, Sun GH, et al. Clinical practice guideline: tinnitus. Otolaryngol Head Neck Surg 2014; 151: Suppl: S1-S40.
- Manche SK, Madhavi J, Meganadhi KR, Jyothi A. Association of tinnitus and hearing loss in otological disorders: a decade-long epidemiological study in a South Indian population. Braz J Otorhinolaryngol 2016; 82: 643-9.
- Bauer C.A. Tinnitus. NEJM 2018; 378:1224-1231.
- Rhinosinusitis - Sinusitie**
- Fokkens WJ, Lund WJ, Hopkins C, et al. Rhino-

logy. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. 2020; 58(Suppl S29)1-464.

Epistaxis

Becker, Walter: Hals-Nasen-Ohren-Heilkunde.

Stuttgart; New York: Thieme 1989

Naumann, Hans-Heinz, Scherer, Hans Hermann (Hrsg.): Differentialdiagnostik in der Hals-Nasen-Ohrenheilkunde. Stuttgart; New York: Thieme, 1998

Strutz, Jürgen; Mann Wolf (Hrsg.): Praxis der HNO-Heilkunde, Kopf- und Halschirurgie. Stuttgart; New York: Thieme, 2001

Vertiges, nystagmus - Schwindel/Nystagmus

Coquoz E. Le vertige et le praticien. Rev Med Suisse Rom 1993; 113: 999-1002.

Liard P. et al. (ed.). Les vertiges. Karger 1993.

Vibert D, Teppa H, Häusler R. Le traitement médicamenteux des vertiges. Rev Med Suisse Rom 1993; 113: 685-8.

Vibert D. Le traitement physiothérapeutique des vertiges. Rev Med Suisse Rom 1993; 113: 689-91.

Hotson JR, Baloh RW. Acute vestibular syndrome. N Engl J Med 1998; 339: 680-5.

Minor LD. Superior canal dehiscence syndrome. Am J Otol 2000; 21: 9-19.

Brandt T. Vertigo, dizziness and falls in the elderly. In: Vertigo, its multisensory syndromes, London: Springer-Verlag 1999: 385-92.

Fontana PE, Zekry D, Gold G. Vertiges: De la plainte au diagnostic. Med Hyg 1999; 57: 2221-7.

Marill KA, Walsh MJ, Nelson BK. Intravenous lorazepam versus dimenhydrinate for treatment of vertigo in the emergency department: a randomized clinical trial. Ann Emerg Med 2000; 36: 310-9.

Irvine C, Richman P, Kaifas C, et al. Intramuscular droperidol versus intramuscular dimenhydrinate for the treatment of acute peripheral vertigo in the emergency department: a randomized clinical trial. Acad Emerg Med 2002; 9: 650-3.

Baloh RW. Vestibular neuritis. N Engl J Med 2003; 348: 1027-32.

Neuhauser, H. K. Epidemiology of vertigo. Curr Opin Neurol 2007; 20: 40-46.

Kattah JC, Talkad AV, Wang DZ et al.: HINTS to diagnose stroke in the acute vestibular syndrome: three-step bedside oculomotor examination more sensitive than early MRI diffusion-weighted imaging. Stroke 2009; 40: 3504-10.

Tarututzer AA, Berkowitz AL, Robinson KA, et al.: Does my dizzy patient have a stroke? A systematic review of bedside diagnosis in acute vestibular syndrome. CMAJ 2011; 183:E571-92.

Tarututzer AA, Berkowitz AL, Robinson KA, et al.: Does my dizzy patient have a stroke? A systematic review of bedside diagnosis in acute vestibular syndrome. CMAJ 2011; 183:E571-92.

Newman-Toker DE, Saber Tehrani AS, Mantokoudis G et al.: Quantitative video-oculography to

help diagnose stroke in acute vertigo and dizziness: toward an ECG for the eyes. Stroke 2013; 44: 1158Y61.

Saber Tehrani AS, Kattah JC, Mantokoudis G et al.: Small strokes causing severe vertigo: frequency of false-negative MRIs and nonlacunar mechanisms. Neurology 2014; 83: 169-73.

Guyot J-P. La neuro-otologie pour le praticien. Rev Med Suisse 2015; 11: 249-50.

Mantokoudis G, Tehrani AS., Wozniak A .et al.: VOR gain by head impulse video-oculography differentiates acute vestibular neuritis from stroke. Otol Neurotol 2015 36:457-65.

Zamaro E, Vibert D, Caversaccio M, Mantokoudis G. «HINTS» bei akutem Schwindel: peripher oder zentral? Schweiz Med Forum 2016; 16: 21-23.

FL. Wuyts, V. Van Rompaey, LK Maes. «SO STONED»: Common Sense Approach of the Dizzy Patient. Front Surg 2016; 3: 32.

Névralgie du trijumeaux

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalgia 2018; 38:1-211.

Vertige positionnel paroxystique bénin

Beigner positioneller Lagerungsschwindel BPLS

Dix MR, Hallpike CS. The pathology, symptomatology and diagnosis of certain disorders of the vestibular system. Proc R Soc Med 1952; 45: 341-54.

Semont A, Freyss G, Witte E. Vertiges positionnels paroxystiques bénins et manœuvre libératoire. Ann Otolaryngol (Paris) 1980; 1096: 473-6.

Semont A, Freyss G, Witte E. Curing the BPPV with a liberatory maneuver. Adv Otorhinolaryngol 1988; 42: 290-293.

Semont A. Le vertige paroxystique bénin. In: Le traitement des troubles vestibulaires. Mémoire. Bibliothèque nationale de Paris, 1984.

Zumstein V, Reglin F. Nystagmus positionnel. In: Les vertiges. Zumstein V, Regli F. 1990; p: 15-16.

Hermann SJ, Tusa RJ, Zee DS et al. Single treatment approaches to benign paroxysmal positional vertigo. Arch Otolaryngol Head Neck Surg 1993; 119:450-454.

Epley JM. Particle repositioning for benign paroxysmal positional vertigo. Otolaryngol Clin North Am 1996; 29: 323-31.

Serafini G, Palmieri AMR, Simincelli C. Benign paroxysmal positional vertigo of posterior semicircular canal: Results in 160 cases treated with Semont's maneuver. Ann Otol Rhinol Laryngol 1996; 105: 770-775.

Furman JM, Cass SP. Primary care: Benigne paroxysmal positional vertigo. N Engl J Med 1999; 341; 1590-6.

von Brevern M, Lempert T. Benigner paroxysmaler Lagerungsschwindel. Nervenarzt 2004; 75: 1027-36.

Maladie WALLENBERG

- Frumkin LR, Baloh RW. Wallenberg's syndrome following a neck manipulation. *Neurology* 1990; 40: 611-5.
- Rigueiro-Veloso MT, Pego-Reigosa R, Branas-Fernandez F, et al. Wallenberg syndrome: a review of 25 cases. *Rev Neurol* 1997; 25: 1561-4.
- Dinichert A, Rufenacht DA, Trbolet N. Dissecting aneurysms of the posterior inferior cerebellar artery: report of four cases and review of the literature. *J Clin Neurosci* 2000; 7: 151-20.

Maladie de Ménière

- Ménière P. Pathologie auriculaire: mémoire sur les lésions de l'oreille interne donnant lieu à des symptômes de congestion cérébrale apoplectiforme. *Gaz Med Pars* 1861; 16: 597-601.
- Saeed SR. Diagnosis and treatment of Ménière's disease. *BMJ* 1998; 316: 368-72.
- Lopez-Escamez JA, Carey J, Chung WH, Goebel JA, Magnusson M, Mandala M, Newman-Toker DE, Strupp M, Suzuki M, Trabalski F, Bisdorff A. Diagnostic criteria for Menière's disease. *J Vest Res* 2015; 25:1-7.

Déficit cochléo-vestibulaire aigu

- Wilson WR, Byl FM, Laird N. The efficacy of steroids in the treatment of idiopathic sudden hearing loss. A double-blind clinical study. *Arch Otolaryngol* 1980; 106: 772-6.
- Hotson JR, Baloh RW. Acute vestibular syndrome. *N Engl J Med* 1998; 339: 680-5.
- Ogawa K, Takei S, Inoue Y, Kanzaki J. Effect of prostaglandin E1 on idiopathic sudden sensorineural hearing loss: a double-blinded clinical study. *Otol Neurotol* 2002; 23: 665-8.
- Suzuki H, Furukawa M, Kumagai M, et al. Defibrinogenation therapy for idiopathic sudden sensorineural hearing loss in comparison with high-dose steroid therapy. *Acta Otolaryngol* 2003; 123: 46-50.

Épiglottite

- Carey MJ. Epiglottitis in adults. *Am J Emerg Med* 1996; 14: 421-4.
- Hebert PC, Ducic Y, Boisvert D, et al. Adult epiglottitis in a Canadian setting. *Laryngoscope* 1998; 108: 64-9.
- Nakamura H, Tanaka H, Matsuda A, et al. Acute epiglottitis: a review of 80 patients. *J Laryngol Otol* 2001; 5: 31-4.
- Templier F, Lentz T, Tazarourte K, et al. Benefit of pharmaceutical anti-oedematous treatment in acute adult epiglottitis. *Ann Fr Anesth Reanim* 2004; 23: 1003-6.
- Simon M, Cour M, Argaud L. Épiglottites aiguës sévères de l'adulte Severe Adult Acute Epiglottitis. *Réanimation* 2016; 25: S62-S68.

Rhinosinusite

- Hamory BH, Sande MA, Sydnor A, et al. Etiology and antimicrobial therapy of acute maxillary sinusitis. *J Infect Dis* 1979; 139: 197-202.
- Berg O, Carenfelt C, Rystedt G, et al. Occurrence of asymptomatic sinusitis in common cold and other acute ENT-infections. *Rhinology* 1986; 24: 223-5.
- Gwaltney JM, Phillips CD, Miller RD, et al. Com-

puted tomographic study of the common cold. *N Engl J Med* 1994; 330: 25-30.

Gwaltney JM. Acute community-acquired sinusitis. *Clin Infect Dis* 1996; 23: 1209-25.

Puhakka T, Makela MJ, Alanen A, et al. Sinusitis in the common cold. *J Allergy Clin Immunol* 1998; 102: 403-8.

Hickner JM, Bartlett JG, Besser RE, et al. Principles of appropriate antibiotic use for acute rhinosinusitis in adults: background. *Ann Intern Med* 2001; 134: 498-505.

Gilbert DN, Moellering RC, Sande MA. The Sanford Guide to antimicrobial therapy; 2003.

Piccirillo JF. Acute Bacterial Sinusitis. *New Engl J Med* 2004; 351: 902-10.

Fokkens WJ, Lund VJ, Mullol J et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. *Rhinology* 2012; 50: 1-12.

Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. *Otolaryngol Head Neck Surg* 2015; 152 (2 Suppl): S1-S39.

PSYCHIATRIE - Geriatrie

Délir (Delirium)

Kahn RL, Goldfarb AI, Pollack M, Peck A: Brief objective measures for the determination of mental status in the aged. *Am J Psychiatry* 1960; 117: 326-328.

Thomas C, Kreisel SH, Oster P, et al. Diagnosing delirium in older hospitalized adults with dementia: adapting the confusion assessment method to international classification of diseases, tenth revision, diagnostic criteria. *J Am Geriatr Soc* 2012; 60: 1471-7.

Grossmann FF, Hasemann W, Gruber A, et al. Screening, detection and management of delirium in the emergency department - a pilot study on the feasibility of a new algorithm for use in older emergency department patients: the modified Confusion Assessment Method for the Emergency Department (mCAM-ED). *Scand J Trauma Resusc Emerg Med* 2014; 22: 19.

Hasemann W, Grossmann FF, Stalder R, et al. Screening and detection of delirium in older ED patients: performance of the modified Confusion Assessment Method for the Emergency Department (mCAM-ED). A two-step tool. *Intern Emerg Med* 2018; 13: 915-922.

Troubles neurocognitifs

Neurokognitive Störung (früher Demenz)

Hughes CP, Berg L, Danziger WL, et al. A new clinical scale for the staging of dementia. *Br J Psychiatry* 1982; 140: 566-72.

Inouye SK, van Dyk CH, Alessi CA. Clarifying Confusion: The Confusion Assessment Method. *Ann Intern Med* 1990; 113: 941-8.

Bennett DA, Wilson RS, Gilley DW, et al. Clinical diagnosis of Binswanger's disease. *J Neurosurg Psychiatry* 1991; 54: 1122-3.

American Psychiatric Association Diagnostic and

- Statistical Manual, 4th edition, APA Press, Washington DC, 1994.
- Canadian study of health and aging working group. Canadian study of health and aging: study methods and prevalence of dementia. *Can Med Assoc J* 1994; 150: 899-913.
- Cummings JL, Mega MS, Gray K et al. The neuropsychiatric inventory: Comprehensive assessment of psychopathology in dementia. *Neurology* 1994; 44: 2308-14.
- Rosen J, Burgio L, Kollar M, et al. A user-friendly instrument for rating agitation in dementia patients. *Am J Geriatr Psychiatry* 1994; 2: 52-9.
- Giannakopoulos P, et al. Démences et détérioration. Pathologie Médicale. Masson, 1995; 2: 405-17.
- Giannakopoulos P, et al. Confusion mentale. Pathologie Médicale. Masson, 1995; 2: 418-28.
- Polvikoski T, Sulkava R, Haltia M, et al. Apolipoprotein E, Dementia, and cortical deposition of beta-amyloid protein: *N Engl J Med* 1995; 333: 1242-7.
- Diagnostisches und statistisches Manual psychischer Störungen DSM-IV. Göttingen: Hogrefe-Verlag; 1996.
- McKeith LG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. *Neurology* 1996; 47: 113-24.
- Snowdon DA, Greiner LH, Mortimer JA, et al. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. *JAMA* 1997; 277: 813-7.
- Hock C, Müller-Spahn F. Verwirrtheitszustände im Alter. *Schweiz Rundsch Med Prax* 1999; 88: 998-1006.
- Inouye SK, Bogardus ST, Charpentier PA, et al. A multicomponent intervention to prevent delirium in hospitalized older patients. *N Engl J Med* 1999; 340: 669-76.
- Tariot PN, Erb R, Podgorski CA, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. *Am J Psychiatry* 1998; 155: 54-61.
- Moroney JT, Tang MX, Berglund L, et al. Low-density lipoprotein cholesterol and the risk of dementia with stroke. *JAMA* 1999; 282: 254-60.
- Ott A, Stolk RP, van Harskamp F, et al. Diabetes mellitus and the risk of dementia: The Rotterdam Study. *Neurology* 1999; 53: 1937-42.
- Gifford DR, Holloway RG, Vickrey BG: Systematic review of clinical prediction rules for neuroimaging in the evaluation of dementia. *Arch Intern Med* 2000; 160: 2855-62.
- Gregg EW, Yaffe K, Cauley JA, et al. Is diabetes associated with cognitive impairment and cognitive decline among older women? Study of osteoporotic fractures research group. *Arch Intern Med* 2000; 160: 174-80.
- Sisco F, Taurel M, Lafont V, et al. Troubles du comportement chez les sujets déments en institution: évaluation à partir de l'inventaire Neuro-psychiatrique pour les équipes soignantes. *L'Année Gérontologique* 2000; 14: 151-71.
- Seshadri S, Beiser A, Selhub J, et al. Plasma ho-
- mocysteine as a risk factor for dementia and Alzheimer's disease. *N Engl J Med* 2002; 346: 476-83.
- Vergheze J, Lipton RB, Hall CB, et al. Abnormality of gait as a predictor factor of non-Alzheimer's dementia. *N Engl J Med* 2002; 347: 1761-8.
- Ely EW, Truman B, Shintani A, et al. Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond Agitation-Sedation Scale (RASS). *JAMA* 2003; 289: 2983-91.
- Reisberg B, Doddy R, Stöffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. *N Engl J Med* 2003; 348: 1331-41.
- Wancata J, Windhaber J, Krautgartner M, et al. The consequences of non-cognitive symptoms of dementia in medical hospital departments. *Int J Psychiatry Med* 2003; 33: 257-1.
- Tariot PN, Farlow R, Frossberg FT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. *KAMA* 2004; 291: 317-24.
- Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc* 2005; 53: 695-9.
- American Academy of Clinical Neuropsychology (AACN) practice guidelines for neuropsychological assessment and consultation. *Clin Neuropsychol* 2007; 21: 209-31.
- Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. *Lancet Neurol* 2007; 6: 734-46.
- Dubois B, Picard G, Sarazin M. Early detection of Alzheimer's disease: new diagnostic criteria. *Dialogues Clin Neurosci* 2009; 11:135-9.
- Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* 2011; 7: 270-9.
- McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* 2011; 7: 263-9.
- Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* 2011; 7: 280-92.
- Chester JG, Beth Harrington M, Rudolph JL. Serial administration of a modified Richmond Agitation and Sedation Scale for delirium screening. *Br J Hosp Med* 2012; 7: 450-3.
- Gold G, Fazio L, Hua Stoltz J. Evaluation du comportement en milieu somatique: utilisation d'une méthode simple et fiable. *Rev Med Suisse* 2012; 8: 2119-21.
- Soto ME, Andrieu S, Villars H, et al. Improving

- care of older adults with dementia : Description of 6299 hospitalizations over 11 years. *J Am Med Dir Assoc* 2012; 13: 486.e1-6.
- Cummings JL, Dubois B, Molinuevo JL et al. International Work Group criteria for the diagnosis of Alzheimer disease. *Med Clin North Am* 2013; 97: 363-8.
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, VA, American Psychiatric Association 2013.
- Dubois B, Hampel H, Feldman HH. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. *Alzheimers Dement* 2016; 12: 292-323.
- Petersen RC, Lopez O, Armstrong MJ et al. Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology* 2018; 90: 126-135.
- De Roeck EE, De Deyn PP, Dierckx E et al. Brief cognitive screening instruments for early detection of Alzheimer's disease: a systematic review. *Alzheimers Res Ther* 2019; 11: 21.
- Neuropsychologisches Assessment**
- Folstein MF, Folstein SE, McHugh PR. Mini-mental state: A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res* 1975; 12: 189-198.
- Nasreddine ZS, Phillips NA, Bédirian V et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc* 2005; 53: 695-9.
- American Academy of Clinical Neuropsychology (AACN) practice guidelines for neuropsychological assessment and consultation. *Clin Neuropsychol* 2007; 21: 209-31.
- Petersen RC, Lopez O, Armstrong MJ et al. Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology* 2018; 90: 126-135.
- MoCA-Test®**
- Nasreddine ZS, Phillips NA, Bédirian V et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc* 2005; 53: 695-9.
- MMS (Mini-mental state Test)**
- Folstein MF, Folstein SE, McHugh PR. Mini-mental state: A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res* 1975; 12: 189-198.
- Delirium tremens**
- Lipowski ZJ. Transient cognitive disorders (delirium, acute confusional states) in the elderly. *Am J Psychiatry* 1983; 140: 1426-36.
- Erkinjuntti T, et al. Dementia among medical inpatients: evaluation of 2000 consecutive admissions. *Arch Intern Med* 1986; 146: 1923-6.
- Lipowski ZL. Delirium in the elderly patient. *N Engl J Med* 1989; 320: 578-82.
- CIM-10/ICD-10: Classification internationale des troubles mentaux et des troubles du comportement. Organisation Mondiale de la Santé, Genève, Paris, Masson, 1993, p: 1-305.
- Brust JC. Agitation and delirium. In: Bogousslavsky J, Caplan L, (eds.). *Stroke syndromes*. Cambridge: Cambridge Univ Press 1995: 134-9.
- DSM-IV: Manuel diagnostique et statistique des troubles mentaux. Traduction française coordonnée par Guelfi JD, Paris, Masson, 1-1008, 1996.
- Ghika J. Delirium chez la personne âgée. *Med Hyg* 1997; 55: 1037-41.
- Winterhalter G, Ferrero F, Bertschy G. Syndrome de sevrage: alcool, médicaments, drogues. In: Restellini A, et al. (éd.). *Urgences Médicales*. Editions Médecine et Hygiène, 1997, p: 455-60.
- Young J, Inouye SK. Delirium in older people. *BMJ* 2007; 334: 842-6.
- Maldonado JR, Sher Y, Das S, et al. Prospective Validation Study of the Prediction of Alcohol Withdrawal Severity Scale (PAWSS) in Medically Ill Inpatients: A New Scale for the Prediction of Complicated Alcohol Withdrawal Syndrome. *Alcohol and Alcoholism* 2015; 50: 509-18.
- Wood E, MD, Albarqouni L, Tkachuk S et al. Will This Hospitalized Patient Develop Severe AlcoholWithdrawal Syndrome? The Rational Clinical Examination Systematic Review. *JAMA* 2018; 320: 825-33.
- Confusion Assessment Method (CAM)**
- Inouye SK, Bogardus ST, Charpentier PA, et al. A multicomponent intervention to prevent delirium in hospitalized older patients. *N Engl J Med* 1999; 340: 669-76.
- Richmond Scale**
- Ely EW, Truman B, Shintani A, et al. Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond Agitation-Sedation Scale (RASS). *JAMA* 2003; 289: 2983-91.
- Mini-mental state (FOLSTEIN)**
- Folstein MF, Folstein SE, McHugh PR. «Mini-mental state»: a practical method for grading the cognitive state of patients for the clinician. *J Psych Res* 1975; 12: 189-98.
- État dépressif, trbl. panique**
- CIM-10/ICD-10: Classification internationale des troubles mentaux et des troubles du comportement. Organisation Mondiale de la Santé, Genève, Paris, Masson, 1-305, 1993.
- Hirschfeld RM. Guidelines for the longterm treatment of depression. *J Clin Psych* 1994; 55(Suppl.): 61-9.
- DSM-IV: Manuel diagnostique et statistique des troubles mentaux. Traduction française coordonnée par Guelfi JD, Paris, Masson, 1-1008, 1996.
- Culpepper L. Escitalopram: a new SSRI for the treatment of depression in primary care. *Primary Care Companion J Clin Psychiatry* 2002; 4: 209-14.

Maladie d'ALZHEIMER

- Mckhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease. *Neurology* 1984; 34: 939-44.
- Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer's disease in a community population of older persons: higher than previously reported. *JAMA* 1989; 262: 2551-6.
- Reisberg B, Schneider, Doody R, et al. Clinical global measures of dementia: position paper from the International Work Group on Harmonization of Dementia Drug Guidelines. *Alzheimer Dis Assoc Disord* 1997; 11 (Suppl.3): S8-S18.
- Giacobini E. Cholinergic foundations of Alzheimer's disease therapy. *J Physiol Paris* 1998; 92: 283-7.
- Mayeux R, Sano M. Treatment of Alzheimer's disease. *N Engl J Med* 1999; 341: 1670-9.
- Zekry D, Fontana P, Laszlo A. La prise en charge médicamenteuse de la maladie d'Alzheimer. *Med Hyg* 1999; 57: 2210-4.
- Seshadri S, Beiser A, Selhub J, et al. Plasma Homocysteine as a risk factor for dementia and Alzheimer's disease. *N Engl J Med* 2002; 346: 476-83.
- McKhann GM, Knopman DS, Chertkow H et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement*. 2011; 7: 263-9.
- DSM-5, Manuel diagnostique et statistique des troubles mentaux. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.

Chute de la personne âgée - Sturz im Alter

- Podsiadlo D, Richardson S. Tire Timed «Up & Go»: A test of basic functional mobility for frail elderly persons. *Am Geriatr Soc* 1991; 39:142-8.
- Duncan PW, Studenski S, Chandler S et al. Functional reach: predictive validity in a sample of elderly male veterans. *J Gerontol A Biol Sci Med Sci* 1992; 47: M93-98.
- Baraff LJ, Della Penna R, Williams N et al. Practice Guideline for the ED management of falls in community dwelling elder persons. *Ann Emerg Med* 1997; 30: 480-9.
- Sloan JP. Protocols in primary care geriatrics. 2d ed. New York: Springer, 1997
- Tinetti ME, Baker DL, Dutcher J, Vincent JE, Rosett RT. Reducing the risk of falls among older adults in the community. Berkeley, CA: Peaceable Kingdom Press, 1997.
- Man-Son-Hing M, Nichol G, Lau A et al. Choosing Antithrombotic Therapy for Elderly Patients With Atrial Fibrillation Who Are at Risk for Falls. *Arch Intern Med*. 1999;159:677-85.
- American Geriatrics Society, British Geriatrics Society and American Academy of Orthopaedic Surgeons Panel on Fall Prevention. Guidelines for the Prevention of Falls in older Persons. *J Amer Geriatric Soc* 2001; 49: 664-72.
- Masud T, Morris RO. Epidemiology of falls. *Age and Ageing* 2001; 30:S4: 3-7.

- Rubenstein LZ, Powers CM, MacLean CH. Quality Indicators for the Management and Prevention of Falls and Mobility Problems in vulnerable elders. *Ann Int Med*. 2001; 135(8): 686-93.
- Wettstein A, Conzelmann M, Heiss HW (Hrsg). Checkliste Geriatrie. Georg Thieme Verlag Stuttgart New York 2001.
- Ensru KE, Blackwell TL, Mangione CM et al. Central nervous system-active medications and risk for falls in older women. *J Am Geriatr Soc* 2002; 50: 1629-37.
- Grob D, Stuck AE. Der Sturz im Alter. In: *Medizinische Notfälle*. Thieme 2003; 439-47.
- Man-Son-Hing M, Laupacis A. Anticoagulant-Related Bleeding in Older Persons With Atrial Fibrillation. *Arch Intern Med* 2003; 163: 1580-86.
- Chang JT, Morton SC, Rubenstein LZ et al. Interventions for the prevention of falls in older adults: systematic review and meta-analysis of randomised clinical trials. *BMJ* 2004; 328: 680.

Ethanol – Alcool

- Jennet B, Gleave J, Wilson P. Brain death in three neurosurgical units. *BMJ* 1981; 282: 533-9.
- Pursell RA, Pudek M, Brubacher J, et al. Derivation and validation of a formula to calculate the contribution of the osmolal gap. *Ann Emerg Med* 2001; 38: 653-9.

Bilan azoté

- Lee HA, et al. A method of determining daily nitrogen requirements. *Postgrad Med J* 1975; 51: 441-5.
- Protein and energy requirements: a joint FAO/WHO memorandum. *Bull World Health Organ* 1979; 57: 65-79.

Park GR. Rapid calculation of nitrogen losses. *Intensive Care Med* 1980; 6: 243-4.

Scrimshaw NS. Criteria for valid nitrogen balance measurement of protein requirements. *Eur J Clin Nutr* 1996; 50 (Suppl 1): S196-7.

Calcium

- Messaï E, (ed.). In: *Guide des chiffres et formules utiles en pratique médicale*. Arnette Blackwell, 1995, p: 38.

Chlore: déficit

- Brimioulle S Vincent JL, Dufaye P, et al. Hydrochloric acid infusion for treatment of metabolic alkalosis: effects on acid-base balance and oxygenation. *Crit Care Med* 1985; 13: 738-42.

Clairance (créatinine, eau libre, Hb), osmolalité

- Smith HW. The kidney: structure and function in health and disease. Oxford University Press, New York 1951, 231-238.

Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. *Nephron* 1976; 16: 31-41.

National Kidney Foundation (NFK) Kidney Disease Outcome Quality Initiative (K/DOQI) Advisory Board. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney*

- Dis 2002; 39 (Suppl. 2): S1-S246.
- Cameron J, Greger R. Renal function and testing of function, in AM Davidson, JS Cameron, JP Grunfeld, et al., Oxford textbook of clinical nephrology. Oxford University Press Oxford 1998, 39-69.
- Rahn KH, Heidenreich S, Bruckner D. How to assess glomerular function and damage in humans. *J Hypertens* 1999; p. 309-317.
- Fer**
- Working group on fortification of salt with iron: Use of common salt fortified with iron in the control and prevention of anemia – a collaborative study. *Am J Clin Nutr* 1982; 35: 1442.
- Crosby WH, O'Neil-Cutting MA. A small-dose iron tolerance test as indicator of mild iron deficiency. *JAMA* 1984; 251: 1986-7.
- Lee R, et al. (eds.). Clinical hematology. 1993, Lea & Febiger.
- Wallach J. Interpretation of Diagnostic Tests. Little Brown, 1996.
- Ruedin P. Traitement de l'anémie liée à l'insuffisance rénale chronique. *Med Hyg* 1998; 56: 2081-4.
- Glycémie et HbA1c**
- Peters AL, Davidson MB, Schriger DL, et al. A clinical approach for the diagnosis of diabetes mellitus: an analysis using glycated hemoglobin levels. *JAMA* 1996; 276: 1246-52.
- Gradient: albumine sérum-ascite**
- Reynolds TB, Ito S, Iwatsuki S. Measurement of portal pressure and its clinical application. *Am J Med* 1970; 49: 649-57.
- Runyon BA. Care of patients with ascites. *N Engl J Med* 1994; 330: 337-42.
- LDL-Cholestérol**
- Friedewald WT, Levy RL, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge. *Clinical Chemistry* 1972; 18: 499-502.
- Recommendations of the Second Joint Task Force of European and other Societies on coronary Prevention. Prevention of coronary heart disease in clinical practice. *Eur Heart J* 1998; 19: 1434-1503.
- Osmolalité**
- Truniger B, Briner V. Troubles du bilan acqueux. *Forum Med Suisse* 2001; N° 1:779-83.
- PARKLAND**
- Scheulen JJ, Munster AM. The Parkland formula in patient with burns and inhalation injury. *J Trauma* 1982; 22: 869-71.
- Poids idéal, indice de la masse corporelle**
- Bray GA, et al. Evaluation of the obese patient. *JAMA* 1976; 235: 1447.
- Physical status: the use and interpretation of anthropometry: report of a WHO expert committee. WHO Tech Rep Ser 1995; 854: 1-452.
- International Obesity Task Force (IOTF). Obesity: preventing and managing the global epidemic.
- Report of a WHO consultation on obesity. Geneva, 3-5 June, 1997 (WHO/NUT/NCD/97.2).
- Calle EE, Thun MJ, Petrelli JM, et al. Body-mass index and mortality in a prospective cohort on U.S. adults. *N Engl J Med* 1999; 341: 1097-1105.
- Pression artérielle moyenne**
- Hall JB, Schmidt GA, Wood LDH, (eds.). Principles of critical care. McGraw-Hill, 1998.
- Sodium: déficit, natrémie corrigée, fraction d'extraction**
- Steffes MW, Freier EF. A simple and precise method of determining true sodium, potassium and chloride concentrations in hyperlipidemia. *J Lab Clin Med* 1976; 88: 683-88.
- Oh MS, Carroll HJ. Regulation of intracellular and extracellular volume. In: Arieff AI, DeFronzo RA (eds.). Fluid, electrolyte, and acid-base disorders. 2nd edition New York: Churchill Livingstone, 1995; 1-28.
- Vitesse de sédimentation**
- Gilbertsen VA. Erythrocyte sedimentation rates in older patients. *Postgrad Med* 1965; 38: A44-A52.
- Bottiger LE, Svedberg CA. Normal erythrocyte sedimentation rate and age. *Br Med J* 1967; 2: 85-7.
- Miller A, Green M, Robinson D. Simple rule for calculating normal erythrocyte sedimentation rate. *Br Med J* 1983; 2: 266.
- Bedell SE, et al. Erythrocyte sedimentation rate. *Am J Med* 1985; 78: 1001-9.
- Sox HC, Liang MH. The erythrocyte sedimentation rate. Guidelines for rational use. *Ann Intern Med* 1986; 104: 515-23.
- Lessing HP, Delmenico S. Une vitesse de sédimentation augmentée. *Schweiz Med Forum* 2007; 7: 765-9.
- RADIOLOGIE**
- NET: www.MRIsafety.com
- TEXTBOOK: Meire H, Cosgrove D, Dewburg K, et al. (ed.). Clinical ultrasound, a comprehensive text. Churchill Livingstone 2001.
- Échographie, échocardiographie**
- Gladisch R. (ed.). Praxis der abdominellen Ultraschalldiagnostik. Schlatter, 1992.
- Coady MA, Rizzo JA, Hammond GL, et al. What is the appropriate size criterion for resection of thoracic aortic aneurysms? *J Thorax Cardiovasc Surg* 1997; 1113: 476-91.
- Deuzat M. (ed.). Ultatrasonographie vasculaire diagnostic. Viogt, 1991.
- Mylonakis E, Calderwood SB. Infective endocarditis in adults. *N Engl J Med* 2001; 345: 1318-30.
- Anévrisme aortique**
- Juvonen T, Ergin MA, Galla JD, et al. Prospective study of the natural history of thoracic aortic aneurysms. *Ann Thorac Surg* 1997; 63: 1533-45.
- Patel HJ, Deeb GM. Ascending and arch aorta. Pathology, natural history and treatment. Circu-

lation 2008; 118: 188-95.

Radiographie standard, thorax

Fleischner FG, Udis SW. Dilatation of the azygos veins, a roentgen sign of venous engorgement. Am J Roentgenol 1952; 67: 659-75.
Chang CH. The normal roentgenographic measurement of the right descending pulmonary artery. Am J Roentgenol 1962; 87: 929-35.

Felson B. (ed.). Principles of chest roentgenology. Saunders 1974.

Conrad PA, Goodman LR, Lainge F, et al. Alteration of endotracheal tube position: flexion and extension of the neck. Crit Care Med 1976; 4: 7-12.

Bismuth V, Bléry M, Rémy J, et al. Traité de radiodiagnostic. Tome IV. Appareil pulmonaire et médiastin. Masson, 1977.

Vasile N. (ed.). I.R.M. corps entier. Vigot, 1988.

Rich S, Chomka E, Hasara L, et al. The prevalence of pulmonary hypertension in the United States. Adult population estimates obtained from measurements of chest roentgenograms from the NHANES II Survey. Chest 1989; 96: 236-41.

Remy J, Caouëville R, Coussement A. Le poumon pathologique. Atlas de sémiologie radiologique. Arnet. Paris, 1990.

Bernadac P, Anthoine D, Hennequin L, et al. Poumon cardiaque. Editions techniques. Encycl Med Chir (Paris-France). Radiodiagnostic Coeur-Poumon-Larynx, 32489R10, 1991.

Armstrong P, Wastie ML. (eds.). Diagnostic Imaging. Blackwell, 1994.

Armstrong P, Wilson AG, Dee P, et al. (eds.). Imaging of diseases of the chest. Mosby 2000.

Muller N, Fraser R, Colman N, et al. Radiologic diagnosis of diseases of the chest. WB Saunders, 2001.

Divers

Steens RD, Summers QA, Tarala RA. Pulmonary alveolar proteinosis in association with Fanconi's anemia and psoriasis. A possible common pathogenetic mechanism. Chest 1992; 102: 637-8.

Eisenberg RL, Margulis AR (eds.). In: Radiology: What to order when. Lippincott - Raven, 1996.

Bonow RO et al. ACC/AHA guidelines for the management of patients with valvular heart disease. Circulation 1998; 98: 1949-84. Also published in: J Heart Valve Dis 1998; 7: 672-707 and JACC 1998; 32: 1486-588.

Webb R, Muller N, Naidich DP. (ed.). High-resolution CT of the lung. Lippincott Williams 2001.

Shellock FG, Crues JV. Commentary: MR safety and the american college of radiology white paper. Am J Roentgenol 2002; 178: 1349-52.

Nodule pulmonaire solitaire

Cummings SR, Lillington GA, Richard RJ. Estimating the probability of malignancy in solitary pulmonary nodules: a Bayesian approach. Am Rev Respir Dis 1986; 134: 449-52.

Swensen SJ, Silverstein MD, Edell ES, et al. Solitary pulmonary nodules: clinical prediction model versus physicians. Mayo Clin Proc 1999;

74: 319-29.

Henschke CI, Yanklevitz D, Westcott J, et al. Work-up of the solitary pulmonary nodule. Radiology 2000; 215: (Suppl.) 607-9.
Ost D, Fein AM, Feinsilver SH. The solitary pulmonary nodule. N Engl J Med 2003; 348: 2535-42.

Douleurs, Opioïdes

NET:

- www.douleur.ch
- www.palliative.org
- www.palliative.info
- www.doloplus.com

Twycross RG. Control of pain. J R Coll Physicians Lond 1984; 18: 32-9.

Foley KM. The treatment of cancer pain. N Engl J Med 1985; 313: 84-95.

World Health Organization (WHO). Cancer Pain Relief and Palliative Care: Report of a WHO Expert Committee. Geneva: WHO, 1986.

Wall PD, Melzack R. (eds.). Textbook of Pain. Churchill Livingstone, 1989.

Kunz KM, Thesien JA, Schroeder ME. Severe episodic pain: management with sublingual sufentanil. J Pain Symptom Manage 1993; 8: 189-90.

Koo D, Hall E, Motson R et al. Palliation of malignant intestinal obstruction using octreotide. Eur J Cancer 1994; 30A: 375-6.

Mercadante S, Lodi F, Sapiro M et al. Long-term ketamine subcutaneous continuous infusion in neuropathic cancer pain. J Pain Symptom Manage 1995; 10: 564-8.

Zech DFJ, Grond S, Lynch J, et al. Validation of World Health Organization guidelines for cancer pain relief: 10-year prospective study. Pain 1995; 63: 65-76.

Hanks GW, de Conno F, Ventafridda V, et al. Morphine in cancer pain: modes of administration. BMJ, 1996; 312: 823-26.

Levy MH. Pharmacologic treatment of cancer pain. N Engl J Med 1996; 335: 1124-32.

McQuay HJ, Tramér M, Nye BA, et al. A systematic review of antidepressants in neuropathic pain. Pain 1996; 68: 217-27.

Rosner H, Rubin L, Kestenbaum A et al. Gabapentin adjunctive therapy in neuropathic pain states. Clin J Pain 1996; 12: 56-8.

Manfredi PL, et al. (ed.). Comprehensive medical management: Opioid analgesia. In: Parris WCV, (ed.). Cancer Pain Management: Principles and Practice, Butterworth-Heinemann, 1997, p: 49-63.

Rosenberg JM, Harrell C, Ristic H, et al. The effect of gabapentin on neuropathic pain. Clin J Pain, 1997; 13: 251-55.

Tudela LL, et al. Protocolo de cuidados paliativos en atención primaria. Formación médica continua, 1997, p. 23.

Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus. JAMA, 1998; 280: 1831-36.

Hewitt DJ, Portenoy RK. Adjuvant drugs for neuropathic cancer pain. In: Portenoy RK, Bruera

- E (eds.). Topics in Palliative Care. Oxford University Press, New York Oxford 1998, p: 41-62.
- Collège des médecins du Québec. Traitement de la douleur: le point sur l'utilisation des narcotiques. QMC, décembre 1998.
- Grond St, Radbruch L, Meuser Th, et al. Assessment and treatment of neuropathic cancer pain following WHO guidelines. *Pain*; 1999; 79: 15-20.
- Portenoy RK, Lesage P. Management of cancer pain. *Lancet* 1999; 353: 1695-1700.
- Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms, and management. *Lancet* 1999; 353: 1959-64.
- Cavigelli A, Dietz V. Poststationäre Nachsorge bei Querschnittgelähmten: ausgewählte internistische Aspekte. *Schweiz Med Wochenschr* 2000; 130: 851-60.
- Guay DPR. Adjunctive agents in the management of chronic pain. *Pharmacotherapy* 2001; 21: 1070-81.
- Association des pharmaciens des établissements de santé du Québec. Guide pratique des soins palliatifs. 3ième édition 2002.
- Breitbart W, Chandler S, Engel B, et al. An alternative algorithm for dosing transdermal fentanyl for cancer-related pain. *Oncology* 2000;14: 695-705. Discussion 705, 709-17.
- Pereira J, Lawson P, Vigano A, et al. Equianalgesic dose ratios for opioids. A critical review and proposals for long-term dosing. *J Pain Symptom Manage* 2001; 22: 672-87.
- Bouhassira D, Attal N, Fermanian J et al. Development and validation of the Neuropathic Pain Symptom Inventory. *Pain* 2004; 108: 248-57.
- Mason L, Moore RA, Derry S, et al. Systematic review of topical capsaicin for the treatment of chronic pain. *BMJ* 2004; 328: 991.
- Bouhassira D, Attal N, Alchaar H et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). *Pain* 2005; 114: 29-36.
- Gilron I, Bailey JM, Tu D, et al. Morphine, Gabapentin, or Their Combination for Neuropathic Pain. *N Engl J Med* 2005; 352: 1324-34.
- Fiellin DA, Pantalon MV, Chawarski MC, et al. Counseling plus Buprenorphine-Naloxone Maintenance Therapy for Opioid Dependence. *N Engl J Med* 2006; 355: 365-74.
- Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. *Neurology* 2008; 70: 1630-5.
- Haanpää M, Treede RD. Diagnosis and classification of neuropathic pain. *Pain: Clin Updates* 2010; XVII;7.
- Wiese AD, Griffin MR, Schaffner W et al. Opioid Analgesic Use and Risk for Invasive Pneumococcal Diseases: A Nested Case-Control Study. *Ann Intern Med* 2018; 168: 396-404.
- general ophthalmology. Appleton & Lange, 1999.
- Trobe JD. (ed.). The physician's guide to eye care. American Academy of Ophthalmology, 2000.
- Décollement de la rétine**
- Asbury T, Vaughan D, Riordan-Eva P, (eds.). General ophthalmology. Appleton & Lange, 1999.
- Trobe JD. (ed.). The physician's guide to eye care. American Academy of Ophthalmology, 2000.
- Urologie**
- Prostate. Hyperplasie prost. bénigne**
- Berry SJ, Coffey DS, Walsh PC et al. The development of human benign prostatic hyperplasia with age. *J Urol* 1984; 132; 474-79.
- Chapple CR. Selective α1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience. *Eur Urol* 1996; 29: 129-67.
- Bosch JL, Hop WC, Kirkels WJ, Schröder FH. The International Prostate Symptom Score in a community-based sample of men between 55 and 74 years of age: prevalence and correlation of symptoms with age, prostate volume, flow rate and residual urine volume. *Br J Urol* 1995; 75: 622-30.
- Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride or both in benign prostatic hyperplasia. *N Engl J Med* 1996; 335: 533-9.
- Smith DS, Catalona WJ, Herschman JD. Longitudinal screening for prostate cancer with prostate specific-antigen. *JAMA* 1996; 276: 1309-15.
- Lieber MM. Pharmacologic therapy for prostate. *Mayo Clin Proc* 1998; 73: 590-6.
- Carter HB, Partin AW. Diagnosis and staging of prostate cancer. *Campbell's Urology*. Walsh PC, Retik AB, Vaughan ED, et al (eds.). WB Saunders 1998; 3: 2519.
- Lowe FC, Roehrbohm CG, Robertson C, et al. Meta-analysis of clinical trials of Permixon® (abstract). *J Urol* 1998; 159: 257.
- Carter HB, Pearson JD. Prostate-specific antigen testing for early diagnosis of prostate cancer: formulation of guidelines. *Urology* 1999; 54: 780-6.
- Kranse R, Beemsterboer P, Rietbergen J, et al. Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam region). *Prostate* 1999; 39: 316-22.
- Lowe FC, Fagelman E. Phytotherapy in the treatment of benign prostatic hyperplasia: an update. *Urology* 1999; 53: 671-8.
- Vallancien G. Alpha-blockers in benign prostatic hyperplasia. *Urology* 1999; 54: 773-5.
- Iselin C. Antigène spécifique de la prostate (PSA): quelle utilité clinique? *Med Hyg* 2000; 58: 1795-6.
- Barry MJ. Prostate-specific-antigen testing for early diagnosis of prostate cancer. *N Engl J Med* 2001; 344: 1373-7.

Ophtalmologie

Glaucome à angle fermé

Asbury T, Vaughan D, Riordan-Eva P, (eds.). Ge-

Thompson IM, Goodman PJ, Tangen CM, et al. The influence of Finasteride on the development of prostate cancer. *N Engl J Med* 2003; 349: 215-24.

Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. *N Engl J Med* 2003; 349: 366-81.

Punglia RS, D'Amico A, Catalona WJ, et al. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. *N Engl J Med* 2003; 349: 335-42.

Hyperactivité vésicale

Van Kerrebroeck P, Serment G, Dreher E. Clinical efficacy and safety of tolterodine compared to oxybutynin in patients with overactive bladder. *Neurorol Urodyn* 1997; 16: 478-9.

Ouslander JG. Management of overactive bladder. *N Engl J Med* 2004; 350: 786-99.

Incontinence urinaire

Hannestad YS, Rortveit G, Sandvik H. A community-based epidemiological survey of female urinary. *J Clin Epidemiol*. 2000; 53: 1150-7.

Abrams P et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. *Neurorol Urodyn* 2002; 21: 167-78.

Hunskaar S1, Burgio K, Diokno A. Epidemiology and natural history of urinary incontinence in women. *Urology* 2003; 62(4 Suppl 1): 16-23.

Brown JS, Bradley CS, Subak LL. Diagnostic Aspects of Incontinence Study (DAISy) Research Group. *Ann Intern Med* 2006; 144: 715-23.

Hunskaar S et al. The prevalence of urinary incontinence in women in four European countries. *BJU Int* 2004; 93: 324-30.

Anger JT et al. The prevalence of urinary incontinence among community dwelling adult women: results from the National Health and Nutrition Examination Survey. *J Urol* 2006; 175: 601-4.

Haab F, et al. Terminologie des troubles fonctionnels du bas appareil urinaire, adaptation française de la terminologie de l'International Continence Society. *Pelv Perineol* 2006; 1: 196-206.

Harris SS et al. Care seeking and treatment for urinary incontinence in a diverse population. *J Urol* 2007; 177: 680-4.

Liapis A, Bakas P, Creatsas G. Long-term efficacy of tension-free vaginal tape in the management of stress urinary incontinence in women: efficacy at 5- and 7-year follow-up. *Int Urogynecol J Pelvic Floor Dysfunct* 2008; 19: 1509-12.

Nygaard I, Barber MD, Burgio KL. Prevalence of symptomatic pelvic floor disorders in US women. *JAMA* 2008; 17; 300: 1311-6.

Ward RM et al. The impact of multichannel urodynamics upon treatment recommendations for female urinary incontinence. *Int Urogynecol J Pelvic Floor Dysfunct* 2008; 19: 1235-41.

Torsion testiculaire

Schalhamon J, Ainoedhofer H, Schleef J, et al. Management of acute scrotum in children - the im-

pact of Doppler ultrasound. *J Pediatr Surg* 2006; 41: 1377-80.

GYNECOLOGIE

Prééclampsie, HELLP-Syndrome

White WB. Management of hypertension during lactation. *Hypertension* 1984; 6: 297-300.

Sibai BM, Mabie WC, Shamsa F, et al. A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. *Am J Obstet Gynecol* 1990; 162: 960-7.

Paran E, Holzberg G, Mazor M, et al. Beta-adrenergic blocking agents in the treatment of pregnancy-induced hypertension. *Int J Clin Pharmacol Ther* 1995; 33: 119-23.

Hohlfeld P, Marty F, De Grandi P, et al. Le livre de l'inténe obstétrique. Médecine-Sciences Flammarion 1998.

Sibai BM. Treatment of hypertension in pregnant women. *N Engl J Med* 2000; 335: 257-65.

Umans JG, Lindheimer MD. Antihypertensive treatment. In: Hypertensive disorders in pregnancy. Lindheimer MD, et al (eds.). Appleton & Lange, Stamford 1999; p. 581-604.

Vogt B, Mohaupt M. Traitement de l'hypertension: cible sur le vieillard et la femme enceinte. *Forum* 2001; 22: 571-5.

Hypertension in pregnancy: Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. *Obstet Gynecol* 2013; 122:1122.

HELLP-Syndrome

Sibai BM, Ramadan MK, Usta I, et al. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). *Am J Obstet Gynecol* 1993; 169: 1000.

Hypertension artérielle et grossesse

Galery E. Hypertension in pregnancy: practical management recommendations. *Drugs* 1995; 49: 555-62.

Sibai BM. Treatment of hypertension in pregnant woman. *N Engl J Med* 1996; 335: 257-65.

Heleva ME, Burrows RF, Smith J, et al. Report of the Canadian hypertension society consensus conference: 1. Definitions, evaluations and classification of hypertensive disorders in pregnancy. *Can Med Assoc J* 1997; 157: 715-25.

Moutquin JM, Garner PR, Burrows RF, et al. Report of the Canadian consensus conference: 2. Nonpharmacologic management and prevention of hypertensive disorders in pregnancy. *Can Med Assoc J* 1997; 157: 907-19.

Rey E, LeLorier J, Burgess E, et al. Report of the Canadian hypertension society consensus conference: 3. pharmacologic treatment of hypertensive disorders in pregnancy. *Can Med Assoc J* 1997; 157: 1245-54.

Hauth JC, Ewell MG, Levine RJ et al. Pregnancy outcomes in healthy nulliparas who developed hypertension. Calcium for Preeclampsia Prevention Study Group. *Obstet Gynecol* 2000;

Buchbinder A, Sibai BM, Caritis S et al. Adverse perinatal outcomes are significantly higher in severe gestational hypertension than in mild preeclampsia. *Am J Obstet Gynecol* 2002; 186: 66.

Sibai BM. Diagnosis and management of gestational hypertension and preeclampsia. *Obstet Gynecol* 2003; 102: 181.

American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. *Obstet Gynecol* 2013; 122: 1122.

LABORATOIRE ET NORMES

Textbooks:

Berkow R. The Merck Manual of diagnosis and therapy. 16th ed. Merck & Co. Inc, 1992.

Jacobs DS, Demott, Grady, et al. Laboratory Test Handbook. 4th ed. Lexi-Comp, Inc., 1996.

Dufour R. Clinical of laboratory data. A practical guide. Lippincott Williams & Wilkins, 1998.

Wallach J. Interpretation of Diagnostic Tests. 7th ed. Lippincott Williams & Wilkins, 2000.

Braunwald E, Fauci, Kasper, et al. Harrison's 15th editions. Principles of International Medicine. Mc Graw-Hill, 2001.

Young DS. Effects of drugs on clinical laboratory tests. 5th ed. AACC Press, 2000.

Young DS. Effects of disease on clinical laboratory tests. 4th ed. AACC Press, 2001.

Laposata M. Laboratory medicine. Clinical pathology in the practice of medicine. ASCP Press, 2002.

Acide folique

Schnyder G, Roffi M, Pin R, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. *N Engl J Med* 2001; 335: 1593-1600.

ALAT, ASAT

Cohen JA, Kaplan MM. The SGOT/SGPT ratio - an indicator of alcoholic liver disease. *Dig Dis Sci* 1979; 24: 835-8.

Rej R. Aminotransferases in disease. *Clin lab Med* 1989 ;9: 667-87.

Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. *N Engl J Med* 2000 ;342: 1266-71.

Lee WM. Drug-induced hepatotoxicity. *N Engl J Med* 2003; 349: 474-85.

ANA

Tan EM, Feltkamp TE, Smolen JS, Butcher B, Dawkins R, Fritzler MJ, et al. Range of antinuclear antibodies in «healthy» individuals. *Arthritis Rheum* 1997; 40: 1601-11.

Solomon DH, Kavanaugh AJ, Schur PH, American College of Rheumatology Ad Hoc. Committee on Immunologic Testing Guidelines.

Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. *Arthritis Rheum* 2002; 47: 434.

Lassoued K, Coppo P, Gouilleux-Gruart V. Place des anticorps antinucléaires en pratique clinique? *Réanimation*. 2005;14:651-6.

Petitpierre S, Aubert V, Leimgruber A, Spertini F, Bart P-A. Utilité de la recherche des autoanticorps dans la pratique quotidienne. *Rev Med Suisse* 2009; 5: 823-31.

Agmon-Levin N, Damoiseaux J, Kallenberg C et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. *Ann Rheum Dis* 2014;73:17-23.

Chan EK, Damoiseaux J, Carballo OG, Conrad K, de Melo Cruvilin W, Francescantonio PL et al. Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns 2014–2015. *Front Immunol* 2015; 6: 412.

BNP

Cheng, V, Kazanagra J. A Rapid Bedside Test for B-Type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. *Am Coll Cardiol* 2001; 37: 386-91.

Dao Q, Krishnaswamy P, Kazanegra R, et al.: Utility of B-Type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. *J Am Coll Cardiol* 2001; 37: 379-85.

Koglin J, Pehlivani S, Schwaiblmair M, et al. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. *J Am Coll Cardiol* 2001; 38; 1934-41.

Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. *N Engl J Med*, 2001; 347, 161-7.

Hess OM, Suter T, Mohacs P. Editorial: Medikamentöse Therapie der Herinsuffizienz. *J Kardiol* 2002; 9: 167-8.

Maisel A. B-type natriuretic peptide measurements in diagnosing congestive heart failure in the dyspneic emergency department patient. *Rev Cardiovasc Med* 2002; 3 (Suppl. 4): S10-7.

Morrison LK, Harrison A, Krishnaswamy P, et al. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. *J Am Coll Cardiol* 2002; 39: 202-9.

Hohi CM, Mitelman BY, Wyer P, et al. Should emergency physicians use B-type natriuretic peptide testing in patients with unexplained dyspnea? *Can J Emerg Med* 2003; 5: 166-8.

Kuster GM, Tanner H, Printzen G, Suter TM, et al. B-type natriuretic peptide for diagnosis and treatment of congestive heart failure. *Swiss med wkly* 2003; 133: 623-8.

Mueller Ch, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. *N Engl J Med* 2004; 350: 647-54.

Bilirubine

Beck K. Icterus. Schattauer. Stuttgart 1968.

CK-MB

Ong L, Reiser P, et al. Left ventricular function

- and rapid release of creatine kinase MB in acute myocardial infarction. *N Engl J Med* 1983; 309: 1-6.
- Schifferli J. Intérêt clinique des isoenzymes de la créatine kinase. *Praxis* 1983; 18: 605-8.
- Lee T, Goldman L. Serum enzyme assays in the diagnosis of acute myocardial infarction. *Ann Intern Med* 1986; 105: 221-33.
- Lee TH, et al. Ruling-out acute myocardial infarction. A prospective multicenter validation of a 12 hour strategy for patients at low risk. *N Engl J Med* 1991; 324: 1239-46.
- CRP (C-réactive protéine)**
- Wallach J. Interpretation of Diagnostic Tests. Little Brown, 1996.
- Fauci A, Braunwald E, (eds.) et al. In: Harrison: Principles of Internal Medicine. 1998 Mc Graw Hill.
- Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. *Circulation* 2003; 107: 360-9.
- Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and markers of inflammation in the prediction of coronary heart disease. *N Engl J Med* 2004; 350: 1387-97.
- Butler CC, Gillespie D, White P et al. C-Reactive Protein Testing to Guide Antibiotic Prescribing for COPD Exacerbations. *NEJM* 2019; 381: 111-20.
- D-dimères**
- Perrier A, Desmarais S, Miron MJ, et al. Non-invasive diagnosis of venous thromboembolism in outpatients including clinical probability, D-dimer and ultrasonography. *Lancet* 1999; 353: 190-5.
- Kearon C, Ginsberg JS, Douketis J, et al. Management of suspected deep venous thrombosis in outpatients by using clinical assessment and D-dimer testing. *Ann Intern Med* 2001; 135: 108-11.
- Ferritin**
- Adams PC, Barton JC. A diagnostic approach to hyperferritinemia with a non-elevated transferrin saturation. *J Hepatol* 2011; 55: 453-58.
- Saglini V, Brissot P. Hyperferritinémie – Algorithme. *Rev Med Suisse* 2012; 8: 1135-7.
- Hémoglobine glycosilée (HbA1c)**
- The diabetes control and complications trial research group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. *N Engl J Med* 1993; 329: 977-86.
- UK Prospective diabetes study (UKPDS) group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. UKPDS group. *Lancet* 1998; 352: 837-53.
- Philippe J. L'hémoglobine glyquée (HbA1c). *Med Hyg* 2000; 58: 1800-1.
- Natriurétique peptide**
- Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. *N Engl J Med* 2002; 347: 161-7.
- Homocyst(e)ine**
- Nygard O, Nordrehaug JE, Refsum H, et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. *N Engl J Med* 1997; 337: 230-6.
- Maghadasi MH, McManus BM, Frohlich JJ. Homocyst(e)ine and coronary artery disease. *Arch Intern Med* 1997; 157: 2299-2308.
- Welch GN, Loscalzo J. Homocysteine and atherosclerosis. *N Engl J Med* 1998; 338: 1042-50.
- Martinetelli I, Taioli E, Bucciarelli P, Akhavan S, et al. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. *Arterioscler Thromb Vasc Biol* 1999; 19: 700-3.
- Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. *Lancet* 1999; 345: 407-13.
- Schnyder G, Roffi M, Pin R, et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. *N Engl J Med* 2001; 345: 1593-1600.
- Seshadri S, Beiser A, Selhub J, et al. Plasma Homocysteine as a risk factor for dementia and Alzheimer's disease. *N Engl J Med* 2002; 346: 476-83.
- Marqueurs tumoraux**
- Bates S. Clinical applications of serum tumor markers. *Ann Int Med* 1991; 115: 632-8.
- Raymond W, Norton RE, Norton SE. Use of biological markers in the diagnosis of cancer of unknown primary tumor. *Semin Oncol* 1993; 20: 251-60.
- Lovis C. Les marqueurs tumoraux. *Med Hyg* 1995; 53: 1038-48.
- Oxygène**
- O'Donohue WJ. Home oxygen therapy. *Clin Chest Med* 1997; 18: 535-45.
- Hall JB, Schmidt GA, Wood LDH, (eds.). Principles of critical care. McGraw-Hill, 1998.
- Rochat Th. Oxygénothérapie au long cours à domicile. *Med Hyg* 1998; 56: 2312-4.
- Anderhub AP, Bloch K, Breitenbüchler A, et al. Lignes directrices 2006 pour l'oxygénothérapie de longue durée à domicile. *Forum Med Suisse* 2007; 7: 87-90.
- Potassium**
- Whang R, Whang DD, Ryan MP. Refractory potassium deficiency. *Arch Intern Med* 1992; 152: 40-45.
- Cohn JN, Kowey PR, Whelton PK, et al. New Guidelines for potassium replacement in clinical practice. *Arch Intern Med* 2000; 160: 2429-36.
- Pancytopenie**
- Fauci A, Braunwald E, (eds.) et al. In: Harrison: Principles of Internal Medicine. 1998 Mc Graw Hill.
- Phosphatase alcaline**

Wallach J. Interpretation of Diagnostic Tests. Little Brown, 1996.

Polyglobulie

Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. *Blood* 2016; 127: 2391-2405.

Troponines

Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiac-specific troponin I levels to predict the risk of mortality on patients with acute coronary syndromes. *N Engl J Med* 1996; 335: 1342-9.
Wallach J. Interpretation of Diagnostic Tests. Little Brown, 1996.
Hamm CW, Goldmann BU, Heeschen C, et al. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. *N Engl J Med* 1997; 337: 1648-53.

Missow E, Calzolari C, Pau B. Circulating cardiac troponin I in severe congestive heart failure. *Circulation* 1997; 96: 2953-8.

Smith SC, Ladenson JH, Mason JW, et al. Elevations of cardiac troponin I associated with myocarditis: experimental and clinical correlates. *Circulation* 1997; 95: 163-8.

Hamm CW, Braunwald E. A classification of unstable angina revisited. *Circulation* 2000; 102: 118-22.

Goldberg RJ, Spencer FA, Fox KA, et al. Prehospital delay in patients with acute coronary syndromes (from the Global Registry of Acute Coronary Events [GRACE]). *Am J Cardiol* 2009; 103: 598-603.

Keller T, Zeller T, Peetz D, et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. *N Engl J Med*. 2009; 361: 868-877.

Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. *N Engl J Med* 2009; 361: 858-67.

Bandstein N, Ljung R, Johansson M, Holzmann MJ. Undetectable highsensitivity cardiac troponin T level in the emergency department and risk of myocardial infarction. *J Am Coll Cardiol* 2014; 63: 2569-78.

Klinkenberg LJ, van Dijk JW, Tan FE, et al. Circulating cardiac troponin T exhibits a diurnal rhythm. *J Am Coll Cardiol* 2014; 63: 1788-95.

Sherwood MW, Kristin Newby L. High-sensitivity troponin assays: evidence, indications, and reasonable use. *J Am Heart Assoc* 2014; 3:e000403.

Müller Ch, Kaufmann U, von Eckardstein A et al. Recommandation relative au changement d'unité de mesure pour la troponine cardiaque. *Swiss Med Forum* 2015; 15: 852-853.

Segraves JM, Fishman WH. Highly Sensitive Cardiac Troponin Assays. *Cardiology in Review* 2015;23: 282-289.

VDRL

Peeling RW, Ye H. Diagnostic tools for preventing and managing maternal and congenital syphilis:

an overview. *Bulletin of the World Health Organization* 2004; 82: 439-46.

Itin P, Bosshard PP, Toutous Trellu L, Schmidt AJ, Vernazza P, Tarr Ph et al. Syphilis: Diagnostik und Behandlung. *Schweiz Med Forum* 2015;15:459

Vitamine D

Forrest KYZ, Stuhldreher WL. Prevalence and correlates of vitamin D deficiency in US adults. *Nutr Res* 2011; 31(1): 48-54.

Vitesse de sédimentation (VS)

Gilbertsen VA. Erythrocyte sedimentation rates in older patients. *Postgrad Med* 1965; 38: A44-A52.

Bottiger LE, Svedberg CA. Normal erythrocyte sedimentation rate and age. *Br Med J* 1967; 2: 85-7.

Bedell SE, et al. Erythrocyte sedimentation rate. *Am J Med* 1985; 78: 1001-9.

Sox HC, Liang MH. The erythrocyte sedimentation rate. Guidelines for rational use. *Ann Intern Med* 1986; 104: 515-23.

Laboratoire: unités SI traditionnelles

Young DS. Standardized reporting of laboratory data. *N Engl J Med* 1974; 290: 368-73.

Le SI pour les professions de la santé. Genève OMS, 1978.

SI-Einheiten in der Medizin. Herbert Lippert. Urban & Schwarzenberg, München/ Wien/ Baltimore, 1978.

Lundberg GD, Iverson C, Radulescu G. Now read this: the SI units are here. *JAMA* 1986; 255: 2329-39.

Young DS. Implementation of SI units for clinical laboratory data. *Ann Intern Med* 1987; 106: 114-29.

PHARMACOLOGIE CLINIQUE Klinische Pharmakologie

Chernow B (ed). Essential of Critical Care Pharmacology. Williams & Wilkins, 1989.

Goodman & Gilman's The Pharmacological basis of therapeutics. McGrawHill, 1997.

Anderson PO, Knoben JE, Troutman WG (eds). Handbook of clinical drug data. Appleton & Lange1999.

Compendium des produits et spécialités pharmaceutiques (CPS). Association des pharmaciens du Canada, 2003.

Lacy CG, Armstrong LL, Lance LL (eds.). Drug information handbook. Lexi-Comp Inc 2002.

Antibiotiques - Antibiotika

Roger M, St-Antoine P, Coutlee F. Vancomycin-resistant enterococci in health care facilities. *N Engl J Med* 2001 ;345: 768-9.

Gilbert DN, Moellering RC, Sande MA. The Sanford Guide to antimicrobial therapy; 2003.

Allergie aux bétalactames

Weiss ME, Adkinson NF. Immediate hypersensitivity reactions to penicillin and related antibiotics. *Clin Allergy* 1988; 18: 515-40.

Shepherd GM. allergy to b-lactam antibiotics.

- Immunol Allergy Clin North Am 1991; 11: 611-33.
- Anderson JA. Allergic reactions to drugs and biological agents. JAMA 1992; 268: 2845-57.
- Lin RY. A perspective on penicillin allergy. Arch Intern Med 1992; 152: 930-7.
- Segreti J, Trenholme GM, Levin S. Antibiotic therapy in the allergic patient. Med Clin North Am 1995; 79: 935-42.
- Anticoagulation - Antikoagulantien**
- Cole MS, et al. Coumarin necrosis - a review of the literature. Surgery 1988; 103: 271-7.
- Smith P, Arneson H, Holme I. The effect of warfarin on mortality and reinfarction. N Engl J Med 1990; 323: 147-52.
- Hirsh J. Oral anticoagulant drugs. N Engl J Med 1991; 324: 1865-75.
- Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79: 1-17.
- Aster RH. Heparin-induced thrombocytopenia and thrombosis. N Engl J Med 1995; 332: 1374-6.
- Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333: 11-7.
- Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-5.
- Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337: 688-98. [Erratum: N Engl J Med 1997; 337: 1567].
- Fifth consensus conference on antithrombotic therapy (1998): summary recommendations. Chest 1998; 114 (Suppl.): 439S-769S.
- Recommendations of the Second Joint Task Force of European and other Societies on coronary Prevention. Prevention of coronary heart disease in clinical practice. Eur Heart J 1998; 19: 1434-1503.
- Kelton JG. The clinical management of heparin-induced thrombocytopenia. Semin Haematol 1999; 36(Suppl.1): 17-21.
- Raible MD. Hematologic complications of heparin-induced thrombocytopenia. Semin Haematol 1999; 25(Suppl.1): 17-21.
- Walenga JM, Jeske WP, Wood JJ, et al. Laboratory tests for heparin-induced Thrombocytopenia: a multicenter study. Semin Haematol 1999; 36(Suppl.1): 22-8.
- Verstraete M, Prentice CR, Samama M, et al. A European view on the North American fifth consensus on antithrombotic therapy. Chest 2000; 117: 1755-70.
- Hirsh J. New anticoagulants. Am Heart J 2001; 142 (2 Suppl.): S3-8.
- Sixth ACCP Consensus Conference on anti-thrombotic therapy. Chest 2001; 119 (Suppl. 1): 1S-336S.
- Dager WE, White RH. Treatment of heparin-induced thrombocytopenia. Ann Pharmacother 2002; 36: 489-503.
- Chong BH. Heparin-induced thrombocytopenia. J Thromb Haemost 2003; 1: 1471-8.
- Verma AK, Levine M, Shalansky SJ, et al. Frequency of heparin-induced thrombocytopenia in critical care patients. Pharmacotherapy 2003; 23: 745-53.
- Warkentin TE, Heddle NM. Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr Hematol Rep 2003; 2: 148-57.
- Vespa PM. Oral anticoagulants and the risk of intracranial hemorrhage. JAMA 2014; 312: 2562-3.
- Antidépresseurs - Antidepressiva**
- Calanca A, Bryois C, Buclin T, (eds.). Vademecum de thérapeutique psychiatrique. Editions Médecine & Hygiène, 1997.
- Woggon B, (ed.). Behandlung mit Psychopharmaka. Verlag Huber, 1998.
- Syndrome sérotoninergique**
- Serotonin syndrome**
- Dunkley EJ, Isbister GK, Sibbitt D, et al. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM 2003; 96: 635-42.
- Chassot M, Livio F, Buclin Th, et al. Syndrome sérotoninergique : mise au point et revue des cas annoncés en Suisse. Rev Med Suisse 2012; 8: 2086-90.
- Antémétiques - Antiemetika**
- ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health-Syst Pharm 1998; 56: 729-64.
- Antidiabétiques oraux - Orale Antidiabetika**
- Gerich JE. Oral hypoglycemic agents. N Engl J Med 1989; 321: 1231-45.
- Jönsson A, Rydberg T, Ekberg G, et al. Slow elimination of glyburide in NIDDM subjects. Diabetes Care 1994; 17: 142-5.
- DeFronzo RA, et al. Efficacy of metformin in patients with non-insuline dependant diabetes mellitus. N Engl J Med 1995; 333: 541-9.
- Stumvoll M, et al. Metabolic effect of metformine in non-insuline dependant diabetes mellitus. N Engl J Med 1995; 333: 550-4.
- UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in over-weight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
- Barman Balfour JA, Plosker GL. Rosiglitazone. Drugs 1999; 57: 921-30.
- Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study: A randomized controlled trial. Lancet 2005; 366: 1279-89.
- Erdmann E, Charbonnel B, Wilcox RG, et al. Pioglitazone in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study. Diabetes Care 2007; 30: 115-21.
- Home PhD, Pocock SJ, Beck-Nielsen H, et al. Ro-

siglitazone Evaluated for Cardiovascular Outcomes — An Interim Analysis. *N Engl J Med* 2007; 357: 28-38.

Antépileptiques - Antiepileptika

McCormack M., Alfrevic BA.A, Bourgeois St. et al. HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans. *N Engl J Med* 2011;364:1134-1143.

Antihistaminiques - Antihistaminika

Desager JP, Horsmans Y. Pharmacokinetic-pharmacodynamic relationships of H1-antihistamines. *Clin Pharmacokinet* 1995; 28: 419-32.

Antihypertenseurs - Antihyperensiva

Taira N. Differences in cardiovascular profile among calcium antagonists. *Am J Cardiol* 1987; 59: 24B-29B.

The fifth report of the joint national committee on detection, evaluation, and treatment of high blood pressure. *Arch Intern Med* 1993; 153: 154-83.

Lüscher TF, Cosentino F. The classification of calcium antagonists and their selection in the treatment of hypertension. *Drugs* 1998; 55: 509-17.

Abernethy DR, Schwartz JB. Drug therapy: Calcium-antagonist drugs. *N Engl J Med* 1999; 341: 1447-57.

Birkenhäger WH, Leeuw PW. Non-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension. *J Hypertens* 1999; 17: 873-81.

Burnett JC. Vasopeptidase inhibition: a new concept in blood pressure management. *J Hypertens* 1999; 17(Suppl.1): 37-43.

Yusuf S et al. Effects of an angiotensin-converting-enzyme inhibitor, Ramipril, on death from cardiovascular events in high-risk patients. *N Engl J Med* 2000; 342,145-53.

AINS/Aspirine - NSAR/ASPIRIN®

Settipane GA. Adverse reactions to aspirin and related drugs. *Arch Intern Med* 1981; 141: 328-32.

Sleiman IF, Mathews KP, McLean JA. Aspirin-sensitive asthma. *Chest* 1985; 87: 386-91.

Duc J, Pécaud A. A propos d'un cas d'arrêt respiratoire. Intolérance à l'aspirine et aux anti-inflammatoires non stéroïdiens. *Med Hyg* 1988; 46: 705-9.

Fries JF, et al. Identification of patients at risk for gastropathy associated with NSAID use. *J Rheumatol* 1990; 17 (Suppl. 20): 12-19.

Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. *N Engl J Med* 1991; 325: 1593-6.

Schlondorff D. Renal complications of nonsteroidal anti-inflammatory drugs. *Kidney Int* 1993; 44: 643-53.

Bronner LL, Kanter DS, Manson JE. Primary prevention of stroke. *N Engl J Med* 1995; 333: 1392-1400.

Bakowsky VS, Hanly JG. Complications of nonsteroidal antiinflammatory drug gastropathy and use of gastric cytoprotection: experience at a tertiary care health centre. *J Rheumatol* 1999;

26: 1557-63.

Hawkey CJ. Cox-2 inhibitors. *Lancet* 1999; 353: 307-14.

Caspi D, Lubart E, Graff E, et al. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. *Arthritis Rheum* 2000; 43: 103-8.

Everts B, Währborg P, Hedner. COX-2-specific inhibitors - the emergence of a new class of analgesic and anti-inflammatory drugs. *Clin Rheumatol* 2000; 19: 331-43.

FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. *N Engl J Med* 2001; 345: 433-42.

Stevenson DD, Sanchez-Borges M, Szczeklik A. Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes. *Ann Allergy Asthma Immunol* 2001; 87: 177-80.

Chandrasekharan NV, Dai H, Roos KL, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. *Proc Natl Acad Sci USA* 2002; 99: 13926-31.

U.S. Preventive Services Task Force (Chair: Berg AO). Aspirin for the prevention of cardiovascular events: recommendation and rationale. *Ann Intern Med* 2002; 136: 157-60.

August P. Initial treatment of hypertension. *N Engl J Med* 2003; 348: 610-17.

Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. *N Engl J Med* 2003; 348: 883-90.

Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. *N Engl J Med* 2003; 348: 891-9.

Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. *J Am Coll Cardiol* 2003; 41: 961-5.

Ridker, PM, Nancy R. Cook, and I-Min Lee, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. *N Engl J Med* 2005; 352: 1293-1304.

Risks of agranulocytosis and aplastic anemia. A first report of their relation to drug use with special reference to analgesics. The International Agranulocytosis and Aplastic Anemia Study. *JAMA* 1986; 256: 1749-57.

Stamer UM, Gundert-Remy U, Biermann E, et al. Metamizol: Überlegungen zum Monitoring zur frühzeitigen Diagnose einer Agranulozytose. *Schmerz* 2017; 31: 5-13.

Aspirine® - Prévention primaire

Jill Belch et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease - *BMJ*; 2008; 337.

Rothwell PM, Price JF, Fowkes Nelson MR, Reid CM, Ames DA et al. Feasibility of conducting a primary prevention trial of low-dose aspirin for

major adverse cardiovascular events in older people in Australia: results from the ASPirin in Reducing Events in the Elderly (ASPREE) pilot study. *Med J Aust* 2008;189:105-9. et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. *Lancet* 2012; 379: 1602-12.

Guirguis-Blake JM, Evans CV, Senger CA, O'Connor EA, Whitlock EP. Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services Task Force. *Ann Intern Med*. 2016; 164: 804-13.

Patrignani P, Patrono C. Aspirin and Cancer. *J Am Coll Cardiol* 2016; 68: 967-76.

Whitlock EP, Burda BU, Williams SB, et al. Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force. *Ann Intern Med*. 2016; 164: 826-35.

Cole BF, Logan RF, Halabi S et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. *J Natl Cancer Inst* 2009; 101: 256-66.

Bowman L, et al. ASCEND: A Study of Cardiovascular Events in Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes; *Am Heart J* 2018; 198: 135-144.

Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. *Lancet* 2018; 392: 387-399. doi: 10.1016/S0140-6736(18)31133-4.

Gaziano JM, Brotons C, Coppolecchia R et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. [Lancet 2018. pii: S0140-6736(18)31924-X]

Arnett DK, Blumenthal RS, Albert MA et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation* 2019; 140: e596-e646. DOI: 10.1161/CIR.0000000000000678

NSAR Überempfindlichkeit

Arnett DK, Blumenthal RS, Albert MA et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation* 2019; 140: e596-e646. DOI: 10.1161/CIR.0000000000000678

White AA, Stevenson DD. Aspirin-Exacerbated Respiratory Disease. *NEJM* 2018; 379: 1060-70. Kowalski ML, Asero R, Baybek S et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. *Allergy* 2013; 68: 1219-32.

Wedi B. Aktuelle Diagnostik der NSAR-Überemp-

findlichkeit. *Allergo J* 2017; 26: 204-11.

Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. *FASEB J* 2004; 18: 790-804.

Ballmer-Weber B. Analgetikaunverträglichkeit: Intoleranz oder Allergie? Therapeutische Umfrage 2019; 76: 23-27. <https://doi.org/10.1024/0040-5930/a001053>

P2Y12 Hemmer

Sibbing D, Kastrati A, Berger PB. Pre-treatment with P2Y12 inhibitors in ACS patients: who, when, why, and which agent? *Eur Heart J* 2016; 37: 1284-1295.

Cholestérol, hypolipémiants

Société Suisse de Cardiologie, Groupe de travail Lipides et Athérosclérose. Recommandations 1999 pour l'indication au traitement du facteur de risque «cholestérol». *Schweiz Ärztezeitung* 1999; 80: 544-8.

Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. *J Am Coll Cardiol* 2002; 40: 2125-34.

Gupta EK, Ito MK. The first in a novel class of selective cholesterol-absorption inhibitors. *Heart Dis* 2002; 4: 399-404.

Sudhop T, Lutjohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. *Circulation* 2002; 106: 1943-8.

Cortisone - Kortison

Haynes RC, Murad F. Adrenocortical steroids. In: Goodman-Gilman A, et al. (eds.). *The pharmacological basis of therapeutics*. Macmillan, New York, 1985.

Keenan GF. Management of complications of glucocorticoid therapy. *Chest* 1997; 18: 507-20. McEvoy CE, Niewohner DE. Adverse effects of corticosteroid therapy for COPD. A critical review. *Chest* 1997; 111: 732-43.

Israel E, Banerjee TR, Fitzmaurice GM, et al. Effect of inhaled glucocorticoids on bone density in premenopausal women. *N Engl J Med* 2001; 345: 941-7.

Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. *N Engl J Med* 2015; 372:1489.

Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. *N Engl J Med* 2015; 372:1500.

Diurétiques - Diuretika

Jacobson HR. Diuretics. Mechanisms of action and uses. *Hosp Pract* 1987; December: 129-56.

Chernow B (ed). *Essential of Critical Care Pharmacology*. Wiliams & Wilkins, 1989.

Brater DC. Diuretic therapy. *N Engl J Med* 1998; 339: 387-95.

Hypnotiques

Greenblatt DJ, Shader RI, Abernethy DR. Current status of benzodiazepines (First of two parts). *N Engl J Med* 1983; 309: 354-8.

Greenblatt DJ, Shader RI, Abernethy DR. Current status of benzodiazepines (Second of two parts). *N Engl J Med* 1983; 309: 410-6.
Calanca A, Bryois C, Buclin T. (eds.). *Vademecum de thérapeutique psychiatrique*. Editions Médecine & Hygiène, 1997.

Magnésium

Reinhart RA. Magnesium metabolism. A review with special reference to the relationship between intracellular content and serum levels. *Arch Intern Med* 1988; 48: 2415-20.

Neuroleptiques - Neuroleptika

Kapsambelis V, Gekiere C, Ginestet D. Classification clinique des neuroleptiques. Étude critique et perspectives actuelles. *Encéphale* 1990; 16: 60-70.
Pabis DJ, Stanislav SW. Pharmacotherapy of aggressive behaviour. *Ann Pharmacother* 1996; 30: 278-87.
Calanca A, Bryois C, Buclin T. (eds.). *Vademecum de thérapeutique psychiatrique*. Editions Médecine & Hygiène, 1997.

Grossesse et médicaments/lactation

Kunz J, Schreiner WE. In: *Pharmakotherapie während der Schwangerschaft und Stillperiode*. 1. Aufl. Thieme Verlag Stuttgart, New York, 1982.
Knoben JE, Anderson PO. *Handbook of Clinical Drug Data*. 7th ed. Hamilton Press 1993; Anderson P. Drug use during breastfeeding. *Clin Pharm*. 1991; 10: 596-624.
Briggs GG, Freeman RK, Yaffe SJ. (eds.). In: *Drugs in pregnancy and lactation*. Williams & Wilkins 1994.
Sibai BM. Treatment of hypertension in pregnant women. *N Engl J Med* 1996; 335: 257-65.
Cloherty JP, Stark AR 1997. *Manual of neonatal care*, 4th edn. Little, Brown & Co Boston.
Delaloye J-F, De Grandi P, Vial Y, Hohlfeld P. (eds.). In: *Médicaments, Grossesse et lactation*. Editions Médecine & Hygiène, Genève, 1997.
Koren G, Pastuszak A, Ito S. Drugs in pregnancy. *N Engl J Med* 1998; 338: 1128-37.

Midazolam

Shapiro BA, Warren J, Egol AB, et al. Practice parameters for intravenous analgesia and sedation for adult patients in the intensive care unit: an executive summary. *Crit Care Med* 1995; 23: 1596-600.

Cytochrome P450 - CYP 450

www.infomed.ch/pharma-kritik/pk21d-98.html
www.hospitalist.net/highlight.htm

Richelson E. Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. *Mayo Clin Proc* 1997; 72: 835-47.

Michalets EL. Clinically significant cytochrome P-450 drug interactions. *Pharmacotherapy* 1998; 18: 84-112.

Desmeules J, Bonnabry P, Dayer P. Hepatic metabolism of drugs. In: Bircher J, et al. (eds.). Oxford textbook of clinical hepatology. Oxford

University Press, 1999.
Oestreicher KM, Desmeules J, Piguet V, et al. Interactions médicamenteuses: le rôle des cytochromes P450. *Med Hyg* 1999; 57: 793-800.
Obach RS. Inhibition of human cytochrome P450 enzymes by constituents of St-John's Wort, an herbal preparation used in the treatment of depression. *J Pharmacol Exp Ther* 2000; 294: 88-95.
Taketomo CK et al. Cytochrome P-450 enzymes and drug metabolism. In: *Pediatric dosage handbook*. 8th edition 2001-2001: 1076-84.
Bonnabry P, Sievering J, Leemann T, et al. Quantitative drug interactions prediction system (Q-DIPS): a dynamic computer-based method to assist in the choice of clinically relevant in vivo studies. *Clin Pharmacokinet* 2001; 40: 631-40.
Ahyu SN, Flood K, Paranjothi S. (eds.). *The Washington Manual of Medical Therapeutics*. Lippincott Williams & Wilkins, 2001, p: 590-607.
Compendium des produits et spécialités pharmaceutiques (CPS) 2003.

Bisphosphonates (cf. Ostéoporose)

Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis, *N Engl J Med* 1990; 323: 73-9.
Miller PD, Watts NB, Licata AA, et al. Cyclical etidronate in the treatment of postmenopausal osteoporosis; efficacy and safety after 7 years of treatment. *Am J Med* 1997; 103: 468-76.
Russel RFF, Rogers MG. Bisphosphonates: from the laboratory to the clinic and back again. *Bone* 1999; 25: 97-106.
Tonino RP, Meunier PF, Emkey R, et al. Skeletal benefits of alendronate: 7-years treatment of postmenopausal osteoporotic women. *J Clin Endocrinol Metabol* 2000; 85: 3109-15.

Procalcitonine

Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections : Cluster-randomised, single-blinded intervention trial. *Lancet* 2004; 363: 600-7.
Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients : A randomized trial. *Am J Respir Crit Care Med* 2008; 177: 498-505.
Boudama L, Luyt CE, Tubach F et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. *Lancet* 2010; 375: 463-74.
Schuetz P, Muller B, Christ-Crain M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. *Cochrane Database Syst Rev* 2012;9:CD007498.
Luong Ba K, Harbarth S, Carballo S. Procalcitonine: doser ou ne pas doser? *Rev Med Suisse* 2013; 9: 1881-5.
Huang DT, Yealy DM, Filbin MR et al. Procalcitonin-Guided Use of Antibiotics for Lower Respiratory Tract Infection. *Am J Respir Crit Care Med* 2013; 187: 103-10.

Psychiatrie - Geriatrie

Saisonale Depression (SAD)

Eastman CI, Young MA, Fogg LF, Liu L, Meaden PM. Bright light treatment of winter depression: a placebo-controlled trial. Arch Gen Psychiatry 1998; 55: 883-9.

Terman M, Terman JS. Controlled trial of naturalistic dawn simulation and negative air ionization for seasonal affective disorder. Am J Psychiatry 2006; 163: 2126-33.

Lam RW, Levitt RD, Levitt AJ, et al. American Psychiatric Association, 168th Annual Meeting, Toronto, Canada, May 2015. New research poster session 2, number 52.

GYNÄKOLOGIE

Präeklampsie

American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol 2013; 122: 1122-1131.

Tranquilli AL, Brown MA, Zeeman GG, Dekker G, Sibai BM: The definition of severe and early-onset preeclampsia. Statements from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Pregnancy Hypertens 2013; 3: 44-47.

Tranquilli AL, Dekker G, Magee L, et al.: The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. Pregnancy Hypertens 2014; 4: 97-104.

Stephan et al.: S1-Leitlinie Hypertensive Schwangerschaftserkrankungen: Diagnostik und Therapie. Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG). Stand: 1. Dezember 2013.

Schäffer L. Präeklampsie: neue Definitionen. Praxis 2018; 107: 1333-7.

Rolinik DL, Wright D, Poon LC, et al.: Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. NEJM 2017; 377: 613-622.

Brown MA, Magee LA, Kenny LC et al. on behalf of the International Society for the Study of Hypertension in Pregnancy (ISSHP). The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice. Hypertension 2018; 72: 24-43.

MEDICAMENTS - BREVIERE

NET: <http://jml.georgetown.edu/jpts/pharmacology>

Textbooks

Chernow B (ed). Essential of Critical Care Pharmacology. Williams & Wilkins, 1989.

Goodman & Gilman's The Pharmacological basis of therapeutics. McGrawHill, 1997.

Morant J, Ruppanner H, (eds.). Arzneimittel Kompendium der Schweiz 2001. Documed 2002. Canadian Pharmacists Association. Compendium of pharmaceuticals and specialities - CPS 2002.

Amiodarone

Mason JW. Amiodarone. N Engl J Med 1987; 316: 455-66.

Martin WJ, Resenow EC. Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part 1). Chest 1988; 93: 1067-75.

Sunderji R, Kanji Z, Gin K. Pulmonary effects of low dose amiodarone: a review of the risks and recommendations for surveillance. Can J Cardiol 2000; 16: 1435-40.

Amlodipin

Bhatia V, Mittal A, Parida A et al. Amlodipine induced gingival hyperplasia: a rare entity. Int J Cardiol 2007; 122: 23-24.

Agratroban

McKeage K, Polsker GL. Drugs 2001; 611: 515-22; discussion 523-4.

Clopidogrel

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348: 1329-39.

Charis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 1998; 129: 394-405.

Harding SA, Boon NA, Flapan AD. Antiplatelet treatment in unstable angina: aspirin, clopidogrel, glycoprotein IIb/IIIa, or all three? Heart 2002; 88: 11-4.

Digoxine

Smith TW. Digitalis: mechanisms of action and clinical use. N Engl J Med 1988; 318: 358-65.

The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525-33.

Levi D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002; 347: 1397-1402.

Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002; 347: 1403-11.

Milrinone

Colucci WS, Wright RF, Jaski BE et al. Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness. Circulation 1986; 73: III 175-83. Mehra MR, Ventura HO, Kapoor C et al. Safety and clinical utility of long-term intravenous milrinone in advanced heart failure. Am J Cardiol 1997; 80: 61-4.

Packer M, Carver JR, Rodeheffer RJ et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1988; 318: 358-75.

Stevenson LW. Inotropic therapy for heart failure. N Engl J Med 1998; 339: 1848-50.

- Yamani HM, Haji SA, Starling RC et al. Comparison of dobutamine-based and milrinone-based therapy for advanced decompensated congestive heart failure: hemodynamic efficacy clinical outcome, and economic impact. *Am Heart J* 2001; 142: 998-1002.
- Hunt SA, Baker DW, Chin MH et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult. *J Am Cardiol* 2001; 38: 2101-13 (also in: *Circulation* 2001; 104: 2996-3007.)
- Midazolam**
- Shapiro BA, Warren J, Egol AB, et al. Practice parameters for intravenous analgesia and sedation for adult patients in the intensive care unit: an executive summary. *Crit Care Med* 1995; 23: 1596-600.
- Vasopressine (ADH)**
- Argenziano M, Choudhri AF, Oz MC, et al. A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. *Circulation* 1997; 96 (Suppl): II-286-90.
- Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. *Circulation* 1997; 95: 1122-5.
- Schrier RW, Cadnapaphornchai MA, Umenishi F. Water-losing and water-retaining states: role of water channels and vasopressin receptor antagonist. *Heart Dis* 2001; 3: 210-4.
- Annan D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. *JAMA* 2002; 288: 862-71.
- Chen P. Vasopressin: new uses in critical care. *Am J Sci* 2002; 324: 146-54.
- Patel BM, Chittock DR, Russel JA, et al. Beneficial effects of short-term vasopressin infusion during severe septic shock. *Anesthesiology* 2002; 96: 576-82
- INTOXICATIONS**
- Centre anti-poison du Québec: Tél: 1-800-563-5060; ou (418) 656-8090.
 - Textbook: Tintinalli, Rothstein & Krome (ed.). Emergency medicine, a comprehensive study guide. 5th edition.
 - Bulletin toxicologique (avril 1999): www.ctq.qc.ca/avril99.pdf
- Done AK. Salicylate intoxication: significance of salicylate in blood in cases of acute ingestion. *Pediatrics* 1960; 26: 800-7.
- Rumack BH, Matthew H. Acetaminophen poisoning and toxicity. *Pediatrics* 1975; 55: 871-6.
- Rumack BH, Peterson RC, Koch GG, et al. Acetaminophen overdose. 662 cases with evaluation of oral N-acetylcysteine treatment. *Arch Intern Med* 1981; 141: 380-5.
- Cohen L, Kitzes R. Magnesium sulfate and digitalis-toxic arrhythmias. *JAMA* 1983; 249: 2808-10.
- Schwartz JA, Koenigsberg MD. Naloxone-induced pulmonary edema. *Ann Emerg Med* 1987; 16: 1294-6.
- Maio RF, Gaukel B, Freeman B. Intralingual injection for narcotic-induced respiratory depression. *Ann Emerg Med* 1987; 16: 572-3.
- Smilkstein MJ, Knapp GL, Kulig KW, et al. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). *N Engl J Med* 1988; 319: 1557-62.
- Hollander JE. The management of cocaine-associated myocardial ischemia. *N Engl J Med* 1995; 333: 1267-72.
- Liebelt EL, Francis PD, Woolf AD. ECG lead aVR versus QRS interval in predicting seizures and arrhythmias in acute tricyclic antidepressant toxicity. *Ann Emerg Med* 1995; 26: 195-201.
- Thom SR, Taber RL, Mendiguren II, et al. Delayed neurological sequelae after carbon monoxide poisoning: prevention by treatment with hyperbaric oxygen. *Ann of Emerg Med* 1995; 25: 474-80.
- Kind B, Krähenbühl S, Wyss PA et al. Dosierung von N-Acetylcystein bei akuter Vergiftung mit Paracetamol. *Schweiz Rdschau Med Praxis* 1996; 85: 935-8.
- Ellenhorn MJ. (ed.). *Ellenhorn's Medical Toxicology*. Williams & Wilkins, 1997.
- Seyffart G. (ed.). *Poison index. The treatment of acute intoxication*. 4. Edition. Pabst science publishers, 1997.
- Goldfrank LR, et al. (eds.). *Goldfrank's Toxicologic Emergencies*. 6th edition, Appleton & Lange, Stanford 1998.
- Hirsh J. Reversal of the anticoagulant effects of warfarin by vitamin K1. *Chest* 1998; 114: 1505-8.
- Lekin JB, Paloucek FP, (eds.). *Poisoning & Toxicology Compendium*. Lexi-Comp, Hudson OH 1998.
- American Academy of Clinical Toxicology (AACT), European Association of Poisons Centers and Clinical Toxicologists (EAPCCT): Position statements: gut decontamination. *J Toxicol Clin Toxicol* 1997; 35: 695-762.
- American Academy of Clinical Toxicology (AACT), European Association of Poisons Centres and Clinical Toxicologists (EAPCCT): Position statements and practice guidelines on the use of multi-dose activated charcoal in the treatment of acute poisoning. *J Toxicol Clin Toxicol* 1999; 37: 731-51.
- Olson KR. (ed.). *Positionning and drug overdoses*. 3rd edition. Appleton & Lange, Stanford CT 1999.
- Guidelines 2000 for cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 8: advanced challengers in resuscitation section 2: Toxicology in ECC. *Circulation* 2000 ; 102 (Suppl. 1): I223-8.
- Woo OF, Mueller PD, Olson KR, et al. Shorter duration of oral N-acetylcysteine therapy for acute acetaminophen overdose. *Ann Emerg Med* 2000; 35: 363-8.
- Lange RA, Hillis L. Cardiovascular complications of cocaine use. *N Engl J Med* 2001; 345: 351-8.
- Meier-Abt PJ, Kupferschmidt H. Dekontamination und wichtigste Antidota. *Schweiz Med Forum*

2001; 1: 402-5.

Albertson TE, Dawson A, de Latorre F, et al. Tox-
ACLS: Toxicologic-oriented advanced cardiac
life support. Ann Emerg Med 2001; 37 (4.
Suppl.): S78-90.

Wallace CI, Dargan PI, Jones AL. Paracetamol
overdose: an evidence based flowchart to guide
management. Emerg Med J 2002; 19: 202-5.

Weber JE, Shofer FS, Larkin GL, et al. Validation
of a brief observation period for patients with
cocaine-associated chest pain. N Engl J Med
2003; 348: 510-7.

Weaver LK, Valentine KJ, Hopkins RO. Carbon
Monoxide Poisoning. Risk Factors for Cognitive
Sequelae and the Role of Hyperbaric Oxygen.
Am J Respir Crit Care Med 2007 ; 176 : 491-7.

Siegal DM, Curnutte JT, Connolly SJ, et al. Ande-
xanet alfa for the reversal of factor Xa inhibitor
activity. N Engl J Med 2015; 373: 2413-2424.

OPHTHALMOLOGIE

Azuara-Blanco A, Burr J, Ramsay C et al. Effecti-
veness of early lens extraction for the treatment
of primary angle-closure glaucoma (EAGLE): a
randomised controlled trial. Lancet 2016;
388:1389-1397

Fahrzeugfahreinigung

Buser M, Christen St, Schär B et al. Fahreignung
und kardiovaskuläre Erkrankungen: gemein-
same Richtlinien der Schweizerischen Gesell-
schaft für Kardiologie und der Schweizerischen
Gesellschaft für Rechtsmedizin. Cardiovasc
Med. 2019;22:w02023